Title,Authors,DOI,DOI link,Venue,Citation count,Year,"population, indication","Reasoning for ""population, indication""",MRONJ latency,"Reasoning for ""MRONJ latency""",Control Group,"Reasoning for ""Control Group""",Procedure and Outcome,"Reasoning for ""Procedure and Outcome""",Study Design,"Reasoning for ""Study Design""",Outcome Documentation,"Reasoning for ""Outcome Documentation""","population, age","Reasoning for ""population, age""",subject size,"Reasoning for ""subject size""",intervention type,"Reasoning for ""intervention type""",diagnostic standard for MRONJ,"Reasoning for ""diagnostic standard for MRONJ""",Screening judgement,"Reasoning for ""Screening judgement""",Screening score
Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis.,"É. Gaudin, L. Seidel, M. Bacevic, E. Rompen, F. Lambert",10.1111/jcpe.12455,https://doi.org/10.1111/jcpe.12455,Journal of Clinical Periodontology,96,2015,no,"The study includes both osteoporosis and oncological patients, which violates the requirement for a pure osteoporosis population.",no,"The abstract does not mention documenting time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study clearly focuses on dental extraction and MRONJ incidence, meeting this criterion.",no,"This is a systematic review/meta-analysis of prospective studies, which doesn't directly meet the criterion for primary research designs.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified.",maybe,"The abstract does not specify the age requirements, though it mentions ""human patients"" which likely implies adults.",maybe,"The abstract does not specify the number of subjects, though as a meta-analysis it likely includes more than 100 subjects.",maybe,"The abstract mentions ""per os ARD"" (oral anti-resorptive drugs) for osteoporosis patients, which meets this criterion. However, it also includes other administration routes and non-bisphosphonate medications.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails critical screening criteria by including a mixed population of osteoporosis and oncological patients, and by being a meta-analysis rather than a primary research design. Multiple key requirements were not met, including specific diagnostic standards, clear documentation of MRONJ latency, and a pure osteoporosis patient population. These significant methodological limitations render the study non-compliant with the established screening criteria.",1.4
THE RISK OF MEDICATION‐RELATED OSTEONECROSIS OF THE JAW AFTER DENTAL EXTRACTION IS HIGHER FOR PATIENTS ON INTRAVENOUS AS COMPARED WITH ORAL ANTIRESORPTIVE DRUGS,E. Abt,10.1016/j.jebdp.2017.03.007,https://doi.org/10.1016/j.jebdp.2017.03.007,Journal of Evidence-Based Dental Practice,2,2017,no,The abstract did not specify if the subjects were osteoporosis patients or if there was a mixed population.,no,"Elicit could not determine the time interval between the start of medication and dental procedure, and between the dental procedure and MRONJ incidence from the abstract.",no,Elicit could not determine from the abstract if the study included a control group of patients not taking anti-resorptive medications.,yes,"The abstract mentions dental extraction, which is one of the specified procedures.",no,"This is a systematic review and meta-analysis, not a primary research study, which is a critical failure as Elicit needs primary research studies.",no,Elicit could not determine the follow-up period from the abstract.,no,Elicit could not determine from the abstract if the subjects were over 18 years old.,no,Elicit could not determine the sample size from the abstract.,no,Elicit could not determine if only oral bisphosphonates were included in the study.,no,Elicit could not determine the diagnostic standards for MRONJ from the abstract.,Exclude,"This systematic review and meta-analysis fails to meet critical screening criteria, primarily because it is not a primary research study. The extremely brief abstract lacks sufficient detail to assess most inclusion requirements, with only the dental extraction procedure being clearly identifiable. Multiple key screening criteria remain unverifiable due to limited information.",0.1
Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis,"A. Srivastava, G. N. Nogueras Gonzalez, Yimin Geng, Alexander M. Won, J. Myers, Yisheng Li, M. Chambers",10.36401/JIPO-21-14,https://doi.org/10.36401/JIPO-21-14,Journal of Immunotherapy and Precision Oncology,8,2021,no,"The study focuses on patients taking antiresorptive (AR) drugs, but appears to include cancer patients (given the mention of antiangiogenic drugs which are typically used in cancer treatment). This fails to meet the criterion of excluding cancer patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",maybe,"The abstract mentions comparing concurrent AA-AR drugs with AA only and AR only groups, but does not explicitly mention a control group of patients not taking any medications.",no,The abstract does not specify any dental procedures leading to MRONJ.,yes,"The abstract mentions including retrospective cohort studies, which meets this criterion.",maybe,"While the study reports MRONJ prevalence, it does not specify the follow-up period.",maybe,The abstract does not specify the age of the subjects.,maybe,The abstract does not specify the total number of subjects in the included studies.,no,"The study includes both AR and AA drugs, and does not specify whether the AR drugs are oral bisphosphonates. It appears to be a broader review of antiresorptive medications.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Exclude,"The study fails key screening criteria by including cancer patients and not focusing exclusively on oral bisphosphonates, which immediately disqualifies it from meeting the specified research parameters. Multiple critical elements are missing or uncertain, including diagnostic standards, dental procedures, and specific medication details, further compromising its alignment with the screening requirements. The broad scope and lack of specificity in patient population and intervention type render the study unsuitable for the intended research focus.",1.4
Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - A retrospective study of 240 patients.,"R. Coropciuc, R. Coopman, M. Garip, E. Gielen, C. Politis, T. Van den Wyngaert, B. Beuselinck",10.1016/j.bone.2023.116722,https://doi.org/10.1016/j.bone.2023.116722,Bone,13,2023,no,"The study includes a mixed population of both osteoporosis and bone metastases patients, which explicitly violates the criterion requiring only osteoporosis patients.",maybe,"The study mentions ""median drug exposure of 43 months"" but doesn't clearly document the specific time intervals required.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study specifically looks at dental extractions and reports MRONJ incidence, meeting this criterion.",yes,"The study is described as retrospective, which is an acceptable design.",maybe,"The study reports MRONJ incidence and includes follow-up information about mucosal healing, suggesting adequate documentation. The follow-up period isn't explicitly stated.",maybe,"While not explicitly stated, the context suggests adult patients (osteoporosis and bone metastases), but this isn't definitively confirmed.",yes,"The osteoporosis cohort has 126 patients, which meets the >100 subject requirement.",maybe,"The abstract only mentions ""antiresorptive agents"" without specifying oral bisphosphonates, which is too vague to confirm it meets the criterion.",maybe,"While MRONJ is discussed, the abstract doesn't explicitly mention diagnostic standards.",Include,"The study involves a mixed population of osteoporosis and bone metastases patients, which directly conflicts with the requirement for a pure osteoporosis patient group. While the research meets some screening criteria like subject size and study design, critical limitations include the lack of a control group and unclear specification of medication type. The mixed population and incomplete documentation of key methodological details significantly compromise the study's alignment with the screening requirements.",2.5
Association between periodontitis and medication-related osteonecrosis of the jaw: a systematic review and meta-analysis.,"A. Lorenzo-Pouso, M. Pérez‐Sayáns, C. Chamorro-Petronacci, P. Gándara-Vila, P. López‐Jornet, Javier Carballo, A. García-García",10.1111/jop.12963,https://doi.org/10.1111/jop.12963,Journal of Oral Pathology & Medicine,36,2019,no,"The abstract mentions ""antiresorptive therapies"" but doesn't specifically state these are for osteoporosis treatment, and appears to include mixed populations (""several antiresorptive therapies and other pharmaceutical interventions"").",no,"No mention of time intervals between medication start, dental procedures, and MRONJ incidence.",maybe,"The abstract mentions ""at-risk non-affected patients"" as a comparison group, but it's unclear if these are patients not taking anti-resorptive medications.",no,"The abstract focuses on periodontal disease as a risk factor for MRONJ, but doesn't specifically study MRONJ incidence following dental procedures.",yes,"The abstract mentions including ""5 cohort studies, and 7 case-control studies"" which meets the criteria.",no,"While the study documents MRONJ, it's not in the context of dental treatment outcomes, and follow-up period is not specified.",no,The abstract does not specify the age of subjects.,no,The abstract doesn't specify the number of subjects in the included studies.,no,"The abstract refers to ""antiresorptive therapies"" broadly and doesn't specify oral bisphosphonates.",maybe,"The abstract mentions ""prefixed definitions"" but doesn't specify the diagnostic standards.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific intervention type, population indication, and procedure-related outcomes. While the study includes appropriate research designs, it lacks precise documentation of key parameters such as subject age, medication specifics, and dental procedure-related MRONJ incidence. The research appears more focused on periodontal disease associations with MRONJ rather than meeting the predefined screening requirements.",1.4
The Prevention of Medication-related Osteonecrosis of the Jaw.,"P. Poxleitner, M. Engelhardt, R. Schmelzeisen, P. Voss",10.3238/arztebl.2017.0063,https://doi.org/10.3238/arztebl.2017.0063,Deutsches Ärzteblatt International,45,2017,no,"The abstract discusses both cancer patients and osteoporosis patients, mentioning ""1-20% of patients with bone metastases"" and ""0.1-2% of patients being treated for osteoporosis."" This mixed population violates the criterion.",no,"The abstract doesn't document specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,The abstract does mention tooth extraction as a procedure and its relationship to MRONJ incidence.,no,"This is a systematic review of other studies, not a primary research study of the required designs.",maybe,"While MRONJ incidence is discussed, the follow-up period is not specified.",maybe,"The abstract does not specify the age requirements, though it likely includes adults given the context.",maybe,"While the abstract mentions a case series of ""over 1200 patients,"" this is not the main study but rather a cited study. The actual study size is not clearly stated.",maybe,"The abstract discusses ""antiresorptive treatment"" and ""bisphosphonates"" but doesn't specify oral administration exclusively.",no,The abstract doesn't mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple screening criteria, including a mixed patient population, lack of specific diagnostic standards, and absence of a clear primary research design. Critical shortcomings include the inclusion of cancer patients alongside osteoporosis patients and the inability to definitively document MRONJ latency periods or follow-up outcomes. These methodological limitations render the study unsuitable for inclusion in the systematic review.",1.4
Interventions for managing medication-related osteonecrosis of the jaw.,"Natalie H Beth-Tasdogan, B. Mayer, H. Hussein, O. Zolk",10.1002/14651858.CD012432.pub2,https://doi.org/10.1002/14651858.CD012432.pub2,Cochrane Database of Systematic Reviews,197,2017,no,"The abstract includes mixed populations of both cancer patients and osteoporosis patients, which is a clear violation of the inclusion criteria that specifically excludes mixed populations and cancer patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",maybe,"The abstract does not explicitly state that the study included a control group of patients not taking anti-resorptive medications, so Elicit could not confirm this criterion was met.",yes,"The abstract mentions dental procedures including extractions and discusses MRONJ incidence following these procedures, which meets the criterion of reporting MRONJ incidence following specific dental procedures.",yes,"The paper is a systematic review of RCTs, which meets the study design criterion.",maybe,"While the abstract discusses MRONJ incidence, it does not specify the follow-up period length.",maybe,"The abstract does not explicitly state the age of the participants, so Elicit could not confirm this criterion was met.",yes,"The abstract mentions 1218 total participants across 5 RCTs, with individual trial sizes ranging from 34 to 700 participants, which meets the criterion of including over 100 subjects for the medication group at the final statistical analysis stage.",no,"The abstract mentions both oral and intravenous bisphosphonates, and includes other medications like denosumab, which does not meet the criterion of only including subjects taking oral bisphosphonate medication for osteoporosis treatment.",no,The abstract does not explicitly mention the diagnostic standards for MRONJ.,Exclude,"The systematic review fails key screening criteria by including mixed patient populations with cancer and osteoporosis, and incorporating both oral and intravenous bisphosphonates. Critical exclusion criteria were not met, particularly regarding population indication and intervention type, which fundamentally disqualifies the study from meeting the specified screening requirements. Multiple other criteria were either uncertain or not addressed, further compromising the study's alignment with the screening protocol.",1.4
Incidence and severity of medication-related osteonecrosis of the jaw in patients with osteoporosis using data from a Korean nationwide sample cohort in 2002 to 2019: a retrospective study,"Su-Youn Ko, Tae-Yoon Hwang, Kiook Baek, Chulyong Park",10.12701/jyms.2023.01116,https://doi.org/10.12701/jyms.2023.01116,Journal of Yeungnam Medical Science,0,2024,yes,"The study specifically focuses on patients with osteoporosis, excluding cancer patients, which clearly meets the criterion.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications, which is a significant missing element.",no,"The abstract doesn't specify which dental procedures were associated with MRONJ incidence, only mentioning ""invasive treatment"" in general terms.",yes,"This appears to be a retrospective cohort study using national health insurance data, which meets the criterion.",no,"While MRONJ incidence is documented (0.17%), the follow-up period isn't specified.",yes,"The study includes patients ""aged 40 years and above,"" which meets the criterion of over 18 years.",maybe,"While the exact number isn't stated, this is described as a ""large-scale cohort study"" using national health insurance data, suggesting it likely includes over 100 subjects. However, this isn't explicitly confirmed.",no,"The study includes both bisphosphonates and SERMs, which doesn't strictly meet the criterion of only oral bisphosphonates. This is a significant deviation from the criteria.",no,"The abstract doesn't mention specific diagnostic standards for MRONJ, which is a missing element.",Include,"A large-scale retrospective cohort study examining medication-related osteonecrosis of the jaw in osteoporosis patients reveals significant methodological limitations, including mixed medication groups and lack of specific dental procedure details. While the research provides insights into MRONJ incidence, it deviates from strict screening criteria by including non-bisphosphonate medications and omitting key diagnostic and procedural specifications. The study's broad approach and national health insurance data offer valuable preliminary findings, but fall short of meeting comprehensive research screening requirements.",2.9
Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses.,"Harry Karna, Jaime González, Harveen S Radia, P. Sedghizadeh, R. Enciso",10.1016/j.oraloncology.2018.08.003,https://doi.org/10.1016/j.oraloncology.2018.08.003,Oral Oncology,26,2018,no,"The study specifically focuses on cancer patients receiving antiresorptive therapy, which is explicitly excluded in the criteria.",no,"The study does not mention the time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study included a control group of patients not taking anti-resorptive medications, which adds 0.2 points to the score.",maybe,"While the study mentions ""dental interventions"" and ""dental treatment,"" it does not specifically detail the procedures listed in the criteria.",yes,"The study includes RCT, case-control, and cohort studies, which meet the study design criteria.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",maybe,"The abstract does not specify the age requirements for the study population, though it is noted that cancer patients are typically adults.",yes,"The study includes 2332 patients, which is well above the 100-subject requirement.",no,"The study does not specify oral bisphosphonates and appears to include general ""antiresorptive therapy"" which may include other medications.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review focuses on cancer patients receiving antiresorptive therapy, which directly conflicts with the specified screening criteria requiring osteoporosis patients. Multiple critical screening requirements were not met, including population indication, intervention type, and diagnostic standards for MRONJ. The study's methodology and population fundamentally diverge from the predefined screening parameters.",1.4
Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis,"Alvaro Limones, L. Sáez-Alcaide, S. Díaz-Parreño, A. Helm, M. Bornstein, P. Molinero-Mourelle",10.4317/medoral.23324,https://doi.org/10.4317/medoral.23324,Medicina Oral,91,2020,no,"The study specifically focuses on cancer patients taking denosumab or zoledronic acid, which explicitly violates the criterion requiring subjects with osteoporosis treatment.",no,The study documents time intervals for medication exposure but not specifically for dental procedures to MRONJ incidence.,no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,no,"The study is a meta-analysis of randomized controlled trials, which is not one of the accepted study designs.",no,"While the study documents MRONJ incidence over time periods, it doesn't specify follow-up after dental procedures.",maybe,"The abstract does not explicitly state the age of subjects, though cancer patients are typically adults.",yes,"The study includes 13,857 patients total, well exceeding the 100-subject requirement.",no,"The study includes both denosumab (non-bisphosphonate) and zoledronic acid (intravenous bisphosphonate), which violates the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients taking denosumab or zoledronic acid, which critically deviates from the required osteoporosis patient population and oral bisphosphonate intervention. Multiple screening criteria were not met, including study design, diagnostic standards, and specific dental procedure documentation, rendering the paper unsuitable for inclusion in the review.",0.1
Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review,"Mampei Kawahara, S. Kuroshima, T. Sawase",10.1186/s40729-021-00323-0,https://doi.org/10.1186/s40729-021-00323-0,International Journal of Implant Dentistry,67,2021,no,"The abstract discusses both cancer patients and osteoporosis patients, indicating a mixed population, which fails to meet the criterion requiring exclusive focus on osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, which is a significant limitation.",no,"While the abstract mentions dental treatment, it does not specifically report MRONJ incidence following the specified procedures.",no,"This is a literature review, not a primary research study of any of the specified designs, so it fails to meet the criterion.",no,The abstract does not provide specific follow-up periods or MRONJ incidence rates.,maybe,"The abstract does not explicitly state the age of the subjects, so this is unclear.",maybe,"The abstract does not mention the sample size, so this is unclear.",no,"While the abstract mentions oral bisphosphonates, it also discusses other medications including denosumab and angiogenesis inhibitors, which is broader than the criterion requires.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This literature review fails to meet multiple screening criteria, including the requirement for a primary research study design and a focused population of osteoporosis patients. The abstract lacks specific details about diagnostic standards, follow-up periods, and MRONJ incidence rates, rendering it insufficient for the specified research parameters.",1.4
"Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan.","M. Ishimaru, S. Ono, K. Morita, H. Matsui, Y. Hagiwara, H. Yasunaga",10.1016/j.joms.2021.12.007,https://doi.org/10.1016/j.joms.2021.12.007,Journal of oral and maxillofacial surgery,33,2021,no,"The study includes both osteoporosis patients and cancer patients, which is a mixed population and violates the criterion.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,"The abstract mentions ""tooth extraction"" as a factor but does not specifically study MRONJ incidence following dental procedures. It appears to be a general risk factor analysis.",yes,"This is a retrospective cohort study, which meets the criterion.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified.",maybe,"While the study is a population-based study using national health insurance data, which typically covers adults, the age of the subjects is not explicitly stated, so the reasoning is uncertain.",yes,"The study includes 2,664,104 osteoporosis patients, which exceeds the 100-subject requirement.",no,"The abstract only mentions ""antiresorptive drugs"" generally, without specifying oral bisphosphonates, which is too broad and does not meet the criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study fails key screening criteria due to a mixed patient population including cancer patients, non-specific intervention type, and lack of focus on dental procedures. While the research is a large retrospective cohort study with substantial patient numbers, it does not meet the precise requirements for the systematic review, particularly regarding population specificity and intervention details. Critical methodological elements such as diagnostic standards, MRONJ latency, and specific dental procedure outcomes are not sufficiently addressed.",2.5
"Location and Gender Differences in Osteonecrosis of the Jaws in Patients Treated with Antiresorptive and Antineoplastic Drugs Undergoing Dentoalveolar Surgical, Systematic Review with Meta-Analysis and Trial Sequential Analysis","M. Dioguardi, F. Spirito, M. Alovisi, R. Aiuto, Daniele Garcovich, V. Crincoli, A. Ballini, G. A. Caloro, L. Lo Muzio",10.3390/jcm12093299,https://doi.org/10.3390/jcm12093299,Journal of Clinical Medicine,5,2023,no,"The abstract mentions both osteoporosis and neoplastic diseases, indicating a mixed population, which fails to meet the criterion requiring exclusive focus on osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not explicitly mention a control group, which is a significant limitation.",yes,"The abstract does discuss extraction procedures and MRONJ incidence, meeting this criterion.",no,"This is a systematic review and meta-analysis, not a primary study design specified in the criteria, which fails to meet the criterion.",maybe,"While MRONJ incidence is discussed, the follow-up period is not specified.",maybe,"The abstract does not specify the age range of the subjects, so this information is unclear.",maybe,"The abstract mentions analyzing 24 studies but does not specify the number of subjects in the medication group, so this information is unclear.",no,"The abstract discusses both oral bisphosphonates and monoclonal antibodies, not exclusively oral bisphosphonates, which fails to meet the criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including exclusive focus on osteoporosis patients, specific intervention type, and primary study design. Mixed population, inclusion of non-bisphosphonate medications, and lack of key methodological details significantly compromise the study's alignment with the predefined screening requirements. The research does not provide sufficient evidence to satisfy the comprehensive screening criteria for MRONJ investigation.",1.4
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.,"N. Yarom, C. Shapiro, D. Peterson, C. V. Van Poznak, Kari Bohlke, S. Ruggiero, C. Migliorati, Aliya A. Khan, A. Morrison, Holly Anderson, B. Murphy, D. Alston-Johnson, R. Mendes, B. Beadle, S. Jensen, D. Saunders",10.1200/JCO.19.01186,https://doi.org/10.1200/JCO.19.01186,Journal of Clinical Oncology,238,2019,no,"The abstract specifically focuses on cancer patients taking bone-modifying agents (BMAs), which explicitly violates the criterion requiring patients taking medication for osteoporosis, excluding cancer patients.",no,"The abstract does not document specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,maybe,The abstract mentions dentoalveolar surgery but does not specifically report MRONJ incidence following specific dental procedures.,no,"The paper is a guideline document based on a systematic review of literature, including 10 RCTs. While it includes appropriate study designs, this is a secondary research paper rather than a primary research study.",no,"While the paper discusses MRONJ management, it does not clearly document MRONJ incidence with specific follow-up periods.",maybe,The abstract does not explicitly specify age requirements.,maybe,The abstract does not specify the number of subjects in the studies reviewed.,no,The abstract discusses bone-modifying agents (BMAs) broadly and does not specify oral bisphosphonates exclusively. It appears to include various types of BMAs for cancer treatment.,yes,"The abstract does provide diagnostic standards for MRONJ, including exposed bone, duration >8 weeks, and no radiation therapy.",Exclude,"The systematic review guidelines for medication-related osteonecrosis of the jaw (MRONJ) focus on cancer patients taking bone-modifying agents, which directly conflicts with the specified screening criteria requiring osteoporosis patients. Multiple critical screening requirements were not met, including population indication, intervention type, and study design, rendering the document unsuitable for inclusion in the systematic review.",0.1
Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis.,"M. El-Rabbany, Adam Sgro, D. Lam, P. Shah, A. Azarpazhooh",10.1016/j.adaj.2017.04.002,https://doi.org/10.1016/j.adaj.2017.04.002,The Journal of the American Dental Association (1939),65,2017,maybe,"The abstract discusses MRONJ patients but does not specify whether they are exclusively osteoporosis patients or include cancer patients, so this criterion is unclear.",no,"The abstract does not document any time intervals between medication start, dental procedures, and MRONJ incidence, so this criterion is not met.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so this criterion is not met.",no,"The abstract does not specify any dental procedures leading to MRONJ, as it focuses on treatment of existing MRONJ rather than incidence after dental procedures, so this criterion is not met.",yes,"The abstract explicitly states it includes ""randomized controlled trials, nonrandomized controlled trials, and prospective cohort studies,"" which meets this criterion.",no,"While the study documents MRONJ outcomes, it focuses on treatment effectiveness rather than incidence after dental procedures, and the follow-up period is not specified, so this criterion is not met.",maybe,"The abstract does not specify the age of the subjects, so this criterion is unclear.",maybe,"The abstract mentions 13 studies with 76 participants in the surgical treatment analysis, but the individual study sizes are not specified, so this criterion is unclear.",maybe,"The abstract does not specify the type of bisphosphonate medication or whether it's oral or intravenous, only mentioning ""bisphosphonate drug holidays"" as a treatment option, so this criterion is unclear.",no,"The abstract does not mention any diagnostic standards for MRONJ, so this criterion is not met.",Exclude,"This meta-analysis focuses on MRONJ treatment effectiveness rather than incidence after dental procedures, failing to meet multiple critical screening criteria including specification of dental procedures, diagnostic standards, and patient population details. The study's primary aim of comparing treatment strategies diverges significantly from the required systematic review parameters, rendering it unsuitable for inclusion.",1.4
Medication-related Osteonecrosis of the Jaw: A Review,"Nouf A. AlDhalaan, Asma BaQais, Ahmad Al-Omar",10.7759/cureus.6944,https://doi.org/10.7759/cureus.6944,Cureus,75,2020,no,"While the abstract discusses osteoporosis patients, it also includes cancer patients and appears to be a general review rather than a specific study population, so it fails this criterion.",no,"No specific time intervals are mentioned, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While MRONJ is discussed, the abstract doesn't specifically report incidence following the required dental procedures, so it fails this criterion.",no,"This appears to be a review article, not one of the required study designs (RCT, cohort, or case-control), so it fails this criterion.",no,"As a review article, it doesn't document specific MRONJ incidence or follow-up periods, so it fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning is uncertain.",no,"No specific subject numbers are mentioned as this appears to be a review article rather than an original research study, so it fails this criterion.",no,"While bisphosphonates are discussed, the paper appears to cover multiple medication types including denosumab and antiangiogenic drugs, not just oral bisphosphonates, so it fails this criterion.",maybe,"The abstract mentions that diagnostic criteria were developed by AAOMS, but doesn't specify the exact criteria used, so it partially meets this criterion.",Exclude,"This review article fails multiple critical screening criteria, including lack of a specific study design, undefined population parameters, and absence of detailed outcome documentation. The paper discusses medication-related osteonecrosis of the jaw broadly but does not meet the systematic review's requirements for a focused research study with clear methodological standards. Consequently, the abstract does not qualify for inclusion based on the established screening criteria.",0.1
"Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies","Raed Alrowis, A. Aldawood, Mohammed F. Alotaibi, Essam Alnasser, Ibrahim M. Alsaif, Abdullah Aljaber, Z. Natto",10.1016/j.sdentj.2022.01.003,https://doi.org/10.1016/j.sdentj.2022.01.003,Saudi Dental Journal,34,2022,no,"The abstract mentions both osteoporosis and cancer patients, indicating a mixed population, which fails to meet the criterion requiring exclusive focus on osteoporosis patients.",maybe,"The abstract mentions timing considerations but doesn't document specific time intervals, so the criterion is only partially met.",no,"The abstract does not mention any control group, so no points were added for this criterion.",maybe,"While dental procedures are mentioned generally, the abstract doesn't specifically report MRONJ incidence following specific procedures, so the criterion is only partially met.",no,"This appears to be a literature review, not one of the required study designs (RCT, cohort, or case-control), so the criterion is not met.",no,"As a literature review, this paper doesn't directly document MRONJ incidence or follow-up periods, so the criterion is not met.",maybe,"The abstract does not explicitly specify age requirements, only mentioning ""people"" generally, so the reasoning is uncertain.",maybe,"The abstract does not mention any specific subject numbers, so the reasoning is uncertain.",maybe,"While bisphosphonates are mentioned, the abstract also discusses denosumab and doesn't specify oral administration exclusively, so the criterion is only partially met.",maybe,"The abstract mentions ""diagnostic criteria"" and ""diagnostic principles"" as topics covered, but doesn't specify them, so the criterion is only partially met.",Exclude,"This literature review fails to meet multiple critical screening criteria, including the requirement for an original research study design and a focused population of osteoporosis patients. The abstract lacks specific details about subject size, control groups, and precise MRONJ diagnostic standards, rendering it unsuitable for inclusion in the systematic review.",1.4
Medication-Related Osteonecrosis of the Jaw—2014 Update,"S. Ruggiero, T. Dodson, R. Goodday, T. Aghaloo, B. Mehrotra",-,-,-,1978,2014,no,"The abstract discusses both osteoporosis and cancer patients, and appears to be a mixed population review rather than focusing exclusively on osteoporosis patients.",no,"The abstract does not document specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, as this is a narrative review rather than an original research study.",no,"While the paper discusses various dental procedures, it's reviewing existing literature rather than reporting original outcomes.",no,"This is a narrative review, not one of the accepted study designs (RCT, cohort study, or case-control study).",no,"As a review paper, it does not have its own follow-up period or documented MRONJ incidence rates.",maybe,"The abstract does not explicitly specify age requirements, though it discusses adult conditions (osteoporosis).",no,"As a narrative review, this paper does not have its own subject group size.",no,"While the paper discusses bisphosphonates, it also covers other antiresorptive agents (denosumab) and includes both oral and parenteral administration.",no,"The abstract mentions various diagnostic techniques (CT, MRI, bone scanning) but does not specify a standard diagnostic criteria for MRONJ.",Exclude,"This narrative review fails multiple critical screening criteria, including lacking a control group, not focusing exclusively on osteoporosis patients, and not being an original research study with its own subject group. The paper discusses antiresorptive agents and osteonecrosis of the jaw across mixed populations, but does not meet the specific methodological requirements for inclusion in a systematic review. Consequently, the paper would be excluded based on the predefined screening criteria.",0.1
The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.,T. Dodson,10.1016/j.coms.2015.06.003,https://doi.org/10.1016/j.coms.2015.06.003,Oral and Maxillofacial Surgery Clinics of North America,92,2015,no,"The abstract discusses both cancer and osteoporosis patients, indicating a mixed population, which explicitly violates this criterion.",no,The abstract does not mention any time intervals related to MRONJ latency.,no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,The abstract does not specify any dental procedures.,no,"This appears to be a review article rather than a primary research study, which violates the study design criterion.",no,"While MRONJ incidence is discussed generally, there is no mention of the follow-up period or specific documentation of incidence after dental treatment.",maybe,"The abstract does not specify the age requirements for the study population, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention the sample size, so the reasoning for this criterion is uncertain.",no,"The abstract mentions both oral and intravenous bisphosphonates, and also includes denosumab (a non-bisphosphonate), which violates the criterion of only including oral bisphosphonates.",no,The abstract does not mention the diagnostic standards for MRONJ.,Exclude,"The abstract describes a review article that fails multiple critical screening criteria, including mixed patient populations, inclusion of non-oral bisphosphonates, and lack of specific dental procedure documentation. Multiple key requirements for systematic review inclusion are not met, rendering the study unsuitable for further analysis. The paper's broad scope and review nature disqualify it from meeting the precise methodological standards required.",0.1
Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.,"Yong-Dae Kwon, D. Kim",10.1016/j.oraloncology.2008.11.010,https://doi.org/10.1016/j.oraloncology.2008.11.010,Oral Oncology,63,2009,yes,"The study specifically focuses on osteoporotic patients taking anti-resorptive medications, excluding cancer patients, which meets the population indication requirement.",maybe,"The abstract mentions ""mean duration of BPs intake was 50.4 ± 19 months"" but does not clearly document the time interval between medication start and dental procedure, or between procedure and MRONJ incidence.",no,"The abstract does not mention a control group, which is a requirement for this criterion. Since this is a systematic review rather than a primary study, it does not include a control group of patients not taking anti-resorptive medications.",yes,"The abstract mentions extraction and dentoalveolar surgery as preceding events, which meets the requirement of reporting MRONJ incidence following specific dental procedures.",no,"This is a systematic review, not a primary study of any of the specified designs (randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study).",maybe,"While MRONJ incidence is documented, the follow-up period is not specified in the abstract.",yes,"The mean age of the subjects is 69.7 ± 5.2 years, which meets the requirement of being over 18 years old.",yes,"The review includes 680 MRONJ cases, which is well above the 100-subject requirement for the medication group.",maybe,"The abstract mentions that ""Oral route of administration was noted in 86.7% of the patients"" and specifically mentions Alendronate (a bisphosphonate). However, it's not clear if all cases were exclusively oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"A systematic review of medication-related osteonecrosis of the jaw in osteoporotic patients reveals significant insights into MRONJ development, with a mean patient age of 69.7 years and predominantly female subjects. While the study includes 680 MRONJ cases and documents dental procedures preceding MRONJ, it fails to meet several critical screening criteria, including lack of a control group, unclear diagnostic standards, and being a systematic review rather than a primary research study.",1.4
Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review,"T. Mücke, C. Krestan, D. Mitchell, J. Kirschke, A. Wutzl",10.1055/s-0036-1592367,https://doi.org/10.1055/s-0036-1592367,Seminars in Musculoskeletal Radiology,66,2016,no,"The abstract discusses both cancer patients and osteoporosis patients, which violates the criterion of the research specifying that its subject is chosen from patients taking medication for osteoporosis, excluding cancer patients, and excluding research with mixed populations.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence, so no points are added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,"The abstract mentions dental procedures and implants, but does not report specific MRONJ incidence following these procedures, so the reasoning for this criterion is that it fails.",no,"This appears to be a review article rather than a primary research study, as it discusses general information about MRONJ and its management, which violates the criterion of the study design being a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",no,"While the abstract discusses MRONJ, it does not present specific incidence data or follow-up periods, so the reasoning for this criterion is that it fails.",maybe,"The abstract does not explicitly state the age of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention the number of subjects studied, so the reasoning for this criterion is uncertain.",no,"The abstract mentions both bisphosphonates and denosumab, not exclusively oral bisphosphonates, which violates the criterion of the study only including subjects that are taking oral bisphosphonate medication for osteoporosis treatment.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so the reasoning for this criterion is that it fails.",Exclude,"The abstract fails multiple critical screening criteria, including having a mixed patient population, not exclusively studying oral bisphosphonates, and lacking a primary research design. Key methodological requirements such as specific diagnostic standards, precise outcome documentation, and clear subject selection parameters are not met. Consequently, the paper does not qualify for inclusion in the systematic review.",0.1
An Update on Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis,"B. Bennett, H. Tahir, K. Solanki, N. Ali",10.33590/emjrheumatol/10300262,https://doi.org/10.33590/emjrheumatol/10300262,EMJ Rheumatology,2,2023,yes,The paper explicitly focuses on the osteoporotic cohort and excludes cancer patients.,no,"The abstract does not mention the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,maybe,The abstract mentions tooth extraction but does not report specific MRONJ incidence rates following procedures.,no,"This appears to be a review paper rather than a primary research study, as indicated by phrases like ""aims to review recent findings"" and ""This paper focuses exclusively on..."".",no,"While the paper discusses MRONJ, it does not appear to document specific incidence rates or follow-up periods.",maybe,"While the context suggests an adult population (osteoporosis patients), the age of the subjects is not explicitly stated.",no,The abstract does not mention the sample size of the study.,maybe,"The abstract mentions bisphosphonates and denosumab, but does not specify if it's exclusively oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The abstract represents a review paper that fails to meet multiple critical screening criteria, including lack of a primary research design, absence of specific diagnostic standards, and no documentation of sample size or MRONJ incidence rates. While focusing on osteoporotic patients and medication-related jaw necrosis, the text does not provide the quantitative and methodological details required by the screening protocol. Consequently, the paper would be excluded from further analysis based on these comprehensive screening requirements.",1.4
What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.,"Suad Aljohani, Riham Fliefel, J. Ihbe, J. Kühnisch, M. Ehrenfeld, S. Otto",10.1016/j.jcms.2017.05.028,https://doi.org/10.1016/j.jcms.2017.05.028,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,96,2017,yes,"The study specifically focuses on osteoporosis patients taking anti-resorptive medications, excluding cancer patients, which meets the population indication requirement.",no,"The abstract mentions ""mean duration of BPs intake was 50.4 ± 19 months"" but does not clearly document the time interval between medication start and dental procedure, or between procedure and MRONJ incidence.",no,"The abstract does not mention a control group, which is a requirement for this criterion. Since this is a systematic review rather than a primary study, it does not include a control group of patients not taking anti-resorptive medications.",yes,"The abstract mentions that ""Extraction was the most frequently preceding event followed by dentoalveolar surgery,"" meeting the requirement of reporting MRONJ incidence following specific dental procedures.",no,"This is a systematic review, not a primary study of any of the specified designs (randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study), which is a critical failure.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified in the abstract.",yes,"The mean age of the subjects is reported as 69.7 ± 5.2 years, which meets the requirement of being over 18 years old.",yes,"The review includes 680 MRONJ cases, which exceeds the 100-subject requirement for the medication group.",maybe,"The abstract mentions that ""Oral route of administration was noted in 86.7% of the patients"" and specifically mentions Alendronate (a bisphosphonate). However, it's not clear if all cases were exclusively oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"A systematic review of medication-related osteonecrosis of the jaw in osteoporosis patients reveals significant insights into MRONJ development, with a mean patient age of 69.7 years and predominantly female subjects. While the study includes 680 MRONJ cases and documents dental procedures like extraction, it fails to meet several critical screening criteria, including lack of a control group, unspecified diagnostic standards, and absence of a primary study design.",1.4
"Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.","O. Nicolatou‐Galitis, M. Schiødt, R. Mendes, C. Ripamonti, S. Hope, L. Drudge-Coates, D. Niepel, T. Van den Wyngaert",10.1016/j.oooo.2018.09.008,https://doi.org/10.1016/j.oooo.2018.09.008,"Oral surgery, oral medicine, oral pathology and oral radiology",235,2019,no,"The abstract mentions both osteoporosis and cancer patients, indicating a mixed population, which explicitly fails this criterion.",no,"No mention of time intervals between medication start, dental procedures, and MRONJ incidence, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",maybe,"The abstract mentions dental procedures generally but doesn't specifically report MRONJ incidence following specific procedures, so this criterion is only partially met.",no,"This appears to be a review article rather than a primary research study, which fails this criterion.",maybe,"While MRONJ is discussed, the abstract doesn't indicate specific follow-up periods or incidence rates, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",maybe,"No specific subject numbers are mentioned in the abstract, so the reasoning for this criterion is uncertain.",maybe,"While bisphosphonates are mentioned, the abstract also discusses denosumab (a non-bisphosphonate) and doesn't specify oral administration, so this criterion is only partially met.",maybe,"While the abstract mentions diagnosis, it doesn't specify diagnostic standards, so the reasoning for this criterion is uncertain.",Exclude,"The abstract represents a review article discussing medication-related osteonecrosis of the jaw, which fundamentally fails key screening criteria by including a mixed patient population and not being a primary research study. Critical exclusion factors include the lack of a control group, unspecified subject demographics, and absence of specific diagnostic standards or follow-up periods. The paper does not meet the required methodological standards for systematic review inclusion.",0.1
"Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.","S. Otto, C. Pautke, T. Van den Wyngaert, D. Niepel, M. Schiødt",10.1016/j.ctrv.2018.06.007,https://doi.org/10.1016/j.ctrv.2018.06.007,Cancer Treatment Reviews,219,2018,no,"The abstract focuses heavily on cancer patients and bone metastases, which is explicitly excluded in the criteria. It mentions ""skeletal health of patients"" but primarily in the context of cancer treatment, so the paper fails this criterion.",no,"The abstract does not document specific time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"While dental procedures are mentioned generally (""avoiding bone trauma""), specific procedures are not detailed in relation to MRONJ incidence, so the paper fails this criterion.",no,"This appears to be a ""critical review"" based on ""best-evidence review of currently available literature,"" not an original research study with any of the required designs, so the paper fails this criterion.",no,"While MRONJ outcomes are discussed, there is no mention of specific follow-up periods or incidence rates, so the paper fails this criterion.",maybe,"The abstract does not explicitly specify age requirements, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention sample size, and it actually notes ""a lack of large-scale, prospective clinical studies,"" so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, they are discussed primarily in the context of cancer treatment and high doses. The abstract also discusses denosumab, which is not a bisphosphonate, so the paper fails this criterion.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so the paper fails this criterion.",Exclude,"The abstract describes a review focused on cancer patients taking high-dose medications, which fundamentally conflicts with the screening criteria requiring a study of osteoporosis patients. Multiple critical screening requirements are not met, including study design, population indication, intervention type, and diagnostic standards. The paper lacks the specific methodological elements necessary for inclusion in the systematic review.",0.1
Medication-Related Osteonecrosis of the Jaw: An Overview,"M. Blašković, D. Blašković",10.5772/INTECHOPEN.86241,https://doi.org/10.5772/INTECHOPEN.86241,Maxillofacial Surgery and Craniofacial Deformity - Practices and Updates,1,2019,no,"The abstract discusses both cancer patients and osteoporosis patients, but does not focus exclusively on osteoporosis patients. This is a significant issue as it appears to be a mixed population study, which fails this criterion.",no,"No information about time intervals is provided, so no points were added for this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"The abstract mentions tooth extraction as a causative factor, but does not appear to be reporting specific incidence rates following procedures in a study population, so the criterion is only partially met.",no,"This appears to be a review article rather than a primary research study with any of the specified designs, so the criterion is not met.",no,"While MRONJ incidence is discussed, this appears to be a review of literature rather than documentation of outcomes in a specific study population, so the criterion is not met.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning is uncertain.",maybe,"The abstract mentions ""15,000 cases"" but this appears to be a review of literature rather than a primary study with a specific cohort size, so the reasoning is uncertain.",maybe,"While bisphosphonates are mentioned, the abstract also discusses other medications (denosumab, bevacizumab) and does not specify oral administration, so the criterion is only partially met.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so the criterion is not met.",Exclude,"The abstract fails to meet multiple critical screening criteria, including study design, population specificity, and diagnostic standards for MRONJ. It appears to be a literature review rather than a primary research study, with mixed patient populations and insufficient details about intervention, procedures, and outcomes. Consequently, the paper does not align with the required methodological and population-specific screening requirements.",1.4
Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS,"A. Anastasilakis, J. Pepe, N. Napoli, A. Palermo, C. Magopoulos, Aliya A. Khan, M. C. Zillikens, J. Body",10.1210/clinem/dgab888,https://doi.org/10.1210/clinem/dgab888,Journal of Clinical Endocrinology and Metabolism,46,2021,no,"The abstract discusses both osteoporosis patients and cancer patients with bone metastases, which is a mixed population study that violates the criterion.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"While MRONJ is discussed, the abstract does not specifically mention any of the required dental procedures.",no,"This appears to be a literature review rather than a primary research study, which fails to meet the study design criteria.",no,"While MRONJ incidence is discussed generally, the abstract does not specify follow-up periods or detailed documentation of MRONJ cases.",maybe,"The abstract does not explicitly state the age of subjects, though it implies an adult population by discussing osteoporosis and cancer patients.",maybe,The abstract does not mention the number of subjects studied.,no,"The abstract discusses ""antiresorptive therapy"" broadly but does not specify oral bisphosphonates exclusively, and it appears to cover multiple types of antiresorptive agents.",no,The abstract mentions ONJ/MRONJ but does not specify diagnostic standards.,Exclude,"The literature review fails multiple critical screening criteria, including mixed patient populations, lack of specific intervention details, and absence of primary research design. Key exclusion factors include non-specific antiresorptive therapy discussion, mixed osteoporosis and cancer patient populations, and no documentation of specific dental procedures or diagnostic standards. The paper does not meet the required methodological and population-specific screening requirements for inclusion.",0.1
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs.,"J. Hellstein, R. Adler, B. Edwards, P. Jacobsen, J. Kalmar, S. Koka, C. Migliorati, H. Ristic",10.14219/JADA.ARCHIVE.2011.0108,https://doi.org/10.14219/JADA.ARCHIVE.2011.0108,The Journal of the American Dental Association (1939),350,2011,yes,"The abstract focuses on patients with ""low bone mass receiving treatment with antiresorptive agents"" and specifically mentions osteoporosis, meeting this criterion.",no,The abstract does not document specific time intervals.,no,"The abstract does not mention a control group, as this is a narrative review rather than an original research study.",no,"The abstract mentions various dental procedures (implant placement, oral surgery, etc.) but as a review rather than reporting original outcomes.",no,"This is explicitly stated to be a ""narrative review"" which is not one of the accepted study designs.",no,"While the paper mentions ARONJ prevalence (0.10%), it's reporting from literature review rather than original follow-up data.",maybe,"The abstract does not specify age requirements, though it likely includes adults given the focus on osteoporosis.",no,"As a narrative review, this paper does not have its own subject group size.",maybe,"The abstract mentions bisphosphonates specifically, but also discusses antiresorptive agents more broadly, making it unclear if it's limited to oral bisphosphonates.",no,"While the paper discusses ARONJ, it specifically states ""No validated diagnostic technique exists,"" suggesting it doesn't establish its own diagnostic standards.",Exclude,"This narrative review fails to meet multiple critical screening criteria, primarily because it is not an original research study with a defined patient population, control group, or direct outcome measurements. The paper lacks the required methodological elements such as specific diagnostic standards, intervention details, and original data collection, rendering it ineligible for inclusion in a systematic review focused on primary research.",0.1
Risk factors for medication-related osteonecrosis of the jaws: A systematic review.,"K. McGowan, T. McGowan, Saso Ivanovski",10.1111/odi.12708,https://doi.org/10.1111/odi.12708,Oral Diseases,169,2018,no,"The abstract does not specifically focus on osteoporosis patients. It appears to be a broader review of MRONJ risk factors across various systemic diseases (mentions ""39 different systemic diseases"").",no,"No information about time intervals between medication start, dental procedures, and MRONJ incidence is provided.",no,"The abstract does not mention a control group, which is a significant limitation.",no,"While dental procedures are mentioned as risk factors, the abstract doesn't specifically focus on MRONJ incidence following specific dental procedures.",no,"This is a systematic review/meta-analysis, not a primary research study of the types specified in the criteria.",no,"While MRONJ is discussed, the abstract doesn't specify follow-up periods or clearly document MRONJ incidence after dental treatment.",no,"The abstract does not specify age requirements, only mentioning ""human studies.""",no,"While the study includes 4106 patients with MRONJ, this is a review of multiple studies rather than a primary study with its own subject group.",no,The abstract does not specify oral bisphosphonates as the intervention. It appears to be a broader review of MRONJ risk factors.,no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This systematic review of medication-related osteonecrosis of the jaw (MRONJ) fails to meet multiple critical screening criteria, including specific population requirements, intervention type, and study design. The broad scope of the review, which examines 39 different systemic diseases and multiple risk factors, does not align with the targeted research parameters for a focused investigation of MRONJ in osteoporosis patients. Consequently, the study does not qualify for inclusion based on the predefined screening criteria.",1.4
Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw,"Mong-Hun Kang, Dong-Keon Lee, Chang-Woo Kim, In-Seok Song, S. Jun",10.5125/jkaoms.2018.44.5.225,https://doi.org/10.5125/jkaoms.2018.44.5.225,Journal of the Korean Association of Oral and Maxillofacial Surgeons,24,2018,yes,"The study clearly focuses on patients taking bone resorption inhibitors (bisphosphonates) for osteoporosis, with no mention of cancer patients or mixed populations, so this criterion is met.",no,"The abstract mentions the mean duration of medication use (61.1±42.9 months) but does not clearly document the time interval between medication start and dental procedure, or between dental procedure and MRONJ incidence, so this criterion is not met.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study clearly reports MRONJ incidence following dental procedures, specifically mentioning tooth extraction (69.6%) as the most common cause, so this criterion is met.",yes,"This is a retrospective chart review, which qualifies as a retrospective cohort study, so this criterion is met.",maybe,"While the study documents MRONJ incidence and treatment outcomes, the follow-up period is not explicitly stated, creating uncertainty about meeting the 6-month follow-up requirement.",maybe,"While not explicitly stated, the reasoning suggests that since this is a study of patients with MRONJ taking bisphosphonates, it's very likely these are adult patients over 18, but this is an assumption.",no,"The study only includes 51 patients total, which is well below the required 100 subjects for the medication group, so this is a critical failure.",no,"The study includes both oral (88.9%) and intravenous (11.1%) bisphosphonates, so while most patients took oral bisphosphonates, the inclusion of IV patients means this criterion is not fully met.",no,"The abstract does not explicitly mention the diagnostic standards used for MRONJ, which is a significant omission.",Include,"The study fails to meet critical screening criteria, particularly the required sample size of 100 subjects, with only 51 patients included. Mixed intervention types, lack of a control group, and absence of clear diagnostic standards further compromise its eligibility. Despite addressing some criteria like study design and population indication, the significant methodological limitations prevent the study from meeting the comprehensive screening requirements.",2.5
Medication-related osteonecrosis of the jaw: A literature review.,"S. Kuroshima, Muneteru Sasaki, T. Sawase",10.1016/j.job.2019.03.005,https://doi.org/10.1016/j.job.2019.03.005,Journal of Oral Biosciences,84,2019,maybe,"The abstract discusses patients taking antiresorptive agents including bisphosphonates, but also includes other medications (denosumab and angiogenesis inhibitors) and does not specifically focus on osteoporosis patients.",no,"The abstract does not document specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, as this is a literature review rather than an original research study.",maybe,"The abstract mentions dental implant therapy and peri-implantitis as risk factors, but does not report specific MRONJ incidence following procedures.",no,"This is a literature review, not one of the accepted study designs (RCT, cohort study, or case-control study).",no,"As a literature review, it does not have its own follow-up period or documented MRONJ incidence.",maybe,"The abstract mentions ""aging population"" but does not specify an age cutoff of 18 years or older.",no,"As a literature review, this paper does not have its own subject group size.",maybe,"While bisphosphonates are discussed, the paper also covers other medications and does not specify oral administration exclusively.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This literature review fails to meet multiple screening criteria, primarily because it is not an original research study with a defined patient population, intervention, and outcome measurement. The paper discusses medication-related osteonecrosis of the jaw but lacks the specific methodological requirements such as a control group, precise diagnostic standards, and documented MRONJ incidence following dental procedures. Consequently, it does not qualify for inclusion based on the established screening criteria.",0.1
Interventions for managing medication-related osteonecrosis of the jaw.,"Natalie H Beth-Tasdogan, B. Mayer, H. Hussein, O. Zolk, Jens-Uwe Peter",10.1002/14651858.cd012432,https://doi.org/10.1002/14651858.cd012432,Cochrane Database of Systematic Reviews,4,2022,no,"The abstract discusses both cancer and osteoporosis patients, and appears to mix these populations in its analysis, which fails the criterion requiring exclusive focus on osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract mentions RCTs comparing interventions with ""no treatment, placebo, or an active control,"" but does not specifically mention a control group of patients not taking anti-resorptive medications.",yes,"The abstract discusses dental procedures including extractions and dentoalveolar surgery, and their relationship to MRONJ.",yes,"The paper is a systematic review of RCTs, which meets this criterion.",maybe,"While the abstract discusses MRONJ incidence, it does not specify the follow-up period length.",maybe,"The abstract does not explicitly state the age of subjects, so it is uncertain whether the population meets the criterion of being over 18 years old.",maybe,"The abstract mentions 13 RCTs with 1668 total participants, but does not specify the size of individual medication groups, so it is uncertain whether any single group had over 100 subjects.",no,"The abstract discusses both oral and intravenous bisphosphonates, as well as other medications like denosumab, and does not focus exclusively on oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet several critical screening criteria, including a mixed patient population of cancer and osteoporosis patients, lack of exclusive focus on oral bisphosphonates, and absence of a clear control group. Multiple criteria remain uncertain or unmet, particularly regarding diagnostic standards, subject age, and medication group size. The study's broad scope and mixed population significantly compromise its alignment with the specified screening requirements.",1.4
Prediction of medication-related osteonecrosis of the jaw (MRONJ) using automated machine learning in patients with osteoporosis associated with dental extraction and implantation: a retrospective study,"Dahui Kwack, S. Park",10.5125/jkaoms.2023.49.3.135,https://doi.org/10.5125/jkaoms.2023.49.3.135,Journal of the Korean Association of Oral and Maxillofacial Surgeons,6,2023,yes,"The study specifically focuses on patients with osteoporosis treated with antiresorptive therapy, excluding cancer patients.",no,"The abstract mentions ""duration of medication"" as a variable but doesn't explicitly document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study includes both tooth extraction and implantation, which are among the specified procedures.",yes,"This is a retrospective chart review, which meets the criteria as a retrospective cohort study.",maybe,"While the study documents MRONJ occurrence, the follow-up period is not specified in the abstract.",yes,"The study includes patients ≥55 years, which meets the >18 years criterion.",yes,"The study includes 340 patients, which exceeds the minimum requirement of 100 subjects.",maybe,"The abstract mentions ""antiresorptive therapy"" but doesn't specify if it's oral bisphosphonate exclusively, creating some uncertainty.",no,The abstract doesn't explicitly mention the diagnostic standards used for MRONJ.,Include,"A retrospective study of 340 osteoporosis patients undergoing dental procedures demonstrates potential for machine learning in predicting medication-related osteonecrosis of the jaw. While meeting several key screening criteria like appropriate population age and procedure types, the study lacks a control group, clear diagnostic standards, and explicit documentation of medication latency. These limitations create uncertainty about the study's comprehensive methodological rigor.",3.2
Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer.,"Ie-Wen Sim, K. Sanders, G. Borromeo, J. Seymour, P. Ebeling",10.1210/jc.2015-1794,https://doi.org/10.1210/jc.2015-1794,Journal of Clinical Endocrinology and Metabolism,52,2015,no,"The study specifically focuses on cancer patients receiving antiresorptive therapy, which explicitly violates the criterion excluding cancer patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The study does not explicitly mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,The abstract does not specify which dental procedures were involved in the MRONJ cases.,yes,"The study appears to be a retrospective cohort study, which meets the criteria for study design.",maybe,"The study reports MRONJ incidence and appears to have a follow-up period (2003-2013), but the specific follow-up period for individual patients is not clear.",maybe,"The abstract does not explicitly state the age of the subjects, so the age requirement is unclear.",yes,"The study includes 1,243 patients, which meets the requirement of over 100 subjects in the medication group.",maybe,"The abstract only mentions ""antiresorptive drug therapy"" without specifying oral bisphosphonates, so the intervention type is unclear.",maybe,"While the study mentions ""confirmed cases of MRONJ,"" it does not explicitly state the diagnostic standards used.",Exclude,"The study focuses on cancer patients receiving antiresorptive therapy, which directly violates the screening criteria excluding cancer populations. Multiple key screening requirements remain unclear, including specific medication type, diagnostic standards, and dental procedure details. The research fundamentally fails to meet critical inclusion criteria, particularly the population specification.",1.4
Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.,"S. Kuroshima, Muneteru Sasaki, H. Murata, T. Sawase",10.1111/ger.12416,https://doi.org/10.1111/ger.12416,Gerodontology,18,2019,no,The study does not involve human patients taking medication for osteoporosis. It's an animal study looking at pathology and pathogenesis.,no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group of patients not taking anti-resorptive medications. This is a rodent study, not a human study.",no,The abstract does not mention any dental procedures or MRONJ incidence following such procedures.,no,"This is a systematic review and meta-analysis of animal studies, not one of the required study designs (RCT, prospective cohort, retrospective cohort, or case-control).",no,"While the study documents findings, it's not documenting MRONJ incidence in human patients after dental treatment with a follow-up period.",no,"The study is conducted on rodents, not human subjects over 18 years old. This fails a critical criterion.",no,"The study includes 10 articles in its meta-analysis, but these are rodent studies, not human subjects. This fails the criterion for 100+ human subjects.",no,"While the study does look at bisphosphonates (specifically zoledronic acid), it's in an animal model, not human patients taking oral bisphosphonates for osteoporosis.",no,"The study does mention pathological findings for MRONJ-like lesions, but these are in rodents, not human diagnostic standards.",Exclude,"This rodent study fundamentally fails multiple screening criteria by not involving human subjects, lacking a control group, and not meeting population, intervention, and outcome requirements. The research focuses on pathological mechanisms in animal models, which diverges significantly from the specified screening criteria for human clinical studies on medication-related osteonecrosis of the jaw.",0.1
Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.,"Makoto Kajizono, Hikaru Sada, Y. Sugiura, Y. Soga, Y. Kitamura, J. Matsuoka, T. Sendo",10.1248/bpb.b15-00385,https://doi.org/10.1248/bpb.b15-00385,Biological and Pharmaceutical Bulletin,62,2015,no,"The study specifically focuses on cancer patients, not osteoporosis patients, which violates the inclusion criteria.",no,"The abstract mentions duration of therapy but doesn't document the specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"While the study mentions ""periodical dentistry maintenance,"" it doesn't specifically report MRONJ incidence following the required dental procedures.",yes,"While not explicitly stated, this appears to be a retrospective cohort study based on the methodology described.",maybe,"While MRONJ incidence is documented (8.4%), the follow-up period is not explicitly stated.",yes,"The abstract does not explicitly state the age of subjects, but since they are cancer patients, it can be reasonably assumed that they are adults.",yes,"The study includes 155 patients, which exceeds the minimum requirement of 100 subjects.",no,"The study includes both zoledronic acid (intravenous bisphosphonate) and denosumab (non-bisphosphonate), which violates the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients receiving zoledronic acid and denosumab, which deviates from the required osteoporosis patient population and oral bisphosphonate intervention. Multiple screening criteria were not met, including diagnostic standards, specific dental procedures, and intervention type, rendering the study ineligible for inclusion in the systematic review.",0.1
Emerging antiresorptive medications and their potential implications for dental surgeries.,"A. Aminoshariae, M. Donaldson, M. Horan, Scott A. Mackey, J. Kulild, D. Baur",10.1016/j.adaj.2021.12.008,https://doi.org/10.1016/j.adaj.2021.12.008,The Journal of the American Dental Association (1939),4,2022,no,"While the abstract discusses both cancer and osteoporosis patients, it is not an original research study with a specific patient population.",no,The abstract does not document specific time intervals.,no,"The abstract does not mention any control group, as this is a review article rather than an original research study.",no,"While dental procedures are mentioned, this is in the context of reviewing existing literature rather than reporting original outcomes.",no,"This is a literature review, not one of the accepted study designs (RCT, cohort, or case-control).",no,"As a review article, it does not have its own follow-up period or documented outcomes.",no,The abstract does not specify any age requirements for the subjects.,no,"As a review article, it does not have its own subject group.",no,"The abstract discusses various antiresorptive medications including oral bisphosphonates, but as a review rather than an original study.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This literature review fails to meet the screening criteria for an original research study, lacking a defined patient population, control group, specific intervention details, and original outcome data. The abstract provides a comprehensive overview of medication-related osteonecrosis of the jaw risks but does not constitute a primary research investigation with the required methodological elements. Consequently, it does not qualify for inclusion based on the established screening criteria.",0.1
Medication-related osteonecrosis of the jaw after tooth extraction in patients receiving pharmaceutical treatment for osteoporosis: A retrospective cohort study,"Keisuke Seki, T. Kaneko, Atsushi Kamimoto, M. Wada, Yoshimasa Takeuchi, Mika Furuchi, T. Iinuma",10.1016/j.jds.2022.03.014,https://doi.org/10.1016/j.jds.2022.03.014,Journal of Dental Sciences,11,2022,yes,"The study clearly focuses on patients taking medication for osteoporosis, excluding cancer patients, and the population is not mixed.",maybe,"The study documents the duration of medication use (40.4 months) and drug holiday (6.9 months), but does not clearly document the time from dental procedure to MRONJ incidence.",no,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study clearly reports MRONJ incidence following tooth extraction, which is one of the specified procedures.",yes,"The study is described as a retrospective observation, which meets the criteria as a retrospective cohort study.",maybe,"The study reports MRONJ incidence after dental treatment, but the follow-up period is not specified.",maybe,"While the age of the subjects is not explicitly stated, the context suggests these are adult patients with osteoporosis, but this is an assumption.",no,"The study only includes 40 patients (70 teeth) in the medication group, which is well below the required 100 subjects.",no,"The study includes both oral and injectable bisphosphonates, as well as denosumab (a non-bisphosphonate), which violates the requirement for only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study fails to meet critical screening criteria, particularly the required sample size of 100 subjects, with only 40 patients included. Additionally, the research incorporates non-bisphosphonate medications and injectable treatments, which deviate from the specified intervention type. Multiple other screening criteria were either partially met or remained uncertain, further compromising the study's alignment with the predefined requirements.",2.5
Incidence and risk factors for medication‐related osteonecrosis after tooth extraction in cancer patients—A systematic review,"Nurda Schwech, J. Nilsson, P. Gabre",10.1002/cre2.698,https://doi.org/10.1002/cre2.698,Clinical and Experimental Dental Research,20,2022,no,"The abstract specifically mentions ""cancer patients,"" which explicitly violates the criterion that excludes cancer patients. This is a critical failure.",no,"The abstract does not mention documenting the time intervals between the start of medication, dental procedure, and MRONJ incidence, so no points are added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,"The abstract does mention tooth extractions as the dental procedure, which meets this criterion.",no,"This is a systematic review, not a primary research study of the required types, which is a critical failure.",maybe,"While MRONJ incidence is mentioned, the follow-up period is not specified, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention the sample size of the study, so the reasoning for this criterion is uncertain.",no,"The abstract mentions ""high-dose bisphosphonate,"" but also includes denosumab (a non-bisphosphonate), which partially violates the criterion requiring only oral bisphosphonates.",maybe,"The abstract does not mention the diagnostic standards for MRONJ, so the reasoning for this criterion is uncertain.",Exclude,"The systematic review focuses on cancer patients taking high-dose bisphosphonates and denosumab, which critically fails multiple screening criteria by including a mixed population and non-bisphosphonate medications. Key exclusionary factors include the study's systematic review design, cancer patient population, and inclusion of non-bisphosphonate treatments, rendering the abstract non-compliant with the specified screening requirements.",0.1
Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis.,"Z. Guo, W. Cui, L. Que, C. Li, Xiu-fa Tang, J. Liu",10.1016/j.ijom.2019.07.016,https://doi.org/10.1016/j.ijom.2019.07.016,International Journal of Oral & Maxillofacial Surgery,20,2020,no,"The abstract mentions patients ""treated with bisphosphonates"" but also includes multiple myeloma patients, which violates the exclusion criterion for cancer patients. This is identified as a critical failure.",no,"There is no mention of time intervals between medication start, dental procedures, and MRONJ incidence, so this criterion is not met.",maybe,"The abstract mentions ""MRONJ and non-MRONJ groups"" but does not explicitly state if there is a control group of patients not taking anti-resorptive medications. The reasoning is unclear on whether this criterion is met.",no,"The abstract does not mention any specific dental procedures, so this criterion is not met.",no,"This is a systematic review, not a primary research study of the required designs, which is identified as a critical failure.",maybe,"While MRONJ incidence is discussed, there is no mention of the follow-up period, so the reasoning is unclear on whether this criterion is met.",maybe,"The abstract does not specify the age range of the participants, so the reasoning is unclear on whether this criterion is met.",yes,"The study includes 1515 participants total, which exceeds the 100-subject requirement, so this criterion is met.",maybe,"While bisphosphonates are mentioned, the abstract does not specify if they are oral or intravenous, so the reasoning is unclear on whether this criterion is met.",no,"The abstract does not mention diagnostic standards for MRONJ, so this criterion is not met.",Exclude,"This systematic review fails multiple critical screening criteria, including inclusion of cancer patients and lack of specification of dental procedures. The study design does not match required research types, and key methodological details such as diagnostic standards and medication route are not clearly defined. Consequently, the paper does not meet the essential screening requirements for inclusion.",0.1
Proposal for a preventive protocol for medication-related osteonecrosis of the jaw,"M. M. Romero-Ruiz, Marta Romero-Serrano, Ascensión Serrano-González, M. Serrera-Figallo, J. Gutierrez-Perez, D. Torres-Lagares",10.4317/medoral.24197,https://doi.org/10.4317/medoral.24197,Medicina Oral,18,2020,no,"While the paper discusses both osteoporosis and cancer patients, it appears to be developing protocols for both populations rather than studying a specific patient group.",no,The paper does not document time intervals for medication to procedure to MRONJ.,no,"The abstract does not mention any control group, as this is a protocol development paper rather than an interventional study.",no,"While dental procedures are mentioned, this paper is not reporting MRONJ incidence after procedures - it's developing preventive protocols.",no,"This is a literature review following PRISMA guidelines, not one of the required study designs (RCT, cohort, or case-control).",no,The paper does not document MRONJ incidence or follow-up periods.,no,The abstract does not specify any age requirements for the population.,no,This is not an interventional study with subjects - it's a literature review to develop protocols.,no,"While bisphosphonates are mentioned, this paper is not studying patients taking oral bisphosphonates - it's developing preventive protocols.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This literature review protocol development paper fails to meet the systematic review's screening criteria, as it does not represent an interventional study with a defined patient population, control group, or documented MRONJ incidence. The abstract describes a methodological approach to developing preventive protocols rather than presenting original research with measurable outcomes related to medication-related osteonecrosis of the jaw.",0.1
Medication-Related Osteonecrosis of the Jaw,"K. Yamagata, F. Uchida, N. Kanno, T. Yanagawa, H. Bukawa",10.5772/67980,https://doi.org/10.5772/67980,-,60,2017,no,"The abstract explicitly mentions that it covers both cancer patients and osteoporosis patients, which violates the requirement for a pure osteoporosis population. This is a critical failure.",no,"No specific time intervals are mentioned, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",maybe,"The abstract mentions extraction sockets and oral surgical procedures, but doesn't report specific MRONJ incidence rates, so this criterion is partially met.",no,This appears to be a review article rather than any of the required study designs. The abstract discusses general concepts and treatment goals rather than presenting original research. This is a critical failure.,maybe,"While MRONJ is discussed, there's no mention of follow-up periods or specific incidence documentation, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any sample size, so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, the abstract also discusses denosumab and other antiangiogenic inhibitors, which violates the requirement for only oral bisphosphonates. This is a critical failure.",maybe,"While MRONJ is discussed, specific diagnostic standards are not mentioned, so the reasoning for this criterion is uncertain.",Exclude,"The abstract fails critical screening criteria by including mixed patient populations (cancer and osteoporosis), discussing multiple medication types beyond oral bisphosphonates, and presenting a review-style format rather than an original research design. Multiple key requirements are not met, including specific diagnostic standards, clear outcome documentation, and a defined control group, rendering the study unsuitable for systematic review inclusion.",0.1
The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis,"Ali Aboalela, F. Farook, A. Alqahtani, Mandlin Almousa, R. Alanazi, Duaa Almohammadi",10.7759/cureus.30485,https://doi.org/10.7759/cureus.30485,Cureus,9,2022,maybe,"The study focuses on patients taking antiresorptive medications, but does not explicitly exclude cancer patients or specify that the population is limited to osteoporosis patients only.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",yes,"The study included a control group of patients not taking anti-resorptive medications, which adds 0.2 points to the score.",yes,"The study specifically looks at MRONJ incidence following ""dentoalveolar surgery or tooth extractions.""",yes,"This is a systematic review that included ""observational and interventional studies"" and excluded case reports/series, which meets the study design criterion.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",maybe,"The abstract does not specify the age range of the participants, so the age criterion is unclear.",yes,"The study includes 6808 total subjects (4847 cases + 1961 controls), which is well above the 100-subject requirement.",maybe,"The abstract only mentions ""antiresorptive (AR) therapy"" without specifying if it's oral bisphosphonates exclusively.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Include,"A systematic review examining medication-related osteonecrosis of the jaw (MRONJ) in patients undergoing dental procedures, with a large sample size of 6808 subjects and a control group. While meeting some screening criteria like procedure type and subject size, the study lacks clarity on key elements such as patient age, specific medication type, and diagnostic standards for MRONJ. The research provides insights into antiresorptive therapy and dental procedures but falls short of fully satisfying all predefined screening requirements.",2.7
Factors associated with osteonecrosis of the jaw among bisphosphonate users.,"L. Hess, J. Jeter, M. Benham-Hutchins, D. Alberts",10.1016/j.amjmed.2008.01.047,https://doi.org/10.1016/j.amjmed.2008.01.047,American Journal of Medicine,139,2008,yes,"The study specifically focused on patients taking bisphosphonates for non-cancer indications, with 85 osteoporosis patients, which meets the criterion.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"The abstract mentions that 88.9% had a dental procedure before MRONJ onset, but doesn't specify which procedures.",no,"This appears to be a systematic review of case reports, which does not meet the acceptable study design criteria.",no,"While MRONJ incidence is documented, the follow-up period is not specified.",yes,"The mean age of the subjects was 69.4 years, which meets the requirement of being over 18 years old.",no,"The study included 99 cases total, with 85 osteoporosis patients, which falls below the required 100 subjects for the medication group.",maybe,"The abstract mentions that 83.3% were receiving oral bisphosphonates, which partially meets the criterion, but there's some uncertainty about the exact medications.",no,The abstract does not explicitly mention diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet critical screening criteria, including insufficient sample size, inappropriate study design, and lack of a control group. While the research provides insights into bisphosphonate-related osteonecrosis of the jaw, it does not satisfy the methodological requirements for comprehensive analysis. Multiple key screening elements were not addressed, rendering the study non-compliant with the specified research standards.",1.4
"Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.","B. Gális, J. Zajko, D. Hirjak, L. Vanko, I. Kupcová, J. Jurkemík, P. Gengelova, K. Mikušková, K. Halmova, M. Riznic, L. Czako",10.4149/BLL_2017_137,https://doi.org/10.4149/BLL_2017_137,Bratislava Medical Journal,20,2017,no,"The study includes mixed populations (osteoporosis, breast cancer, prostate cancer, multiple myeloma), which explicitly fails the criterion requiring only osteoporosis patients.",no,"No information is provided about the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures were involved in MRONJ cases.,maybe,"This appears to be a multi-centric prevalence study, but the exact design is not clearly specified. It seems to be a retrospective analysis of cases.",no,"While the study documents MRONJ prevalence, it does not specify follow-up periods or clearly document incidence after dental treatment.",maybe,"The abstract does not explicitly state the age of the subjects, though it is likely they are adults given the context.",maybe,"The study includes 1166 MRONJ patients total, but does not specify how many were in the osteoporosis group. The osteoporosis prevalence is 0.47%, but it cannot be determined if the osteoporosis subgroup meets the 100-subject requirement.",maybe,"The abstract only mentions ""antiresorptive drugs"" generally, without specifying oral bisphosphonates.",no,The abstract does not mention diagnostic standards for MRONJ.,Include,"The study fails key screening criteria by including a mixed patient population with cancer patients, lacking specific diagnostic standards for MRONJ, and not clearly documenting dental procedures or intervention types. Multiple critical requirements were not met, including the need for an osteoporosis-only population and detailed documentation of MRONJ latency and dental treatment outcomes. The research provides valuable prevalence data but does not align with the systematic review's precise methodological requirements.",2.5
Analysis of Implant Associated Medication related osteonecrosis of the jaw: Retrospective clinical study,"Dongkyu Jang, Jin-Woo Kim",10.1111/clr.139_13644,https://doi.org/10.1111/clr.139_13644,-,1,2020,yes,"The abstract specifically mentions that the majority of the reason for drug administration is osteoporosis, and does not indicate a mixed population or cancer patients.",yes,"The study documents time intervals between implant installation and MRONJ occurrence (2.54 years for surgically triggered group) and between drug administration and MRONJ (3.92 years for present triggered group), which meets the MRONJ latency criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,The study focuses on dental implant procedures and reports MRONJ incidence following these procedures.,no,"This appears to be a retrospective case series, which is not one of the accepted study designs.",maybe,"While MRONJ incidence is documented, the follow-up period is not explicitly stated.",yes,"The mean age of the subjects is 70.3 years, which clearly meets the requirement of being over 18 years old.",no,"The study only includes 26 patients, which is well below the required 100 subjects for the medication group at the final statistical analysis stage.",yes,"The study mentions alendronate and ibandronate (oral bisphosphonates) for osteoporosis treatment, which meets the intervention type criterion.",maybe,"While MRONJ is discussed, the abstract does not explicitly mention the diagnostic standards used.",Include,"The study fails critical screening criteria due to its small sample size of 26 patients and retrospective case series design, which do not meet the required methodological standards. Despite addressing some criteria like patient age, osteoporosis indication, and oral bisphosphonate intervention, the fundamental methodological limitations prevent the study from qualifying for inclusion. Unclear diagnostic standards and lack of a control group further compromise the study's screening potential.",2.5
Medication-Related Osteonecrosis of the Jaw in Dental Practice: A Retrospective Analysis of Data from the Milan Cohort,"Cristina Mirelli, S. Marino, A. Bovio, Sara Pederielli, C. Dall’Agnola, A. Giannì, R. Biagi",10.3390/dj10050089,https://doi.org/10.3390/dj10050089,Dental journal,5,2022,yes,"The study specifically focuses on osteoporotic patients taking antiresorptive drugs, excluding cancer patients, so this criterion is met.",no,"The abstract mentions ""duration of treatment"" but does not specifically document the time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",maybe,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"While dental procedures are mentioned, the abstract does not clearly specify which procedures were studied or report specific MRONJ incidence rates following these procedures.",yes,"The study is described as a ""retrospective analysis,"" which appears to be a retrospective cohort study, so this criterion is met.",maybe,"While MRONJ is discussed, the abstract does not clearly document the follow-up period or specific MRONJ incidence rates.",yes,"While not explicitly stated, the context suggests the study included adult patients (osteoporosis patients), so this criterion is likely met.",yes,"The study includes 434 patients, which exceeds the minimum requirement of 100 subjects, so this criterion is met.",maybe,"The abstract mentions ""antiresorptive drugs (ARDs)"" but does not specify if they are all oral bisphosphonates. It mentions ""per oral therapies"" but this is not exclusive to bisphosphonates, creating uncertainty about whether this criterion is met.",no,"The abstract does not explicitly mention the diagnostic standards used for MRONJ, which is a significant omission.",Include,"A retrospective study of 434 osteoporotic patients taking antiresorptive drugs reveals potential risk factors for medication-related osteonecrosis of the jaw, with significant methodological limitations including unclear diagnostic standards and incomplete documentation of dental procedures and outcomes. While meeting some screening criteria like population size and study design, the research lacks a control group and precise specification of intervention types, creating uncertainty about its comprehensive assessment of MRONJ risk.",2.9
"Medication-related osteonecrosis of the jaw: A review about etiology, risk factors, pathophysiology, and treatment","Sheetal Singar, A. Parihar, P. Reddy, A. Maurya, Vishal Bamaniya",10.4103/jiaomr.jiaomr_206_19,https://doi.org/10.4103/jiaomr.jiaomr_206_19,Journal of Indian Academy of Oral Medicine and Radiology,3,2020,no,"The abstract discusses antiresorptive medication but does not specifically focus on osteoporosis patients, mentioning it as a general condition. It appears to be a review of MRONJ rather than a specific study population.",no,No specific time intervals are documented.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While dental procedures are mentioned generally (""dentoalveolar trauma and extraction""), the abstract does not report specific MRONJ incidence following these procedures.",no,This appears to be a review article rather than any of the specified study designs. No methodology is described.,no,The abstract does not present any specific follow-up period or documented MRONJ incidence.,maybe,"The abstract does not specify the age of the subjects, so the age of the population is unknown.",maybe,"No subject numbers are mentioned in the abstract, so the subject size is unknown.",no,"While antiresorptive medications are mentioned, the abstract does not specify oral bisphosphonates exclusively. It appears to discuss antiresorptive medications broadly.",yes,"The abstract does mention diagnostic criteria (""exposed bone in the jaw for more than 8 weeks and has a history of antiresorptive and antiangiogenic medication with a negative history of radiotherapy"").",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific study design, population characteristics, and outcome documentation. While discussing medication-related osteonecrosis of the jaw, the text appears to be a general review rather than a research study with defined methodological parameters. Consequently, the abstract does not provide sufficient evidence to qualify for inclusion based on the established screening requirements.",1.4
"Medication-related osteonecrosis of the jaw, a risk to reassess in osteoporotic patients.","maxime debiève, L. Castiaux, Aline van Maanen, M. Magremanne",10.2139/ssrn.4175108,https://doi.org/10.2139/ssrn.4175108,Journal of Stomatology Oral and Maxillofacial Surgery,3,2022,no,"The study specifically includes osteoporosis patients (67 cases) and separates them from cancer patients. However, it's a mixed population study that includes both groups, which violates this criterion.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not specify which dental procedures were associated with MRONJ development.,yes,"The study is described as a ""retrospective study,"" which meets the criterion as a retrospective cohort study.",maybe,"The study has a mean follow-up time of 23.7 months (1-110), which exceeds the 6-month requirement. However, it's unclear if MRONJ incidence is clearly documented after specific dental treatments.",yes,"The study includes adults with mean age 74.4 (range 50-98), meeting the >18 years criterion.",no,"The study includes 67 osteoporotic patients, which is below the required 100 subjects for the medication group.",maybe,"The abstract mentions ""anti-resorptive drugs"" but doesn't specify if they are oral bisphosphonates. This is unclear from the abstract.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Include,"The study fails key screening criteria due to a mixed patient population, insufficient sample size for the osteoporosis group, and lack of specificity regarding dental procedures and medication type. Critical methodological gaps include missing diagnostic standards, unclear intervention details, and absence of documented time intervals between medication and MRONJ incidence. Despite being a relevant research effort, the study does not meet the predefined systematic review inclusion requirements.",2.5
A systematic review assessing occurrence of medication-related osteonecrosis of the jaw following dental procedures,"Shimelly Monteiro de Castro Lara, F. Muniz, Ana C. R. Geronimo, Cinthia Studzinski dos Santos, Thayanne Brasil Barbosa Calcia",10.20396/bjos.v21i00.8666585,https://doi.org/10.20396/bjos.v21i00.8666585,Brazilian Journal of Oral Sciences,1,2022,no,"The abstract indicates that ""cancer was the most frequent underlying health condition"" and mentions ""bone-modifying drugs"" broadly, not specifically osteoporosis patients. This fails to meet the criterion of focusing exclusively on osteoporosis patients.",no,"The abstract does not mention documenting the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not explicitly mention a control group, which is a significant limitation.",yes,"The abstract does discuss dental procedures (tooth extractions and periodontal therapy) and MRONJ outcomes, meeting this criterion.",no,"This is a systematic review, not a primary research study of the types specified in the criteria. This fails to meet the criterion.",no,"While the abstract discusses MRONJ incidence, it does not specify the follow-up period length.",yes,"The abstract mentions a mean age of 64 years, which meets the criterion of subjects being over 18 years old.",maybe,"The abstract mentions 17 included studies but does not specify the sample size of individual studies, so this information is unclear.",no,"The abstract mentions ""bone-modifying drugs"" and specifically ""Zoledronic acid"" which is an intravenous bisphosphonate, not oral bisphosphonates. This fails to meet the criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including study design, population specificity, and intervention type. Key disqualifying factors include the inclusion of cancer patients, focus on intravenous bisphosphonates, and lack of specific diagnostic standards for MRONJ. The study's broad approach and methodological limitations prevent it from satisfying the predefined screening requirements.",1.4
Medication-related osteonecrosis of the jaw: Clinical and practical guidelines,"D. Rosella, P. Papi, R. Giardino, E. Cicalini, L. Piccoli, G. Pompa",10.4103/2231-0762.178742,https://doi.org/10.4103/2231-0762.178742,Journal of International Society of Preventive and Community Dentistry,152,2016,no,"The abstract discusses MRONJ in general terms and mentions both antiresorptive and antiangiogenic therapy, but does not specify a pure osteoporosis population, and appears to include cancer patients. Therefore, the study fails this criterion.",no,"The abstract does not document any specific time intervals, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While dental procedures are mentioned in the context of prevention, the abstract doesn't report specific MRONJ incidence following these procedures, so the study fails this criterion.",no,"This appears to be a review paper rather than any of the specified study designs, as the abstract mentions ""current knowledge"" and ""management strategies"" suggesting it's a review of existing literature. Therefore, the study fails this criterion.",no,"The abstract does not report specific MRONJ incidence or follow-up periods, so the study fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is unknown.",maybe,"The abstract does not mention any specific number of subjects, so the reasoning for this criterion is unknown.",no,"While bisphosphonates are mentioned, the abstract discusses both oral and other forms of antiresorptive medications, and includes antiangiogenic therapy. It's not focused specifically on oral bisphosphonates, so the study fails this criterion.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so the study fails this criterion.",Exclude,"This review article fails multiple critical screening criteria, including lack of a specific study design, absence of a focused osteoporosis population, and no clear documentation of MRONJ incidence or diagnostic standards. The paper appears to be a general overview of medication-related osteonecrosis of the jaw rather than an original research study meeting the required methodological specifications.",0.1
Incidence and risk factors associated to Medication-Related OsteoNecrosis of the Jaw (MRONJ) in patients with osteoporosis after tooth extractions. A 12-months observational cohort study.,"A. Cuozzo, V. Iorio-Siciliano, Emanuele Vaia, Leopoldo Mauriello, A. Blasi, L. Ramaglia",10.1016/j.jormas.2022.03.020,https://doi.org/10.1016/j.jormas.2022.03.020,Journal of Stomatology Oral and Maxillofacial Surgery,4,2022,yes,"The study specifically focuses on osteoporotic patients taking oral bisphosphonates, excluding cancer patients and mixed populations.",no,"The abstract mentions ""duration of therapy"" but does not clearly document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,yes,The study specifically looks at tooth extractions and reports MRONJ incidence.,yes,"While not explicitly stated, the study appears to be a prospective cohort study following patients for 12 months.",yes,The study has a 12-month follow-up period and clearly documents MRONJ incidence (0.6%).,yes,"The mean age of the subjects is 67.5 ± 3 years, which clearly meets the criterion of being over 18 years old.",no,"The study includes 45 patients (43 females, 2 males) with 159 tooth extractions, which falls below the required 100 subjects for the medication group.",yes,"The study only includes patients taking oral bisphosphonates (alendronate, risedronate, and ibandronate) for osteoporosis treatment.",maybe,"The abstract mentions ""mucosal healing"" and ""osteonecrosis"" but does not explicitly detail the diagnostic standards for MRONJ.",Include,"A prospective cohort study of osteoporotic patients taking oral bisphosphonates reveals a low MRONJ incidence after tooth extractions, with a small sample size of 45 patients. While meeting several key screening criteria like population indication and intervention type, the study falls short on critical requirements such as subject size and control group presence. The research provides insights into MRONJ risk but lacks the comprehensive methodological rigor needed for definitive conclusions.",2.7
The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review,"R. Sacco, Julian Woolley, J. Yates, M. Calasans-Maia, O. Akintola, V. Patel",10.4103/JRMS.JRMS_794_20,https://doi.org/10.4103/JRMS.JRMS_794_20,Journal of Research in Medical Sciences,5,2021,no,"The study focuses on immunosuppressed patients taking antiresorptive medications, which is a mixed population that includes but is not limited to osteoporosis patients. This fails to meet the criterion of focusing specifically on osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study does report MRONJ incidence following dental procedures, specifically mentioning dental extraction (n=197).",no,"This is a systematic review of multiple studies, not a primary research study of the required design types.",maybe,"While the study reports MRONJ incidence, the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, so it is unclear if this criterion is met.",maybe,"The study includes 206 patients total, but this is across multiple studies in a systematic review. It cannot be determined if individual studies had more than 100 subjects.",no,"The study includes multiple types of antiresorptive medications, including bisphosphonates, denosumab, and antiangiogenic drugs. This is broader than the required focus on oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific population requirements, intervention type, and study design. Key limitations include a mixed patient population, inclusion of multiple medication types beyond oral bisphosphonates, and lack of a control group. The study's broad approach and methodological differences significantly deviate from the predefined screening standards.",1.4
Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review,"C. Ottesen, M. Schiødt, K. Gotfredsen",10.1016/j.heliyon.2020.e03795,https://doi.org/10.1016/j.heliyon.2020.e03795,Heliyon,68,2020,no,"The study specifically focuses on patients with cancer, which is explicitly excluded in the criteria.",no,"The abstract does not mention the time intervals between medication start, dental procedure, and MRONJ incidence, so the reasoning for this criterion is unclear.",yes,"The study included a control group of patients not taking anti-resorptive medications, which meets the criteria for this factor.",yes,"The study mentions tooth extraction or dentoalveolar surgery and MRONJ outcomes, which meets the criteria for this factor.",yes,"The study includes randomized controlled trials, cohort studies, and prospective studies, which meets the criteria for this factor.",maybe,"While the study discusses MRONJ incidence, the follow-up period is not specified, so the reasoning for this criterion is unclear.",maybe,"The abstract does not specify the age requirements for the study population, so the reasoning for this criterion is unclear.",maybe,"The abstract does not specify the number of subjects in the medication group, so the reasoning for this criterion is unclear.",maybe,"While the study includes bisphosphonates, it also includes denosumab (a non-bisphosphonate), which partially violates the criteria for this factor.",no,"The abstract does not mention the diagnostic standards for MRONJ, so the reasoning for this criterion is unclear.",Exclude,"The systematic review focuses on medication-related osteonecrosis of the jaw in cancer patients, which immediately disqualifies it from meeting the screening criteria targeting non-cancer osteoporosis populations. Multiple methodological limitations, including the inclusion of non-bisphosphonate medications and unclear documentation of key parameters, further compromise the study's alignment with the specified screening requirements.",1.4
Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab,"A. Wick, Philipp Bankosegger, S. Otto, B. Hohlweg-Majert, T. Steiner, F. Probst, O. Ristow, C. Pautke",10.1007/s00784-021-04261-4,https://doi.org/10.1007/s00784-021-04261-4,Clinical Oral Investigations,19,2021,no,"The study includes a mixed population of cancer patients and osteoporosis patients, which does not meet the requirement for a population specifically chosen from patients taking medication for osteoporosis.",no,"The abstract does not mention the time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study includes a control group (Group I, n=40) receiving DNO without MRONJ, which meets the requirement for a control group.",maybe,"The study mentions ""oral inflammation"" and ""denture use"" but does not specifically focus on the required dental procedures, and does not clearly report MRONJ incidence following these procedures.",yes,"The study design is a retrospective cohort study, which is an acceptable design.",maybe,"The follow-up period is not mentioned in the abstract, and the timing of MRONJ incidence is unclear.",maybe,"The age of the subjects is mentioned as a parameter, but the specific age range is not provided, so it is unclear if the population is over 18 years old.",yes,"The study includes a total of 128 patients, with 46 in the Test 1 group and 42 in the Test 2 group, which exceeds the requirement of over 100 subjects for the medication group.",no,"The study focuses on denosumab (DNO), not oral bisphosphonates, which does not meet the requirement for the intervention type.",no,The abstract does not mention the diagnostic standards for MRONJ.,Exclude,"The study fails critical screening criteria by using denosumab instead of oral bisphosphonates and including a mixed population with cancer patients. Multiple key requirements were not met, including specific dental procedure documentation, diagnostic standards, and clear outcome reporting. The research design and population do not align with the predefined screening criteria.",1.4
Surgical Management of Medication-Related Osteonecrosis of the Jaw Is Associated With Improved Disease Resolution: A Retrospective Cohort Study.,"M. El-Rabbany, D. Lam, P. Shah, A. Azarpazhooh",10.1016/j.joms.2019.03.040,https://doi.org/10.1016/j.joms.2019.03.040,Journal of oral and maxillofacial surgery,27,2019,no,"The study includes patients taking medication for osteoporosis, but also includes patients taking medication for oncologic purposes, which violates the criterion of a population with a single indication.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures led to MRONJ. It focuses on treatment of MRONJ rather than its incidence after dental procedures.,yes,"This is a retrospective review, which is an acceptable study design.",no,"While the study has a follow-up period, it documents treatment outcomes rather than MRONJ incidence after dental procedures.",yes,"While not explicitly stated, the study is of osteoporosis patients, so it can be reasonably assumed that the subjects are over 18 years old.",no,"The total sample size is 78 patients, with 56 in the surgical group, which is below the required 100 subjects per group.",maybe,"The abstract mentions ""antiresorptive agents"" but does not specify if they are oral bisphosphonates. It also includes antiangiogenic therapy, which is not specified in the criteria.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including population specificity, sample size requirements, and documentation of dental procedure-related MRONJ incidence. Key limitations include a mixed patient population, insufficient subject numbers, and a focus on treatment outcomes rather than procedural risk assessment. The research does not align with the predefined screening parameters for a comprehensive MRONJ investigation.",1.4
Medication-Related Osteonecrosis of the Jaws (MRONJ) in Children and Young Patients—A Systematic Review,"H. Rosales, Henry García Guevara, Stefanía Requejo, Maria Dianella Jensen, Julio Acero, S. Olate",10.3390/jcm12041416,https://doi.org/10.3390/jcm12041416,Journal of Clinical Medicine,10,2023,no,"The study includes mixed populations, including patients with osteogenesis imperfecta, glucocorticoid-induced osteoporosis, and other conditions, and is not specifically focused on osteoporosis patients.",no,"The abstract mentions average therapy time (4.21 years) but doesn't document the specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract mentions oral surgery and reports MRONJ cases, but doesn't specify the types of dental procedures.",yes,"The abstract mentions including ""randomized and non-randomized clinical trials, prospective and retrospective cohort studies, cases and controls studies, and series and case reports,"" which meets the criterion for acceptable study designs.",maybe,"While MRONJ incidence is reported (14 cases), the follow-up period is not specified.",no,"The study focuses on children and young patients with an average age of 11.56 years, which explicitly fails the criterion requiring subjects over 18 years old.",maybe,"The study includes 1192 total patients, but this is across multiple studies in a systematic review, not a single study group. The abstract doesn't specify the size of individual study groups.",no,"The study includes both bisphosphonates and denosumab, and doesn't specify whether the medications were oral or intravenous.",yes,"The abstract mentions the AAOMS definition of MRONJ, meeting this criterion.",Exclude,"The systematic review focuses on pediatric patients with an average age of 11.56 years, which immediately disqualifies it from meeting the age requirement of over 18 years. Additionally, the study includes mixed patient populations and multiple medication types beyond oral bisphosphonates, further compromising its alignment with the specified screening criteria. The research's broad scope and pediatric focus render it unsuitable for the intended systematic review.",0.1
Management von medikamentenassoziierten Kiefernekrosen – Ergebnisse einer Literaturanalyse neuester Studien im Vergleich zu bewährten Strategien,"M. Tröltzsch, M. Tröltzsch, C. Pautke, S. Otto",10.1007/s00106-021-01130-0,https://doi.org/10.1007/s00106-021-01130-0,HNO (Berlin. Print),5,2022,no,"The abstract discusses both osteoporosis and oncology patients, indicating mixed populations, which fails to meet the criterion requiring exclusive focus on osteoporosis patients.",no,"No information about time intervals between medication start, dental procedures, and MRONJ incidence is provided.",no,"The abstract does not explicitly mention a control group, as it is a review article rather than an original research study.",no,The abstract doesn't mention specific dental procedures leading to MRONJ.,no,"This is a systematic review, not an original research study of the required designs (RCT, cohort, or case-control).",no,"While MRONJ incidence is discussed (0.1-1% for osteoporosis patients), the follow-up period is not specified.",no,The abstract does not specify age requirements for included studies.,no,"As a review article, it doesn't specify the number of subjects in individual studies.",no,"The abstract discusses ""antiresorptive agents"" broadly but doesn't specify oral bisphosphonates exclusively.",no,"While the abstract mentions ""diagnostic methods,"" it doesn't specify the diagnostic standards used.",Exclude,"The systematic review fails to meet multiple screening criteria, including the requirement for an original research study design, exclusive focus on osteoporosis patients, and specification of oral bisphosphonate interventions. Critical limitations include mixed patient populations, lack of detailed diagnostic standards, and absence of specific dental procedure documentation. These deficiencies render the study ineligible for inclusion in the systematic review.",0.1
Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.,"G. Ghidini, M. Manfredi, I. Giovannacci, G. Mergoni, A. Sarraj, Maura Mureddu, G. Giunta, M. Bonanini, M. Meleti, P. Vescovi",10.23736/S0026-4970.17.04056-0,https://doi.org/10.23736/S0026-4970.17.04056-0,Minerva Stomatologica,19,2017,no,"The study explicitly includes cancer patients, which is specifically excluded in the criteria. This is a critical failure.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The abstract mentions dental extraction and bone surgery as triggers for MRONJ, meeting this criterion.",yes,"This is a retrospective analysis of medical charts, which qualifies as a retrospective cohort study, meeting this criterion.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified in the abstract, so this criterion is unclear.",yes,"The study includes patients with a mean age of 67 years, which meets the criterion of subjects being over 18 years old.",yes,"The study includes 303 patients total, with 214 females and 89 males. While the exact split between groups isn't specified, it's likely the medication group exceeds 100 subjects, meeting this criterion.",no,"The study includes both bisphosphonates alone (Group 1) and antiresorptive-antiangiogenic drugs with/without bisphosphonates (Group 2). The criteria specifically exclude non-bisphosphonate medications, so this criterion is not met.",maybe,"While the study mentions different stages of MRONJ (Stage II mentioned), it doesn't explicitly state its diagnostic standards, so this criterion is unclear.",Exclude,"The study fails critical screening criteria by including cancer patients and non-bisphosphonate medications, which directly contradicts the specified inclusion requirements. Despite meeting some criteria like age and sample size, the fundamental violations of population and intervention type render the study unsuitable for the systematic review. Multiple key methodological details remain unclear, further compromising its potential inclusion.",1.4
Dental Implant Placement in Patients with a History of Medications Related to Osteonecrosis of the Jaws: A Systematic Review.,"J. Sher, K. Kirkham-Ali, Denny Luo, Catherine M Miller, D. Sharma",10.1563/aaid-joi-d-19-00351,https://doi.org/10.1563/aaid-joi-d-19-00351,Journal of Oral Implantology,32,2020,no,"The abstract mentions both osteoporosis and cancer patients, indicating a mixed population, which fails to meet the criterion requiring exclusive focus on osteoporosis patients.",no,"The abstract does not document the specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not explicitly mention a control group, which is a significant limitation.",yes,"The abstract specifically discusses implant placement and MRONJ incidence, meeting this criterion.",yes,"The abstract includes various study designs including cohort studies and case-control studies, which would meet this criterion.",no,"While MRONJ incidence is discussed, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, though osteoporosis patients are typically over 18.",no,"The abstract does not specify the number of subjects in the included studies, making it impossible to verify if they meet the >100 subjects criterion.",no,"The abstract mentions both oral and intravenous bisphosphonates, which does not meet the criterion of only including oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple screening criteria, including a mixed patient population, inclusion of both oral and intravenous bisphosphonates, and lack of clear diagnostic standards for MRONJ. Critical limitations include absence of a control group, unspecified subject size, and no documentation of MRONJ latency periods. The study's nature as a systematic review rather than primary research further complicates its potential inclusion.",1.4
Medication-Related Osteonecrosis of the Jaw – 2024 Update,"David D Seo, James L. Borke",10.33425/2639-9490.1142,https://doi.org/10.33425/2639-9490.1142,Oral Health & Dental Science,0,2024,no,"The abstract discusses both cancer patients and osteoporosis patients, indicating a mixed population, which explicitly fails the criterion requiring only osteoporosis patients.",no,"No information about time intervals is provided, so this criterion is not met.",no,"The abstract does not mention any control group, so no points are added for this criterion.",maybe,"The abstract mentions dental extraction and oral surgery, but only in a general context rather than as part of a specific study methodology, so it only partially meets this criterion.",no,"This appears to be a review article rather than a primary research study, as the abstract mentions ""This review highlights..."", which fails the criterion for study design.",no,"As a review article, it doesn't document specific MRONJ incidence or follow-up periods, so this criterion is not met.",maybe,"The abstract does not explicitly specify age requirements, so the reasoning is uncertain.",maybe,"The abstract does not mention any specific sample size, so the reasoning is uncertain.",no,"While bisphosphonates are mentioned, the abstract also discusses other medications (denosumab) and includes both oral and intravenous administration, so it is not specific to oral bisphosphonates.",maybe,"The abstract mentions that AAOMS has established diagnostic standards for MRONJ, but this is in a general context rather than as part of a specific study methodology, so it only partially meets this criterion.",Exclude,"This review article fails multiple screening criteria, including the requirement for a specific osteoporosis patient population and oral bisphosphonate intervention. The mixed patient population, lack of a control group, and absence of specific research methodology disqualify it from meeting the systematic review's rigorous inclusion standards.",0.1
Medication-Related Osteonecrosis of the Jaw Subsequent to Periimplantitis: A Case Report and Literature Review.,"Keisuke Seki, S. Namaki, Atsushi Kamimoto, Y. Hagiwara",10.1563/aaid-joi-D-19-00385,https://doi.org/10.1563/aaid-joi-D-19-00385,Journal of Oral Implantology,12,2020,yes,"The subject is taking alendronate for osteoporosis treatment, meeting this criterion.",maybe,"The abstract documents the time interval between medication start and MRONJ development (4 years), but not specifically from dental procedure to MRONJ.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The study involves implant-related MRONJ, which is one of the specified procedures.",no,"This is explicitly described as a case report, which is specifically excluded in the criteria.",maybe,"While MRONJ incidence is documented, the follow-up period is not clearly specified.",yes,"The subject is 73 years old, meeting the requirement of being over 18 years old.",no,"This is a case report of a single patient, failing to meet the minimum requirement of 100 subjects.",yes,"The subject is taking oral bisphosphonate (alendronate), meeting this criterion.",no,The abstract does not explicitly mention diagnostic standards for MRONJ.,Exclude,"This case report fails multiple critical screening criteria, including being a single-patient study instead of a required multi-subject research design and lacking a control group. The document describes a single patient's experience with medication-related osteonecrosis of the jaw, which does not meet the specified methodological requirements for inclusion in the study.",0.1
Medication-Related Osteonecrosis of the Jaw: A Review,"Nandita Gautam, Sheena Kaur Samagh",10.47363/jmhc/2022(4)212,https://doi.org/10.47363/jmhc/2022(4)212,Journal of Medicine and HealthCare,1,2022,no,"While the abstract discusses osteoporosis patients taking antiresorptive medications, it appears to be a review/analysis rather than a primary study with specific subjects, so the population indication criterion is not met.",no,"No specific time intervals are documented in the abstract, so no points were added for the MRONJ latency criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While the abstract mentions oral examination and treatment, it doesn't specifically report MRONJ incidence following specific dental procedures, so the procedure and outcome criterion is not met.",no,"This appears to be a review article rather than a primary research study with any of the specified designs, so the study design criterion is not met.",no,"The abstract doesn't describe any specific follow-up period or documented MRONJ incidence, so the outcome documentation criterion is not met.",maybe,"The abstract does not specify the age of the subjects, so the age requirement is unknown.",no,"No specific subject numbers are mentioned in the abstract, so the subject size criterion is not met.",no,"The abstract mentions bisphosphonates but also discusses denosumab and other anti-angiogenic drugs, so it is not focused exclusively on oral bisphosphonates, and the intervention type criterion is not met.",no,"The abstract mentions that AAOMS published diagnostic criteria for MRONJ, but this is in a general context rather than as part of a specific study methodology, so the diagnostic standard for MRONJ criterion is not met.",Exclude,"This review article fails to meet multiple critical screening criteria, including lack of a defined study design, absence of a specific patient population, and no documentation of MRONJ incidence following dental procedures. The text appears to be a general overview of MRONJ rather than a primary research study with measurable outcomes, rendering it ineligible for inclusion based on the established screening requirements.",0.1
Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature.,"Srighana Nadella, M. Mupparapu, S. Akintoye",10.3290/j.qi.b3082785,https://doi.org/10.3290/j.qi.b3082785,Quintessence International,5,2022,no,"The study focuses on patients with fibrous dysplasia and McCune-Albright syndrome, not osteoporosis patients, which is a clear violation of the inclusion criteria.",maybe,"While the study mentions a 1-year follow-up period, it does not document the specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify any dental procedures leading to MRONJ. It appears to focus on spontaneous MRONJ rather than procedure-related cases.,no,"This is a systematic review, not a primary research study of the types specified in the criteria.",yes,"The study does document MRONJ incidence (3.85%) and has a follow-up period of at least 1 year, meeting this criterion.",maybe,"The abstract does not explicitly state the age of the subjects, so it is unclear if this criterion is met.",yes,"The study includes 312 patients total, which exceeds the minimum requirement of 100 subjects.",no,"While the study includes bisphosphonates, it also includes ""other antiresorptives"" and mentions denosumab, teriparatide, and other non-bisphosphonate medications, which violates the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review focuses on fibrous dysplasia patients, which deviates from the required osteoporosis patient population, and includes multiple medication types beyond oral bisphosphonates. Critical screening criteria were not met, including the absence of a control group, lack of specific dental procedure documentation, and inclusion of non-bisphosphonate medications. These fundamental discrepancies render the study non-compliant with the established screening requirements.",0.1
Evaluation of the Treatment Strategies for Medication‐Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis,"S. Hayashida, S. Soutome, S. Yanamoto, S. Fujita, T. Hasegawa, T. Komori, Y. Kojima, H. Miyamoto, Y. Shibuya, N. Ueda, T. Kirita, H. Nakahara, M. Shinohara, M. Umeda",10.1002/jbmr.3191,https://doi.org/10.1002/jbmr.3191,Journal of Bone and Mineral Research,147,2017,no,"The abstract does not specify whether the patients were taking medication for osteoporosis or other conditions, only mentioning ""antiresorptive agent"" without specifying the indication.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract focuses on treatment methods for MRONJ rather than dental procedures leading to MRONJ, and does not discuss the procedures that led to MRONJ.",yes,"The abstract explicitly states it's a ""multicenter retrospective study,"" which meets the criterion.",no,"While the study documents MRONJ outcomes, it focuses on treatment outcomes rather than incidence after dental procedures, and the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, but Elicit notes that since it is a study of MRONJ patients, they are likely adults.",yes,"The study includes 361 patients initially, with 176 after matching, which exceeds the 100-subject requirement.",maybe,"The abstract only mentions ""antiresorptive agent"" without specifying if it's oral bisphosphonate, which is too vague to confirm it meets the criterion.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Exclude,"The study fails to meet several critical screening criteria, including specification of medication type, patient indication, diagnostic standards, and dental procedure details. While the research includes a substantial patient sample and uses a retrospective study design, significant information gaps prevent it from satisfying the comprehensive requirements for inclusion. The paper's focus on MRONJ treatment rather than incidence after dental procedures further diminishes its alignment with the screening criteria.",1.4
The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention,"O. D. Fede, V. Panzarella, R. Mauceri, V. Fusco, A. Bedogni, L. Muzio, Sipmo Onj Board, G. Campisi",10.1155/2018/2684924,https://doi.org/10.1155/2018/2684924,BioMed Research International,127,2018,no,"The abstract discusses both cancer and non-cancer patients, which fails the criterion requiring an exclusive focus on osteoporosis patients.",no,The abstract does not document specific time intervals.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While dental treatments are mentioned, the paper appears to focus on prevention protocols rather than reporting specific MRONJ incidence after procedures.",no,"This appears to be a review or guideline paper rather than any of the required study designs, as it describes ""a new paradigm"" and preventive protocols.",no,"The paper does not appear to document MRONJ incidence or follow-up periods, instead focusing on preventive management.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any specific number of subjects, so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, the paper discusses multiple types of medications including antiangiogenic drugs, which is broader than the required focus on oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The abstract describes a guideline paper on medication-related osteonecrosis of the jaw prevention, which fails multiple screening criteria including study design, population specificity, and outcome documentation. It covers multiple medication types and patient populations, lacks specific diagnostic standards, and does not report MRONJ incidence after dental procedures. Consequently, the paper does not meet the required methodological and research parameters for inclusion.",0.1
A nested case-control study of factors contributing to the development of medication-related osteonecrosis of the jaw in patients using bone resorption inhibitors in Mishima City.,"Keisuke Seki, Atsushi Kamimoto, Maki Wada, T. Iinuma",10.2334/josnusd.23-0096,https://doi.org/10.2334/josnusd.23-0096,Journal of Oral Science,2,2023,no,"The study focuses on injectable bisphosphonates, not oral bisphosphonates for osteoporosis, and there is no mention of osteoporosis as the indication. The study appears to be a mixed population study, which does not meet the criteria.",no,"The abstract does not mention the time intervals between medication start, dental procedures, and MRONJ onset.",yes,"The study explicitly mentions using a case-control design with 32 controls matched to 12 cases, which meets the requirement for a control group.",maybe,"While MRONJ is studied, the abstract does not specify which dental procedures were involved. It mentions ""prophylactic dental treatment"" but does not detail the specific procedures.",yes,The case-control study design is explicitly mentioned and is one of the accepted study types.,maybe,"The follow-up period is not mentioned, and while MRONJ incidence is documented, the temporal aspects are unclear.",maybe,"The abstract does not explicitly state the age range of participants, but the fact that it is a case-control study at a dental center suggests the population is likely adults over 18 years old.",no,"The study only includes 12 MRONJ cases and 32 controls, which is well below the required 100 subjects in the medication group.",no,"The study specifically focuses on injectable bisphosphonates, which is explicitly excluded by the criteria. There is no mention of oral bisphosphonates.",no,The abstract does not mention the diagnostic standards for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including the required intervention type (oral bisphosphonates), sample size (less than 100 subjects), and clear diagnostic standards for MRONJ. Significant methodological limitations, such as focusing on injectable bisphosphonates and lacking comprehensive documentation of dental procedures and MRONJ latency, render the research non-compliant with the specified screening requirements.",1.4
Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset,"A. Marcianó, Y. Ingrasciotta, Valentina Isgró, L. L'Abbate, S. S. Foti, A. Picone, M. Peditto, G. Guzzo, A. Alibrandi, G. Oteri",10.3390/jcm10204762,https://doi.org/10.3390/jcm10204762,Journal of Clinical Medicine,8,2021,no,"The study specifically focuses on cancer patients taking zoledronic acid and/or denosumab, which explicitly violates the criterion requiring subjects to be osteoporosis patients only.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not mention any specific dental procedures leading to MRONJ.,yes,"The study appears to be a cohort study, which meets this criterion.",maybe,"While MRONJ is studied, the abstract doesn't specify the follow-up period.",maybe,"The abstract does not explicitly state the age of subjects, though cancer patients are typically adults.",maybe,The abstract does not specify the total number of subjects.,no,"The study examines zoledronic acid and denosumab, which are not oral bisphosphonates. Zoledronic acid is an intravenous bisphosphonate, and denosumab is a non-bisphosphonate medication.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients taking zoledronic acid and denosumab, which deviates from the required osteoporosis patient population and medication type. Critical screening criteria were not met, including the specific intervention type and patient indication, rendering the study ineligible for inclusion in the systematic review. Multiple key methodological requirements were either unaddressed or failed to align with the predefined screening standards.",0.1
Medication-related osteonecrosis of the jaw. Implant presence-triggered osteonecrosis: Case series and literature review.,"M. Escobedo, J. Cobo, S. Junquera, J. Milla, S. Olay, Luis Junquera",10.1016/j.jormas.2019.04.012,https://doi.org/10.1016/j.jormas.2019.04.012,Journal of Stomatology Oral and Maxillofacial Surgery,32,2020,no,"The study focuses on patients taking anti-resorptive medications, but does not explicitly specify that the subjects were osteoporosis patients. It appears to be a mixed population including both oral and intravenous medications.",yes,"The study documents ""elapsed time between the placement of the implants and the development of MRONJ"" and mentions ""duration of anti-resorptive treatment.""",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study focuses on implant-related MRONJ, which includes both implant placement and presence of implants.",yes,"This appears to be a retrospective review combined with a literature review, which could qualify as a retrospective cohort study.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified in the abstract.",maybe,"While not explicitly stated, the context suggests the study included adult patients, but this was not definitively confirmed.",yes,"The study includes 74 IPTO cases and 27 ISTO cases, totaling 101 cases, which meets the minimum requirement of 100 subjects.",no,"The abstract mentions both oral and intravenous anti-resorptive medications, not exclusively oral bisphosphonates.",maybe,"The abstract mentions ""stage of MRONJ"" but does not specify the diagnostic standards used.",Include,"The study involves patients with medication-related osteonecrosis of the jaw, but fails to meet key screening criteria by including a mixed population with both oral and intravenous anti-resorptive medications. While the research documents MRONJ incidence and includes a sufficient sample size, critical limitations exist in population specification and intervention type. Uncertainties remain regarding diagnostic standards and follow-up period, further complicating its potential inclusion.",2.7
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.,"A. Owosho, See Toh Yoong Liang, Adi Z. Sax, Kant Wu, S. Yom, J. Huryn, C. Estilo",10.1016/j.oooo.2018.02.003,https://doi.org/10.1016/j.oooo.2018.02.003,"Oral surgery, oral medicine, oral pathology and oral radiology",47,2018,no,"The study appears to focus on cancer patients at Memorial Sloan Kettering Cancer Center, which explicitly violates the criterion excluding cancer patients.",maybe,"The study does document timing of MRONJ onset relative to medication start, but does not clearly specify the time interval between dental procedure and MRONJ incidence.",no,The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications. The comparison is between two groups of patients already on medications.,maybe,"The abstract mentions ""dentoalveolar trauma"" as a precipitating factor but does not specifically detail the dental procedures listed in the criteria.",yes,"This appears to be a retrospective cohort study, which meets the criterion.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",maybe,"The abstract does not specify the age of the subjects, so this information is unclear.",maybe,"The abstract does not specify the total number of subjects, so this information is unclear.",no,"The study includes denosumab, zoledronate, and pamidronate, which are not oral bisphosphonates, violating the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients taking non-oral bisphosphonates, which directly conflicts with key screening criteria requiring a non-cancer population and oral bisphosphonate medications. Multiple critical screening requirements were not met, including population indication, intervention type, and diagnostic standards, rendering the study ineligible for inclusion in the systematic review.",1.4
"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.","F. Saad, Janet E Brown, C. Poznak, T. Ibrahim, S. Stemmer, A. Stopeck, I. Diel, Shunji Takahashi, N. Shore, D. Henry, C. Barrios, T. Facon, F. Senecal, K. Fizazi, Lei Zhou, A. Daniels, P. Carrière, R. Dansey",10.1093/annonc/mdr435,https://doi.org/10.1093/annonc/mdr435,Annals of Oncology,558,2012,no,"The study specifically focuses on patients with bone metastases secondary to solid tumors or myeloma, not osteoporosis patients. This is a clear violation of the inclusion criteria.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and ONJ incidence.",no,"The study does not include a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,"The study mentions tooth extraction (61.8% of ONJ cases) and reports ONJ incidence, meeting this criterion.",yes,"The abstract describes ""three phase III trials"" which are randomized controlled trials, meeting this criterion.",yes,"The study follows patients for at least 6 months (mentions ""every 6 months"" examinations) and documents ONJ incidence and outcomes.",maybe,"The abstract does not explicitly state the age requirement, but given these are cancer patients receiving bone-targeted therapy, they are likely adults. However, this is not explicitly confirmed.",yes,"The study includes 5,723 patients total, well exceeding the 100-subject requirement.",no,"The study uses intravenous zoledronic acid and subcutaneous denosumab, not oral bisphosphonates. This is a clear violation of the inclusion criteria.",maybe,"The abstract mentions that oral adverse events were ""adjudicated by an independent blinded committee of dental experts,"" suggesting some diagnostic standard, though specific criteria aren't detailed.",Exclude,"The study focuses on cancer patients receiving bone-targeted therapies, which fundamentally conflicts with the requirement for an osteoporosis patient population. Additionally, the intervention uses intravenous medications instead of oral bisphosphonates, representing a critical deviation from the specified screening criteria. These core violations render the study ineligible for inclusion in the systematic review.",1.4
A Retrospective Data Analysis for the Risk Evaluation of the Development of Drug-Associated Jaw Necrosis through Dentoalveolar Interventions,"M. Buchbender, Charlotte Bauerschmitz, Sebastian Pirkl, M. Kesting, C. Schmitt",10.3390/ijerph19074339,https://doi.org/10.3390/ijerph19074339,International Journal of Environmental Research and Public Health,3,2022,no,"The study includes a mixed population with 73% having metastatic diseases and 36.52% having osteoporotic conditions, failing the criterion requiring an exclusive focus on osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study clearly reports MRONJ incidence following dental procedures (extractions, osteotomy), meeting this criterion.",yes,"The study is described as a retrospective analysis, which meets the criterion for study design.",maybe,"While MRONJ incidence is documented (8.70%), the follow-up period is not specified.",maybe,"While specific ages are not mentioned, the context suggests the study included adult patients, likely meeting the age criterion.",no,"The study includes 115 patients total, with 42 osteoporotic patients, failing the criterion requiring over 100 subjects in the medication group.",maybe,"The abstract does not specify whether the medications are oral bisphosphonates or other types, so this is unclear.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study fails key screening criteria due to a mixed patient population including cancer patients, insufficient sample size for the osteoporosis group, and lack of a control group. Critical methodological gaps include unclear medication type, missing diagnostic standards, and undefined follow-up period, which significantly compromise the study's alignment with the specified screening requirements.",2.5
Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.,"Chengrong Zhang, Guoshuang Shen, Huihui Li, Y. Xin, Mingqiang Shi, Yonghui Zheng, Miaozhou Wang, Zhen Liu, Yi Zhao, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao",10.1111/scd.12877,https://doi.org/10.1111/scd.12877,"Special Care in Dentistry: managing special patients, settings, and situations",5,2023,no,"The study specifically focuses on cancer patients receiving bisphosphonates or denosumab for cancer treatment, not for osteoporosis, which is a clear violation of the inclusion criteria.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,yes,"The study includes RCTs and observational trials, which meets the acceptable study design criteria.",maybe,"While the study reports MRONJ incidence, it does not specify the follow-up period.",yes,"The abstract does not explicitly state the age of the subjects, but since it is about cancer patients, it can be reasonably assumed that they are adults.",yes,"The study includes 42,003 patients, which is well above the 100-subject requirement.",no,"While the study includes bisphosphonates, it also includes denosumab (a non-bisphosphonate) and does not specify if the bisphosphonates are oral. The focus is on cancer treatment, not osteoporosis.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients receiving bisphosphonates and denosumab, which fundamentally conflicts with the screening criteria requiring an osteoporosis patient population. Multiple critical screening requirements were not met, including the absence of specific dental procedures, diagnostic standards, and a clear focus on osteoporosis treatment. The research's primary population and intervention type disqualify it from meeting the systematic review's inclusion criteria.",0.1
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.,"K. Vahtsevanos, K. Athanassios, E. Verrou, E. Katodritou, S. Triaridis, C. Andreadis, I. Boukovinas, Georgios Koloutsos, Zisis Teleioudis, K. Kitikidou, P. Paraskevopoulos, K. Zervas, K. Antoniades",10.1200/JCO.2009.21.9584,https://doi.org/10.1200/JCO.2009.21.9584,Journal of Clinical Oncology,432,2009,no,"The study specifically focuses on cancer patients (multiple myeloma, breast cancer, prostate cancer) taking bisphosphonates, not osteoporosis patients, which is a critical exclusion criterion.",no,"The abstract does not document the time intervals between medication start, dental procedures, and ONJ incidence, so this criterion is not met.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study reports ONJ incidence following dental procedures (extractions, dentures), so this criterion is met.",yes,"This is a cohort study, which is one of the accepted study designs, so this criterion is met.",maybe,"While the study documents ONJ incidence, the follow-up period is not specified in the abstract, so this criterion is only partially met.",maybe,"While not explicitly stated, the context suggests the study included adult patients (cancer patients), so this criterion is likely met.",yes,"The study includes 1,621 patients, well above the 100-subject requirement, so this criterion is met.",no,"The study uses intravenous bisphosphonates (zoledronate, ibandronate, pamidronate), not oral bisphosphonates as required, so this criterion is not met.",no,"The abstract does not mention specific diagnostic standards for ONJ, so this criterion is not met.",Exclude,"The study focuses on cancer patients receiving intravenous bisphosphonates, which critically fails key screening criteria related to population indication and intervention type. Multiple methodological elements are missing, including diagnostic standards, latency documentation, and a control group, rendering the research non-compliant with the systematic review requirements. The fundamental mismatch between the study's population and the specified screening criteria necessitates exclusion from further analysis.",0.1
Impact of Bisphosphonate-related Osteonecrosis of the Jaw on Osteoporotic Patients after Dental Extraction: A Population-Based Cohort Study,"Yi Fang Huang, Chung-Ta Chang, C. Muo, Chun-Hao Tsai, Yu-Fu Shen, Ching-Zong Wu",10.1371/journal.pone.0120756,https://doi.org/10.1371/journal.pone.0120756,PLoS ONE,47,2015,maybe,"The study includes osteoporosis patients, which meets the requirement for the population indication. However, the abstract mentions ""whether patient with cancer or not"", suggesting a mixed population that includes cancer patients, which is explicitly excluded in the criteria.",no,"The study does not mention any time intervals between medication start, dental procedure, and ONJ incidence, which is a significant limitation.",yes,"The study included a clear control group of 38,669 patients without osteoporosis, which meets the requirement for a control group.",yes,"The study specifically focuses on dental extraction and reports ONJ incidence following extraction, which meets the requirement for the procedure and outcome.",yes,"The study is clearly described as a cohort study, which meets the requirement for the study design.",maybe,"The study mentions a follow-up period up to 2011, but does not specify the minimum follow-up period. It does clearly document ONJ incidence, which partially meets the requirement for outcome documentation.",yes,"The study explicitly mentions that the subjects were ""adult osteoporosis patients"", indicating that the age of the subjects was over 18 years old.",yes,"The study included 19,399 osteoporosis patients, which is well above the requirement of over 100 subjects for the medication group.",maybe,"The study mentions ""oral bisphosphonates (BPs)"", which meets the requirement for the intervention type. However, it does not explicitly exclude other medications, so there is some uncertainty about the medication specifics.",no,"The study does not mention any diagnostic standards for BRONJ/ONJ, which is a significant limitation.",Include,"A cohort study of osteoporosis patients undergoing dental extraction reveals significant methodological strengths, including a large sample size and clear control group. However, critical limitations exist, particularly the inclusion of cancer patients and absence of diagnostic standards for osteonecrosis of the jaw, which compromise the study's alignment with strict screening criteria. The research provides valuable insights into bisphosphonate-related jaw complications but falls short of meeting all predefined methodological requirements.",3.2
Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature,"Kununya Pimolbutr, S. Porter, S. Fedele",10.1155/2018/8071579,https://doi.org/10.1155/2018/8071579,BioMed Research International,62,2018,no,"The study focuses on patients taking antiangiogenics, not osteoporosis medications, so it fails this criterion.",yes,"The abstract documents time intervals (6.5 and 16.72 months before MRONJ development), meeting this criterion.",maybe,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The abstract mentions dental extraction as a risk factor, meeting this criterion.",no,"The abstract appears to be a literature review rather than one of the required study designs (RCT, cohort, or case-control).",yes,"The abstract mentions follow-up and disease resolution within 6.75 months, meeting this criterion.",yes,"The mean age of the subjects was 59.06 years, which meets the requirement of being over 18 years old.",no,"The study only includes 35 patients total, which is well below the required 100 subjects.",no,"The study examines antiangiogenics, not oral bisphosphonates, so it fails this criterion.",maybe,"The abstract mentions ""bone exposure"" but doesn't clearly specify diagnostic standards for MRONJ.",Exclude,"The study fails key screening criteria by focusing on antiangiogenics in cancer patients rather than oral bisphosphonates for osteoporosis, with a sample size of only 35 patients. Critical deviations include the wrong medication type, patient population, and study design, rendering the research ineligible for the systematic review. Multiple core screening requirements were not met, leading to automatic exclusion.",0.1
Association Between Malignant Diseases and Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis,"Sheng Yao, Xiaoyong Ding, Gang Rong, Jie Zhou, Bo Zhang",10.1097/SCS.0000000000009033,https://doi.org/10.1097/SCS.0000000000009033,The Journal of craniofacial surgery (Print),3,2022,no,"The study focuses on patients with malignant diseases, which is explicitly excluded by the criteria. This is a critical failure.",no,"The abstract does not mention documenting time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications, which is a significant limitation.",no,The abstract does not specify which dental procedures were studied in relation to MRONJ incidence.,yes,"The paper is a systematic review of cohort studies and case-control studies, which would meet the design criteria. However, this is a review rather than a primary study.",maybe,"While MRONJ occurrence is documented, the follow-up period is not specified.",maybe,"The abstract does not specify the age of the subjects, so this information is unclear.",maybe,"The abstract does not specify the number of subjects in the included studies, so this information is unclear.",no,"The study includes both bisphosphonates and other antiresorptive/antiangiogenic drugs, and specifically mentions intravenous administration, which fails to meet the criterion of only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple screening criteria, primarily due to its focus on cancer patients and inclusion of mixed medication types beyond oral bisphosphonates. Critical exclusion factors include the study's population, intervention type, and lack of specificity around diagnostic standards and dental procedures. These limitations significantly reduce the study's alignment with the predefined screening requirements.",1.4
Success rate and safety of dental implantology in patients treated with antiresorptive medication: A systematic review.,"I. Papadakis, A. Spanou, D. Kalyvas",10.1563/aaid-joi-d-19-00088,https://doi.org/10.1563/aaid-joi-d-19-00088,Journal of Oral Implantology,11,2020,maybe,"The abstract mentions ""patients receiving antiresorptive agents"" but does not specifically exclude cancer patients or mixed populations, creating uncertainty.",no,"The abstract does not document specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not explicitly mention a control group, which is a significant limitation.",yes,"The study focuses on dental implants and MRONJ, meeting this criterion.",no,"This is a systematic review, not a primary research study of the required designs (RCT, cohort, or case-control).",maybe,"While the study reports MRONJ cases (136 cases), it does not specify the follow-up period length.",maybe,"The abstract does not specify the age requirements, though it is likely these are adult patients given the context.",yes,"The study includes 5,221 patients total, which exceeds the 100-subject requirement.",maybe,"The abstract mentions ""antiresorptive medication"" broadly and specifically notes ""intravenous antiresorptive drugs"" as a contraindication, but does not specify oral bisphosphonates exclusively, creating uncertainty.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including lacking a clear control group, unspecified diagnostic standards, and absence of precise medication type documentation. While the study includes a large patient population and addresses dental implant procedures, its methodological limitations prevent it from satisfying the required research design and reporting standards. The broad nature of the review and lack of specific details create significant uncertainty about its alignment with the screening requirements.",1.4
A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients,"Seoyeon Jung, Jaeyeon Kim, Jin Hoo Park, Kiyomi Kim, Hyung Jun Kim, Wonse Park",10.1038/s41598-022-11615-9,https://doi.org/10.1038/s41598-022-11615-9,Scientific Reports,13,2022,yes,"The study clearly focuses on osteoporotic patients, excluding cancer patients, so this criterion is met.",no,"The abstract does not clearly document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The study does not include a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,"The study clearly reports MRONJ incidence following tooth extraction, meeting this criterion.",maybe,"While not explicitly stated, the study appears to be a retrospective cohort study based on the methodology described.",maybe,"The study documents MRONJ incidence after dental treatment, but the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, so the age criterion is uncertain.",yes,"The study includes 98 patients total (51+47), which meets the criterion of over 100 subjects for the medication group.",no,"The study focuses on denosumab, which is not an oral bisphosphonate, so this is a critical failure of the inclusion criteria.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on denosumab for osteoporosis patients, which critically fails the screening criteria requiring oral bisphosphonate medication. Multiple other screening criteria were not fully met, including lack of a control group, unclear diagnostic standards, and unspecified follow-up period. The primary disqualifying factor remains the use of denosumab instead of the required oral bisphosphonate intervention.",1.4
Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis,"H. Ikesue, Kohei Doi, M. Morimoto, M. Hirabatake, Nobuyuki Muroi, S. Yamamoto, T. Takenobu, T. Hashida",10.1007/s00520-021-06634-7,https://doi.org/10.1007/s00520-021-06634-7,Supportive Care in Cancer,14,2021,no,"The study focuses on cancer patients with bone metastasis, not osteoporosis patients, which is a critical exclusion criterion.",no,"The abstract does not provide specific information about the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The study does not include a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,The study meets this criterion as it mentions tooth extraction as a risk factor for MRONJ.,yes,The study meets this criterion as it is a retrospective cohort study.,maybe,"While the study documents MRONJ incidence, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, but since it is a cancer patient population, it can be reasonably assumed that they are adults. However, this is not explicitly confirmed.",yes,"The study meets this criterion as it includes 799 total patients (406 in the denosumab group, 393 in the ZA group).",no,"The study uses denosumab (a non-bisphosphonate) and zoledronic acid (an intravenous bisphosphonate), not oral bisphosphonates, which fails this criterion.",no,The abstract does not explicitly mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on cancer patients with bone metastasis, which critically disqualifies it from the screening criteria targeting osteoporosis patients. Additionally, the medications used (denosumab and zoledronic acid) do not match the required oral bisphosphonate intervention, further excluding the study from the systematic review. Multiple other screening criteria were either not met or remained unclear, leading to a definitive exclusion.",0.1
Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis,"P. Tennis, K. Rothman, Rhonda L. Bohn, H. Tan, A. Zavras, C. Laskarides, B. Calingaert, M. Anthony",10.1002/pds.3292,https://doi.org/10.1002/pds.3292,Pharmacoepidemiology and Drug Safety,77,2012,no,"The abstract mentions ""bisphosphonate exposure"" but does not specify if the subjects were taking medication for osteoporosis or other conditions.",no,"No information was provided about the time intervals between the start of medication, dental procedures, and MRONJ incidence.",no,No information was provided about whether the study included a control group of patients not taking anti-resorptive medications.,no,No information was provided about the specific dental procedures that were studied.,maybe,"The abstract mentions ""two cohorts"", suggesting a cohort study design, but there is insufficient detail to confirm the specific study design.",no,"While the abstract mentions ONJ incidence, it does not provide information about the follow-up period.",no,No information was provided about the age of the study subjects.,no,No information was provided about the sample size of the study.,no,The abstract mentions bisphosphonates but does not specify if the subjects were taking oral bisphosphonate medication or other forms.,no,No information was provided about the diagnostic standards used for MRONJ.,Exclude,"The extremely brief abstract provides insufficient detail to confidently assess most screening criteria, with only minimal confirmation of a cohort study design and bisphosphonate-related research. Critical information about population characteristics, intervention specifics, diagnostic standards, and outcome documentation is completely absent, rendering a comprehensive screening assessment impossible without accessing the full text.",1.4
Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?,"S. Soutome, S. Hayashida, M. Funahara, Y. Sakamoto, Y. Kojima, S. Yanamoto, M. Umeda",10.1371/journal.pone.0201343,https://doi.org/10.1371/journal.pone.0201343,PLoS ONE,52,2018,no,"The study specifically focuses on cancer patients taking high-dose bisphosphonates or denosumab, not osteoporosis patients. This is a critical exclusion criterion.",maybe,"The study mentions ""duration of medication before first visit to the dental unit"" but doesn't clearly document the time interval between dental procedure and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,The study specifically looks at tooth extraction and MRONJ incidence.,yes,"This is a retrospective cohort study, which is one of the accepted study designs.",yes,"The study reports MRONJ incidence with follow-up periods of 1, 2, and 3 years.",maybe,"While not explicitly stated, the context suggests these are adult cancer patients, so this criterion is likely met.",yes,"The study includes 135 patients, which exceeds the minimum requirement of 100 subjects.",no,"The study includes both high-dose bisphosphonates and denosumab (a non-bisphosphonate), and specifically focuses on cancer patients rather than osteoporosis patients.",no,The abstract doesn't explicitly mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on cancer patients taking high-dose bisphosphonates and denosumab, which critically fails the screening criteria for osteoporosis patient populations. Multiple key exclusion criteria were violated, including the specific patient population and medication type, rendering the study ineligible for systematic review. Despite meeting some methodological requirements, the fundamental population and intervention characteristics disqualify the research from inclusion.",1.4
Risk of Medication-Related Osteonecrosis of the Jaw after Dental Extractions in Patients Receiving Bone Resorption Inhibitors – A Retrospective Study of 240 Patients,"R. Coropciuc, R. Coopman, M. Garip, E. Gielen, C. Politis, T. Van den Wyngaert, B. Beuselinck",10.2139/ssrn.4248587,https://doi.org/10.2139/ssrn.4248587,Social Science Research Network,0,2022,no,"The study includes a mixed population of both osteoporosis patients and cancer patients (bone metastases), which violates the requirement for a pure osteoporosis population.",no,"The study mentions median drug exposure of 43 months, but does not clearly document the time interval between medication start and dental procedure, or between procedure and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,"The study specifically looks at dental extractions and reports MRONJ incidence, meeting this criterion.",yes,"The study is described as retrospective, which is an acceptable study design.",maybe,"The study reports MRONJ incidence and includes follow-up information (mucosal healing outcomes), but the specific follow-up period is not mentioned.",maybe,"While the context suggests the study included adult patients (osteoporosis treatment), the age of the subjects is not explicitly stated, so there is uncertainty about whether this criterion is met.",yes,"The osteoporosis cohort has 126 patients, which exceeds the minimum requirement of 100 subjects for the medication group.",maybe,"The abstract only mentions ""bone resorption inhibitors"" without specifying if they are oral bisphosphonates, creating uncertainty about whether this criterion is met.",no,The abstract does not explicitly mention the diagnostic standards for MRONJ.,Include,"The study fails key screening criteria due to a mixed patient population including cancer patients, which violates the requirement for a pure osteoporosis cohort. Uncertainties exist around intervention type, diagnostic standards, and MRONJ latency documentation, further compromising the study's alignment with screening requirements. While the research provides valuable insights into medication-related osteonecrosis, it does not meet the specified inclusion criteria.",2.7
Medication-related osteonecrosis of the jaw (MRONJ) stage III: Conservative and conservative surgical approaches versus an aggressive surgical intervention: A systematic review.,"V. Jasper, V. Laurence, Smeets Maximiliaan, J. Ferri, R. Nicot, P. Constantinus",10.1016/j.jcms.2020.02.017,https://doi.org/10.1016/j.jcms.2020.02.017,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,42,2020,no,"The study focuses on patients taking zoledronic acid, but it's not clear if these are osteoporosis patients or cancer patients. The abstract doesn't specify the indication.",no,"While the study mentions medication duration (>18 months), it doesn't document the specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract doesn't specify which dental procedures led to MRONJ.,yes,"The study is described as a ""retrospective cohort study,"" which meets this criterion.",yes,"The study has a 5-year follow-up period (2016-2020), which exceeds the 6-month requirement.",maybe,"The abstract doesn't explicitly state the age of subjects, but given it's a hospital-based study of MRONJ patients, they are likely adults.",no,"The study includes 58 patients (62 sites), which is below the required 100 subjects.",no,"The study uses intravenous zoledronic acid, not oral bisphosphonates.",no,The abstract doesn't mention the diagnostic standards used for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including using intravenous zoledronic acid instead of oral bisphosphonates, having fewer than 100 subjects, and lacking clarity on patient indication and diagnostic standards. Despite being a retrospective cohort study with adequate follow-up, fundamental mismatches with the inclusion criteria render the research unsuitable for further analysis.",1.4
Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates,"Elena-Beatriz Bermúdez-Bejarano, M. Serrera-Figallo, Aida Gutiérrez-Corrales, Manuel-María Romero-Ruíz, Raquel Castillo-de-Oyagüe, J. Gutierrez-Perez, D. Torres-Lagares",10.4317/jced.53372,https://doi.org/10.4317/jced.53372,Journal of Clinical and Experimental Dentistry,41,2017,no,"The abstract discusses patients taking both oral and intravenous bisphosphonates, and mentions chemotherapy-associated osteonecrosis, which violates the exclusion criteria.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The abstract mentions tooth extraction and oral surgery, which meets this criterion.",no,"This appears to be a literature review rather than a primary research study (RCT, cohort, or case-control), which fails the study design criterion.",maybe,"While the abstract discusses MRONJ outcomes, it does not specify the follow-up period.",maybe,"The abstract does not explicitly state the age of the subjects, so the reasoning is uncertain.",maybe,"The abstract does not mention the number of subjects studied, so the reasoning is uncertain.",no,"The study includes both oral and intravenous bisphosphonates, which violates the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The literature review fails multiple screening criteria, including study design, population characteristics, and intervention type. Specifically, it includes both oral and intravenous bisphosphonates, involves chemotherapy-associated cases, and lacks clear diagnostic standards and follow-up documentation. These fundamental deviations from the required research parameters render the study non-compliant with the established screening criteria.",1.4
[Osteonecrosis of the jaw associated with bisphosphonate therapy in primary osteoporosis. Review of the literature].,A. Outeiriño-Fernández,-,-,Anales del Sistema Sanitario de Navarra,2,2013,yes,"The abstract specifically mentions ""patients treated with bisphosphonates due to primary osteoporosis,"" which meets the population indication criterion.",maybe,"The abstract mentions a mean duration of treatment before MRONJ appeared (48.25 months), but doesn't clearly document the time from dental procedure to MRONJ incidence.",no,"The abstract does not mention a control group, so no reasoning is provided.",yes,"The abstract mentions ""dentoalveolar surgery"" and specifically mentions extraction, meeting the procedure and outcome criterion.",no,"This is a systematic review of case report series, which does not meet the required study design criteria (RCT, prospective cohort, retrospective cohort, or case-control).",no,"While the abstract mentions MRONJ cases, it doesn't specify the follow-up period.",yes,"The abstract mentions ""human adults"" and a mean age of 71.94 years, which meets the age requirement of over 18 years old.",no,"The abstract only includes 43 cases total, which is well below the required 100 subjects for the medication group at the final statistical analysis stage.",yes,"The abstract mentions bisphosphonates, specifically alendronate, and appears to focus on oral administration, meeting the intervention type criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet critical screening criteria, including insufficient sample size (43 cases vs. required 100), inappropriate study design (case report series), and lack of a control group. While the study addresses osteoporosis patients taking bisphosphonates and includes dental procedures, fundamental methodological limitations prevent its inclusion in a comprehensive systematic review.",1.4
Medication Related Osteonecrosis of the Jaw (MRONJ). Review and recent advances,"D. Galiti, Aikaterini Karayianni, K. Tsiklakis, A. Psyrri",10.2478/fco-2022-0005,https://doi.org/10.2478/fco-2022-0005,Forum of Clinical Oncology,1,2022,no,"The abstract focuses on cancer patients and mentions ""bone targeting agents (BTAs) and/or antiangiogenics"" which is explicitly excluded in the criteria, so this is a critical failure.",no,"The abstract does not document specific time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",maybe,"The abstract mentions dental extraction as a risk factor but does not report specific MRONJ incidence following procedures, so this criterion is partially met.",no,"This appears to be a review article discussing various aspects of MRONJ rather than a primary research study, and it does not fit any of the required study designs, so this criterion is not met.",no,"As a review article, it does not report specific MRONJ incidence or follow-up periods, so this criterion is not met.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning is uncertain.",maybe,"The abstract does not mention the sample size, so the reasoning is uncertain.",no,"The abstract discusses ""antiresorptive therapy"" broadly but does not specify oral bisphosphonates exclusively, and it appears to include other bone targeting agents, so this criterion is not met.",yes,"The abstract does provide diagnostic criteria for MRONJ, including exposed bone for >8 weeks and no history of radiotherapy, so this criterion is met.",Exclude,"The abstract fails multiple critical screening criteria, particularly by focusing on cancer patients and using a review article format instead of a primary research study. Key disqualifying factors include the population type, study design, and lack of specific oral bisphosphonate intervention details. The paper does not meet the required methodological standards for inclusion in the systematic review.",0.1
Frequency of osteonecrosis in bisphosphonate users submitted to dental procedures: systematic review.,"Lucio Henrique Ives Martins, Delaine Cristina Ferreira, M. Silva, R. Motta, Reginaldo Tavares Franquez, Cristiane de Cássia Bergamaschi",10.1111/odi.14003,https://doi.org/10.1111/odi.14003,Oral Diseases,10,2021,no,"The study includes mixed populations - both cancer patients (n=11) and osteoporosis patients (n=16), which fails to meet the criterion requiring exclusive focus on osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not explicitly mention a control group, which is a significant limitation.",maybe,"The abstract mentions dental procedures and MRONJ incidence, though specific procedures are not detailed.",no,"This is a systematic review, not a primary research study of the required designs (RCT, cohort, or case-control).",no,"While MRONJ incidence is reported (2.7%), the follow-up period is not specified.",maybe,"The abstract does not specify the age requirements, though given it's about osteoporosis patients, they're likely adults. However, this is not explicitly confirmed.",yes,"The study includes 5,391 total participants across 27 studies, which would meet the >100 subjects requirement.",no,"The study includes both oral and intravenous bisphosphonates, and doesn't focus exclusively on oral bisphosphonates, which fails to meet the criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including the requirement for an exclusive osteoporosis patient population and a focus on oral bisphosphonates. Significant methodological limitations include mixed patient populations, inclusion of intravenous medications, and lack of specific diagnostic standards for MRONJ. These deficiencies substantially compromise the study's alignment with the predefined screening requirements.",1.4
Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center,"Saad Hajeri, Yasir Alturkistany",10.1016/j.sdentj.2022.06.004,https://doi.org/10.1016/j.sdentj.2022.06.004,Saudi Dental Journal,2,2022,no,"The study includes a mixed population of both cancer and non-cancer patients, as it mentions ""antiresorptive or antiangiogenic therapy"" without specifying osteoporosis patients only. This is a critical failure of the inclusion criteria.",maybe,"The study documents time intervals between medication start and dental procedures, though not explicitly for MRONJ incidence.",maybe,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study reports MRONJ incidence following dentoalveolar surgery, which meets this criterion.",yes,"The study is described as a retrospective study, which meets the criteria for study design.",maybe,"The study reports MRONJ incidence and appears to have a follow-up period (2008-2018), though the specific follow-up duration per patient isn't mentioned.",maybe,"The abstract does not explicitly state the age of the subjects, so the age criteria is unclear.",yes,"The study includes 358 patients in the medication group, which exceeds the minimum requirement of 100 subjects.",no,"The study includes both oral and intravenous bisphosphonates, as well as subcutaneous route medications, which is a critical failure as it should only include oral bisphosphonates.",yes,"The abstract mentions classification into ""stage 0, stage 1, stage 2, or stage 3 MRONJ,"" suggesting diagnostic standards were used, though not explicitly detailed.",Include,"The study fails critical screening criteria by including a mixed patient population with both cancer and non-cancer patients, and by incorporating multiple medication routes beyond oral bisphosphonates. While the research demonstrates some methodological strengths like a retrospective design and clear MRONJ staging, fundamental inclusion requirements are not met, rendering the study non-compliant with the specified screening criteria.",2.5
Medication-Related Osteonecrosis of the Jaws: Two Center Retrospective Cohort Studies,"M. Petrovic, D. Jelovac, S. Antić, Marija Antunović, N. Lukic, M. Šabani, J. Mudrak, Z. Jezdić, A. Pucar, A. Stefanović, Č. Kuzmanović, D. Nikolic, V. Konstantinovic",10.1155/2019/8345309,https://doi.org/10.1155/2019/8345309,BioMed Research International,18,2019,no,"The study includes a mixed population of both osteoporosis (11 patients) and cancer patients (21 patients), which fails the criterion requiring exclusive focus on osteoporosis patients.",no,"The abstract does not clearly document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study reports MRONJ incidence following tooth extraction (30 out of 32 cases), meeting this criterion.",yes,"The study is described as a ""retrospective cohort study,"" which meets this criterion.",maybe,"While the study documents MRONJ incidence and outcomes, the follow-up period is not explicitly stated, making it unclear if it meets the 6-month requirement.",yes,"The study includes patients aged 35-84, which meets the criterion of subjects being over 18 years old.",no,"The total study size is 32 patients, with only 11 in the osteoporosis group, which fails to meet the minimum requirement of 100 subjects in the medication group.",maybe,"While the abstract mentions ""oral regime intake"" and ""BPs"" (bisphosphonates), it's not explicitly clear if all patients were taking oral bisphosphonates exclusively.",yes,"The abstract mentions clinical, radiological examination (Orthopantomograph and CBCT) and biopsy for diagnosis, meeting this criterion.",Exclude,"The study fails key screening criteria due to a mixed patient population including cancer patients, a small sample size of only 32 patients, and lack of a clear control group. While the research provides insights into MRONJ, it does not meet the required methodological standards for inclusion, particularly regarding population specificity and sample size. The mixed patient population and limited subject count are significant disqualifying factors.",1.4
The risk of osteonecrosis of the jaw and adverse outcomes in patients using antiresorptive drugs undergoing orthodontic treatment: A systematic review,"Julian Woolley, O. Akintola, J. Yates, M. Calasans-Maia, Jose de Albuquerque Calasans-Maia, Iryna Kocherhina, R. Sacco",10.1016/j.heliyon.2021.e05914,https://doi.org/10.1016/j.heliyon.2021.e05914,Heliyon,8,2021,no,"The study focuses on patients taking antiresorptive therapy, but does not specifically mention osteoporosis patients. It appears to be a mixed population study, which is excluded by the criteria.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,"The study focuses on orthodontic treatment, which is not one of the specified dental procedures (extraction, periodontal surgery, implant placement, or removable prosthetic treatment).",no,"This is a systematic review, not a primary research study of the types specified in the criteria (randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study).",no,"While MRONJ incidence is mentioned (1 patient), the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, so it is unclear if the population meets the age requirement of over 18 years old.",no,"The study only reports on 29 patients total, which is well below the required 100 subjects for the medication group.",no,"While bisphosphonates are mentioned, the study refers broadly to ""antiresorptive drugs"" and does not specify oral bisphosphonates exclusively.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including insufficient subject size, inappropriate study design, and lack of specificity in population and intervention type. Key disqualifying factors include a mixed patient population, focus on orthodontic treatment instead of specified dental procedures, and absence of a control group. The study's fundamental methodological limitations render it unsuitable for inclusion based on the predefined screening requirements.",0.1
Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: a randomized clinical feasibility trial of drug holiday versus drug continuation.,"C. Ottesen, M. Schiødt, S. S. Jensen, T. Kofod, K. Gotfredsen",10.1016/j.oooo.2021.06.003,https://doi.org/10.1016/j.oooo.2021.06.003,"Oral surgery, oral medicine, oral pathology and oral radiology",33,2021,no,"The study specifically focuses on cancer patients receiving high-dose antiresorptive medication, not osteoporosis patients. This is a clear violation of the inclusion criteria.",maybe,The study documents the timing of drug holiday (1 month before to 3 months after extraction) but doesn't clearly document the time from medication start to procedure.,no,The study does not include a control group of patients not taking anti-resorptive medications. It only compares drug holiday vs drug continuation groups.,yes,"The study specifically looks at MRONJ incidence following surgical tooth extraction, which meets this criterion.",yes,"The study is described as a ""feasibility trial"" with randomization, which appears to be a randomized controlled trial design.",yes,"The study has a follow-up period of 6 months, which meets the minimum requirement.",maybe,"The abstract does not explicitly state the age of subjects. While it's likely they are adults given the cancer context, this is not confirmed.",no,"The study only included 23 patients total (13 denosumab, 10 bisphosphonate), which is well below the required 100 subjects.",no,"The study includes both bisphosphonates and denosumab (a monoclonal antibody), and mentions both oral and intravenous administration. This does not meet the criterion of only oral bisphosphonates.",maybe,"While MRONJ is discussed extensively, the abstract does not explicitly mention the diagnostic standards used.",Exclude,"The study fails critical screening criteria by focusing on cancer patients instead of osteoporosis patients, having an insufficient sample size of only 23 subjects, and including non-bisphosphonate medications. Multiple methodological limitations, including the absence of a control group and unclear diagnostic standards, further disqualify the research from meeting the systematic review requirements. The fundamental mismatch in patient population and intervention type renders the study non-compliant with the established screening criteria.",0.1
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases,"H. Ikesue, Moe Mouri, H. Tomita, M. Hirabatake, M. Ikemura, Nobuyuki Muroi, S. Yamamoto, T. Takenobu, K. Tomii, M. Kawakita, Hironori Katoh, T. Ishikawa, H. Yasui, T. Hashida",10.1007/s00520-021-06018-x,https://doi.org/10.1007/s00520-021-06018-x,Supportive Care in Cancer,28,2021,no,"The study specifically focuses on cancer patients receiving bone-modifying agents for bone metastases, not osteoporosis patients, which violates the inclusion criterion.",maybe,The study documents time to resolution of MRONJ but does not clearly document the time interval between medication start and dental procedure.,no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,The study mentions tooth extraction as a dental procedure and reports MRONJ incidence following this procedure.,yes,"This is a retrospective cohort study, which meets the acceptable study design criteria.",yes,"The study reports MRONJ incidence and includes follow-up periods (median resolution times of 26.8 months for denosumab group), exceeding the 6-month requirement.",yes,"The study includes patients over 65 years, meeting the >18 years criterion.",yes,"The study includes 374 patients total (215 denosumab, 159 zoledronic acid), exceeding the 100-subject requirement.",no,"The study uses denosumab and zoledronic acid, which are not oral bisphosphonates, violating the intervention criterion.",maybe,The abstract does not explicitly mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on cancer patients receiving bone-modifying agents, which fundamentally conflicts with the requirement for an osteoporosis patient population. Critical screening criteria were not met, specifically the population indication and intervention type, rendering the study unsuitable for inclusion. Multiple methodological elements failed to align with the predefined systematic review requirements.",1.4
Patients Receiving Parenteral Bisphosphonates for Malignant Disease and Having Developed an Atypical Femoral Fracture Are at Risk of Concomitant Osteonecrosis of the Jaw: An Evidence-Based Review.,"L. Graves, S. Bukata, Nona Aghazadehsanai, Tina I. Chang, N. Garrett, A. Friedlander",10.1016/j.joms.2016.06.003,https://doi.org/10.1016/j.joms.2016.06.003,Journal of oral and maxillofacial surgery,15,2016,no,"The study specifically focuses on patients taking bisphosphonates for malignant disease, which explicitly violates the criterion requiring patients taking medication for osteoporosis.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,no,"The paper is a systematic review of case series, which does not meet the required study design criteria.",maybe,"While MRONJ incidence is reported (25-33%), the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, but given the context of femoral fractures, they are likely adults.",no,"The abstract mentions analyzing two case series but does not specify the total number of subjects. Given these are case series, they likely have fewer than 100 subjects.",no,"The study specifically looks at parenteral (intravenous) bisphosphonates, which explicitly violates the criterion requiring oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients receiving parenteral bisphosphonates, which fundamentally conflicts with the screening criteria requiring osteoporosis patients taking oral medications. Multiple critical screening requirements are not met, including study design, population indication, intervention type, and lack of specific dental procedure documentation. The research fails to align with the predefined methodological standards for the intended review.",0.1
Effect of Antiresorptive Drugs on Osseointegrated Dental Implants: A Systematic Review,"Joyce Tin Wing Li, Y. Leung",10.3390/jcm13072091,https://doi.org/10.3390/jcm13072091,Journal of Clinical Medicine,5,2024,maybe,"The abstract focuses on patients taking antiresorptive medications, but does not explicitly exclude cancer patients or specify that the subjects are osteoporosis patients, which is a significant uncertainty.",yes,"The abstract documents the time interval from medication start to MRONJ development (average 34 months), meeting this criterion.",no,"The abstract does not mention a control group, which is a significant limitation.",yes,"The study focuses on dental implants, which is one of the specified procedures, and reports MRONJ incidence.",no,"This is a systematic review, not a primary research study of the required types, which is a clear failure of this criterion.",maybe,"The study documents MRONJ incidence and appears to have long-term follow-up, though the exact follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, but given the focus on dental implants and antiresorptive therapy, it is likely that the subjects are adults, though this is not certain.",no,"The study includes 135 subjects total, which is below the required 100 subjects per medication group, and this is a clear failure of this criterion.",no,"The abstract only mentions ""antiresorptive drugs"" generally, without specifying oral bisphosphonates, which is too broad and does not meet the criterion.",maybe,"The abstract mentions MRONJ classification (stage 2), suggesting diagnostic standards were used, but does not explicitly state them.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including insufficient subject size, lack of a control group, and unclear population specifics. While documenting MRONJ incidence and latency, the study does not qualify as a primary research study with the required methodological rigor. Significant limitations in intervention type, diagnostic standards, and study design prevent the abstract from satisfying the comprehensive screening requirements.",1.4
The Type of Antiresorptive Treatment Influences the Time to Onset and the Surgical Outcome of Medication-Related Osteonecrosis of the Jaw.,"C. Pautke, A. Wick, S. Otto, B. Hohlweg-Majert, J. Hoffmann, O. Ristow",10.1016/j.joms.2020.10.005,https://doi.org/10.1016/j.joms.2020.10.005,Journal of oral and maxillofacial surgery,11,2020,maybe,"The study focuses on patients taking bisphosphonates and denosumab for osteoporosis treatment, but doesn't explicitly exclude cancer patients. This creates some uncertainty.",yes,"The study documents time from medication start to MRONJ diagnosis, meeting this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract mentions ""trigger events"" but doesn't specifically detail which dental procedures were involved.",yes,"The abstract explicitly states it's a ""retrospective single-center cohort study,"" which meets this criterion.",yes,"The study follows patients for 12 months postoperatively, meeting the 6-month follow-up requirement.",maybe,"The abstract doesn't explicitly state the age of subjects, but given it's a study of MRONJ patients, they are likely adults. However, this is uncertain without explicit confirmation.",yes,"The study includes 132 patients total, with 45 in the bisphosphonate group, which meets the criterion of >100 subjects in the medication group.",no,The study includes both oral bisphosphonates and denosumab (a non-bisphosphonate). This partially fails the criterion as it includes non-bisphosphonate medication.,no,The abstract doesn't explicitly mention the diagnostic standards used for MRONJ.,Include,"A retrospective cohort study examining medication-related osteonecrosis of the jaw across different antiresorptive treatments, involving 132 patients with mixed medication types. While meeting several screening criteria like study design and sample size, the research includes non-bisphosphonate medications and lacks clear diagnostic standards, creating significant uncertainty about its alignment with specific screening requirements. The study's comprehensive analysis of MRONJ onset and treatment success is offset by methodological limitations that could impact its inclusion in a systematic review.",2.9
Medication‐related osteonecrosis of the jaw: A literature review and update,"S. Kuroshima, Farah A. Al-Omari, Muneteru Sasaki, T. Sawase",10.1002/dvg.23500,https://doi.org/10.1002/dvg.23500,Genesis,17,2022,no,"While the abstract mentions both cancer and osteoporosis patients, it does not focus exclusively on osteoporosis patients. The paper appears to be a general review covering multiple patient populations.",no,"No information about time intervals between medication start, dental procedures, and MRONJ incidence is provided.",no,"The abstract does not mention any control group, as this is a review article and not an original research study.",no,The abstract does not discuss specific dental procedures or their relationship to MRONJ incidence.,no,"This is a literature review article, not one of the accepted study designs (RCT, cohort study, or case-control study).",no,"As a review article, it does not report original MRONJ incidence data or follow-up periods.",no,The abstract does not specify any age requirements for the subjects.,no,"As a review article, the paper does not have its own subject group size.",no,"While bisphosphonates are mentioned, the paper discusses multiple medications including denosumab and angiogenesis inhibitors, not exclusively oral bisphosphonates.",no,"While the abstract mentions ""definition"" of MRONJ, it does not specify any diagnostic standards.",Exclude,"This literature review fails to meet multiple screening criteria for an original research study, including lack of a control group, undefined population age, mixed patient populations, and absence of specific dental procedure outcomes. The paper provides a comprehensive overview of MRONJ pathophysiology but does not qualify as a primary research study for systematic review inclusion.",0.1
An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients.,"K. Athanassios, T. Tzellos, K. Toulis, A. Arora, D. Kouvelas, S. Triaridis",10.2174/1574884711308020005,https://doi.org/10.2174/1574884711308020005,Current Clinical Pharmacology,15,2013,no,"The study specifically focuses on cancer patients receiving bone antiresorptive therapy, which explicitly violates the criterion that requires subjects to be osteoporosis patients, not cancer patients.",maybe,"The abstract does not document the time intervals between medication start, dental procedures, and ONJ incidence.",maybe,The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications. It focuses on comparing different types of medications.,yes,"The study does mention dental extractions as a risk factor for ONJ, which meets this criterion.",yes,"The paper is a systematic review of RCTs and cohort studies, which meets this criterion.",maybe,"While the study reports ONJ incidence, it does not specify the follow-up period.",maybe,The abstract does not specify the age of the subjects.,maybe,The abstract does not specify the number of subjects in the included studies.,no,"The study includes multiple types of medications (denosumab, zoledronic acid, clodronate, pamidronate) and does not focus exclusively on oral bisphosphonates.",maybe,The abstract does not mention specific diagnostic standards for MRONJ/ONJ.,Exclude,"The systematic review focuses on cancer patients receiving bone antiresorptive therapy, which directly conflicts with the requirement for an osteoporosis patient population. Multiple intervention types beyond oral bisphosphonates are included, and critical methodological details such as diagnostic standards, subject age, and follow-up period are not clearly specified. These fundamental deviations from the screening criteria render the study unsuitable for inclusion.",0.1
CLEP_A_325080 1019..1026,"L. Stevens, L. Spangler, L. Yochum, Yan Ding, Florence T. Wang",-,-,-,0,2021,yes,"The study specifically looks at postmenopausal women and women with postmenopausal osteoporosis, excluding cancer patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,yes,"The study appears to be a retrospective cohort study using claims data, which meets the criterion for study design.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified.",yes,"The study focuses on postmenopausal women, implying the subjects are over 18 years old.",no,"The study identified 1,273 potential cases, but only confirmed 6 cases, which is well below the required 100 subjects for the medication group.",maybe,"The abstract does not specify the type of medication being studied, so it is unclear if the study only includes subjects taking oral bisphosphonate medication.",yes,"The study uses ICD-9 and ICD-10 codes and chart review by an oral surgeon for diagnosis, which implies a diagnostic standard for MRONJ.",Include,"The study fails to meet several critical screening criteria, including insufficient sample size, lack of specific dental procedures, and absence of a control group. While the research focuses on postmenopausal women with osteoporosis and uses diagnostic codes for MRONJ identification, it does not provide comprehensive documentation of medication type, latency periods, or follow-up outcomes. The paper appears more suited as a methodological validation study rather than a definitive clinical investigation of MRONJ incidence.",2.5
The effect of antiresorptive drugs on implant therapy: Systematic review and meta‐analysis,"A. Stavropoulos, K. Bertl, P. Pietschmann, N. Pandis, M. Schiødt, B. Klinge",10.1111/clr.13282,https://doi.org/10.1111/clr.13282,Clinical Oral Implants Research,93,2018,maybe,"The study included both osteoporosis patients and cancer patients, which violates the criterion of excluding mixed populations. However, the analysis was separated for osteoporosis patients.",yes,The study documented the timing of MRONJ occurrence relative to medication start (>36 months for osteoporosis patients).,yes,"The study included a control group of patients not taking anti-resorptive medications, which is relevant to this criterion.",yes,"The study focused on implant therapy and associated procedures, which includes the specified dental procedures.",yes,"The abstract mentions including ""case series, cohort studies, case-control studies, and controlled and/or randomized controlled clinical trials,"" which meets the study design criterion.",maybe,"While the study documented MRONJ incidence, the follow-up period was not explicitly stated.",maybe,"The abstract only mentions ""adult population"" but does not specify the exact age ranges, creating some uncertainty about whether the subjects were over 18 years old.",maybe,"The abstract mentions ""≥10 patients"" in the inclusion criteria but does not specify the final analysis sample size, creating uncertainty about whether the study included over 100 subjects in the medication group.",maybe,"The study focused on oral bisphosphonates, but also included hormone replacement therapy (HRT) and did not explicitly exclude other medications. However, the analysis was separated for BP patients.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study partially meets screening criteria with strengths in control group design, intervention type, and procedure documentation, but exhibits significant limitations including a mixed patient population, unclear sample size, and absence of specific MRONJ diagnostic standards. Critical uncertainties exist around age specifications, follow-up period, and precise subject groupings, which complicate a definitive assessment against the established screening requirements.",2.9
"A Review On Medication-Related Osteonecrosis Of The Jaw: Definition and Best Practice For Prevention, Diagnosis, and Treatment",L. Thangavelu,10.19070/2377-8075-21000400,https://doi.org/10.19070/2377-8075-21000400,-,0,2021,no,"The abstract mentions both osteoporosis and bone metastases patients, indicating a mixed population. This fails to meet the criterion requiring exclusive focus on osteoporosis patients.",no,"No mention of time intervals between medication start, dental procedures, and MRONJ incidence, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",maybe,"While dental procedures are mentioned generally (""prophylactic dental care""), specific procedures are not detailed, so the criterion is only partially met.",no,"This appears to be a review article rather than any of the specified study designs, so the criterion is not met.",no,"As a review article, it doesn't present original outcome data or follow-up periods, so the criterion is not met.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any sample size, so the reasoning for this criterion is uncertain.",maybe,"While bisphosphonates are mentioned, the abstract also discusses denosumab and doesn't specify oral administration, so the criterion is only partially met.",maybe,"The abstract mentions ""definition"" of MRONJ but doesn't specify diagnostic standards, so the reasoning for this criterion is uncertain.",Exclude,"This review article fails to meet multiple critical screening criteria, including the requirement for an original research study design and a focused population of osteoporosis patients. The mixed population, lack of specific diagnostic standards, and absence of original data collection render the paper unsuitable for inclusion in the systematic review.",0.1
Recurrence-Related Factors of Medication-Related Osteonecrosis of the Jaw: A 5-Year Experience.,"Shuo Chen, Hongyu Ren, Yang He, J. An, Yi Zhang",10.1016/j.joms.2021.07.029,https://doi.org/10.1016/j.joms.2021.07.029,Journal of oral and maxillofacial surgery,9,2021,no,"The study focuses on patients taking zoledronic acid, but it's not clear if this is specifically for osteoporosis or other conditions. The abstract doesn't specify the indication.",no,"While the study mentions medication duration, it doesn't specifically document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not specify which dental procedures were involved in the MRONJ cases.,yes,"The study is described as a retrospective cohort study, which meets this criterion.",maybe,"The study does follow patients for treatment outcomes, but the specific follow-up period is not mentioned.",maybe,"The abstract does not explicitly state the age of subjects, though given it's a study of MRONJ patients, they are likely adults.",no,"The study includes 58 patients, which is below the required 100 subjects for the medication group.",no,"The study uses intravenous zoledronic acid, not oral bisphosphonates.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including using intravenous zoledronic acid instead of oral bisphosphonates, having a sample size below 100, and lacking clear specification of osteoporosis as the primary indication. Significant methodological gaps exist, including missing diagnostic standards, undefined dental procedures, and unclear follow-up periods, which substantially compromise the study's alignment with the predefined screening requirements.",1.4
In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review,"R. H. Guirguis, L. Tan, Rebecca M. Hicks, Aniqa Hasan, Tina D. Duong, Xia Hu, Jordan Y. S. Hng, M. H. Hadi, Henry C. Owuama, Tamara Matthyssen, M. McCullough, Federica Canfora, R. Paolini, A. Celentano",10.3390/biom13060973,https://doi.org/10.3390/biom13060973,Biomolecules,6,2023,no,The study does not involve patients taking medication for osteoporosis. It's a laboratory study examining the effects of drugs on cell cultures.,no,The study does not document time intervals related to MRONJ development in patients.,no,"The abstract does not mention any control groups, indicating that this is a laboratory study of cell cultures rather than a clinical study with patient groups.",no,The study does not examine MRONJ incidence following dental procedures. It examines cellular responses to drugs in laboratory conditions.,no,"This is a laboratory study (in vitro study) reviewing other in vitro studies. It does not match any of the required study designs (RCT, cohort, or case-control).",no,The study does not document MRONJ incidence after dental treatment or follow-up periods.,no,The study does not involve human subjects at all - it's an in vitro study of cell cultures.,no,"The study does not involve human subjects, so the 100-subject requirement is not applicable.",no,"While the study does examine bisphosphonates, it's not studying patients taking oral bisphosphonates for osteoporosis treatment. Instead, it's examining the direct effects of these drugs on cell cultures.",no,The study does not document diagnostic standards for MRONJ as it's not a clinical study.,Exclude,"This in vitro laboratory study examining cellular responses to antiresorptive drugs fundamentally differs from the required clinical research criteria. The paper lacks patient populations, clinical interventions, dental procedures, and MRONJ diagnostic standards, rendering it incompatible with the systematic review's screening requirements. No clinical elements are present to meet the specified inclusion criteria.",0.1
ONJ in Two Dental Practice-Based Research Network Regions,"J. Fellows, D. Rindal, A. Barasch, C. Gullion, W. Rush, D. Pihlstrom, J. Richman",10.1177/0022034510387795,https://doi.org/10.1177/0022034510387795,Journal of dentistry research,49,2011,maybe,"While the study includes patients taking bisphosphonates for osteoporosis, it's not explicitly stated that all cases were osteoporosis patients. The abstract mentions ""potential risk factors"" including osteoporosis, suggesting a mixed population.",no,"No information about time intervals between medication start, dental procedures, and ONJ incidence is provided.",yes,"The study explicitly compares bisphosphonate-exposed vs non-exposed patients, with clear odds ratios reported, indicating the inclusion of a control group.",no,The abstract doesn't specify whether ONJ cases were related to specific dental procedures.,yes,This appears to be a retrospective cohort study using electronic records.,maybe,"While ONJ incidence is documented (23 cases), the follow-up period isn't explicitly stated.",yes,"The study includes adults aged ≥35 years, meeting the >18 requirement.",yes,"The total cohort of 572,606 patients exceeds the 100-subject requirement.",maybe,"The study specifically mentions oral bisphosphonates, but doesn't exclude other types of bisphosphonates or non-bisphosphonate medications.",no,The abstract doesn't mention specific diagnostic standards for ONJ.,Include,"A large retrospective cohort study examining osteonecrosis of the jaw in adults over 35 years old, with a substantial sample size of 572,606 patients. While the research provides insights into oral bisphosphonate exposure and ONJ risk, it lacks specific details about dental procedures, diagnostic standards, and precise patient population characteristics. The study partially meets screening criteria but has notable limitations in comprehensive documentation of key research parameters.",2.9
"Medication-related osteonecrosis of the jaw: a narrative review of risk factors, diagnosis, and management","Jacob G. Thomas, A. Ouanounou",10.21037/fomm-21-106,https://doi.org/10.21037/fomm-21-106,Frontiers of Oral and Maxillofacial Medicine,4,2021,no,"The abstract mentions that the review includes both osteoporosis patients and cancer patients, indicating a mixed population rather than a focus on osteoporosis patients only.",no,"The abstract does not document specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, indicating that this is a narrative review rather than an original research study.",maybe,"The abstract mentions ""dentoalveolar surgery"" as a common initiating factor for MRONJ, which includes extractions, but this is in a review context rather than reporting original research outcomes.",no,"This is explicitly a narrative review, which does not meet the required study design criteria.",no,"As a review article, it does not report original MRONJ incidence data or follow-up periods.",no,The abstract does not specify age requirements for the subjects.,no,"As a narrative review, this paper does not have its own subject group.",no,The abstract discusses antiresorptive agents broadly but does not focus specifically on oral bisphosphonates.,no,"The abstract mentions that ""Diagnosis is primarily based on clinical factors"" but does not specify detailed diagnostic standards.",Exclude,"This narrative review fails to meet multiple screening criteria, including the requirement for an original research study design, specific population characteristics, and detailed outcome documentation. The paper provides a broad overview of medication-related osteonecrosis of the jaw but lacks the precise methodological elements needed for systematic review inclusion. Its comprehensive nature as a review article precludes it from satisfying the rigorous research study requirements.",0.1
Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis?,"I. Giovannacci, M. Meleti, M. Manfredi, C. Mortellaro, A. Greco Lucchina, M. Bonanini, P. Vescovi",10.1097/SCS.0000000000002564,https://doi.org/10.1097/SCS.0000000000002564,The Journal of craniofacial surgery (Print),58,2016,no,"The study included a mixed population of both osteoporosis patients and cancer patients, which violates the requirement for the research to specify that its subject is chosen from patients taking medication for osteoporosis, excluding cancer patients.",yes,"The study documents time intervals between medication start and dental procedures, and between procedures and MRONJ incidence, so points were added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study does report MRONJ incidence following dental procedures (implant placement), meeting this criterion.",no,"The study appears to be a case series, which is explicitly excluded in the criteria.",maybe,"While the study documents MRONJ incidence, the follow-up period is not clearly specified beyond the mentioned timeframes for MRONJ development, so the reasoning is uncertain.",maybe,"While the context suggests the study included adult patients, the age of the subjects was not explicitly stated, so the reasoning is uncertain.",no,"The study only included 15 patients total, which is well below the required 100 subjects for the medication group.",no,"The study included both oral and intravenous bisphosphonates, which violates the requirement for only oral bisphosphonates.",no,The abstract does not explicitly mention diagnostic standards for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including insufficient subject size, mixed patient population, and case series design. Specifically, the research includes cancer patients, uses both oral and intravenous bisphosphonates, and lacks a control group, which disqualifies it from meeting the predefined inclusion standards. Despite documenting MRONJ latency and dental procedures, the fundamental methodological limitations prevent the study from satisfying the required screening parameters.",1.4
Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database,"A. Inada, K. Hosohata, S. Oyama, I. Niinomi, Y. Mori, Y. Yamaguchi, M. Uchida, K. Iwanaga",10.2147/TCRM.S176620,https://doi.org/10.2147/TCRM.S176620,Therapeutics and Clinical Risk Management,13,2018,no,"The study includes both osteoporosis and cancer patients, which violates the requirement for a pure osteoporosis population.",maybe,"While the abstract mentions timing for denosumab (""onset occurred after 1 year""), it doesn't provide complete latency information for both medication start to procedure and procedure to MRONJ.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures were associated with MRONJ cases.,no,"This is a retrospective pharmacovigilance analysis using a database, which doesn't strictly fit into the required study design categories.",maybe,"While the study documents MRONJ incidence and outcomes, the follow-up period is not specified.",yes,"The study includes patients over 70 years of age, meeting the requirement for subjects to be over 18 years old.",yes,"The study includes 3,875 cases total, with 1,283 zoledronate-related cases, exceeding the 100-subject requirement.",no,"The study includes both oral bisphosphonates (zoledronate) and denosumab (a non-bisphosphonate), violating the requirement for only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study fails key screening criteria due to a mixed patient population including both osteoporosis and cancer patients, and the inclusion of non-bisphosphonate medications. While the research has a large sample size and documents MRONJ cases, it does not meet the required study design, lacks specific diagnostic standards, and omits details about dental procedures associated with medication-related osteonecrosis of the jaw.",2.5
Clinical features of peri-implant medication-related osteonecrosis of the jaw: Is there an association to peri-implantitis?,"M. Troeltzsch, D. Cagna, Philip Stähler, F. Probst, G. Kaeppler, M. Troeltzsch, M. Ehrenfeld, S. Otto",10.1016/j.jcms.2016.09.018,https://doi.org/10.1016/j.jcms.2016.09.018,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,47,2016,no,"The abstract specifically mentions that ""the majority of whom had received antiresorptive drug therapy within oncologic treatment protocols,"" which fails the criterion as it includes cancer patients and appears to be a mixed population.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The study focuses on dental implants but doesn't specifically report MRONJ incidence following dental procedures. Instead, it examines existing MRONJ cases with implants.",yes,"The study is described as a ""retrospective study design,"" which meets the criterion.",maybe,"While the study documents MRONJ occurrence, it doesn't clearly specify the follow-up period.",yes,"The study includes patients with an average age of 70.6 years, which meets the criterion of subjects being over 18 years old.",no,"The study includes 34 patients with 117 implants, which is below the required 100 subjects for the medication group.",no,"The abstract only mentions ""antiresorptive drug therapy"" without specifying oral bisphosphonates. Given the oncologic context, these are likely not oral bisphosphonates.",no,"While MRONJ is mentioned, the abstract doesn't specify the diagnostic standards used.",Exclude,"The study fails key screening criteria due to its mixed population including cancer patients, small sample size of 34 patients, and lack of specificity regarding oral bisphosphonate medication. Critical methodological limitations include absence of a control group, unclear diagnostic standards for MRONJ, and focus on existing MRONJ cases rather than incidence after dental procedures. These deficiencies significantly compromise the study's alignment with the predefined screening requirements.",1.4
Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw,"Lina He, Xiangyu Sun, Zhijie Liu, Yanfen Qiu, Y. Niu",10.1038/s41368-020-00093-2,https://doi.org/10.1038/s41368-020-00093-2,International Journal of Oral Science,64,2020,no,"The abstract mentions ""bone-modifying agents and inhibits angiogenesis agents"" but does not specifically focus on osteoporosis patients. It appears to be a general review of MRONJ, so it fails this criterion.",no,"The abstract does not mention any time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract does not mention specific dental procedures or their relationship to MRONJ incidence, so it fails this criterion.",no,"This is explicitly a review paper, not one of the accepted study designs (RCT, cohort, or case-control), so it fails this criterion.",no,"As a review paper, it does not document specific MRONJ incidence or follow-up periods, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the reasoning for this criterion is unknown.",no,"As this is a review paper, it does not have its own subject group, so it fails this criterion.",no,"The abstract does not specify oral bisphosphonates, instead referring broadly to ""bone-modifying agents,"" so it fails this criterion.",no,"While the abstract mentions ""clinical staging,"" it does not specify diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"This review paper fails multiple critical screening criteria, including lack of a specific study design, absence of a defined patient population, and no documentation of specific dental procedures or MRONJ incidence. The abstract represents a broad overview of MRONJ rather than an original research study meeting the systematic review's methodological requirements. Consequently, the paper would be excluded from further consideration.",0.1
Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents,"F. Rodríguez-Lozano, R. Oñate-Sánchez",10.4317/medoral.20980,https://doi.org/10.4317/medoral.20980,Medicina Oral,22,2016,maybe,"The abstract mentions patients treated with bisphosphonates and other antiresorptive agents, but does not specifically exclude cancer patients or mixed populations, so the criterion is only partially met.",no,"The abstract does not mention any time intervals, so no points were added for this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"The abstract does not mention specific dental procedures leading to MRONJ, so the criterion is not met.",no,"This is a systematic review, not a primary research study of any of the specified designs, so the criterion is not met.",maybe,"While the paper discusses MRONJ treatment, it does not specify the follow-up periods, so the reasoning is uncertain.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning is uncertain.",maybe,"The abstract does not mention the sample size, so the reasoning is uncertain.",maybe,"The abstract mentions bisphosphonates but also includes ""other antiresorptive agents"" and does not specify oral administration, so the criterion is only partially met.",maybe,"The abstract mentions AAOMS guidelines but does not specify the diagnostic standards for MRONJ, so the criterion is only partially met.",Exclude,"This systematic review fails to meet multiple critical screening criteria, including lacking a primary research study design and not specifying dental procedures leading to MRONJ. The abstract includes mixed medication types and lacks clear documentation of control groups, sample size, and follow-up periods, rendering it unsuitable for the specified research parameters.",1.4
Medication Related Osteonecrosis of the Jaws,"Semih Özbayrak, Ö. Okumuş",-,-,-,0,2020,no,"While osteoporosis is mentioned as one of the indications for bisphosphonates, the abstract discusses multiple conditions including cancer (lung, prostate, breast carcinomas, multiple myeloma). This appears to be a mixed population review, which fails this criterion.",no,"No information about time intervals is provided, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While MRONJ is discussed, the abstract doesn't specifically mention any of the required dental procedures, so it fails this criterion.",no,"This appears to be a review article rather than a primary research study with any of the specified designs, so it fails this criterion.",no,"The abstract doesn't mention specific follow-up periods or documented MRONJ incidence rates, so it fails this criterion.",maybe,"The abstract does not specify the age requirements for the population, so the information is unknown.",maybe,"No specific subject numbers are mentioned in the abstract, so the information is unknown.",maybe,"The abstract discusses bisphosphonates but also includes other medications (RANK-L inhibitors) and doesn't specify oral vs. intravenous administration, so it only partially meets this criterion.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"This review article fails multiple screening criteria, including the requirement for a specific study design and a focused population of osteoporosis patients. The abstract discusses medication-related osteonecrosis across multiple conditions and does not provide the detailed methodological information needed to meet the specified research parameters. Consequently, the paper does not qualify for inclusion based on the established screening criteria.",0.1
Prevention of medication-related osteonecrosis of the jaw: institutional insights from a retrospective study.,"YS Chang, S. Nanayakkara, A. Yaacoub, SC Cox",10.1111/adj.13050,https://doi.org/10.1111/adj.13050,Australian dental journal,0,2024,maybe,"The study specifies that 85.4% of patients were taking medication for osteoporosis, meeting this criterion. However, it's unclear if there were any cancer patients in the remaining 14.6%.",no,"The abstract does not document the time interval between medication start and dental procedure, or between dental procedure and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study clearly reports MRONJ incidence following dental extractions, meeting this criterion.",yes,"The study is described as a retrospective study, which meets the criteria.",no,"The study reports MRONJ incidence (5.5%) at 8 weeks follow-up, which falls short of the required 6-month follow-up period.",yes,"The median age of the subjects was 74 years (IQR 67-80), which clearly meets the requirement of being over 18 years old.",yes,"The study includes 329 patients, exceeding the minimum requirement of 100 subjects.",maybe,"The abstract mentions Denosumab (66.9%) but doesn't specify if other medications were bisphosphonates, creating uncertainty about whether the study meets the oral bisphosphonate requirement.",no,The abstract does not explicitly mention the diagnostic standards used for MRONJ.,Include,"A retrospective study of 329 patients with a median age of 74 years examined medication-related osteonecrosis of the jaw following dental extractions, with 85.4% of patients taking osteoporosis medications. While meeting several screening criteria, the study had significant limitations including a short 8-week follow-up, unclear medication types, and absence of a control group, which compromise its comprehensive assessment of MRONJ risk.",2.7
Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review.,"P. López‐Jornet, A. Sánchez Pérez, Rui Amaral Mendes, A. Tobías",10.1016/j.jcms.2016.05.004,https://doi.org/10.1016/j.jcms.2016.05.004,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,74,2016,no,"The study focuses on patients taking bisphosphonates, but does not specify if they are exclusively osteoporosis patients or include cancer patients. The population appears to be mixed.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,The study does discuss dental extractions and their relationship to MRONJ incidence.,no,"This is a systematic review, not a primary research study of any of the specified designs.",maybe,"While outcomes are documented, the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, though it mentions ""patients"" suggesting they are adults.",yes,"The study includes 697 dental extractions in the preventive group and 123 patients in the treatment group, meeting the requirement of over 100 subjects.",no,"The abstract specifically mentions ""bisphosphonates intravenously"" which explicitly fails this criterion as it excludes intravenous administration.",no,"While MRONJ is discussed, the abstract does not mention specific diagnostic standards.",Exclude,"The systematic review fails multiple screening criteria, including being a review rather than a primary research study, using intravenous bisphosphonates, and having a mixed patient population. Critical methodological requirements such as specific diagnostic standards, clear age demographics, and precise intervention types were not met, rendering the study ineligible for inclusion. The paper's focus on treatment strategies for medication-related osteonecrosis of the jaw does not align with the predefined screening criteria.",0.1
Medication‐Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium,"Guang Yang, Roy Williams, Lishu Wang, N. Farhadfar, Yiqing Chen, Alexander T. Loiacono, Jiang Bian, L. Holliday, J. Katz, Y. Gong",10.1002/jbmr.4708,https://doi.org/10.1002/jbmr.4708,Journal of Bone and Mineral Research,4,2022,no,"The study specifically focuses on cancer patients taking IV bisphosphonates or denosumab, which explicitly violates the criterion requiring subjects to be osteoporosis patients only.",no,"While the study uses Kaplan-Meier analysis for time to MRONJ diagnosis, it doesn't specifically document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract doesn't mention any specific dental procedures leading to MRONJ.,yes,"This appears to be a retrospective cohort study using electronic health records, which meets the acceptable study design criteria.",yes,"The study documents MRONJ incidence and has a follow-up period of approximately 9 years (2012-2021), meeting the 6-month requirement.",yes,"The abstract doesn't explicitly state the age of subjects, but since it's studying cancer patients, it can be reasonably assumed that the subjects are adults over 18 years old.",yes,"The study includes 5,689 participants, well above the 100-subject requirement.",no,"The study focuses on intravenous bisphosphonates and denosumab, which explicitly violates the criterion requiring only oral bisphosphonates.",maybe,The abstract doesn't explicitly mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on cancer patients taking intravenous bisphosphonates and denosumab, which deviates from the required osteoporosis patient population and oral medication criteria. Multiple screening requirements were not met, including the absence of specific dental procedures, unclear diagnostic standards, and lack of documented time intervals for MRONJ incidence. These critical deviations render the study unsuitable for inclusion in the systematic review.",1.4
Genetic predisposition for medication-related osteonecrosis of the jaws: a systematic review.,"J. S. P. D. Silva, E. Pullano, N. Raje, M. Troulis, Meredith August",10.1016/j.ijom.2019.04.014,https://doi.org/10.1016/j.ijom.2019.04.014,International Journal of Oral & Maxillofacial Surgery,13,2019,no,"The study included patients with multiple myeloma, which is a cancer condition, and therefore fails to meet the criterion of excluding cancer patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study included a control group of patients not taking anti-resorptive medications, which meets the criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,no,"This is a systematic review, not a primary research study of the types specified in the criteria, so it fails to meet the study design criterion.",no,"While MRONJ is the outcome of interest, the abstract does not specify the follow-up period.",maybe,"The abstract does not explicitly state the age of the subjects, so the age criterion is uncertain.",yes,The total number of patients (3301) exceeds the minimum requirement of 100 subjects for the medication group.,maybe,"While bisphosphonates are mentioned, the abstract does not specify if all medications were oral bisphosphonates, so this criterion is uncertain.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple screening criteria, including the requirement for a primary research study design and the exclusion of cancer patients. Significant methodological limitations include the lack of specific dental procedures, undefined diagnostic standards, and absence of clear follow-up documentation for medication-related osteonecrosis of the jaws. The study's focus on genetic variations and inclusion of multiple myeloma patients further disqualifies it from meeting the predefined screening requirements.",1.4
Revisiting best practice guidelines and patient care workflow for managing the risk of medication-related osteonecrosis of the jaw: comparative summary and case studies.,"Jen-Jih Chen, Chia-Yu Wu, Kristina Gallagher, Chin‐Wei Wang",10.3290/j.qi.b4213007,https://doi.org/10.3290/j.qi.b4213007,Quintessence International,1,2023,no,"The abstract discusses patients taking antiresorptive medications but does not specify if they are exclusively osteoporosis patients or include cancer patients. It appears to be a mixed population discussion, so the paper fails this criterion.",no,"No mention of time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"The abstract mentions relevant procedures (extraction, implant placement) and MRONJ, but only in the context of case studies, so the paper partially meets this criterion.",no,"This appears to be a review of guidelines with case studies, not a primary research study of any of the required designs, so the paper fails this criterion.",maybe,"While outcomes are discussed, the follow-up period is not specified, so the reasoning is uncertain.",maybe,"The abstract does not explicitly state the age of the subjects, so the reasoning is uncertain.",no,"The abstract only mentions three case studies, which is well below the required 100 subjects, so the paper fails this criterion.",maybe,"While antiresorptive medications are mentioned, the abstract does not specify oral bisphosphonates exclusively, so the reasoning is uncertain.",maybe,"While the paper discusses MRONJ management, it doesn't explicitly mention diagnostic standards, so the reasoning is uncertain.",Exclude,"This guideline review with case studies fails multiple critical screening criteria, including insufficient sample size, lack of a control group, and absence of a primary research design. The paper does not meet the required methodological standards for inclusion, particularly regarding population specificity, intervention type, and study design. Consequently, the abstract would be excluded from a systematic review based on the predefined screening criteria.",1.4
Risk Factors Influencing Medication-Related Osteonecrosis of the Jaws (MRONJ) Following Dental Extraction Among Osteoporotic Patients in Taiwan.,"Ling-Ying Wei, Yi-Wen Cheng, Wei-Yih Chiu, Sang-Heng Kok, Hao-Hong Chang, Shih-Jung Cheng, Jang-Jaer Lee",10.1002/hed.28011,https://doi.org/10.1002/hed.28011,Head and Neck,0,2024,yes,"The study clearly focuses on osteoporotic patients taking anti-resorptive therapy, excluding cancer patients, so this criterion is met.",yes,"The study documents time intervals between medication start and dental procedures (mentions ""drug treatment exceeding 24 months"" and ""3 or more months of interruption""), meeting this criterion.",no,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications, so this criterion is not met.",yes,"The study specifically focuses on dental extraction procedures and MRONJ incidence, meeting this criterion.",yes,"The abstract explicitly states this is a ""retrospective cohort study,"" which meets this criterion.",maybe,"While the study documents MRONJ incidence after dental treatment, the follow-up period is not explicitly stated, so this criterion is partially met.",maybe,"While specific ages are not mentioned, the study refers to ""osteoporotic patients"" which typically implies an adult population over 18 years old, so this criterion is likely met.",yes,"The study includes 937 patients with 1067 dental extractions, well exceeding the 100-subject requirement, so this criterion is met.",maybe,"The study includes both oral bisphosphonates (alendronate) and non-bisphosphonates (denosumab, zoledronate), so this criterion is partially met as it includes non-bisphosphonates.",no,"The abstract does not explicitly mention the diagnostic standards used for MRONJ, so this criterion is not met.",Include,"A retrospective cohort study of 937 osteoporotic patients undergoing dental extractions reveals complex risk factors for medication-related osteonecrosis of the jaw, with significant insights into drug duration, interruption, and patient age. While the research provides valuable clinical data, it includes both bisphosphonate and non-bisphosphonate medications, lacks a control group, and does not explicitly detail diagnostic standards or follow-up periods. The study meets several key screening criteria but has notable methodological limitations.",3.5
Medication-Related Osteonecrosis of the Jaw: A Systematic Review of Case Reports and Case Series,"Filipa Frutuoso, F. Freitas, M. Vilares, Helena Francisco, D. Marques, J. Caramês, André Moreira",10.3390/diseases12090205,https://doi.org/10.3390/diseases12090205,Diseases,0,2024,no,"The abstract mentions patients receiving ""antiresorptive or antiangiogenic drugs"" but doesn't specifically focus on osteoporosis patients, suggesting a mixed population including cancer patients. This fails to meet the criterion.",no,"While the abstract mentions ""average administration duration of 60.88 months,"" it doesn't document the specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, which is a significant limitation.",no,The abstract doesn't specify which dental procedures led to MRONJ cases.,no,"This is a review of case reports and case series, which explicitly fails this criterion as it's not one of the accepted study designs.",no,"While the study documents MRONJ cases and treatments, it doesn't specify a follow-up period.",yes,"The study includes adults (average age 66.27 years), meeting this criterion.",no,"The study includes 151 cases total, which is below the required 100 subjects per medication group.",maybe,"The study includes zoledronic acid (32% of cases) and mentions ""oral route"" (26% of cases), but also includes other medications. This partially meets the criterion but is not specific enough.",no,The abstract mentions MRONJ stages but doesn't explicitly state diagnostic standards.,Exclude,"The study fails to meet multiple critical screening criteria, including an inappropriate study design of case series review, a mixed patient population, and insufficient sample size. Key limitations include the absence of a control group, lack of specificity in medication type, and no clear documentation of dental procedures leading to MRONJ. These significant methodological shortcomings render the study non-compliant with the established screening requirements.",1.4
Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience,"G. Favia, A. Tempesta, L. Limongelli, V. Crincoli, E. Maiorano",10.1155/2016/1801676,https://doi.org/10.1155/2016/1801676,International Journal of Dentistry,27,2016,no,"The study includes mixed populations - both bone neoplastic localizations and osteoporosis patients, which explicitly violates the criterion requiring only osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures led to MRONJ.,yes,This appears to be a retrospective cohort study based on the description of following patients from 2003 to 2015.,yes,"The study has a maximum follow-up of 13 years and documents MRONJ outcomes, including healing rates and recurrence.",maybe,"The abstract does not explicitly state the age of subjects, though given it's about osteoporosis patients, they are likely adults.",yes,"The study includes 244 patients, which exceeds the minimum requirement of 100 subjects.",no,"The study focuses on denosumab, which is not an oral bisphosphonate, and this explicitly violates the criterion requiring oral bisphosphonates.",yes,"The abstract mentions ""clinical and radiological examinations"" and ""dimensional staging system"" for MRONJ diagnosis.",Exclude,"The study fails key screening criteria by including a mixed patient population with cancer patients and using denosumab instead of oral bisphosphonates. Critical methodological limitations include the absence of a control group, unspecified dental procedures leading to MRONJ, and lack of documented time intervals between medication and MRONJ incidence. These significant deviations from the required screening parameters render the study unsuitable for inclusion in the systematic review.",1.4
Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology,"V. Fusco, D. Santini, G. Armento, G. Tonini, G. Campisi",10.1080/14740338.2016.1177021,https://doi.org/10.1080/14740338.2016.1177021,Expert Opinion on Drug Safety,78,2016,no,"The abstract focuses on cancer patients and discusses various medications including antiangiogenic agents and targeted therapy, which explicitly fails the criterion as it's not focused on osteoporosis patients.",no,"There is no mention of time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract does not mention any specific dental procedures, so it fails this criterion.",no,"This appears to be a review article rather than a primary research study with one of the required designs, so it fails this criterion.",no,"While MRONJ is discussed, there's no mention of specific follow-up periods or documented incidence rates, so it fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any specific subject numbers, so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, the paper discusses multiple medication types including antiangiogenic agents and targeted therapy, not exclusively oral bisphosphonates, so it fails this criterion.",no,"The abstract mentions diagnostic criteria but actually criticizes current criteria as ""too much restrictive or incomplete."" It doesn't specify its own diagnostic standards, so it fails this criterion.",Exclude,"This review article fails multiple systematic review screening criteria, primarily due to its focus on cancer patients and multiple medication types beyond oral bisphosphonates. The paper lacks specific details about study design, subject population, dental procedures, and MRONJ diagnostic standards, rendering it ineligible for inclusion in the systematic review.",0.1
A comparative study of the clinical characteristics of patients with medication-related osteonecrosis of the jaw and osteoporosis or malignancy.,"Zhiqiang Feng, An Jingang, Yang He, Yi Zhang",10.1016/j.oooo.2022.04.049,https://doi.org/10.1016/j.oooo.2022.04.049,"Oral surgery, oral medicine, oral pathology and oral radiology",2,2022,no,"The study includes both osteoporosis and malignancy patients, making this a mixed population study, which is a critical failure as the criteria specifically exclude mixed populations.",maybe,"The study documents incubation periods (57.0 ± 42.8 months for osteoporosis group), but doesn't clearly specify the time from medication start to dental procedure.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract doesn't specify which dental procedures led to MRONJ.,yes,"This appears to be a retrospective cohort study comparing two groups, which meets the criterion.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",yes,"While not explicitly stated, the study is of osteoporosis patients, so it can be reasonably assumed that the subjects are over 18 years old.",no,"The osteoporosis group only had 12 patients (14 lesions), which is well below the required 100 subjects.",yes,"The abstract mentions ""oral bisphosphonates"" specifically for the osteoporosis group, meeting this criterion.",maybe,"While MRONJ is discussed, the abstract doesn't explicitly mention diagnostic standards.",Exclude,"The study fails key screening criteria due to a mixed patient population and insufficient sample size, with only 12 osteoporosis patients. Critical methodological limitations include lack of specified dental procedures, unclear diagnostic standards, and absence of a control group. These deficiencies significantly compromise the study's alignment with the predefined screening requirements.",1.4
Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database,"Shinya Toriumi, Akinobu Kobayashi, Y. Uesawa",10.3390/ph13120467,https://doi.org/10.3390/ph13120467,Pharmaceuticals,18,2020,no,"The study appears to include a mixed population taking various medications, not specifically focused on osteoporosis patients. It includes cancer patients and other conditions, so it fails to meet the population indication criterion.",no,"No information is provided about time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, which is a significant limitation.",no,The abstract does not mention any specific dental procedures or their relationship to MRONJ incidence.,maybe,"The study appears to be a database analysis study, but the exact design methodology is not clearly specified. It seems to be more of a risk factor analysis rather than one of the specified study designs.",no,"While MRONJ is discussed, there is no mention of follow-up periods or specific documentation of incidence after dental treatment.",maybe,"The abstract mentions ""elderly"" as a risk factor but does not specify exact age ranges, so it is unclear if the population age criterion is met.",maybe,"The study uses a ""large voluntary reporting database"" but does not specify the exact number of subjects, so the subject size criterion is unclear.",no,"While bisphosphonates are included, the study also looks at multiple other medications (denosumab, prednisolone, etc.), so it fails to meet the intervention type criterion for focusing specifically on oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including a specific focus on oral bisphosphonates for osteoporosis, clear diagnostic standards for MRONJ, and documentation of dental procedures and outcomes. The research involves a mixed population with various medications and lacks precise details about subject age, sample size, and follow-up periods. Consequently, the abstract does not align with the required methodological and population-specific parameters.",1.4
P052 A literature review of anti-resorptive medications and reports of MRONJ,"Nikou Gharooni-Dowrani, Hanan Muhammad, Tarun Nagpal",10.1016/j.bjoms.2023.08.123,https://doi.org/10.1016/j.bjoms.2023.08.123,British Journal of Oral and Maxillofacial Surgery,0,2023,no,"While the abstract mentions antiresorptive medications, it does not specifically state that the subjects are osteoporosis patients, and appears to be a general review of MRONJ cases, so it fails this criterion.",no,"The abstract does not mention any time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While MRONJ is mentioned, the abstract does not specify any particular dental procedures, so it fails this criterion.",no,"This is explicitly stated to be a literature review, not one of the accepted study designs (RCT, cohort, or case-control), so it fails this criterion.",no,"The abstract does not mention any specific follow-up period or documentation of MRONJ incidence, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the age criterion is unknown.",maybe,"The abstract does not mention any specific sample size, so the subject size criterion is unknown.",no,"While antiresorptive medications are mentioned, the abstract does not specify oral bisphosphonates exclusively, so it fails this criterion.",no,"The abstract does not mention any diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"This literature review fails to meet multiple critical screening criteria, including specific study design requirements, population characteristics, and detailed outcome documentation. The abstract lacks essential details about subject selection, intervention specifics, and diagnostic standards for medication-related osteonecrosis of the jaw. Consequently, the paper does not qualify for inclusion based on the predefined screening criteria.",0.1
Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.,"F. Hallmer, Ó. Bjarnadóttir, B. Götrick, P. Malmström, G. Andersson",10.1016/j.oooo.2020.04.808,https://doi.org/10.1016/j.oooo.2020.04.808,"Oral surgery, oral medicine, oral pathology and oral radiology",18,2020,no,"The study specifically focuses on breast cancer patients with bone metastases, not osteoporosis patients, which is a clear violation of the inclusion criteria.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract does not specify which dental procedures were involved in the MRONJ cases, so the reasoning is uncertain.",yes,"The study is described as a prospective cohort study, which meets the acceptable study design criteria.",yes,"The study has a follow-up period of 77 months (well over 6 months) and clearly documents MRONJ incidence, so this criterion is met.",maybe,"While the population consists of breast cancer patients, who are typically adults, the age of the subjects is not explicitly stated, so the reasoning is uncertain.",yes,"The study includes 242 patients, which exceeds the minimum requirement of 100 subjects, so this criterion is met.",no,"The study examines zoledronic acid and denosumab, which are not oral bisphosphonates. Zoledronic acid is an intravenous bisphosphonate, and denosumab is a non-bisphosphonate medication, which is a clear violation of the inclusion criteria.",maybe,"The abstract does not explicitly mention the diagnostic standards used for MRONJ, so the reasoning is uncertain.",Exclude,"The study focuses on breast cancer patients with bone metastases, which critically fails the population indication criterion for osteoporosis research. Additionally, the medications used (zoledronic acid and denosumab) do not meet the specified intervention type of oral bisphosphonates, further disqualifying the study from inclusion. Multiple other screening criteria remain uncertain or unaddressed, rendering the paper unsuitable for the systematic review.",0.1
Critical Analysis of the Effect of Antiresorptive Drugs on Osteonecrosis Associated With Dental Implants: An Umbrella Review,"Mansi Dahiya, Pankaj Dhawan, Sapna Rani, Vidushi Saxena",10.7759/cureus.71506,https://doi.org/10.7759/cureus.71506,Cureus,0,2024,maybe,"The abstract focuses on ARD therapy but doesn't explicitly specify osteoporosis patients, potentially including mixed populations. This is a significant concern.",no,"The abstract doesn't mention documenting time intervals between medication start, dental procedure, and MRONJ incidence.",yes,"The abstract mentions ""non-ARD participants"" in the meta-analysis, suggesting control groups were included.",yes,"The study does focus on dental implant procedures and MRONJ outcomes, meeting this criterion.",no,"This is a systematic review, not a primary research study. This fails the criterion as we're looking for primary research.",maybe,"While MRONJ incidence is reported (2-17%), the follow-up period is not specified.",maybe,"The abstract doesn't explicitly mention age requirements, so this is uncertain.",no,"The abstract mentions 524 failed implants total, but this is across multiple studies in a systematic review, not a primary study. This criterion is not applicable as this is a review paper.",maybe,"The abstract only mentions ""antiresorptive drug (ARD)"" therapy broadly, not specifically oral bisphosphonates. This is a significant concern.",no,The abstract doesn't mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including lack of clarity on patient population, intervention type, and diagnostic standards for MRONJ. While the study addresses dental implant procedures and MRONJ outcomes, its nature as a review paper and absence of specific details about patient selection, medication type, and follow-up period render it unsuitable for inclusion. The broad scope and methodological limitations prevent it from satisfying the required screening parameters.",1.4
"Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan","Takahiro Kunihara, H. Tohmori, Manabu Tsukamoto, M. Kobayashi, Toshiya Okumura, H. Teramoto, T. Hamasaki, Takuma Yamasaki, Tsuyoshi Nakagawa, N. Okimoto, S. Fujiwara",10.1007/s00198-023-06732-8,https://doi.org/10.1007/s00198-023-06732-8,Osteoporosis International,11,2023,no,"The study includes both osteoporosis and cancer patients, which is a mixed population that is explicitly excluded in the criteria. This is a major limitation for inclusion.",no,"The study does not mention any time intervals between medication start, dental procedures, and MRONJ incidence, which does not meet the criterion for MRONJ latency.",yes,"The study explicitly includes a control group of people without antiresorptive agents, which meets the criterion for a control group.",no,"The study does not mention any specific dental procedures leading to MRONJ, and only reports overall incidence, which does not meet the criterion for procedure and outcome.",yes,"The study appears to be a retrospective cohort study using registry data, which meets the criterion for study design.",maybe,"The study reports MRONJ incidence and has a follow-up period of 5 years, which meets the 6-month requirement. However, it lacks specific documentation of post-dental treatment incidence, which is a partial limitation.",maybe,"The age of the subjects is not explicitly mentioned in the abstract, so it is unclear if the population is over 18 years old.",maybe,"The study includes 98 eligible ONJ patients total, but it is unclear if the osteoporosis group alone meets the 100-subject requirement.",maybe,"The study only mentions ""antiresorptive agents"" without specifying oral bisphosphonates, so it is unclear if only oral bisphosphonates were included.",yes,"The study explicitly mentions using the American Association of Oral and Maxillofacial Surgeons criteria for diagnosing MRONJ, which meets the criterion for diagnostic standard.",Include,"The study presents significant limitations for inclusion, primarily due to a mixed population of osteoporosis and cancer patients, which violates the specified screening criteria. Critical gaps exist in documenting specific dental procedures, medication type, and patient age, while the research fails to meet several key methodological requirements. Despite some strengths in study design and diagnostic standards, the fundamental screening criteria are not sufficiently addressed.",2.5
Management of Medication-related Osteonecrosis of the Jaw (MRONJ) risk in patients due to commence anti-resorptive/anti-angiogenic drugs - how should pre-drug-treatment dental preventive care be organised?,B. Steel,10.1922/CDH_4582Steel11,https://doi.org/10.1922/CDH_4582Steel11,Community Dental Health,4,2019,no,"The abstract discusses patients taking MRONJ-associated drugs but does not specifically mention osteoporosis patients or exclude cancer patients. It appears to be a mixed population study, so it fails this criterion.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"While the abstract discusses dental preventive care, it does not specifically report MRONJ incidence following specific dental procedures, so it fails this criterion.",no,"This appears to be a review of strategies rather than a primary research study of any of the specified designs, so it fails this criterion.",no,"While the abstract mentions ""effectiveness of the service in reducing MRONJ incidence,"" it does not clearly document MRONJ incidence with a specific follow-up period, so it fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning is uncertain.",maybe,"The abstract does not provide specific subject numbers, so the reasoning is uncertain.",no,"The abstract only mentions ""MRONJ-associated drugs"" without specifying oral bisphosphonates, so it fails this criterion.",no,"The abstract does not mention diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific study design, intervention type, and outcome documentation requirements. It appears to be a review of preventive care strategies rather than a primary research study examining MRONJ incidence, lacking the precise clinical details needed to satisfy the screening criteria. The paper's focus on organizational aspects of preventive care diverges significantly from the required research parameters.",1.4
Local radiographic risk factors for MRONJ in osteoporotic patients undergoing tooth extraction.,"C. Moreno-Rabié, Hugo Gaêta-Araujo, André Ferreira-Leite, W. Coucke, E. Gielen, T. Van den Wyngaert, R. Jacobs",10.1111/odi.14496,https://doi.org/10.1111/odi.14496,Oral Diseases,7,2023,yes,The study specifically focuses on osteoporotic patients treated with antiresorptive drugs (ARD) without mention of cancer patients or mixed populations.,no,"The abstract does not mention documenting the time intervals between medication start, dental procedure, and MRONJ incidence.",yes,"The study included a control group of patients not taking anti-resorptive medications, which adds 0.2 points to the score.",yes,The study specifically focuses on tooth extraction and reports MRONJ incidence following this procedure.,yes,"The study is explicitly described as a ""retrospective, longitudinal, case-control study,"" which meets the criteria.",maybe,"While the study documents MRONJ incidence (7.5% of patients, 3.1% of sites), the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age range of participants, but given that it is an osteoporosis study, it is likely that the subjects are adults over 18 years old.",yes,"The study includes 120 patients with 354 tooth extractions, which is well above the 100-subject requirement.",maybe,"While the study mentions ""antiresorptive drugs (ARD),"" it does not specify if these are exclusively oral bisphosphonates, creating significant uncertainty.",maybe,The abstract does not explicitly state the diagnostic standards used for MRONJ.,Include,"A retrospective case-control study examining medication-related osteonecrosis of the jaw in osteoporotic patients undergoing tooth extraction, with a robust sample size of 120 patients and clear documentation of MRONJ incidence. The research meets key screening criteria including appropriate study design, specific population focus, and dental procedure outcome, though some uncertainties exist regarding medication type and diagnostic standards. Multiple radiographic risk factors were identified, providing insights into potential MRONJ development.",4
Surgical Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw: Six-Year Experience of a Single Institution.,"R. Lopes, G. Rabelo, A. Rocha, P. Carvalho, F. Alves",10.1016/j.joms.2015.01.008,https://doi.org/10.1016/j.joms.2015.01.008,Journal of oral and maxillofacial surgery,61,2015,maybe,"The abstract mentions bisphosphonates are used for ""osteoporosis, hypercalcemia of malignancy, and bone metastases"" but does not specify if the study population is exclusively osteoporosis patients, so this is a significant uncertainty.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract focuses on surgical treatment of existing MRONJ rather than MRONJ incidence following dental procedures, which is a fundamental mismatch with the review's focus.",yes,"The study is described as a ""retrospective study,"" which meets the criteria for study design.",no,"While the study documents outcomes, it is focused on surgical treatment outcomes rather than MRONJ incidence after dental treatment, and the follow-up period is not specified.",yes,"The study includes patients aged 39-83 years (mean 65.6 ± 10.6), which meets the requirement of subjects being over 18 years old.",no,"The study includes only 33 patients with 46 MRONJ sites, which is well below the required 100 subjects for the medication group.",maybe,"The abstract mentions bisphosphonates but does not specify if they are oral or intravenous, which is a crucial missing detail.",no,The abstract does not explicitly mention diagnostic standards for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including insufficient sample size, unclear patient population, and lack of specific diagnostic standards for MRONJ. While the research involves bisphosphonate-related jaw osteonecrosis, it fundamentally differs from the desired focus on MRONJ incidence after dental procedures, rendering it unsuitable for inclusion. Significant methodological gaps and misalignment with screening requirements prevent this study from meeting the established criteria.",1.4
Evaluation of Various Therapeutic Approaches in Treating Medication-related Osteonecrosis of the Jaw: A Systematic Review,"Mário Jorge Augusto de Andrade, Marilia Oliveira Coelho Dutra Leal, C. Jodas, Renato Assis Machado, A. Bachesk, R. G. Teixeira",10.9734/jammr/2024/v36i45400,https://doi.org/10.9734/jammr/2024/v36i45400,Journal of Advances in Medicine and Medical Research,0,2024,no,"The abstract mentions patients taking Zoledronic acid, Alendronate, and Pamidronate, but does not specify if these are exclusively for osteoporosis treatment. It appears to be a mixed population study including various indications.",no,"While the abstract mentions treatment durations, it does not document the specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not specify which dental procedures led to MRONJ incidence.,no,"This is a systematic review, not a primary study of any of the specified designs (RCT, cohort, or case-control).",no,"While the study documents MRONJ cases, it does not specify follow-up periods.",maybe,"The abstract does not explicitly state the age of subjects, so this is unclear.",maybe,"The study includes 2,079 patients total, which exceeds the 100-subject requirement. However, this is a systematic review of multiple studies, not a primary study.",no,"The study includes both oral (Alendronate) and intravenous (Zoledronic acid, Pamidronate) bisphosphonates, which fails the criterion of only including oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails multiple screening criteria, including mixed population indications, inclusion of both oral and intravenous bisphosphonates, and lack of a control group. Critical methodological requirements such as specific diagnostic standards, dental procedure details, and precise MRONJ latency documentation are not met. The study's design as a systematic review rather than a primary research study further disqualifies it from meeting the established screening criteria.",0.1
Pathogenesis of Medication-Related Osteonecrosis of the Jaw: Odontogenic Infection-Preceding Type and Osteonecrosis-Preceding Type,"Yuki Sakamoto, Shunsuke Sawada, Y. Kojima",10.7759/cureus.60223,https://doi.org/10.7759/cureus.60223,Cureus,1,2024,no,"The study includes patients with malignancy and those taking denosumab (a non-bisphosphonate), which violates the criterion of focusing only on osteoporosis patients.",maybe,"The study mentions ""administration period"" but doesn't clearly document the specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract doesn't clearly specify which dental procedures were involved in the MRONJ cases. While it mentions ""odontogenic MRONJ,"" it doesn't detail specific procedures.",yes,"The study is described as a retrospective review, which meets the criterion as a retrospective cohort study.",maybe,"While the study documents MRONJ cases, the follow-up period is not specified in the abstract.",maybe,"While not explicitly stated, the context suggests the study included adult patients, but this was not definitively confirmed.",yes,"The study includes 145 patients, which meets the criterion of over 100 subjects.",no,"The study includes patients taking denosumab (a non-bisphosphonate) and doesn't specify if all patients were taking oral bisphosphonates, which violates the criterion.",maybe,"While the study examines radiographic images and various clinical parameters, it doesn't explicitly state its diagnostic standards for MRONJ.",Exclude,"The study fails key screening criteria by including cancer patients and non-bisphosphonate medications, which deviates from the specified research parameters. Multiple critical screening requirements remain unmet or uncertain, including diagnostic standards, specific dental procedures, and follow-up documentation. The research design and population do not align with the predefined inclusion criteria.",1.4
Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates,M. Kos,10.5114/aoms.2015.50964,https://doi.org/10.5114/aoms.2015.50964,Archives of medical science : AMS,25,2015,no,"The study specifically focused on oncologic patients, which is explicitly excluded in the criteria.",no,"The abstract does not document the specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking bisphosphonates, so no points were added for this criterion.",yes,"The study mentions dental surgery and periodontal events as procedures, which meets this criterion.",yes,"The study is described as a ""retrospective review,"" which meets the criteria as a retrospective cohort study.",maybe,"While the study reports BRONJ incidence (9.64%), the follow-up period is not explicitly stated.",maybe,"While the context suggests the study included adult patients, this was not definitively confirmed in the abstract.",yes,"The study included 197 patients, which exceeds the minimum requirement of 100 subjects.",no,"The study included intravenous bisphosphonates (zoledronate, pamidronate, ibandronate), which is explicitly excluded in the criteria.",no,The abstract does not explicitly mention diagnostic standards for BRONJ.,Exclude,"The study focuses on oncologic patients taking intravenous bisphosphonates, which directly conflicts with the specified screening criteria for population and intervention type. Multiple critical screening requirements were not met, including the exclusion of cancer patients and the use of non-oral bisphosphonate medications. These fundamental deviations render the study ineligible for inclusion in the systematic review.",0.1
Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study,"C. Brunner, M. Arvandi, Christian Marth, Daniel Egle, Florentina Baumgart, Miriam Emmelheinz, Benjamin Walch, Johanna Lercher, C. Iannetti, Ewald Wöll, Agnes Pechlaner, August Zabernigg, B. Volgger, Maria Castellan, Oliver Tibor Andraschofsky, Alice Markl, M. Hubalek, Michael Schnallinger, S. Puntscher, Uwe Siebert, S. Schönherr, L. Forer, E. Bruckmoser, J. Laimer",10.1200/JCO.24.00171,https://doi.org/10.1200/JCO.24.00171,Journal of Clinical Oncology,4,2024,no,"The study specifically focuses on breast cancer patients with bone metastases, not osteoporosis patients, which is a clear violation of the inclusion criteria.",maybe,"The study does document time intervals from treatment initiation to MRONJ development (4.6-8.4 years), but not specifically from dental procedures.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,yes,"This is a retrospective multicenter study, which meets the acceptable study design criteria.",maybe,"While the study documents MRONJ incidence, it doesn't specify the follow-up period length.",yes,"While not explicitly stated, given this is a breast cancer population, it can be reasonably assumed that all subjects are over 18 years old.",yes,"The study includes 639 patients, well above the 100-subject requirement.",no,"The study includes both bisphosphonates and denosumab, and doesn't specify if the bisphosphonates were oral. The mixed intervention population violates this criterion.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on breast cancer patients with bone metastases, which deviates from the required osteoporosis patient population and includes mixed medication interventions. Critical screening criteria were not met, including the absence of a control group, lack of specified dental procedures, and unclear diagnostic standards for MRONJ. These significant methodological limitations render the study unsuitable for the systematic review.",1.4
Medication‐related osteonecrosis of the jaw – a current review,"F. Domah, Nirmal Shah, J. Domah, Raunaq Shah",10.1111/ORS.12329,https://doi.org/10.1111/ORS.12329,-,3,2018,no,"The abstract discusses antiresorptive agents in general but does not specify that the subjects are exclusively osteoporosis patients, so it fails this criterion.",no,"No information about time intervals is provided, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"The abstract does not mention specific dental procedures or their relationship to MRONJ incidence, so it fails this criterion.",no,"This appears to be a literature review (""Three databases were searched"") rather than any of the required study designs, so it fails this criterion.",no,"The abstract does not mention any specific follow-up period or documented MRONJ incidence, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the age requirement is unknown.",no,"No specific subject numbers are mentioned in the abstract, and it indicates this is a literature review rather than a primary study, so it fails this criterion.",no,"While antiresorptive agents are mentioned, the abstract specifically notes that ""the repertoire of antiresorptive medication keeps expanding"" and doesn't focus exclusively on oral bisphosphonates, so it fails this criterion.",no,"While osteonecrosis is discussed, specific diagnostic standards are not mentioned, so it fails this criterion.",Exclude,"This literature review fails to meet multiple critical screening criteria, including lack of a control group, undefined population characteristics, absence of specific intervention details, and no primary research design. The abstract discusses medication-related osteonecrosis of the jaw in general terms but does not provide the specific methodological and population details required for inclusion in the study.",0.1
Is Medication Related Osteonecrosis of the Jaw around implants a rare entity ? A case series with a focus on etiopathophysiology.,"Jean Massaad, M. Magremanne",10.1016/j.jormas.2021.12.002,https://doi.org/10.1016/j.jormas.2021.12.002,Journal of Stomatology Oral and Maxillofacial Surgery,5,2021,no,"The study includes a mixed population - 4 patients with osteoporosis and 2 with cancer, which fails to meet the criterion requiring only osteoporosis patients.",maybe,"The abstract mentions that MRONJ occurred ""months or years after initiation of ARD treatment"" but doesn't provide specific time intervals.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study focuses on dental implants, which is one of the specified procedures.",yes,"This is a retrospective analysis, which meets the criterion.",no,"While the study documents MRONJ incidence, the follow-up period is not specified.",yes,"The study includes adults (median age 64, range 50-83), meeting this criterion.",no,"The study only includes 6 patients total (4 with osteoporosis), which is well below the required 100 subjects.",no,"The abstract only mentions ""antiresorptive drug (ARD) treatment"" without specifying oral bisphosphonates, which is insufficient to meet the criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including a mixed patient population with cancer patients, an extremely small sample size of only 6 patients, and lack of a control group. Insufficient details about medication type, diagnostic standards, and follow-up period further compromise the study's eligibility. The research does not provide the comprehensive data required by the screening protocol.",1.4
"A SINGLE REFERENCE CENTER, 2 YEARS RETROSPECTIVE STUDY ON THE RISK FACTORS ASSOCIATED WITH ANTI-RESORPTIVE MEDICATION-RELATED OSTEONECROSIS OF THE JAWS IN OSTEOPOROTIC AND ONCOLOGICAL PATIENTS","P. Pignatelli, G. Podda, D. Pergolini, F. Rocchetti, U. Romeo, G. Tenore, D. Gaglioti",10.32388/LPILZ7,https://doi.org/10.32388/LPILZ7,-,1,2021,no,"The study includes both oncological and osteoporotic patients, which violates the requirement for a pure osteoporosis population.",maybe,"The abstract mentions ""drug treatment duration"" but does not specifically document the time intervals required for MRONJ latency.",no,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study does mention dental extraction as a procedure and reports MRONJ incidence, meeting this criterion.",maybe,"The abstract suggests this is a retrospective review of cases, but the exact study design is not clearly specified.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",maybe,"The abstract does not specify the age range of the subjects, so it is unclear if the population meets the age requirement of over 18 years old.",maybe,"The abstract does not specify the total number of subjects, so it is impossible to verify if the study meets the requirement of over 100 subjects in the medication group.",no,"The study includes both bisphosphonates and Denosumab (a non-bisphosphonate), and mentions Zolendronate (which is typically IV), which does not meet the requirement for oral bisphosphonates only.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails key screening criteria by including a mixed population of oncological and osteoporotic patients, and incorporating non-bisphosphonate medications. Critical methodological details are missing, including specific diagnostic standards, precise study design, and comprehensive documentation of MRONJ latency and follow-up periods. These significant deviations from the required screening parameters render the study non-compliant with the established research protocol.",1.4
Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.,T. Shibahara,10.1620/tjem.247.75,https://doi.org/10.1620/tjem.247.75,Tohoku journal of experimental medicine,58,2019,no,"The abstract mentions both osteoporosis and cancer patients, and appears to be a general overview rather than a study of a specific population, so it fails the criterion of focusing exclusively on osteoporosis patients.",no,"No information about time intervals is provided, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While dental procedures are mentioned (extraction, dental implants, dentures), this is in the context of risk factors rather than reporting specific outcomes, so it fails this criterion.",no,"This appears to be a review article (""This article overviews..."") rather than any of the required study designs, so it fails this criterion.",no,"No specific follow-up period or documented MRONJ incidence is mentioned, so it fails this criterion.",maybe,"The abstract does not explicitly specify age requirements, though it discusses a ""super-aging society"" in Japan, so the reasoning is uncertain.",no,"The abstract does not mention any specific number of subjects as this appears to be a review article rather than an original research study, so it fails this criterion.",no,"While bisphosphonates are mentioned, the abstract discusses multiple types of medications including denosumab and angiogenesis inhibitors, not focusing exclusively on oral bisphosphonates, so it fails this criterion.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific study design, population focus, and outcome documentation requirements. It appears to be a broad review article discussing medication-related osteonecrosis of the jaw rather than an original research study with defined methodological parameters. Consequently, the text does not satisfy the detailed screening criteria for inclusion in the research analysis.",0.1
The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols,"O. Di Fede, F. Canepa, V. Panzarella, R. Mauceri, Carmine Del Gaizo, A. Bedogni, V. Fusco, P. Tozzo, G. Pizzo, G. Campisi, A. Galvano",10.3390/ijerph18168432,https://doi.org/10.3390/ijerph18168432,International Journal of Environmental Research and Public Health,24,2021,no,"The abstract mentions ""antiresorptive and antiangiogenic agents"" but does not specifically state these are for osteoporosis treatment, and appears to include mixed populations, so the study fails this criterion.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence, so the study fails this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,"The abstract focuses on treatment of MRONJ rather than incidence following dental procedures, so the study fails this criterion.",no,"This is a systematic review with pooled analysis, not a primary study of the required designs, so the study fails this criterion.",no,"While the study documents outcomes, it is focused on treatment success rather than MRONJ incidence after dental procedures, so the study fails this criterion.",maybe,"The abstract does not explicitly state the age of the subjects, so the reasoning for this criterion is uncertain.",yes,"The study includes 1137 patients in the pooled analysis, which exceeds the 100-subject requirement, so the study meets this criterion.",no,"The abstract does not specify oral bisphosphonates, only mentioning ""antiresorptive and antiangiogenic agents"" which is too broad, so the study fails this criterion.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so the study fails this criterion.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific population indication, intervention type, and study design requirements. While the study includes a large sample size, it does not align with the targeted research parameters for oral bisphosphonate-related MRONJ incidence in osteoporosis patients. The focus on treatment outcomes rather than dental procedure-related MRONJ incidence further disqualifies the study from meeting the established screening criteria.",0.1
Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-α) inhibitors: a systematic review.,"Roberto Sacco, Roberto Sacco, Roberto Sacco, Sagar Shah, R. Leeson, V. Moraschini, C. Mourao, O. Akintola, A. Lalli",10.1016/j.bjoms.2019.09.023,https://doi.org/10.1016/j.bjoms.2019.09.023,British Journal of Oral and Maxillofacial Surgery,38,2019,no,"The study focuses on patients taking TNF-α inhibitors for inflammatory conditions, NOT osteoporosis patients. This is a clear violation of a critical criterion.",maybe,"The study does document the time interval between medication start and MRONJ development (mean 62.5 months), but this would be irrelevant given other violations.",no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"The abstract mentions ""invasive surgery"" as a precipitating factor in 5 cases, but doesn't specify if these were the required dental procedures.",no,"This appears to be a systematic review of case reports/case series, which is explicitly excluded by the criteria.",no,"While the study documents MRONJ incidence, the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of subjects, though given the conditions (rheumatoid arthritis, Crohn's disease), they are likely adults.",no,"The study only includes 6 patients total, far below the required 100 subjects. This is a clear violation of a critical criterion.",no,"The study examines TNF-α inhibitors, not oral bisphosphonates. This is a clear violation of a critical criterion.",no,"While the study discusses ONJ/OM, it doesn't explicitly mention diagnostic standards.",Exclude,"The study focuses on TNF-α inhibitors for inflammatory conditions, which fundamentally differs from the required osteoporosis patient population and oral bisphosphonate intervention. With only six patients and a systematic review design of case reports, the research fails to meet critical screening criteria including subject size, intervention type, and study design. Multiple core requirements are unambiguously violated, rendering the study ineligible for inclusion.",0.1
Assessment of a Claims-Based ICD-9 and ICD-10 Medication-Related Osteonecrosis of the Jaw Algorithm in the United States,"Lauren A S Stevens, L. Spangler, L. Yochum, Yan Ding, Florence T. Wang",10.2147/CLEP.S325080,https://doi.org/10.2147/CLEP.S325080,Clinical Epidemiology,0,2021,yes,"The study specifically looks at postmenopausal women and women with postmenopausal osteoporosis, which meets the criterion of focusing on osteoporosis patients without mixed populations.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence, failing this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract does not mention any specific dental procedures leading to MRONJ, failing this criterion.",yes,"This appears to be a retrospective cohort study using insurance claims data, which meets the criterion for study design.",maybe,"While the study documents MRONJ cases, the follow-up period is not specified in the abstract, so it is uncertain whether this criterion is met.",yes,"The study focuses on postmenopausal women, which implies the subjects are over 18 years old, meeting this criterion.",no,"The study identified 1,273 potential cases, but only confirmed 6 cases, which is well below the required 100 subjects for the medication group, failing this criterion.",maybe,"The abstract does not specify the type of medication being studied, so it is uncertain whether the intervention type meets the criterion.",maybe,"The study uses ICD-9 and ICD-10 codes for initial identification, followed by chart review by an oral surgeon for confirmation. While this is a diagnostic process, it is not clearly stated if there are specific diagnostic standards for MRONJ, so it only partially meets this criterion.",Include,"The study focuses on postmenopausal women with osteoporosis, using a retrospective cohort design, but fails to meet several critical screening criteria including insufficient sample size, lack of specific dental procedures, and absence of a control group. While the research aims to validate MRONJ identification algorithms, it does not provide comprehensive documentation of medication type, latency periods, or follow-up outcomes. The small number of confirmed cases (only 6) significantly limits the study's generalizability and applicability.",2.5
Evaluation of MRONJ Risk and Associated Factors in Patients Receiving Antiresorptive and/or Antiangiogenic Drug Therapy: A Retrospective Cohort Study,Ömer Ekici,10.5505/tjo.2022.3359,https://doi.org/10.5505/tjo.2022.3359,Turkish Journal of Oncology,0,2022,maybe,"The abstract mentions ""antiresorptive and antiangiogenic drugs therapy"" but does not specify if the study population was exclusively osteoporosis patients or included cancer patients. Therefore, Elicit could only partially confirm that this criterion was met.",no,"The abstract does not mention the time intervals between the start of medication, dental procedure, and MRONJ incidence, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention a control group, so Elicit could not confirm whether this criterion was met.",yes,"The abstract mentions ""tooth extraction and other dentoalveolar surgical procedures"", which meets this criterion.",no,"The abstract does not explicitly state the study design, so Elicit could not confirm whether this criterion was met.",maybe,"While the abstract mentions MRONJ as an outcome, it does not specify the follow-up period, so Elicit could only partially confirm that this criterion was met.",maybe,"The abstract does not explicitly mention the age requirements of the study population, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention the sample size, so Elicit could not confirm whether this criterion was met.",maybe,"The abstract mentions ""antiresorptive drugs"" but does not specify if they were oral bisphosphonates or other types, so Elicit could only partially confirm that this criterion was met.",no,"The abstract does not mention the diagnostic standards for MRONJ, so Elicit could not confirm whether this criterion was met.",Include,"The abstract lacks critical methodological details required to comprehensively assess screening criteria, with only one criterion definitively met and two partially satisfied. Multiple key requirements such as control group, sample size, study design, and diagnostic standards remain unconfirmed due to the abstract's brevity. Significant uncertainty exists regarding the study's alignment with the specified screening criteria.",2.8
Comparing the Surgical Response of Bisphosphonate-Related Versus Bisphosphonate-Related Osteonecrosis of the Jaws.,"B. Palla, E. Burian, A. Deek, C. Scott, John G. Anderson, N. Callahan, E. Carlson",10.1016/j.joms.2020.11.017,https://doi.org/10.1016/j.joms.2020.11.017,Journal of oral and maxillofacial surgery,5,2020,no,"The study focuses on patients taking denosumab, which is not a bisphosphonate, so it fails to meet the criterion requiring oral bisphosphonate medication.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract doesn't specify the dental procedures that led to MRONJ, only discussing surgical treatment of MRONJ.",no,"This appears to be a literature review with case analysis, not one of the accepted study designs (RCT, prospective cohort, retrospective cohort, or case-control).",no,"While the study documents MRONJ outcomes, it doesn't specify the follow-up period.",yes,"The study includes patients with age range 19-77 years, meeting the >18 years criterion.",no,"The study only includes 20 patients, which is well below the required 100 subjects for the medication group.",no,"The study specifically focuses on denosumab, which is not an oral bisphosphonate, so it fails to meet the criterion.",maybe,"The abstract mentions MRONJ staging (I, II, III) but doesn't explicitly state diagnostic standards.",Exclude,"The study fails to meet multiple critical screening criteria, including the required intervention type (oral bisphosphonates), subject size (only 20 patients), and study design (literature review). Key disqualifying factors include the use of denosumab instead of oral bisphosphonates, insufficient sample size, and lack of specified dental procedures leading to MRONJ. These fundamental mismatches render the study ineligible for inclusion in the systematic review.",0.1
Bisphosphonates: Clinical Applications and Adverse Events in Dentistry.,"A. Polymeri, George J Kodovazenitis, A. Polymeris, Mado Komboli",10.3290/j.ohpd.a34370,https://doi.org/10.3290/j.ohpd.a34370,Oral Health & Preventive Dentistry,14,2015,no,"The abstract focuses on cancer patients and mentions ""systemic metabolic bone diseases"" but does not specifically focus on osteoporosis patients. This appears to be a mixed population study, which is explicitly excluded.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, so no points were added for this criterion.",maybe,"The abstract mentions dental extraction as a procedure related to BRONJ, but this is in the context of a review rather than reporting specific outcomes.",no,This appears to be a literature review rather than one of the accepted study designs.,no,"As a review article, it does not document specific MRONJ incidence or follow-up periods.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is uncertain.",no,The abstract does not mention the sample size as this appears to be a review article rather than an original research study.,no,"The abstract discusses both intravenous and oral bisphosphonates, and does not focus exclusively on oral bisphosphonates.",no,"While the abstract mentions BRONJ, it does not specify the diagnostic standards used.",Exclude,"This literature review fails multiple critical screening criteria, including lack of a control group, mixed patient population, and absence of specific research design requirements. The study focuses on cancer patients and intravenous bisphosphonates, diverging from the targeted osteoporosis patient population and oral medication intervention. Consequently, the abstract does not meet the systematic review's fundamental inclusion standards.",0.1
Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review.,"F. Goker, E. Grecchi, F. Grecchi, L. Francetti, M. Del Fabbro",10.26355/eurrev_202103_25430,https://doi.org/10.26355/eurrev_202103_25430,European Review for Medical and Pharmacological Sciences,21,2021,no,"While the abstract mentions ""patients under current or previous treatment with antiresorptive and/or angiogenic agents,"" it does not specifically focus on osteoporosis patients and appears to include mixed populations.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, as this is a systematic review of treatment options rather than a primary study with controls.",no,"While the abstract discusses treatment options for MRONJ, it does not specifically focus on MRONJ incidence following dental procedures.",no,"This is a systematic review, not a primary study of any of the required designs (RCT, cohort, or case-control).",no,"While the abstract mentions ""improvement in healing,"" it does not specifically document MRONJ incidence after dental treatment or mention follow-up periods.",no,The abstract does not specify age requirements or restrictions for included studies.,no,"The abstract mentions ""at least 3 cases"" as an inclusion criterion, which is far below the required 100 subjects.",no,The abstract does not specify oral bisphosphonates exclusively and appears to include various antiresorptive agents.,no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This systematic review fails to meet multiple screening criteria, including lack of a control group, unspecified population age, mixed patient population, insufficient subject size, and absence of specific diagnostic standards for MRONJ. The study does not focus on oral bisphosphonates, dental procedures, or MRONJ incidence, and is fundamentally a review of treatment options rather than a primary research study examining MRONJ risk.",0.1
Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study.,"T. Yamazaki, M. Yamori, T. Ishizaki, K. Asai, K. Goto, Katsu Takahashi, T. Nakayama, K. Bessho",10.1016/j.ijom.2012.06.020,https://doi.org/10.1016/j.ijom.2012.06.020,International Journal of Oral & Maxillofacial Surgery,165,2012,no,"The abstract doesn't specify that patients are taking medication for osteoporosis, only mentioning ""bisphosphonates"" without indication.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and ONJ incidence.",yes,"The study explicitly includes a control group of 3090 patients without BP administration, which meets the requirement for a control group.",yes,"The study specifically looks at tooth extraction and reports ONJ incidence, meeting the procedure and outcome criterion.",yes,"The study is explicitly described as a cohort study, meeting the study design criterion.",maybe,"While the study reports ONJ incidence, the follow-up period is not specified in the abstract.",maybe,"The abstract doesn't explicitly state the age requirement, though it mentions patients ""aged 65 years or older"" in one analysis, suggesting an adult population but not definitively.",yes,"The study includes 126 patients in the BP group, meeting the >100 subject requirement.",no,"The study includes both oral and intravenous bisphosphonates, and doesn't specify the type of bisphosphonates used, failing the criterion requiring only oral bisphosphonates.",no,The abstract doesn't mention diagnostic standards for MRONJ/ONJ.,Include,"The study includes a control group and adequate sample size, but critically fails to meet several key screening criteria, including specification of osteoporosis as the medication indication and exclusive use of oral bisphosphonates. Diagnostic standards for MRONJ are not mentioned, and the follow-up period remains unclear, further compromising the study's alignment with the screening requirements.",2.7
Medication-Related Osteonecrosis of the Jaw – 2022 Update,S. Ruggiero,-,-,-,221,2022,no,"While the abstract discusses MRONJ in relation to medication, it does not specifically state that the subjects are osteoporosis patients or exclude cancer patients, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention any time intervals, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention any control group, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention specific dental procedures or MRONJ incidence rates, so Elicit could not confirm whether this criterion was met.",no,"This appears to be a position paper/review document, not a primary research study of any of the specified types, so Elicit determined that this criterion was not met.",no,"The abstract does not mention any follow-up periods or documented MRONJ incidence, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not specify the age requirements of the subjects, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention any subject numbers, so Elicit could not confirm whether this criterion was met.",no,"While bisphosphonates are mentioned, the abstract appears to be a position paper/review rather than a primary research study, so Elicit could not confirm whether this criterion was met.",no,"While the abstract mentions ""diagnosis and management strategies,"" it does not specify diagnostic standards, so Elicit could not confirm whether this criterion was met.",Exclude,"This position paper fails to meet multiple critical screening criteria, particularly the requirement for a primary research study design. The document appears to be a clinical guideline update rather than an original research investigation, lacking specific details about patient populations, interventions, and outcomes. Consequently, the abstract does not provide sufficient information to confirm compliance with the systematic review's methodological requirements.",0.1
LOW RISK OF SPONTANEOUS MEDICATION-RELATED OSTEONECROSIS OF THE JAW IN FIBROUS DYSPLASIA PATIENTS AFTER ANTIRESORPTIVE THERAPIES: A SYSTEMATIC REVIEW,"Srighana Nadella, M. Mupparapu, S. Akintoye",10.1016/j.oooo.2021.08.043,https://doi.org/10.1016/j.oooo.2021.08.043,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2022,no,"The study focuses on patients with fibrous dysplasia (FD) and McCune-Albright syndrome (MAS), not specifically osteoporosis patients, which is a clear violation of the inclusion criteria.",no,"While the study mentions a 2-year therapy period, it doesn't document the specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,"The study focuses on spontaneous MRONJ occurrence, not MRONJ following specific dental procedures, which fails the criterion.",no,"This is a systematic review, not a primary research study of the required designs (RCT, cohort, or case-control).",no,"While the study has a follow-up period (2 years), it doesn't document MRONJ incidence after dental treatment.",maybe,"The abstract does not explicitly state the age of the subjects, so it is unclear if this criterion is met.",no,"The abstract mentions only 3 eligible articles with no specific mention of subject numbers, so it likely fails the requirement of including over 100 subjects in the medication group.",no,"While the study includes bisphosphonates, it also includes other antiresorptives (denosumab, teriparatide, etc.) and is not limited to oral bisphosphonates, which fails the criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review focuses on fibrous dysplasia and McCune-Albright syndrome patients, which fundamentally differs from the required osteoporosis patient population. Multiple screening criteria are unmet, including study design, intervention type, and outcome focus, rendering the paper ineligible for inclusion. The research's scope and methodology do not align with the specified screening requirements.",0.1
Predictive risk factors of medication-related osteonecrosis of the jaw,"A. Rodriguez-Archilla, Irene Rodriguez-Soriano",-,-,-,1,2019,no,"The abstract discusses both cancer and osteoporosis patients, indicating a mixed population, which fails to meet the criterion requiring an exclusive focus on osteoporosis patients.",no,"The abstract mentions ""duration of treatment"" as a factor but does not document specific time intervals, so it fails to meet this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract mentions relevant dental procedures (tooth extraction, implant placement, periodontal treatment, removable denture wearers) but does not clearly report MRONJ incidence following these procedures, so it partially meets this criterion.",maybe,"The abstract does not clearly state the study design, so the reasoning for this criterion is uncertain.",no,"The abstract does not mention the follow-up period or clearly document MRONJ incidence, so it fails to meet this criterion.",maybe,"The abstract does not explicitly state the age of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention the number of subjects in the study, so the reasoning for this criterion is uncertain.",maybe,"While the abstract mentions ""antiresorptive drugs,"" it does not specify oral bisphosphonates exclusively, so the reasoning for this criterion is uncertain.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so it fails to meet this criterion.",Include,"The abstract fails to meet multiple critical screening criteria, including a mixed patient population, lack of specific diagnostic standards, and absence of clear outcome documentation. Significant uncertainties exist regarding study design, subject size, intervention type, and follow-up period, which prevent the abstract from satisfying the comprehensive screening requirements. The text appears more like a general review of medication-related osteonecrosis of the jaw rather than a focused clinical research study.",2.5
"Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study.","F. Hallmer, G. Andersson, B. Götrick, G. Warfvinge, J. Anderud, T. Bjørnland",10.1016/j.oooo.2018.08.015,https://doi.org/10.1016/j.oooo.2018.08.015,"Oral surgery, oral medicine, oral pathology and oral radiology",70,2018,no,"The study includes patients taking bisphosphonates and denosumab for osteoporosis, but also includes patients on high-dose denosumab (likely cancer patients). This mixed population is a significant issue.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study mentions tooth extraction and periodontal disease as initiating factors for MRONJ, which meets this criterion.",yes,"The study is described as a ""prospective cohort study,"" which meets this criterion.",no,"The study has a follow-up period of 2 months, which is less than the required 6 months.",maybe,"The abstract does not explicitly state the age of the subjects, but Elicit notes that since the study is on osteoporosis patients, they are likely adults.",no,"The study only includes 55 patients total, which is well below the required 100 subjects for the medication group.",no,"The study includes both oral and intravenous bisphosphonates, as well as denosumab. This mixed intervention type fails the criterion requiring only oral bisphosphonates.",maybe,The abstract does not explicitly mention diagnostic standards for MRONJ.,Exclude,"The study fails key screening criteria due to a mixed patient population including cancer patients, a small sample size of 55 patients, and inclusion of multiple medication types beyond oral bisphosphonates. Critical shortcomings include a short 2-month follow-up period and lack of clear diagnostic standards for MRONJ, rendering the research unsuitable for comprehensive analysis. Despite meeting some criteria like study design and procedure documentation, the fundamental methodological limitations prevent meaningful inclusion.",1.4
Management and maintenance of oral health: Personalized primary prevention strategies and protocols in patients at risk of developing medication-related osteonecrosis of the jaw,"Giovanna Mosaico, C. Casu",10.36922/itps.1419,https://doi.org/10.36922/itps.1419,INNOSC Theranostics and Pharmacological Sciences,1,2024,no,"The abstract discusses both osteoporosis and bone cancer metastases patients, indicating a mixed population, which fails to meet the criterion requiring exclusive focus on osteoporosis patients.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While dental procedures are mentioned (tooth extraction, bone surgery), this is in the context of risk factors rather than reporting specific MRONJ incidence following procedures, which fails to meet the criterion.",no,"This appears to be a review article rather than any of the specified study designs, which fails to meet the criterion.",no,"The abstract does not report specific MRONJ incidence or follow-up periods, which fails to meet the criterion.",maybe,"The abstract does not explicitly specify age requirements, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any specific subject numbers, so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, the abstract discusses multiple types of antiresorptive medications including denosumab and antiangiogenic agents, not exclusively oral bisphosphonates, which fails to meet the criterion.",no,"The abstract does not mention specific diagnostic standards for MRONJ, which fails to meet the criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific study design requirements, population exclusivity, and outcome documentation. As a review article discussing preventive strategies for medication-related osteonecrosis of the jaw, it lacks the precise research parameters needed for inclusion, such as a defined control group, specific subject size, and detailed MRONJ incidence reporting. The mixed patient population and broad medication discussion further disqualify it from meeting the established screening standards.",0.1
Comparison of the Effectiveness of Conservative and Surgical Treatment of Medication-Related Osteonecrosis of the Jaw: a Systematic Review,"Rial Seluki, Moshe Seluki, I. Vaitkevičienė, E. Jagelavičienė",10.5037/jomr.2023.14401,https://doi.org/10.5037/jomr.2023.14401,eJournal of Oral Maxillofacial Research,3,2023,maybe,"The abstract focuses on MRONJ patients but does not specify whether they are exclusively osteoporosis patients or include cancer patients, which is a significant uncertainty.",no,"The abstract does not mention documenting time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,"While the abstract discusses treatment of MRONJ, it does not specifically mention the dental procedures leading to MRONJ.",yes,"The abstract mentions including 7 cohort studies and 2 RCTs, which meets the study design criterion.",yes,"The abstract mentions follow-up periods ranging from 6-60 months, meeting the minimum 6-month requirement.",maybe,"The abstract does not explicitly state the age of the subjects, though it is likely that the study includes adult patients since it is a systematic review of MRONJ treatment.",maybe,"As a systematic review including 9 studies, it likely includes more than 100 subjects total, but the size of individual study groups cannot be confirmed.",maybe,"The abstract does not specify the type of medication (oral bisphosphonates vs. others), which is a critical missing detail.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The systematic review lacks critical details about patient population, medication type, and specific dental procedures, creating significant uncertainty across multiple screening criteria. While the study includes appropriate research designs and follow-up periods, it fails to definitively meet key requirements such as diagnostic standards, control group composition, and precise intervention characteristics. The fundamental mismatch between the review's objectives and the study's focus on treatment outcomes further complicates its potential inclusion.",2.5
Medication-related osteonecrosis of the jaw and dental implants failures: a systematic review.,"Riccardo Guazzo, L. Sbricoli, S. Ricci, E. Bressan, A. Piattelli, F. Iaculli",10.1563/aaid-joi-d-16-00057,https://doi.org/10.1563/aaid-joi-d-16-00057,Journal of Oral Implantology,31,2016,maybe,"The abstract discusses patients taking antiresorptive agents, including bisphosphonates, but does not specifically exclude cancer patients or mixed populations, so this criterion is partially met.",no,"The abstract does not document specific time intervals between medication start, dental procedure, and ONJ incidence, so this criterion is not met.",no,"The abstract does not mention a control group, so this criterion is not applicable since the paper is a systematic review rather than a primary study.",yes,"The abstract mentions dental implants placement and ONJ development, which meets this criterion.",no,"This is a systematic review, not a primary research study of any of the specified designs, so this criterion is not met.",maybe,"While the abstract discusses ONJ incidence after dental treatment, it does not specify follow-up periods, so this criterion is partially met.",maybe,"The abstract does not specify the age requirements of the population, so this information is unclear.",no,"As a systematic review, this paper does not have its own subject group size, so this criterion is not applicable.",no,"The abstract mentions ""oral antiresorptive agents"" but also includes ""others antiresorptive agents,"" suggesting it is not limited to oral bisphosphonates, so this criterion is not fully met.",no,"The abstract does not mention specific diagnostic standards for ONJ, so this criterion is not met.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including lack of a control group, unspecified population age, and inclusion of mixed antiresorptive agents beyond oral bisphosphonates. While addressing dental implant placement and osteonecrosis of the jaw, the study does not provide specific diagnostic standards, time intervals, or follow-up periods required by the screening protocol. Consequently, the paper does not qualify for inclusion based on the established criteria.",1.4
Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws - A retrospective cohort study.,"Ana Silva Martins, J. A. Correia, F. Salvado, C. Caldas, Nuno R Santos, A. Capelo, Paulo Palmela",10.1016/j.jcms.2017.07.014,https://doi.org/10.1016/j.jcms.2017.07.014,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,30,2017,no,"The abstract mentions ""antiresorptives"" but does not specifically state these are for osteoporosis treatment. Elicit notes that the study appears to be a mixed population as it mentions ""primary disease"" as a factor.",no,"The study documents timing of medication discontinuation and healing time, but not specifically the time from medication start to dental procedure.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures led to MRONJ.,yes,"The study is described as a ""retrospective longitudinal cohort study,"" which meets the criterion for study design.",maybe,"The study has a follow-up period (2004-2016) and documents MRONJ outcomes, but the specific follow-up period per patient is not mentioned.",maybe,"The abstract does not explicitly state the age of the subjects, but Elicit notes that since it is a study of MRONJ patients, they are likely adults.",no,"The study includes 77 patients, which is below the required 100 subjects.",no,"The abstract mentions ""antiresorptives"" and ""route of administration"" but does not specify oral bisphosphonates exclusively. Elicit notes that the study appears to include various types of antiresorptive medications.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study fails key screening criteria due to a small sample size (77 patients), mixed patient population, and lack of specificity regarding osteoporosis treatment and dental procedures. Critical shortcomings include absence of a control group, unclear diagnostic standards, and insufficient documentation of medication type and dental intervention details. These limitations prevent the study from meeting the comprehensive screening requirements.",2.5
"ymposium : Imaging modalities for drug-related osteonecrosis of the aw ( 1 ) , role of imaging in drug-related osteonecrosis of the jaw : An pto-date review ( secondary publication )","akoto Tsuchimochia, Tohru Kurabayashib",-,-,-,18,2019,no,"The abstract mentions medications for osteoporosis but also mentions bone metastasis of malignancies, suggesting a mixed population. This fails to meet the criterion of excluding cancer patients.",no,"The abstract does not document any time intervals, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"The abstract does not mention any specific dental procedures or MRONJ incidence following these procedures, so this criterion is not met.",maybe,"The abstract does not specify the study design, so the information is unknown.",no,"The abstract does not mention the follow-up period or clearly document MRONJ incidence, so this criterion is not met.",maybe,"The abstract does not specify the age of the subjects, so the information is unknown.",maybe,"The abstract does not mention the number of subjects, so the information is unknown.",maybe,"While medications for osteoporosis are mentioned, the abstract does not specify oral bisphosphonates or exclude other types of medications, so the information is unknown.",no,"The abstract does not mention any diagnostic standards for MRONJ, so this criterion is not met.",Exclude,"The abstract lacks critical details required by the screening criteria, including specific population characteristics, study design, and diagnostic standards for MRONJ. Multiple key requirements are unmet, such as excluding cancer patients, documenting dental procedures, and specifying outcome measurements. The text appears to be a general review rather than a primary research study, rendering it unsuitable for the specified screening process.",1.4
Bacterial diversity in medication-related osteonecrosis of the jaw.,"F. Hallmer, T. Bjørnland, G. Andersson, J. Becktor, A. K. Kristoffersen, M. Enersen",10.1016/j.oooo.2016.11.011,https://doi.org/10.1016/j.oooo.2016.11.011,"Oral surgery, oral medicine, oral pathology and oral radiology",46,2017,no,"The study includes a mixed population of 10 osteoporosis patients and 8 cancer patients, which explicitly fails the criterion requiring only osteoporosis patients and excluding cancer patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,no,"This appears to be a case series of 18 consecutive patients, which is explicitly excluded by the criteria.",no,"While MRONJ is documented, the follow-up period is not mentioned.",maybe,"The abstract does not explicitly state the age of the subjects, so the age of the population is unclear.",no,"The study only includes 18 total patients (10 osteoporosis + 8 cancer), which is well below the required 100 subjects for the medication group.",no,"The abstract only mentions ""antiresorptive treatment"" generally and does not specify oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails key screening criteria due to a mixed patient population including cancer patients, a small sample size of only 18 patients, and a case series design that does not meet methodological requirements. Critical shortcomings include lack of specificity about intervention type, absence of a control group, and no documentation of dental procedures or MRONJ latency, rendering the study unsuitable for systematic review inclusion.",0.1
The risk of osteonecrosis on alveolar healing after tooth extraction and systemic administration of antiresorptive drugs in rodents: a systematic review.,"V. Poubel, C. A. B. Silva, L. Mezzomo, G. De Luca Canto, E. Rivero",10.1016/j.jcms.2017.11.008,https://doi.org/10.1016/j.jcms.2017.11.008,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,19,2017,no,"The study focuses on rodents with MRONJ, not human patients taking medication for osteoporosis, which fails to meet the criterion.",no,"The abstract does not mention documenting time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points are added for this criterion.",yes,"The study does look at MRONJ following tooth extraction, which is one of the specified procedures.",no,"This is a systematic review of animal studies, not a primary research study of the required design types.",no,"While MRONJ incidence is documented, the follow-up period is not specified.",no,"The study is conducted on rodents, not human subjects over 18 years, which violates the inclusion criteria.",maybe,"The abstract does not specify the number of subjects in the included studies, though it mentions 20 papers were included in the final synthesis.",no,"While the study mentions bisphosphonates, it's in the context of rodent studies, not human oral bisphosphonate treatment for osteoporosis.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This systematic review of rodent studies fails to meet multiple critical screening criteria, primarily because it involves animal research rather than human subjects. The study does not include human patients over 18 years old, lacks a control group, and does not document human osteoporosis treatment with oral bisphosphonates. Consequently, the research does not align with the specified inclusion requirements for the review.",0.1
"Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India","P. Sankar, SA Thilak, P. Nayak, Jp K Tripathy, B. Satheesan, A. Rajitha",10.4103/ccd.ccd_696_17,https://doi.org/10.4103/ccd.ccd_696_17,Contemporary Clinical Dentistry,2,2018,no,"The study specifically focuses on cancer patients taking antiresorptive medications, which explicitly violates the criterion requiring subjects to be osteoporosis patients only.",no,"The abstract mentions duration of medication but doesn't clearly document the time intervals between medication start, dental procedure, and ONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,maybe,"The abstract mentions ""dental intervention"" but doesn't specify which procedures were included.",yes,"The study is described as a ""retrospective record review,"" which qualifies as a retrospective cohort study.",maybe,"While the study reports ONJ incidence (8.1%), the follow-up period is not specified.",maybe,"The abstract doesn't explicitly state the age range of subjects, though being a cancer center study, they are likely adults.",yes,"The study includes 183 patients, which meets the criterion of over 100 subjects.",no,"The study focuses on zoledronic acid (ZA), which is an intravenous bisphosphonate, not an oral bisphosphonate as required.",no,The abstract does not mention the diagnostic standards used for ONJ.,Exclude,"The study focuses on cancer patients taking intravenous zoledronic acid, which directly conflicts with the screening criteria requiring osteoporosis patients and oral bisphosphonates. Multiple critical screening requirements were not met, including population indication, intervention type, and diagnostic standards for MRONJ. The research fundamentally diverges from the specified inclusion parameters, rendering it unsuitable for the intended analysis.",1.4
Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid,"GEORGE-ADRIAN Ciobanu, A. Camen, Mihaela Ionescu, D. Vlad, C. Munteanu, M. Gheorghiță, C. Lungulescu, I. Staicu, Elena-Claudia Sin, L. Chivu, R. Mercuț, S. Popescu",10.3390/jcm12113747,https://doi.org/10.3390/jcm12113747,Journal of Clinical Medicine,4,2023,no,"The study specifically focuses on cancer patients receiving zoledronic acid for bone metastases, which explicitly violates the criterion requiring patients taking medication for osteoporosis.",no,"While the study mentions ""treatment duration,"" it doesn't specifically document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,The abstract does not mention any specific dental procedures or their relationship to MRONJ incidence.,yes,"The abstract describes this as an ""observational retrospective investigation,"" which meets the criterion as a retrospective cohort study.",no,"While the study documents MRONJ occurrence, it doesn't specify the follow-up period or clearly document MRONJ incidence after dental treatment.",yes,"The study includes patients aged 22-84 years (mean 64.65), which meets the criterion of subjects being over 18 years old.",yes,"The study includes 174 patients, which exceeds the minimum requirement of 100 subjects for the medication group.",no,"The study uses zoledronic acid, which is an intravenous bisphosphonate, not an oral bisphosphonate as required. Additionally, it's used for cancer treatment, not osteoporosis.",maybe,"The abstract mentions ""international guidelines"" for MRONJ diagnosis, though specific standards aren't detailed.",Exclude,"The study focuses on cancer patients receiving zoledronic acid for bone metastases, which fundamentally conflicts with the screening criteria requiring osteoporosis patients taking oral bisphosphonates. Critical deviations include the wrong patient population, medication type, and absence of specific dental procedure documentation, rendering the study non-compliant with multiple essential screening requirements. These substantial discrepancies necessitate exclusion from the systematic review.",0.1
"A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit.","U. Disel, A. Besen, Ö. Özyi̇lkan, E. Er, T. Canpolat",10.1016/j.oraloncology.2011.07.030,https://doi.org/10.1016/j.oraloncology.2011.07.030,Oral Oncology,38,2012,no,"The study focuses on patients with cancer and antiangiogenic therapy, not osteoporosis patients. This explicitly fails the criterion which requires subjects taking medication for osteoporosis.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications. In fact, it specifically focuses on patients who ""had not been previously exposed to any antiresorptive drug treatments.""",maybe,"The abstract mentions that ""an invasive procedure was the most common trigger of MRONJ"" but doesn't specify which procedures.",no,"This is a review article analyzing other studies, not a primary research study with any of the required designs.",maybe,"While the study documents MRONJ incidence and mentions follow-up for recurrence, it doesn't specify the follow-up period length.",maybe,The abstract does not specify the age of subjects.,no,"The study includes only 36 total patients, well below the required 100 subjects.",no,"The study focuses on antiangiogenic drugs (anti-VEGF), not oral bisphosphonates. This explicitly fails the criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients with antiangiogenic therapy, which fundamentally differs from the required osteoporosis patient population taking bisphosphonates. With only 36 patients and a review article design, the research fails critical screening criteria including subject size, intervention type, and study design. Multiple key methodological requirements are not met, rendering the study unsuitable for inclusion.",0.1
A Comprehensive Quality Meta-Review of Genetic and Pharmacogenomic Aspects of Medication-Related Osteonecrosis of The Jaw (MRONJ),"Roberto Sacco, S. Olate, M. Calasans-Maia, N. Sacco, A. Acocella, Carlos Fernando de Almeida Barros Mourão, V. Moraschini, O. Akintola, R. Guerra, J. Yates",10.3390/app122312289,https://doi.org/10.3390/app122312289,Applied Sciences,1,2022,no,"While the abstract mentions antiresorptive medications, it does not specifically focus on osteoporosis patients and appears to be a broader review of genetic factors in MRONJ.",no,No information about time intervals is provided.,no,"The abstract does not mention any control groups, as this is a meta-review of other systematic reviews rather than a primary study.",no,"While MRONJ is discussed, the abstract does not mention specific dental procedures.",no,"This is a meta-review of systematic reviews and meta-analyses, not a primary study with any of the required designs.",no,The abstract does not discuss specific follow-up periods or MRONJ incidence rates.,no,The abstract does not specify any age requirements or restrictions for the population.,no,"As a meta-review, this paper does not have its own subject population.",no,"The abstract mentions ""antiresorptive and antiangiogenic medications"" broadly, not specifically oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This meta-review fails to meet multiple critical screening criteria, including lack of a primary study design, absence of specific dental procedure outcomes, and no clear documentation of MRONJ incidence. The paper's focus on genetic and pharmacogenomic aspects of MRONJ, rather than clinical outcomes, renders it unsuitable for inclusion in the systematic review.",0.1
Prognosis of Medication-Related Osteonecrosis of the Jaws in Metastatic Prostate Cancer Patients.,"Ling-Ying Wei, S. Kok, Yen-Ching Lee, Wei-Yih Chiu, J. Wang, Shih-Jung Cheng, Hao Chang, Jang-Jaer Lee",10.1111/odi.13737,https://doi.org/10.1111/odi.13737,Oral Diseases,11,2020,no,"The study specifically focuses on prostate cancer patients taking medication for bone metastasis, NOT osteoporosis patients. This is a clear violation of the inclusion criteria.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not specify which dental procedures led to MRONJ.,yes,"The study is described as a retrospective cohort study, which meets the criteria.",no,"While the study documents MRONJ outcomes with a 12-month follow-up period, it focuses on treatment outcomes rather than incidence after dental procedures.",yes,"While not explicitly stated, prostate cancer patients are typically over 18 years old.",yes,"The study includes 95 patients with 122 MRONJ lesions, which meets the minimum requirement of 100 subjects.",no,"The study includes both zoledronic acid (intravenous bisphosphonate) and denosumab (non-bisphosphonate), which violates the criterion requiring only oral bisphosphonates.",maybe,The abstract does not explicitly mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on prostate cancer patients taking antiresorptive medications, which fundamentally conflicts with the screening criteria requiring an osteoporosis patient population. Multiple critical screening requirements were not met, including medication type, patient indication, and documentation of dental procedures leading to MRONJ. The research design and patient population render the study ineligible for inclusion in the systematic review.",0.1
Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic review,"M. Diniz-Freitas, J. Limeres",10.4317/medoral.20963,https://doi.org/10.4317/medoral.20963,Medicina Oral,30,2016,no,"The study includes patients taking antiresorptive drugs, but does not specify if they are exclusively osteoporosis patients. It appears to be a mixed population including cancer patients (mentions antiangiogenic drugs).",no,"The abstract does not mention documenting time intervals between medication start, dental procedure, and ONJ incidence.",no,"The abstract does not explicitly mention a control group, which is a significant limitation.",yes,"The study does focus on tooth extraction and ONJ incidence, meeting this criterion.",no,"The abstract explicitly states that no randomized controlled trials were found, and all publications were case series or cohort studies, which fails to meet the acceptable study design criteria.",maybe,"While ONJ incidence is reported, the follow-up period is not specified.",maybe,"The abstract does not specify the age requirements for the study population, so this is unclear.",no,"The abstract mentions 13 included articles with data on 11 intravenous and 5 oral bisphosphonate patients, indicating this is a review of other studies rather than a primary study with over 100 subjects.",no,"The study includes both oral and intravenous bisphosphonates, as well as antiangiogenic drugs, which does not meet the criterion of only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for ONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including lack of a control group, mixed patient population, and inclusion of both oral and intravenous bisphosphonates. The study design of case series and cohort studies does not align with the required methodological standards, and key diagnostic and outcome documentation elements are missing. Consequently, the paper does not satisfy the essential screening requirements for inclusion.",1.4
A retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities,"C. Bacci, Alessia Cerrato, E. Bardhi, A. Frigo, Selma Ahcene Djaballah, S. Sivolella",10.1007/s00520-021-06587-x,https://doi.org/10.1007/s00520-021-06587-x,Supportive Care in Cancer,16,2021,no,"The abstract does not specify whether patients were taking medication for osteoporosis or other conditions. It appears to be a mixed population study as it mentions ""oncologist"" in group 5, suggesting cancer patients were included.",no,"The abstract does not mention documenting time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,"While the study discusses preventive dental visits and treatments, it doesn't specifically report MRONJ incidence following the required dental procedures. It appears to be studying the opposite - how preventive care affects MRONJ risk.",yes,"The abstract explicitly states this is a retrospective study, which meets the criteria.",no,"While the study documents MRONJ staging, it doesn't clearly document MRONJ incidence after dental treatment, and the follow-up period is not mentioned.",maybe,"The abstract does not explicitly state the age of subjects, so this is unclear.",no,"The study started with 93 patients but excluded 22, leaving 71 cases, which is below the required 100 subjects.",maybe,"The abstract does not specify the type of medication patients were taking. It only mentions ""medication-related"" osteonecrosis, so this is unclear.",yes,"The abstract mentions using the ""Italian SIPMO/SICMF 2.0 staging system"" for MRONJ classification, which implies diagnostic standards were used.",Exclude,"The study fails critical screening criteria, particularly by including a mixed patient population with cancer patients and having a sample size below 100 subjects. Multiple key requirements were not met, including specific diagnostic standards, intervention type, and outcome documentation. The research design fundamentally differs from the systematic review's targeted investigation of medication-related osteonecrosis.",1.4
MRONJ in patients treated with bisphosphonates or other agents: a 5-year retrospective study,"F. Mazzoni, C. Arena, N. Testa, V. Zavaglia, A. Nori, A. Santarelli",10.3389/conf.fphys.2019.27.00029,https://doi.org/10.3389/conf.fphys.2019.27.00029,Frontiers in Physiology,0,2019,no,"The study includes a mixed population of both osteoporosis and cancer patients, which fails to meet the criterion requiring the research to specify that its subject is chosen from patients taking medication for osteoporosis, excluding cancer patients and research with mixed populations.",maybe,"The study documents drug administration time (mean 65.6 ± 35.8 months for group A), but doesn't clearly document the time interval between medication start and dental procedure, or between procedure and MRONJ incidence, which partially meets the criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The abstract mentions dental procedures (extraction) and MRONJ incidence, which meets the criterion.",yes,"The study is described as a ""retrospective study,"" which meets the criterion as a retrospective cohort study.",yes,"The study includes follow-up ""at days 10, 30, and every 2 months up to 1 year,"" which meets the 6-month follow-up requirement.",yes,"The study includes patients with a mean age of 66.7 ± 12.0 years (range 43-86 years), which meets the criterion of subjects being over 18 years old.",no,"The study includes 53 total patients, with 32 in the bisphosphonate group, which fails to meet the criterion requiring the study to include over 100 subjects in the medication group at the final statistical analysis stage.",maybe,"The study includes both bisphosphonates and other medications (denosumab), and doesn't specify if the bisphosphonates were oral, which partially meets the criterion requiring the study to only include subjects taking oral bisphosphonate medication for osteoporosis treatment.",yes,"The abstract clearly defines diagnostic criteria for MRONJ, including ""exposed bone or bone that can be probed through a fistula in the maxillofacial region that persists for more than 8 weeks,"" which meets the criterion.",Include,"The study fails key screening criteria due to a mixed patient population including both osteoporosis and cancer patients, and a small sample size of only 53 total patients with 32 in the bisphosphonate group. While the research meets some methodological requirements like diagnostic standards and follow-up protocols, critical exclusion criteria prevent its inclusion in the review. The lack of a control group and unclear specification of oral bisphosphonate administration further compromise the study's eligibility.",2.5
Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study.,"Se Hwa Kim, Young-Kyun Lee, Tae-Young Kim, Y. Ha, S. Jang, H. Y. Kim",10.1016/j.bone.2020.115650,https://doi.org/10.1016/j.bone.2020.115650,Bone,18,2020,yes,"The study specifically focuses on osteoporosis patients, with no mention of cancer patients or mixed populations, meeting the requirement for the population indication.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and ONJ incidence.",yes,"The study explicitly includes a control group of 164,926 age- and sex-matched subjects with no BP prescriptions, which meets the requirement for a control group.",yes,"The study explicitly mentions tooth extraction and periodontal disease as risk factors for ONJ, meeting the requirement for the procedure and outcome.",yes,"This appears to be a retrospective cohort study using national health insurance data, meeting the requirement for the study design.",yes,"The study has a 4-year follow-up period (exceeding the 6-month requirement) and clearly documents ONJ incidence, meeting the requirement for outcome documentation.",yes,"While not explicitly stated, the study mentions ""advanced age (≥70 years)"" as a risk factor, implying the population is adults over 18 years old.",yes,"The study includes 164,926 BP users, well above the 100-subject requirement for the medication group.",maybe,"The abstract mentions ""bisphosphonates"" but doesn't specify if they are oral or intravenous, creating some uncertainty about the intervention type.",no,The abstract doesn't mention specific diagnostic standards for ONJ.,Include,"A large-scale retrospective cohort study examining osteoporosis patients taking bisphosphonates, with a robust control group and comprehensive follow-up period. The research meets most screening criteria, including appropriate population selection, dental procedure documentation, and significant sample size, though some details about medication type and diagnostic standards remain unclear. Despite minor uncertainties, the study demonstrates strong methodological rigor in investigating medication-related jaw necrosis.",4.3
Management of Tooth Extraction in Patients Taking Antiresorptive Drugs: An Evidence Mapping Review and Meta-Analysis,"Chang Liu, Y. Xiong, T. Zhu, Wei Liu, W. Tang, W. Zeng",10.3390/jcm12010239,https://doi.org/10.3390/jcm12010239,Journal of Clinical Medicine,7,2022,maybe,"The abstract mentions ""patients taking antiresorptive drugs"" but does not specifically exclude cancer patients or mixed populations. The reasoning is that the information provided in the abstract partially meets the criterion, as it does not clearly specify that the research was conducted on patients taking medication for osteoporosis, excluding cancer patients and mixed populations.",maybe,"The abstract mentions ""3-month follow-up"" but does not document the specific time intervals required. The reasoning is that the information provided in the abstract partially meets the criterion, as it does not clearly document the time interval between the start of medication and the dental procedure, and the time interval between the dental procedure and MRONJ incidence.",maybe,"The abstract mentions ""versus control"" in the results, but it is unclear if this refers to patients not taking antiresorptive medications. The reasoning is that the information provided in the abstract is uncertain regarding whether a control group of patients not taking anti-resorptive medications was included.",yes,"The study focuses on tooth extraction and MRONJ incidence, which meets this criterion. The reasoning is that the information provided in the abstract meets the criterion, as the study reports MRONJ incidence following tooth extraction.",no,"This is a systematic review/meta-analysis, not a primary study of the required designs. The reasoning is that the information provided in the abstract does not meet the criterion, as the study design is not a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",no,"The study reports MRONJ incidence and mentions follow-up periods, but as a review paper, it is not directly documenting primary outcomes. The reasoning is that this criterion is not applicable, as the paper is a review rather than a primary study.",maybe,The abstract does not explicitly mention the age requirements for the study population. The reasoning is that the information provided in the abstract is uncertain regarding whether the age of the subjects was over 18 years old.,no,"As this is a review/meta-analysis of 15 primary studies and 5 reviews, it does not directly report subject numbers. The reasoning is that this criterion is not applicable, as the paper is a review rather than a primary study.",no,"The abstract refers to ""antiresorptive drugs"" broadly, not specifically oral bisphosphonates. The reasoning is that the information provided in the abstract does not meet the criterion, as the study does not focus exclusively on subjects taking oral bisphosphonate medication for osteoporosis treatment.",no,"The abstract does not mention specific diagnostic standards for MRONJ. The reasoning is that the information provided in the abstract does not meet the criterion, as the study does not mention its diagnostic standards for MRONJ.",Exclude,"This systematic review/meta-analysis fails to meet several critical screening criteria, including specific intervention type, study design, and diagnostic standards for MRONJ. While the study addresses tooth extraction and MRONJ, it lacks the precise population characteristics, intervention specificity, and primary outcome documentation required by the screening protocol. Consequently, the paper does not qualify for inclusion in the systematic review.",1.4
Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review,"António Granate-Marques, Carlos Polis-Yanes, Maria Seminario-Amez, E. Jané‐Salas, J. López‐López",10.4317/medoral.22691,https://doi.org/10.4317/medoral.22691,Medicina Oral,30,2019,no,"The abstract mentions ""benign bone diseases"" and does not specifically focus on osteoporosis patients, indicating a mixed population study.",maybe,The abstract mentions duration of treatment (>3 years) but does not specifically document the time intervals required for this criterion.,no,"The abstract does not explicitly mention a control group, which is a significant limitation.",yes,"The study does look at relevant procedures (implants, sinus lift, guided bone regeneration) and their relationship to osteonecrosis.",no,"This appears to be a literature review rather than a primary research study (RCT, cohort, or case-control).",no,The abstract does not specify the follow-up period or clearly document MRONJ incidence rates.,maybe,"The abstract does not specify the age requirements, though it likely includes adults given the context.",no,The abstract does not specify the number of subjects in the included studies.,no,"The study includes ""bisphosphonates and other anti-resorptive and antiangiogenic agents,"" which is broader than just oral bisphosphonates.",no,"While ""osteonecrosis"" is mentioned, specific diagnostic standards are not detailed in the abstract.",Exclude,"The literature review fails multiple screening criteria, including lack of a specific osteoporosis patient population, inclusion of non-bisphosphonate medications, and absence of a clear control group. Methodological limitations such as mixed patient populations, undefined diagnostic standards, and insufficient outcome documentation prevent the study from meeting the required screening standards. The research design as a literature review rather than a primary research study further disqualifies it from meeting the specified criteria.",1.4
"Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users","Pia Eiken, D. Prieto-Alhambra, R. Eastell, Bo Abrahamsen",10.1007/s00198-017-4132-y,https://doi.org/10.1007/s00198-017-4132-y,Osteoporosis International,31,2017,yes,"The study specifically focuses on patients taking alendronate for osteoporosis, excluding cancer patients, which meets this criterion.",maybe,"The abstract does not document the specific time intervals between medication start, dental procedures, and ONJ incidence.",maybe,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications, so this criterion is not met.",maybe,"The abstract does not specify which dental procedures were associated with ONJ cases, which is a significant limitation.",yes,"The study is described as an ""open nationwide register-based cohort study containing one nested case-control study,"" which meets the acceptable study design criteria.",yes,"The study has a long follow-up period (mean 6.8 years) and clearly documents ONJ incidence, meeting this criterion.",yes,"The study includes patients aged 50-94, which meets the requirement of subjects being over 18 years old.",yes,"The study includes 61,990 patients, well exceeding the 100-subject requirement for the medication group.",yes,"The study focuses on oral alendronate (a bisphosphonate) for osteoporosis treatment, meeting this criterion.",maybe,"The abstract mentions ""surgically treated ONJ"" but does not explicitly state the diagnostic standards used, creating some uncertainty.",Include,"A large-scale cohort study examining alendronate users for osteoporosis demonstrates strong methodological elements including appropriate age range, intervention type, and substantial sample size. However, critical screening criteria remain unaddressed, particularly regarding specific dental procedures, control group composition, and precise diagnostic standards for medication-related jaw necrosis. The research provides valuable insights but lacks complete alignment with comprehensive screening requirements.",3.5
Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation,"O. Şahin, O. Odabaşı, Toghrul Aliyev, B. Tatar",10.5125/jkaoms.2019.45.2.108,https://doi.org/10.5125/jkaoms.2019.45.2.108,Journal of the Korean Association of Oral and Maxillofacial Surgeons,12,2019,no,"The study includes a mixed population - both cancer patients (Group I) and osteoporosis patients (Group II), which violates the criterion requiring only osteoporosis patients.",no,"The abstract mentions ""duration of drug treatment"" but doesn't specifically document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures led to MRONJ.,yes,"This appears to be a retrospective review of medical records, which would qualify as a retrospective cohort study.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",maybe,"While not explicitly stated, the context suggests adult patients, but this isn't definitively confirmed.",no,"The total sample size is 52 patients (23 cancer + 29 osteoporosis), which is below the required 100 subjects for the medication group.",no,"The study includes both bisphosphonates and ""antiresorptive, antiangiogenic drugs,"" which is broader than the required oral bisphosphonates only.",yes,"The abstract mentions using the ""American Association of Oral and Maxillofacial Surgeons staging system"" for classification, which implies diagnostic standards were used.",Exclude,"The study fails key screening criteria due to a mixed patient population including cancer patients, a sample size below 100, and inclusion of broader medication types beyond oral bisphosphonates. Critical methodological limitations include unspecified dental procedures, lack of clear latency documentation, and absence of a control group, which significantly compromise the study's alignment with the predefined screening requirements.",1.4
Medication-Related Osteonecrosis of the Jaw: A Systematic Review and a Bioinformatic Analysis,"Galina Laputková, I. Talian, Vladimíra Schwartzová",10.3390/ijms242316745,https://doi.org/10.3390/ijms242316745,International Journal of Molecular Sciences,2,2023,no,"The abstract mentions ""anti-resorptive or anti-angiogenic agents"" but does not specifically focus on osteoporosis patients, indicating a broader review of MRONJ mechanisms.",no,"No information about time intervals between medication start, dental procedures, and MRONJ incidence is provided.",no,"The abstract does not mention any control group, indicating that this is a systematic review of genetic/molecular studies rather than a clinical study with controls.",no,The abstract does not discuss any dental procedures or their relationship to MRONJ incidence.,no,"This is a systematic review of molecular studies, not a clinical study with any of the required designs (RCT, cohort, or case-control).",no,The study does not document MRONJ incidence after dental treatment or follow-up periods.,no,The abstract does not specify any age requirements or restrictions for the included studies.,no,The abstract mentions analyzing 12 studies but does not specify the number of subjects in those studies.,no,"The abstract refers to ""anti-resorptive or anti-angiogenic agents"" broadly, not specifically oral bisphosphonates.",no,The abstract does not mention any diagnostic standards for MRONJ.,Exclude,"This systematic review of molecular mechanisms fails to meet the specified screening criteria for a clinical study on medication-related osteonecrosis of the jaw. The research focuses on genetic and molecular pathways rather than clinical outcomes, patient populations, or dental procedures, rendering it non-compliant with the established inclusion requirements.",0.1
The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.,"Wei-Yih Chiu, J. Chien, Wei-Shiung Yang, J. Juang, Jang-Jaer Lee, K. Tsai",10.1210/jc.2013-4119,https://doi.org/10.1210/jc.2013-4119,Journal of Clinical Endocrinology and Metabolism,40,2014,yes,"The study clearly focuses on patients taking medication for osteoporosis, specifically excluding mixed populations.",maybe,"The study documents time intervals between medication start and ONJ occurrence (mentions ""after 1 year of drug exposure""), but does not specify the time from dental procedure to ONJ.",maybe,"The abstract mentions comparing alendronate to raloxifene, but does not explicitly state that there was a control group of patients not taking any medications.",no,The abstract does not mention any specific dental procedures leading to ONJ.,yes,"This appears to be a retrospective cohort study using electronic medical records, which meets the criteria.",yes,"The study has a long follow-up period (12 years) and clearly documents ONJ incidence, meeting this criterion.",maybe,"While not explicitly stated, the study focuses on osteoporosis patients, which typically implies an adult population over 18 years old. However, this is an assumption.",maybe,"While exact numbers are not provided, the study reports incidence rates per 100,000 persons and covers a 12-year period, suggesting a large sample size likely over 100 subjects.",no,"The study includes both oral alendronate (bisphosphonate) and raloxifene (non-bisphosphonate), which partially fails the criterion as it includes non-bisphosphonate medication.",no,"The abstract mentions ""manual confirmation of ONJ"" but does not specify the diagnostic standards.",Include,"A retrospective cohort study examining osteoporosis medication and jaw necrosis reveals complex findings with partial alignment to screening criteria. While demonstrating long-term follow-up and clear outcome documentation, the research includes non-bisphosphonate medications and lacks specificity about dental procedures and diagnostic standards. The study provides insights into medication-related jaw complications but does not fully meet all predefined screening requirements.",2.9
Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.,"L. Hauer, J. Jambura, D. Hrusak, M. Chalupova, P. Pošta, S. Rusnak, V. Vyskočil",10.5507/bp.2018.081,https://doi.org/10.5507/bp.2018.081,"Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia",16,2020,yes,"The study specifically focuses on osteoporotic patients taking anti-resorptive medications, excluding cancer patients.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract doesn't specify which dental procedures led to MRONJ. It focuses on surgical treatment of MRONJ rather than the procedures that caused it.,yes,"This is a retrospective evaluation, which is one of the accepted study designs.",yes,"The study has a follow-up period of 20.5 months, which exceeds the 6-month requirement, and documents MRONJ outcomes.",maybe,"While not explicitly stated, the context suggests these are adult patients with osteoporosis. However, this is not definitively confirmed.",no,"The study includes only 26 patients, which is well below the required 100 subjects.",maybe,"The study includes both bisphosphonates (69.2%) and denosumab (15.4%), with some patients having both. This partially meets the criterion as it's not exclusively oral bisphosphonates.",maybe,"The abstract mentions staging (stage 1, 2, and 3) but doesn't explicitly describe the diagnostic standards used.",Include,"The study fails to meet several critical screening criteria, including an insufficient sample size of only 26 patients and lack of clarity on dental procedures leading to MRONJ. While the research focuses on osteoporotic patients and uses an acceptable retrospective design, significant methodological limitations prevent it from qualifying for systematic review inclusion. The small sample size, mixed medication types, and absence of detailed diagnostic and procedural documentation are key disqualifying factors.",2.7
Risk factors for the development of medication-related osteonecrosis of the jaw and effects of tooth extraction with local infection,"Norio Nakamura, M. Otsuru, Taro Miyoshi, Koki Suyama, K. Omori, Kota Morishita, S. Soutome, S. Rokutanda, Kei-ichiro Miura, Masahiro Umeda",10.1016/j.jds.2023.10.006,https://doi.org/10.1016/j.jds.2023.10.006,Journal of Dental Sciences,2,2023,no,"The abstract mentions ""patients receiving antiresorptive agent (ARA) therapy"" but does not specify if these are osteoporosis patients or if there is a mixed population, so Elicit could not confirm if this criterion was met.",no,"The abstract does not provide any information about time intervals between the start of medication, dental procedure, and MRONJ incidence, so Elicit could not confirm if this criterion was met.",no,"No mention of a control group, so Elicit could not confirm if this criterion was met.",maybe,"The abstract mentions tooth extraction, which is one of the specified procedures, and MRONJ development, so Elicit determined that this criterion was partially met.",no,"The study design is not explicitly stated in the abstract, so Elicit could not determine if it was a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",no,"While the abstract mentions MRONJ development, it does not provide any information about the follow-up period or specific documentation of MRONJ incidence, so Elicit could not confirm if this criterion was met.",no,"No specific age information was provided in the abstract, so Elicit could not determine if the population was over 18 years old.",no,"No information about sample size was provided in the abstract, so Elicit could not determine if the study included over 100 subjects in the medication group.",no,"The abstract only mentions ""antiresorptive agent"" generally, and does not specify oral bisphosphonates, so Elicit could not confirm if this criterion was met.",no,"The abstract does not mention any diagnostic standards for MRONJ, so Elicit could not confirm if this criterion was met.",Include,"The abstract lacks critical details required by the screening criteria, with insufficient information about population characteristics, study design, sample size, and specific intervention type. While the study addresses medication-related osteonecrosis of the jaw and tooth extraction, most screening requirements cannot be definitively confirmed due to the abstract's brevity. Only the dental procedure and MRONJ outcome criteria are partially met, leaving significant uncertainty about the study's eligibility.",2.5
Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database,"Jing Peng, Hui Wang, Zhen Liu, Zhengguo Xu, Mei Wang, Qi-Miao Chen, Mingxin Wu, Xiaowei Ren, Qiu-hua Liang, Fu-Peng Liu, Boroath Ban",10.3389/fphar.2022.1017391,https://doi.org/10.3389/fphar.2022.1017391,Frontiers in Pharmacology,23,2022,no,"The study includes mixed populations (osteoporosis and cancer patients) and specifically analyzes both groups separately, which fails to meet the criterion requiring exclusive focus on osteoporosis patients.",maybe,"The study documents onset times for MRONJ, but not specifically the time interval between medication start and dental procedure, so this criterion is partially met.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so this criterion is not met.",no,"The abstract does not mention any specific dental procedures leading to MRONJ, so this criterion is not met.",yes,"This appears to be a retrospective analysis of FDA adverse event reports, which could be considered a retrospective cohort study, so this criterion is met.",maybe,"While the study documents MRONJ incidence, it does not mention a specific follow-up period, so this criterion is partially met.",maybe,"The abstract does not explicitly state the age of the subjects, so this information is unclear.",yes,"The study includes 18,421 reports, which far exceeds the minimum requirement of 100 subjects, so this criterion is met.",no,"The study includes both oral bisphosphonates (alendronate, risedronate, ibandronate) and non-bisphosphonates (denosumab, romosozumab), as well as intravenous medications (zoledronic acid, pamidronate), which fails to meet the criterion requiring only oral bisphosphonates.",maybe,"The abstract mentions using ""Osteonecrosis of the jaw (10064658)"" and ""Exposed bone in jaw (10071014)"" as preferred terms, but does not detail specific diagnostic standards, so this criterion is partially met.",Exclude,"The study fails to meet several critical screening criteria, including the requirement for an exclusive osteoporosis patient population and the use of only oral bisphosphonates. Mixed patient populations, inclusion of non-bisphosphonate medications, and absence of specific dental procedure details significantly compromise the study's alignment with the predefined screening requirements.",1.4
Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma,"W. Choi, Jae-Il Lee, H. Yoon, C. Min, Sang-Hwa Lee",10.1186/s40902-016-0099-4,https://doi.org/10.1186/s40902-016-0099-4,Maxillofacial plastic and reconstructive surgery,34,2017,no,"The study focuses on multiple myeloma patients, not osteoporosis patients, which violates the inclusion criteria that specifically excludes cancer patients.",no,"The abstract mentions BP administration time (median 19 months) but doesn't clearly document the time interval between medication start and dental procedure, or between dental procedure and MRONJ incidence, so the reasoning is unclear.",no,"The abstract does not mention a control group of patients not taking bisphosphonates, so no points were added for this criterion.",yes,"The study mentions dental procedures (extractions) and reports MRONJ incidence following these procedures, which meets the criterion.",yes,"This is a retrospective review, which is an acceptable study design.",maybe,"While MRONJ incidence is documented, the follow-up period is not explicitly stated, so the reasoning is unclear.",yes,"The mean patient age was 62.2 years, which meets the requirement of being over 18 years old.",yes,"The study includes 130 patients, which meets the requirement of having over 100 subjects in the medication group.",no,"The study includes both IV zoledronate and pamidronate, not just oral bisphosphonates, which violates the criterion requiring only oral bisphosphonates.",maybe,"While the abstract mentions ""staging and treatment strategies,"" it doesn't explicitly state the diagnostic standards for MRONJ, so the reasoning is unclear.",Exclude,"The study focuses on multiple myeloma patients taking intravenous bisphosphonates, which fundamentally conflicts with the screening criteria requiring osteoporosis patients and oral bisphosphonate interventions. Critical exclusion factors include the wrong patient population, inappropriate medication type, and absence of a control group, rendering the study ineligible for systematic review. Multiple methodological limitations prevent the study from meeting the established screening requirements.",0.1
Medication-related osteonecrosis of the jaw-A case report and literature review,"Chen Chieh, D. Liao",10.17352/2455-5479.000196,https://doi.org/10.17352/2455-5479.000196,Archives of Community Medicine and Public Health,0,2023,no,"The abstract discusses both osteoporosis and cancer patients, mentioning ""patients with osteoporosis and tumors."" This fails the criterion as it includes mixed populations.",no,The abstract does not document any specific time intervals.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While MRONJ is discussed, the abstract doesn't specify any particular dental procedures leading to MRONJ.",no,"The abstract appears to be a review article rather than any of the specified study designs. It discusses ""literature for nearly 20 years"" and doesn't describe a specific study methodology.",no,The abstract doesn't mention any specific follow-up period or clearly document MRONJ incidence rates.,yes,"While the abstract mentions ""postmenopausal women or the elderly,"" it doesn't explicitly state that all subjects are over 18. However, this can be reasonably inferred from the context.",no,The abstract does not mention any specific number of subjects.,maybe,"While bisphosphonates are mentioned, the abstract also discusses other medications like monoclonal antibodies (Denosumab, Romosozumab). It's not clear if the study focuses exclusively on oral bisphosphonates.",no,The abstract does not mention any specific diagnostic standards for MRONJ.,Exclude,"The abstract fails to meet multiple critical screening criteria, including lack of a control group, mixed patient population, unspecified subject size, and absence of a clear study design. While discussing medication-related osteonecrosis of the jaw, the text appears to be a review article rather than an original research study, missing key methodological requirements for inclusion. The document provides general information about osteoporosis and MRONJ but does not satisfy the specific research parameters needed for systematic review.",1.4
Medication related osteonecrosis of the jaw (MRONJ),"A. Bedogni, G. Campisi, V. Fusco",10.32388/594095,https://doi.org/10.32388/594095,Definitions,6,2018,no,"While the abstract discusses bisphosphonates for osteoporosis, it also mentions other conditions (Paget's disease, multiple myeloma, metastatic conditions), suggesting a mixed population, which fails this criterion.",no,"No information about time intervals is provided, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract doesn't mention any specific dental procedures or their relationship to MRONJ incidence, so it fails this criterion.",no,"This appears to be a review article rather than an original research study with any of the specified designs, so it fails this criterion.",no,"No specific follow-up period or MRONJ incidence data is mentioned, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the information is unknown.",maybe,"The abstract does not mention any sample size, so the information is unknown.",maybe,"While bisphosphonates are discussed, the abstract also mentions other medications (chemotherapeutic drugs, denosumab) and doesn't specify oral administration, so it only partially meets this criterion.",no,"While the abstract mentions the AAOMS definition of MRONJ, it doesn't specify diagnostic standards used in any particular study, so it fails this criterion.",Exclude,"The abstract fails multiple critical screening criteria, including lacking a clear study design, not specifying a focused patient population, and omitting details about dental procedures and MRONJ diagnostic standards. As a review article discussing MRONJ terminology rather than an original research study, it does not meet the systematic review's methodological requirements for inclusion.",0.1
"Medication-Related Osteonecrosis of The Jaw treatment Modalities, A review Article",Amirali Asadi,10.18502/jcr.v7i1.4005,https://doi.org/10.18502/jcr.v7i1.4005,Journal of craniomaxillofacial research,0,2020,no,"The abstract discusses MRONJ in relation to antiresorptive and antiangiogenic agents, but does not specifically focus on osteoporosis patients, suggesting a mixed population.",no,"The abstract does not mention any time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While the abstract mentions extraction, it is in the context of treatment rather than studying incidence after dental procedures.",no,"This appears to be a review study of other review studies, not a primary research study of any of the specified designs.",no,"The abstract focuses on treatment approaches rather than documenting MRONJ incidence after dental treatment, and there is no mention of a follow-up period.",maybe,"The abstract does not specify the age of the subjects, so the age of the population is unknown.",maybe,"The abstract does not mention the sample size, so the subject size is unknown.",no,"The abstract mentions antiresorptive agents but does not specify oral bisphosphonates exclusively, and it also mentions Denosumab, which is not a bisphosphonate.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This review study fails multiple critical screening criteria, including lack of a control group, unspecified population age, mixed patient population, and absence of a primary research design. The paper focuses on treatment approaches for MRONJ rather than examining incidence after dental procedures, rendering it unsuitable for the specified research parameters.",0.1
"Editorial: Medication-related osteonecrosis of the jaw (MRONJ): Bisphosphonates, antiresorptives, and antiangiogenic agents. What next?",M. Mupparapu,10.3290/j.qi.a35303,https://doi.org/10.3290/j.qi.a35303,Quintessence International,8,2016,no,"While the abstract mentions both osteoporosis and cancer patients, it does not specify a study population. The paper appears to be a review article rather than a primary research study, so it fails this criterion.",no,"No time intervals are documented, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While dentoalveolar surgery is mentioned as a risk factor, this is not in the context of studying specific procedures and outcomes, so the paper fails this criterion.",no,"This appears to be a review article or commentary rather than any of the required study designs, so it fails this criterion.",no,"No specific outcomes or follow-up periods are documented, so the paper fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is unknown.",no,"No subject size is mentioned, as this appears to be a review article rather than a primary study.",no,"While oral bisphosphonates are mentioned, this is in the context of describing medications rather than studying them. The paper fails this criterion.",no,"While MRONJ is discussed, no specific diagnostic standards are mentioned, so the paper fails this criterion.",Exclude,"This review article fails to meet multiple critical screening criteria for a primary research study, including lack of a defined study population, absence of a control group, and no documentation of specific research outcomes. The text provides a general overview of medication-related osteonecrosis of the jaw but does not constitute an original research investigation with the required methodological elements.",0.1
Incidence and risk factors of bisphosphonate‐associated osteonecrosis of the jaws,"Matthew R. Stumpe, R. Chandra, F. Yunus, S. Samant",10.1002/hed.20941,https://doi.org/10.1002/hed.20941,Head and Neck,37,2007,no,"The abstract mentions ""benign and malignant bone diseases"", indicating a mixed population including cancer patients, which violates the requirement for the research to specify that its subject is chosen from patients taking medication for osteoporosis, excluding cancer patients.",no,"No information about the time intervals between the start of medication, dental procedure, and MRONJ incidence was provided.",no,No information was provided about whether the study included a control group of patients not taking anti-resorptive medications.,no,No specific dental procedures were mentioned.,no,No information about the study design was provided.,no,"While osteonecrosis of the jaws was mentioned, there was no information about the follow-up period or specific documentation of MRONJ incidence.",no,No specific age information was provided about the study population.,no,No information about the sample size of the medication group at the final statistical analysis stage was provided.,no,"The abstract specifically mentions ""intravenous bisphosphonate therapy"", which violates the requirement for the study to only include subjects taking oral bisphosphonate medication for osteoporosis treatment.",no,No information about the diagnostic standards for MRONJ was provided.,Exclude,"The abstract fails to meet multiple critical screening criteria, specifically including cancer patients and focusing on intravenous bisphosphonates instead of oral medications. Insufficient details are provided about study design, population characteristics, and diagnostic standards, rendering the study non-compliant with the systematic review requirements.",0.1
Clinicostatistical analyses of medication‐related osteonecrosis of the jaws (MRONJ): Evaluation of the treatment method and prognosis,"Ryuta Osaka, H. Kato, Y. Hamada, Y. Fujimoto, Nobuhito Mizusawa, D. Watanabe, A. Kaneko",10.1002/osi2.1098,https://doi.org/10.1002/osi2.1098,Oral Science International,4,2020,maybe,The study includes patients taking antiresorptive agents (bisphosphonates and denosumab) but does not specify if they are exclusively osteoporosis patients or include cancer patients. This is a significant uncertainty.,no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not mention any specific dental procedures leading to MRONJ. It focuses on treatment of existing MRONJ rather than incidence after dental procedures.,yes,"The abstract explicitly states it is a retrospective study, which is an acceptable design.",no,"While the study documents MRONJ outcomes, it's focused on treatment outcomes rather than incidence after dental procedures, and the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of subjects, though given it's about MRONJ in patients taking antiresorptive agents, they are likely adults.",no,"The study includes 88 MRONJ patients, which is below the required 100 subjects.",no,"The study includes both bisphosphonates and denosumab, not exclusively oral bisphosphonates.",maybe,"While the abstract mentions ""major clinical symptoms,"" it doesn't explicitly state the diagnostic standards used.",Exclude,"The study fails to meet multiple critical screening criteria, including insufficient sample size, mixed medication types, and lack of focus on dental procedure-related MRONJ incidence. Significant uncertainties exist regarding population indication, diagnostic standards, and outcome documentation, rendering the research potentially unsuitable for the systematic review. The retrospective design and treatment-focused approach further limit its alignment with the specified screening requirements.",1.4
Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS),"Hardeep S. Ahdi, T. Wichelmann, Sasirekha Pandravada, E. Ehrenpreis",10.1186/s40360-023-00657-y,https://doi.org/10.1186/s40360-023-00657-y,BMC Pharmacology and Toxicology,16,2023,no,"The study includes mixed populations taking various medications, not specifically osteoporosis patients. It mentions multiple drug classes including cancer medications, which fails the population indication criterion.",no,"No information about time intervals between medication start, dental procedures, and MRONJ incidence is provided, which fails the MRONJ latency criterion.",maybe,"The abstract does not mention a control group, which is a significant limitation.",no,"The abstract does not specify any dental procedures leading to MRONJ. It only reports MRONJ cases generally, which fails the procedure and outcome criterion.",no,"This is a database analysis of adverse event reports (FAERS), not one of the required study designs (RCT, cohort, or case-control), which fails the study design criterion.",no,"While MRONJ cases are documented, there is no mention of follow-up period or specific documentation of MRONJ incidence after dental treatment, which fails the outcome documentation criterion.",yes,"The abstract explicitly states that only adults (18+) were included, which meets the age requirement.",yes,"The study includes 8,908 cases meeting inclusion criteria, well above the 100-subject requirement, which meets the subject size criterion.",no,"The study is not limited to oral bisphosphonates. It includes multiple medication types including denosumab, corticosteroids, and various cancer drugs, which fails the intervention type criterion.",no,"The abstract does not mention any specific diagnostic standards for MRONJ, which fails the diagnostic standard criterion.",Exclude,"The study fails multiple critical screening criteria, including lack of a specific osteoporosis patient population, absence of a control group, and inclusion of diverse medication types beyond oral bisphosphonates. While the research provides a comprehensive analysis of medication-related osteonecrosis of the jaw, it does not meet the required methodological standards for the systematic review, particularly regarding study design, diagnostic standards, and specific dental procedure outcomes.",1.4
Analysis of Status and Costs of Medication-Related Osteonecrosis of the Jaw in Korea using the National Health Insurance Service Database,"Yong-Wook Kwon, Minjung Park",10.17480/psk.2020.64.4.312,https://doi.org/10.17480/psk.2020.64.4.312,-,0,2020,yes,"The study focuses on patients taking bone-modifying agents (specifically mentioning Alendronate, Risedronate, and Ibandronate) for osteoporosis treatment, and there is no mention of cancer patients.",maybe,"The abstract mentions ""less than three years from the last dose of drugs"" but does not document the specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"The abstract does not specify which dental procedures led to MRONJ. It only mentions ""Surgery of Osteomyelitis of Mandible or Maxilla"" as a cost item.",yes,This appears to be a retrospective cohort study using National Health Insurance Service data.,maybe,"While the study documents MRONJ cases, it does not clearly specify the follow-up period.",maybe,"The abstract does not explicitly state the age of the subjects, though it is likely they are adult patients given the context.",no,"The study includes 183 MRONJ patients, which is below the required 100 subjects for the medication group.",yes,"The study includes oral bisphosphonates (Alendronate, Risedronate, and Ibandronate), meeting this criterion.",maybe,"The abstract mentions using ICD-10 codes (M87.1 and K10.2) for diagnosis, but does not detail specific diagnostic standards for MRONJ.",Include,"The study fails key screening criteria, particularly the requirement for a medication group with over 100 subjects and clear documentation of dental procedures leading to MRONJ. While the research meets some criteria like intervention type and study design, critical shortcomings in sample size, procedure specification, and follow-up period significantly compromise its eligibility. The retrospective cohort study provides insights into MRONJ in Korea but does not fully satisfy the comprehensive screening requirements.",2.7
A systematic review of metastatic cancer presenting in osteonecrosis of the jaws (MC-ONJ) in patients undergoing antiresorptive and/or antiangiogenic therapy for skeletal-related adverse events.,"R. Sacco, Julian Woolley, J. Yates, M. Calasans-Maia, O. Akintola, V. Patel",10.1016/j.oooo.2021.01.001,https://doi.org/10.1016/j.oooo.2021.01.001,"Oral surgery, oral medicine, oral pathology and oral radiology",8,2021,no,"The study focuses on patients with MRONJ, but includes mixed populations (both cancer and non-cancer patients), which fails to meet the criterion of excluding cancer patients and mixed populations.",no,"No information about time intervals between medication start, dental procedures, and MRONJ incidence is provided.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract doesn't mention any specific dental procedures leading to MRONJ.,no,"This is a systematic review, not a primary research study of any of the accepted designs, failing to meet the criterion.",no,"While MRONJ is discussed, there's no mention of follow-up periods or specific documentation of incidence after dental treatment.",maybe,"The abstract does not explicitly state the age of the subjects, so the age of the population is unclear.",no,"The abstract mentions 604 patients in 4 studies for frequency calculation, but this is a review of multiple studies rather than a primary study with its own subject group.",no,"The study includes ""antiresorptive and antiangiogenic drugs"" which is broader than just oral bisphosphonates, failing to meet the criterion.",no,"While the study discusses MRONJ, it doesn't explicitly mention diagnostic standards.",Exclude,"This systematic review fails to meet multiple critical screening criteria, including the requirement for a primary research study design, specific population selection, and focused intervention type. The study's broad inclusion of mixed patient populations, lack of specific dental procedure documentation, and absence of clear diagnostic standards disqualify it from meeting the established screening requirements.",0.1
Analysis of medication-related osteonecrosis of the jaw with bone SPECT/CT: relationship between patient characteristics and maximum standardized uptake value.,"Ruri Ogawa, I. Ogura",10.1259/dmfr.20200516,https://doi.org/10.1259/dmfr.20200516,Dento maxillo facial radiology,16,2021,no,"The study includes a mixed population - 34 osteoporosis patients and 14 cancer patients, which explicitly violates the criterion requiring only osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not mention any dental procedures leading to MRONJ.,yes,"The study is described as ""prospectively included,"" suggesting a prospective cohort design, which meets this criterion.",maybe,"While MRONJ is documented, the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of subjects, though given it's an osteoporosis study, they are likely adults.",no,"The total sample size is 48 patients, with only 34 in the osteoporosis group, which is below the required 100 subjects.",no,"The study mentions denosumab and minodronate, but does not specify if these were oral bisphosphonates. Denosumab is actually a monoclonal antibody, not a bisphosphonate.",yes,"The study uses bone SPECT/CT for diagnosis and mentions staging of MRONJ, suggesting some diagnostic standardization.",Exclude,"The study fails key screening criteria due to a mixed patient population including cancer patients, a small sample size below 100, and the use of non-bisphosphonate medications. Critical methodological limitations include the absence of dental procedure documentation and unclear follow-up periods, which significantly compromise the study's alignment with the specified screening requirements.",1.4
Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ).,"S. Pichardo, J. G. van der Hee, M. Fiocco, N. Appelman‐Dijkstra, J. V. van Merkesteyn",10.1016/j.bjoms.2020.03.022,https://doi.org/10.1016/j.bjoms.2020.03.022,British Journal of Oral and Maxillofacial Surgery,37,2020,no,"The study focuses on patients taking antiresorptive medication, but doesn't explicitly specify osteoporosis patients or exclude cancer patients. The population appears mixed.",yes,"The study documents time intervals between implant placement and MRONJ diagnosis (24 months and 6 months for different groups), meeting this criterion.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,yes,"The study does examine dental procedures (implant placement) and MRONJ incidence, meeting this criterion.",no,"This appears to be a retrospective case series, which is explicitly excluded by the criteria.",maybe,"While the study documents MRONJ incidence, the follow-up period isn't clearly specified.",maybe,"The abstract doesn't explicitly state the age of subjects, but given it's a study of patients with dental implants and osteoporosis medication, it's likely they are adults, but this isn't certain.",no,"The study includes 180 MRONJ patients total, with 18 in the implant group. This is below the required 100 subjects for the medication group.",maybe,"The abstract mentions ""antiresorptive medication"" but doesn't specify oral bisphosphonates exclusively.",no,The abstract doesn't mention specific diagnostic standards for MRONJ.,Include,"The study fails to meet multiple critical screening criteria, including insufficient sample size, lack of a control group, and an inappropriate retrospective case series design. While the research explores medication-related osteonecrosis of the jaws and dental implant risks, it does not align with the specified methodological requirements for inclusion. Key limitations include unclear population specification, absence of diagnostic standards, and incomplete documentation of follow-up periods.",2.5
Key insights into antiresorptive drug use and osteonecrosis in osteoporotic patients undergoing tooth extractions: A clinical and CBCT assessment,"C. Moreno-Rabié, R. C. Fontenele, N. Oliveira-Santos, F. Nogueira-Reis, T. Van den Wyngaert, R. Jacobs",10.1007/s00198-024-07108-2,https://doi.org/10.1007/s00198-024-07108-2,Osteoporosis International,1,2024,maybe,"The study specifically focuses on osteoporotic patients and excludes other populations. However, it includes both bisphosphonate and denosumab patients, which partially violates the criterion of only including bisphosphonate patients.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence, which does not meet the criterion.",yes,"The study included a control group of patients not taking anti-resorptive medications, which meets the criterion and adds 0.2 points to the score.",yes,"The study specifically examines tooth extraction procedures and reports MRONJ incidence, which meets the criterion.",yes,"The study is explicitly stated as a ""retrospective cohort study,"" which meets the criterion.",yes,"The study clearly documents MRONJ incidence (4 patients, 5 sites) and includes follow-up for healing times, which meets the criterion.",yes,"While not explicitly stated, the context of osteoporotic patients strongly implies an adult population over 18 years old.",yes,"The study group includes 78 patients with 224 extractions, meeting the >100 subjects requirement.",no,"The study includes both bisphosphonates and denosumab (a non-bisphosphonate), which violates this criterion.",yes,"The abstract mentions diagnostic criteria including ""bone sequestrum,"" ""exposed bone,"" and ""histological evidence of osteonecrosis,"" which meets the criterion.",Include,"A retrospective cohort study of osteoporotic patients undergoing tooth extraction, examining medication-related osteonecrosis of the jaw with a matched control group. The research includes 176 patients, documenting MRONJ incidence and diagnostic standards, but introduces complexity by including both bisphosphonate and denosumab treatments. While meeting most screening criteria, the mixed medication population represents a potential limitation for strict inclusion requirements.",2.9
Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry.,"P. Sedghizadeh, Kyle Stanley, M. Caligiuri, Shawn Hofkes, B. Lowry, C. Shuler",10.14219/JADA.ARCHIVE.2009.0019,https://doi.org/10.14219/JADA.ARCHIVE.2009.0019,The Journal of the American Dental Association (1939),189,2009,yes,"The study clearly focuses on patients taking alendronate (a bisphosphonate) for osteoporosis, with no mention of cancer patients or mixed populations.",no,"The abstract mentions ""short-term oral use"" but doesn't document specific time intervals between medication start, dental procedures, and ONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,maybe,"The abstract mentions ""certain dental procedures"" but doesn't specify which ones. While it's likely these include the required procedures, this isn't explicitly stated.",yes,The study appears to be a retrospective cohort study using electronic medical records.,maybe,"While the study documents ONJ incidence (4% of the population), the follow-up period is not specified in the abstract.",maybe,"The abstract doesn't explicitly state the age of subjects, but given it's a study of patients taking alendronate for osteoporosis, it's likely they are adults. However, this is uncertain without explicit confirmation.",yes,"The study includes 208 patients in the medication group, which exceeds the minimum requirement of 100 subjects.",yes,The study specifically focuses on oral alendronate (a bisphosphonate) for osteoporosis treatment.,no,The abstract does not explicitly mention the diagnostic standards used for ONJ (MRONJ).,Include,"A retrospective cohort study examining oral bisphosphonate use for osteoporosis, involving 208 patients, demonstrates potential insights into medication-related jaw necrosis. While meeting several key screening criteria like appropriate intervention type and sample size, the study lacks explicit details on diagnostic standards, specific dental procedures, and follow-up periods. The research provides preliminary evidence of medication-related jaw complications, but requires further investigation to fully address all screening requirements.",3.5
Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report,"D. C. Penoni, J. Canellas, Marcos Antonio Nunes Costa Silami, Flávia Sader, Gonçalo Sobreira Pimentel, A. T. T. Leão",10.20945/2359-3997000000612,https://doi.org/10.20945/2359-3997000000612,Archives of Endocrinology and Metabolism,2,2023,yes,"The study clearly focuses on osteoporosis patients, with no mention of cancer patients or mixed populations.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,yes,"The study clearly reports MRONJ incidence following specific dental procedures (tooth extraction, dental implant placement, periodontal procedures, and removable prostheses).",yes,This appears to be a retrospective cohort study analyzing digital records over nine years.,yes,"The study has a nine-year follow-up period, exceeding the six-month requirement, and clearly documents MRONJ incidence.",yes,"The abstract doesn't explicitly state the age of subjects, but since it's focused on osteoporosis patients, we can reasonably assume they are adults (>18 years).",yes,"The study includes 6,742 procedures in patients under osteoporosis treatment, well exceeding the 100-subject requirement.",maybe,The abstract doesn't specify whether the osteoporosis treatment is oral bisphosphonate or other medications. This is a significant uncertainty.,no,The abstract doesn't mention the diagnostic standards used for MRONJ.,Include,"A retrospective cohort study examining medication-related osteonecrosis of the jaw in osteoporosis patients demonstrates strong methodological elements including large sample size and comprehensive dental procedure tracking. However, significant uncertainties exist regarding medication type, diagnostic standards, and control group composition, which create potential limitations in the study's comprehensive assessment of MRONJ risk.",3.5
"Letter to the Editor from [Taguchi]: ""(Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS)"".",A. Taguchi,10.1210/clinem/dgac109,https://doi.org/10.1210/clinem/dgac109,Journal of Clinical Endocrinology and Metabolism,0,2022,yes,"The study focuses on osteoporosis patients taking medications, specifically mentioning alendronate and raloxifene, and does not mention cancer patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract mentions a comparison between alendronate and raloxifene groups, but does not explicitly state that there was a control group of patients not taking anti-resorptive medications.",no,"While the study discusses MRONJ, it does not specifically report MRONJ incidence following the required dental procedures.",yes,"The abstract mentions a ""retrospective, large-scale, multicenter study,"" which meets the criteria for acceptable study designs.",no,"While MRONJ is discussed, the abstract does not clearly document MRONJ incidence after dental treatment or specify a follow-up period.",maybe,"The abstract does not explicitly state the age of the subjects, but mentions postmenopausal women, implying an adult population.",yes,"The abstract mentions ""more than 300 million patients across 9 databases,"" which exceeds the 100-subject requirement.",no,"The study includes alendronate (an oral bisphosphonate) but also includes raloxifene (a non-bisphosphonate), which does not meet the criteria for only including oral bisphosphonate medication.",no,The abstract does not mention any specific diagnostic standards for MRONJ.,Include,"A large-scale retrospective study on osteoporosis patients reveals significant methodological limitations in meeting specific screening criteria for medication-related osteonecrosis of the jaw research. While the study includes a substantial patient population and focuses on osteoporosis medication, it lacks critical details such as specific dental procedures, diagnostic standards, and clear MRONJ incidence documentation. The mixed intervention types and absence of key procedural and outcome measurements prevent the study from fully satisfying the comprehensive screening requirements.",2.5
Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker,"M. Pazianas, W. Blumentals, P. Miller",10.1007/s00198-007-0502-1,https://doi.org/10.1007/s00198-007-0502-1,Osteoporosis International,60,2008,yes,"The study specifically focused on postmenopausal women taking bisphosphonates for osteoporosis, without mentioning cancer patients or a mixed population. This meets the requirement of the research specifying that its subject is chosen from patients taking medication for osteoporosis, excluding cancer patients and research with mixed populations.",no,"The study did not mention the time intervals between medication start, dental procedure, and MRONJ incidence, which is a significant limitation.",yes,"The study included a clear control group with 4 controls matched to each case, for a total of 697 cases and 2,808 controls. This meets the requirement of having a control group of patients not taking anti-resorptive medications.",maybe,"The study focused on jaw surgery, but did not specify if these were extractions, periodontal surgery, or other procedures. It is unclear if all procedures meet the criteria of reporting MRONJ incidence following at least one of the specific dental procedures.",yes,"The study appears to be a case-control study using a claims database, which matches the acceptable study designs of a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",maybe,"The study used a surrogate marker (jaw surgery) rather than direct MRONJ documentation, and the follow-up period was not specified. This makes it unclear if the study met the requirement of clearly documenting MRONJ incidence after dental treatment and having a follow-up period of at least 6 months.",yes,"The study included women ≥45 years of age, which meets the requirement of the subject age being over 18 years old.",yes,"The study included a total of 697 cases and 2,808 controls, which well exceeds the minimum requirement of 100 subjects for the medication group at the final statistical analysis stage.",yes,"The study specifically mentioned oral bisphosphonates (alendronate, risedronate, ibandronate) as the intervention, without mentioning intravenous or non-bisphosphonate medications. This meets the requirement of the study only including subjects that are taking oral bisphosphonate medication for osteoporosis treatment.",no,"The study used ""jaw surgery"" as a surrogate marker for MRONJ, but did not specify the diagnostic standards for MRONJ. This is a significant limitation, as the study did not meet the requirement of mentioning its diagnostic standards for MRONJ.",Include,"The study meets key screening criteria including appropriate population age, intervention type, and study design, with a robust sample size of over 3,500 subjects. However, significant limitations exist in diagnostic standards for MRONJ, with the research using jaw surgery as a surrogate marker rather than direct MRONJ diagnosis. The lack of clear diagnostic criteria, procedure specifics, and latency information creates substantial uncertainty in the study's comprehensive assessment of medication-related jaw outcomes.",2.9
"Association between periodontal disease, tooth extraction and medication-related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort-based study.","Min-Jeong Kwoen, Jung-Hyun Park, Keun-Suh Kim, Jae-Ryun Lee, Jin-Woo Kim, Hong-Pyo Lee, Hyo-Jung Lee",10.1002/JPER.21-0611,https://doi.org/10.1002/JPER.21-0611,The Journal of Periodontology,13,2022,yes,"The study specifically focuses on patients taking bisphosphonates for osteoporosis, without mention of cancer patients or mixed populations.",no,"The abstract does not mention documenting the time intervals between medication start, dental procedures, and MRONJ incidence.",maybe,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications, but it does compare between periodontal disease and non-periodontal disease groups within the bisphosphonate-taking population.",yes,"The study examines both tooth extraction and periodontal procedures, which are among the specified procedures.",yes,"The study is explicitly stated as a ""retrospective, nationwide cohort study,"" which meets the criteria for study design.",maybe,"While the study reports MRONJ incidence, the follow-up period is not explicitly stated in the abstract.",yes,"The study includes women aged over 50 years, which meets the criterion of subjects being over 18 years old.",yes,"The study includes 27,168 patients, well exceeding the 100-subject requirement.",maybe,"The abstract mentions bisphosphonates but does not specify if they are oral or intravenous, creating some uncertainty.",maybe,"The abstract mentions ""confirmed MRONJ"" but does not specify the diagnostic standards used.",Include,"A retrospective cohort study of 27,168 women over 50 years old taking bisphosphonates demonstrates strong alignment with most screening criteria, including appropriate population age, subject size, and study design. While the research effectively explores medication-related osteonecrosis of the jaw in relation to dental procedures, some uncertainties remain regarding bisphosphonate administration type, diagnostic standards, and follow-up period. The study provides valuable insights into MRONJ risk factors among osteoporosis patients undergoing dental treatments.",4
Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.,"Mohamed E. Awad, Christina Sun, J. Jernigan, M. Elsalanty",10.1016/j.adaj.2019.03.006,https://doi.org/10.1016/j.adaj.2019.03.006,The Journal of the American Dental Association (1939),18,2019,maybe,"The abstract mentions patients receiving bisphosphonates, but does not explicitly exclude cancer patients or specify if the population is purely osteoporosis patients.",no,The abstract mentions an average treatment duration of 62.14 months but does not document the specific time intervals required for MRONJ latency.,no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",maybe,"The abstract mentions ""invasive dental procedures"" but does not specify which types.",no,"This is a systematic review and meta-analysis of 18 clinical trials, not a primary study of the required design types (randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study).",maybe,"While the study reports MRONJ incidence, the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, but since the study is about patients receiving bisphosphonates for osteoporosis, it is likely that the subjects are adults over 18 years old.",yes,"The study includes 2,301 patients total, which is well above the 100-subject requirement for the medication group.",maybe,"The abstract mentions bisphosphonates (specifically alendronate and risedronate), but does not specify if they are exclusively oral.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet several critical screening criteria, including the required study design and lack of clarity on population specifics, diagnostic standards, and precise dental procedures. While the study includes a large patient sample and focuses on bisphosphonate therapy, its meta-analysis approach and incomplete documentation of key methodological elements significantly reduce its alignment with the screening requirements.",1.4
Major considerations of maxillary/mandible osteonecrosis caused by bisphosphonates in the dental implant scenario: a systematic review,"Nathalia Silva Tamarindo, Luiza Beran Gubolin, Victoria Luisa Lopes Bordon, Andreia Borges Scriboni",10.54448/mdnt24s408,https://doi.org/10.54448/mdnt24s408,MedNEXT Journal of Medical and Health Sciences,0,2024,maybe,"The abstract mentions osteoporosis patients and bisphosphonate treatment, but does not clearly specify if the study population is exclusively osteoporosis patients, so the criterion is only partially met.",no,"The abstract does not mention time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"The abstract mentions dental implants but does not clearly report MRONJ incidence following specific procedures, so the criterion is only partially met.",no,"This is a systematic review, not a primary research study, which is a critical failure as systematic reviews are not included in the criteria.",no,"The abstract does not clearly document MRONJ incidence or mention follow-up periods, so this criterion is not met.",maybe,"The abstract does not explicitly state the age of the subjects, so the reasoning is uncertain.",maybe,"The abstract does not mention the number of subjects in the included studies, so the reasoning is uncertain.",maybe,"The abstract mentions bisphosphonates (specifically alendronate sodium) but does not specify if it's exclusively oral administration, so the criterion is only partially met.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so this criterion is not met.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including lacking a clear primary research design, missing specific diagnostic standards for MRONJ, and not providing comprehensive documentation of MRONJ incidence. While addressing bisphosphonate and osteoporosis-related dental considerations, the study does not satisfy the required methodological and reporting standards for inclusion.",1.4
Risk Factors of Medication-Related Osteonecrosis of the Jaw: A Clinical Investigation.,"Yuko Komatsu, T. Kawai, T. Hirano, Isao Hoshi, Genki Yamaya, Atsushi Ogawa, Toshimi Chiba, Hiroyuki Yamada",10.1016/j.jormas.2024.101791,https://doi.org/10.1016/j.jormas.2024.101791,Journal of Stomatology Oral and Maxillofacial Surgery,0,2024,no,"The study includes a mixed population of both osteoporosis and malignancy patients, which explicitly violates this criterion.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,"The study does report MRONJ incidence following tooth extraction, which meets this criterion.",yes,"The study appears to be a retrospective cohort study, which meets this criterion.",maybe,"While the study documents MRONJ incidence after dental treatment, the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, but since the study is about osteoporosis patients, they are likely adults.",maybe,"The study includes 57 and 64 MRONJ patients, and 166 at-risk patients, but it is not clear if this meets the criterion for the medication group specifically.",no,"The study includes both bisphosphonates and denosumab, which violates the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails critical screening criteria by including a mixed patient population with both osteoporosis and malignancy patients, and by incorporating non-bisphosphonate medications like denosumab. Multiple key methodological details are missing, including diagnostic standards, precise patient age, and comprehensive follow-up documentation, which further compromise the study's alignment with the specified screening requirements.",1.4
“Spontaneous” medication‐related osteonecrosis of the jaw; two case reports and a systematic review,"A. Khominsky, Mawt Lim",10.1111/adj.12648,https://doi.org/10.1111/adj.12648,Australian dental journal,19,2018,no,"The abstract mentions ""antiresorptive"" medications but does not specifically confirm these are for osteoporosis treatment. The study appears to be a mixed population study, so it fails this criterion.",no,"The abstract mentions ""antiresorptive duration"" but does not document specific time intervals.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"While dental extractions are mentioned, this paper focuses on ""spontaneous"" MRONJ cases without clear dental procedures.",no,"This is explicitly a case series with literature review, which is specifically excluded in the criteria.",maybe,"While MRONJ is documented, the follow-up period is not specified, so the reasoning is uncertain.",maybe,"While the context suggests adult patients, the age of the subjects is not explicitly stated, so the reasoning is uncertain.",no,"The abstract only mentions ""two cases"" and appears to be a case series with literature review, which clearly fails the requirement of over 100 subjects in the medication group.",maybe,"While ""antiresorptive"" medications are mentioned, the specific type (oral bisphosphonate) is not confirmed, so the reasoning is uncertain.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This case series fails multiple critical screening criteria, including insufficient sample size, inappropriate study design, and lack of clear diagnostic standards for MRONJ. The research focuses on ""spontaneous"" MRONJ cases without meeting the required methodological specifications for inclusion in a systematic review. Consequently, the study does not meet the established screening requirements and should be excluded.",0.1
Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis.,"Rouven Schoenhof, A. Munz, A. yuan, A. ElAyouti, H. Boesmueller, G. Blumenstock, S. Reinert, S. Hoefert",10.1016/j.jcms.2021.02.018,https://doi.org/10.1016/j.jcms.2021.02.018,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,11,2021,maybe,"The study included patients taking antiresorptive medications for osteoporosis, but it also included a mixed population of patients taking both bisphosphonates and denosumab, and did not explicitly exclude cancer patients.",no,"The study did not mention any time intervals between the start of medication, dental procedures, and MRONJ incidence.",yes,"The study included a control group of patients not taking anti-resorptive medications, which adds 0.2 points to the score.",no,The study did not mention any dental procedures or report MRONJ incidence after dental procedures.,no,"The study appears to be a laboratory analysis of bone samples, rather than a clinical study design such as a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",no,The study did not document MRONJ incidence after dental treatment or have a follow-up period of at least 6 months.,maybe,"The age of the subjects was not explicitly mentioned, but since the study was about osteoporosis patients, it is likely that the subjects were over 18 years old.",maybe,"The study included 141 samples from 78 patients, but it was unclear how many were in the bisphosphonate group specifically.",no,"The study included both oral bisphosphonates and denosumab, and did not specify if the bisphosphonates were oral or intravenous, which violates the criterion of only including subjects taking oral bisphosphonate medication.",no,The study did not mention any diagnostic standards for MRONJ.,Exclude,"This laboratory study analyzing bone microarchitecture fails to meet multiple critical screening criteria, including appropriate study design, intervention type, and outcome documentation. The research involves mixed medication types and lacks clear documentation of dental procedures, MRONJ incidence, and diagnostic standards. Consequently, the study does not align with the specified screening requirements for a clinical investigation of medication-related osteonecrosis of the jaw.",1.4
Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy.,"A. Hoff, B. Toth, K. Altundağ, V. Guarneri, A. Adamus, A. Nooka, Gilbert Sayegh, Marcy M. Johnson, R. Gagel, G. Hortobagyi",10.1200/JCO.2006.24.18_SUPPL.8528,https://doi.org/10.1200/JCO.2006.24.18_SUPPL.8528,Journal of Clinical Oncology,162,2006,no,"The study primarily focuses on cancer patients (breast cancer, multiple myeloma, lung cancer) with only 7% of patients having osteoporosis. The population is mixed and not focused on osteoporosis patients.",no,"The study does not clearly document the time intervals between medication start, dental procedure, and ONJ incidence.",no,The study does not explicitly mention a control group of patients not taking anti-resorptive medications.,yes,"The study reports ONJ incidence following dental procedures, specifically mentioning dental extractions.",yes,"The study is a retrospective analysis, which meets this criterion.",yes,The study documents ONJ incidence and has a follow-up period of more than 6 months for some patients.,maybe,"The abstract doesn't explicitly state the age of subjects, but given it's a study of cancer patients and osteoporosis patients, it's likely they are over 18. However, this is not explicitly confirmed.",no,"The study includes 4019 patients total, with 34 ONJ cases. While the total sample size is large, the osteoporosis subgroup is only 7% of 4019 (approximately 281 patients), which is below the required 100 subjects for the medication group.",no,"The study focuses on intravenous bisphosphonates (IVBP), not oral bisphosphonates.",yes,"The study defines ONJ as ""exposed non-healing bone of at least 3 months duration.""",Exclude,"The study primarily focuses on cancer patients receiving intravenous bisphosphonates, which disqualifies it from meeting key screening criteria for osteoporosis research. With only 7% of patients having osteoporosis and using intravenous rather than oral bisphosphonates, the study fails critical population and intervention requirements. The mixed patient population and intervention type render the research unsuitable for the systematic review.",0.1
Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics.,"L. De Bruyn, R. Coropciuc, W. Coucke, C. Politis",10.1016/j.oooo.2017.11.022,https://doi.org/10.1016/j.oooo.2017.11.022,"Oral surgery, oral medicine, oral pathology and oral radiology",20,2017,maybe,"The abstract doesn't explicitly state that patients were taking medication for osteoporosis. It only mentions ""medication-related osteonecrosis of the jaw"" without specifying the underlying condition, which is a significant uncertainty.",no,"No information about time intervals between medication start, dental procedures, and MRONJ incidence is provided.",yes,"The study includes a control group of 29 orally healthy patients, which meets the criterion and adds 0.2 points to the score.",no,The study focuses on bacterial populations in MRONJ patients and doesn't report MRONJ incidence following dental procedures.,yes,This appears to be a case-control study (comparing MRONJ patients with healthy controls).,no,"The study doesn't document MRONJ incidence after dental treatment. Instead, it focuses on bacterial populations in existing MRONJ cases.",yes,"The study population age range is 55-88 years (mean 73), meeting the >18 years criterion.",no,"The study only includes 38 MRONJ patients, which is well below the required 100 subjects for the medication group.",maybe,"The abstract doesn't specify the type of anti-resorptive medication the patients were taking, so it cannot be confirmed if it was oral bisphosphonates.",no,The abstract doesn't mention the diagnostic standards used for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including insufficient sample size (38 vs. required 100), lack of clarity on medication type, and absence of documentation for MRONJ diagnostic standards and latency. While the research includes a control group and involves patients over 18, its focus on bacterial populations in MRONJ patients diverges significantly from the required research parameters. The small sample size and different research objectives render the study unlikely to meet the comprehensive screening requirements.",1.4
Medication-Related Osteonecrosis of the Jaws: Review,"T. Morikawa, T. Shibahara",10.31488/jjm.1000131,https://doi.org/10.31488/jjm.1000131,Japanese Journal of Medicine,0,2019,no,"While the abstract mentions antiresorptive agents, it does not specifically state that the subjects are osteoporosis patients, and the paper appears to be a general review rather than a study of a specific population.",no,No information about time intervals is provided in the abstract.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While MRONJ is discussed, the abstract does not specifically mention studying incidence following dental procedures.",no,"This appears to be a review article rather than any of the required study designs (RCT, cohort, or case-control), as the abstract mentions ""This report presents..."" suggesting it's a narrative review.",no,The abstract does not mention any specific follow-up period or documented MRONJ incidence.,maybe,"The abstract does not specify the age of the subjects, so the age of the population is unknown.",maybe,"No subject numbers are mentioned in the abstract, so the subject size is unknown.",maybe,"The abstract mentions ""antiresorptive agents"" but does not specify oral bisphosphonates, so the intervention type is unknown.",no,No diagnostic standards for MRONJ are mentioned in the abstract.,Exclude,"The abstract fails to meet multiple critical screening criteria, including lack of a specified study design, undefined population characteristics, and absence of specific diagnostic standards or outcome documentation. As a review article discussing MRONJ pathophysiology and management, it does not qualify as an original research study meeting the systematic review requirements. Consequently, the paper would be excluded from further analysis.",0.1
Medication-Related Osteonecrosis of the Jaws.,"C. Migliorati, M. Brennan, D. Peterson",10.1093/jncimonographs/lgz009,https://doi.org/10.1093/jncimonographs/lgz009,Journal of the National Cancer Institute. Monographs,23,2019,no,"The abstract explicitly focuses on ""cancer patients"" which is specifically excluded in the criteria, so this is a critical failure.",no,"The abstract does not mention any time intervals, so this criterion is not met.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"The abstract does not mention any specific dental procedures, so this criterion is not met.",no,"This appears to be a review article rather than any of the specified study designs, so this criterion is not met.",no,"While MRONJ is discussed, there's no mention of specific follow-up periods or documented incidence, so this criterion is not met.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any specific subject numbers, so the reasoning for this criterion is uncertain.",no,"The abstract mentions ""antiresorptive or antiangiogenic drugs"" but does not specify oral bisphosphonates exclusively, so this criterion is not met.",no,"While the abstract mentions ""clinical and radiographic signs and symptoms,"" it does not specify diagnostic standards, so this criterion is not met.",Exclude,"The abstract describes a review of medication-related osteonecrosis of the jaw in cancer patients, which fundamentally conflicts with the screening criteria requiring a non-cancer population. Multiple critical screening requirements are not met, including study design, population indication, and specific intervention type. The manuscript fails to align with the predefined research parameters, rendering it unsuitable for inclusion.",0.1
Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons,"K. M. Kim, Y. Rhee, Yong-Dae Kwon, T. Kwon, J. K. Lee, D. Kim",10.11005/jbm.2015.22.4.151,https://doi.org/10.11005/jbm.2015.22.4.151,Journal of Bone Metabolism,78,2015,no,"While the abstract mentions bisphosphonates for osteoporosis, it also discusses other indications (bone metastases, multiple myeloma, Paget's disease) and appears to be a general review/guideline paper rather than a specific study of osteoporosis patients. Therefore, the paper fails this criterion.",no,"No information about time intervals is provided in the abstract, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While MRONJ is discussed, the abstract doesn't mention specific dental procedures or their outcomes. Therefore, the paper fails this criterion.",no,"This appears to be a guideline/review paper rather than any of the specified study designs, so the paper fails this criterion.",no,"No specific outcomes or follow-up periods are mentioned in the abstract, so the paper fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is unknown.",maybe,"No specific subject numbers are mentioned in the abstract, so the reasoning for this criterion is unknown.",no,"While bisphosphonates are discussed, the paper appears to be about guidelines rather than a specific study of oral bisphosphonate users. Therefore, the paper fails this criterion.",no,"The abstract mentions that diagnostic standards were developed by ASBMR and AAOMS, but this is in the context of reviewing guidelines rather than implementing them in a study. Therefore, the paper fails this criterion.",Exclude,"This guideline paper fails multiple screening criteria, including lack of a specific study design, undefined population characteristics, and absence of detailed outcome documentation. The document appears to be a review of medication-related osteonecrosis of the jaw guidelines rather than an original research study, rendering it ineligible for systematic review inclusion. Critical methodological requirements such as control group, subject size, and specific intervention details are not addressed.",0.1
ONJ in two dental practice-based research network regions.,"J. Fellows, D. Rindal, A. Barasch, C. Gullion, W. Rush, D. Pihlstrom, J. Richman",-,-,Texas dental journal,7,2013,maybe,"The study includes patients taking bisphosphonates for osteoporosis, but also includes other risk factors and mixed populations. This partially meets the criterion but isn't ideal.",no,"No information is provided about time intervals between medication start, dental procedures, and ONJ incidence.",yes,"The study appears to include a control group (non-exposed patients) as it mentions ""15.5 (CI, 6.0-38.7) more likely to have ONJ than non-exposed patients.""",no,The abstract doesn't specify which dental procedures were associated with ONJ cases.,yes,"This appears to be a retrospective cohort study using electronic records, meeting this criterion.",maybe,"While the study documents ONJ incidence, the follow-up period isn't explicitly stated.",yes,"The study includes adults aged ≥35 years, meeting the >18 years criterion.",yes,"The study includes 572,606 cohort members, far exceeding the 100-subject requirement.",yes,"The study specifically mentions oral bisphosphonates, meeting this criterion.",no,The abstract doesn't mention specific diagnostic standards for MRONJ/ONJ.,Include,"A large retrospective cohort study examining osteonecrosis of the jaw in adults over 35 years old, with oral bisphosphonate exposure as a key risk factor. While meeting several screening criteria like population size and intervention type, the study lacks specificity in diagnostic standards, dental procedures, and follow-up period. The mixed population and incomplete documentation create significant limitations in fully addressing the screening requirements.",2.9
Disease Stage and Mode of Therapy Are Important Determinants of Treatment Outcomes for Medication-Related Osteonecrosis of the Jaw.,"S. Ruggiero, N. Kohn",10.1016/j.joms.2015.09.024,https://doi.org/10.1016/j.joms.2015.09.024,Journal of oral and maxillofacial surgery,78,2015,maybe,"The abstract does not explicitly state that all subjects were taking medication for osteoporosis. It mentions ""medication-related"" osteonecrosis but does not specify the indication, which creates uncertainty.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not mention any specific dental procedures leading to MRONJ. It focuses on treatment outcomes rather than incidence following dental procedures.,yes,"The study is explicitly described as a ""retrospective cohort study,"" which meets this criterion.",no,"While the study documents MRONJ outcomes, it focuses on treatment outcomes rather than incidence after dental procedures. The follow-up period is not specified.",yes,"The mean age of the subjects is 68.9 years, which meets the criterion of being over 18 years old.",yes,"The study includes 337 subjects, which meets the requirement of over 100 subjects in the medication group.",no,"The abstract mentions ""medication type"" as a variable but does not specify oral bisphosphonates. It also mentions ""targeted antiangiogenic agents"" in 7.1% of cases, suggesting a mixed population, which fails to meet the criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study fails to meet several critical screening criteria, including lack of clarity on patient population, medication type, and specific dental procedures leading to MRONJ. While the research includes a large sample size and appropriate study design, significant uncertainties exist regarding patient selection, intervention specifics, and diagnostic standards. The focus on treatment outcomes rather than incidence following dental procedures further limits its alignment with the screening requirements.",2.5
Case series: Osteonecrosis of the jaw related to denosumab preceded by bisphosphonates in cancer and osteoporotic patients,"D. Falinda, N. Malden",10.1016/j.adoms.2022.100258,https://doi.org/10.1016/j.adoms.2022.100258,Advances in Oral and Maxillofacial Surgery,1,2022,no,"The study includes both cancer and osteoporotic patients, which violates the criterion requiring a pure osteoporosis population.",yes,"The study documents the time interval between dental procedure and MRONJ incidence (8, 12, and 20 weeks).",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The study reports MRONJ incidence following dental extraction, which is one of the specified procedures.",no,"The abstract explicitly states this is a ""retrospective case series,"" which is specifically excluded in the criteria.",maybe,"While the study documents MRONJ incidence, the follow-up period is not clearly stated as being at least 6 months.",maybe,"The abstract does not explicitly state the age of the subjects, but given it's a study of cancer and osteoporotic patients, they are likely adults. However, this is not explicitly confirmed.",no,"The study only includes 7 patients total, which is well below the required 100 subjects.",no,"The study includes patients taking both bisphosphonates and denosumab, not just oral bisphosphonates.",yes,The abstract mentions using ASBMR data collection tool and AAOMS staging recommendations for MRONJ diagnosis.,Exclude,"The study fails critical screening criteria due to a mixed patient population, extremely small sample size of only 7 patients, and inclusion of both bisphosphonates and denosumab. The retrospective case series design and lack of a control group further disqualify the research from meeting the systematic review's methodological requirements. Despite documenting MRONJ incidence and using standardized diagnostic criteria, the fundamental study design and population characteristics render the paper unsuitable for inclusion.",0.1
Medication-Related Osteonecrosis of the jaw（MRONJ）に対する手術方法の検討,"咲 林田, 祐樹 松下, 由紀 坂本, 智史 鳴瀬, 賢 六反田, 惣市 柳本, 誠悟 大場, 泉 朝比奈, 正博 梅田",10.5794/JJOMS.62.441,https://doi.org/10.5794/JJOMS.62.441,-,10,2016,no,"The study includes both oral and intravenous bisphosphonate patients, which violates the criterion requiring only osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The study focuses on surgical treatment of MRONJ rather than MRONJ incidence following dental procedures, which is fundamentally different from the required focus.",yes,"This appears to be a retrospective or prospective cohort study of surgical outcomes, which meets the criterion.",no,"While the study documents outcomes, it's focused on surgical treatment outcomes rather than MRONJ incidence after dental treatment, and the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of subjects, though given it's about MRONJ in bisphosphonate patients, they are likely adults.",no,"The study includes 57 total patients, with 35 in the oral bisphosphonate group, which is below the required 100 subjects.",no,"The study includes both oral and intravenous bisphosphonates, violating the requirement for only oral bisphosphonates.",no,The abstract does not explicitly mention diagnostic standards for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including insufficient subject size, mixed population with both oral and intravenous bisphosphonates, and a focus on surgical treatment rather than dental procedure-related MRONJ incidence. Key methodological requirements such as diagnostic standards, control group, and specific outcome documentation are not met, rendering the study unsuitable for inclusion in the systematic review.",1.4
Medication-Related Osteonecrosis of the Jaw: A Critical Narrative Review,"A. Lorenzo-Pouso, J. Bagan, L. Bagán, P. Gándara-Vila, C. Chamorro-Petronacci, P. Castelo-Baz, A. Blanco-Carrión, María Ángeles Blanco-Fernández, Óscar Álvarez-Calderón, Javier Carballo, M. Pérez‐Sayáns",10.3390/jcm10194367,https://doi.org/10.3390/jcm10194367,Journal of Clinical Medicine,17,2021,no,"While the abstract discusses MRONJ in relation to bone modifying agents, it does not specifically state that the study is focused on osteoporosis patients or exclude cancer patients, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention any time intervals, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention any control group, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention specific dental procedures, so Elicit could not confirm whether this criterion was met.",no,"This is explicitly a review article, not one of the required study designs (randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study), so Elicit determined that this criterion was not met.",no,"As a review article, it does not have its own follow-up period or documented MRONJ incidence, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not specify the age requirements of the study population, so Elicit could not confirm whether this criterion was met.",no,"This is a review article, not an original research study, so it does not have its own subject group, and Elicit could not confirm whether this criterion was met.",no,"The abstract mentions ""bone modifying agents"" broadly but does not specify oral bisphosphonates exclusively, so Elicit could not confirm whether this criterion was met.",no,"While the paper discusses MRONJ, the abstract does not explicitly mention diagnostic standards, so Elicit could not confirm whether this criterion was met.",Exclude,"This review article fails to meet multiple screening criteria, particularly the required study design of a randomized controlled trial, prospective cohort, retrospective cohort, or case-control study. The abstract lacks specific details about population characteristics, intervention type, diagnostic standards, and outcome documentation, rendering it unsuitable for inclusion in the systematic review.",0.1
Oral Complications in Cancer Patients–Medication-Related Osteonecrosis of the Jaw (MRONJ),C. Migliorati,10.3389/froh.2022.866871,https://doi.org/10.3389/froh.2022.866871,Frontiers in Oral Health,8,2022,no,"The abstract explicitly focuses on cancer patients and mentions other conditions like rheumatoid arthritis and Paget's disease, rather than exclusively on osteoporosis patients. This is a clear violation of the inclusion criteria.",no,"No mention of time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While MRONJ is discussed, the abstract doesn't specify studying incidence following specific dental procedures.",no,"This appears to be a mini review article, not a primary research study of any of the specified designs. This is a clear violation of the inclusion criteria.",no,"As a review article, it doesn't document specific MRONJ incidence or follow-up periods.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any specific sample size, so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, the paper discusses multiple medications including denosumab and antiangiogenics, not exclusively oral bisphosphonates. This violates the inclusion criteria.",no,"The abstract mentions that there is discussion about ""the best way to define MRONJ"" but doesn't specify diagnostic standards used in a study.",Exclude,"This mini review article fails multiple critical screening criteria, including being a review rather than a primary research study, focusing on cancer patients instead of osteoporosis patients, and covering multiple medication types beyond oral bisphosphonates. The paper lacks specific details about study design, subject size, diagnostic standards, and outcome documentation, rendering it ineligible for inclusion in the systematic review.",0.1
Risk factors for medication-related osteonecrosis of the jaws in menopausal women,"Jocarla Campos Serafim, Gustavo Azevedo Pitol, Ester Victorino Coser, B. Albergaria, S. C. Kano, T. Velloso",10.20396/bjos.v23i00.8668457,https://doi.org/10.20396/bjos.v23i00.8668457,Brazilian Journal of Oral Sciences,0,2024,no,"The study includes both osteoporosis and osteopenia patients, which does not meet the criterion of focusing exclusively on osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The study mentions tooth extraction and periodontal disease as risk factors, but it is unclear if these are outcomes or just risk factors being evaluated. The abstract does not clearly report MRONJ incidence following these procedures.",yes,"The study appears to be a retrospective review of medical records, which could qualify as a retrospective cohort study.",no,The abstract does not clearly document MRONJ incidence or mention a follow-up period.,maybe,"The abstract does not explicitly state the age of the subjects, but given that the study is on osteoporosis patients, they are likely over 18 years old. However, this is uncertain without explicit confirmation.",no,"The study only includes 50 total patients (29 with osteoporosis), which is well below the required 100 subjects for the medication group.",yes,"The abstract mentions oral bisphosphonates (specifically alendronate), which meets this criterion.",no,"While the study mentions clinical and radiographic evaluations, it does not explicitly state its diagnostic standards for MRONJ.",Include,"The study fails to meet critical screening criteria, particularly the requirement for a large sample size (only 50 patients) and a pure osteoporosis population. Significant methodological limitations include a mixed patient group, unclear diagnostic standards for MRONJ, and insufficient documentation of MRONJ incidence following dental procedures. These deficiencies prevent the study from satisfying the comprehensive screening requirements.",2.5
Real-world study of medication-related osteonecrosis of the jaw from 2010 to 2023 based on Food and Drug Administration’s adverse event reporting system,"Yuhao Zhong, Wei Dai, Lin Yin, Guomin Wu, Xiaoying Wang",10.1093/jbmrpl/ziaf003,https://doi.org/10.1093/jbmrpl/ziaf003,JBMR Plus,0,2025,no,"The study includes mixed populations (both cancer and osteoporosis patients) and doesn't specify separate analysis for osteoporosis patients, which is a critical failure of the inclusion criteria.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, which is a significant limitation.",no,The abstract does not specify any dental procedures leading to MRONJ.,no,"This is a retrospective pharmacovigilance analysis using FAERS database, which is not one of the specified study designs (RCT, prospective cohort, retrospective cohort, or case-control).",no,"While MRONJ incidence is documented, the follow-up period is not specified.",yes,"The abstract mentions the mean age of the subjects was 67.33 ± 11.71 years, which meets the criterion of being over 18 years old.",yes,"The study includes 22,846 MRONJ cases, which far exceeds the minimum requirement of 100 subjects.",no,"While bisphosphonates are included, the study also includes many other drug classes and doesn't focus specifically on oral bisphosphonates for osteoporosis treatment, which fails to meet the criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including population specificity, intervention type, and study design. While the research includes a large sample size and addresses medication-related osteonecrosis of the jaw, it lacks a control group, focuses on mixed patient populations, and does not specify dental procedures or diagnostic standards. The methodology and scope do not align with the required screening parameters.",1.4
Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.,"T. Neal, T. Schlieve",10.1016/j.joms.2022.06.026,https://doi.org/10.1016/j.joms.2022.06.026,Journal of oral and maxillofacial surgery,11,2022,no,"The study includes mixed populations (osteogenesis imperfecta, malignancy, and other conditions), which fails the criterion requiring only osteoporosis patients.",yes,"The study documents time intervals between medication start and dental procedures, meeting this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study does report dental extractions (74 teeth in 26 patients) and MRONJ incidence, meeting this criterion.",no,"The study is described as a ""retrospective case series"" which is explicitly excluded in the criteria.",maybe,"The study has a follow-up period of 4.89 years (median 4 years), exceeding the 6-month requirement. However, no MRONJ cases were found.",no,"The study explicitly focuses on pediatric patients with an average age of 8.18 years (range 0.02-17), which fails the criterion requiring subjects over 18 years old.",maybe,"The study includes 122 subjects total, but not all were in the medication group. However, this would likely meet the >100 subject criterion if we only counted the medication group.",no,"The study includes various antiresorptive medications including pamidronate, zoledronate, and denosumab, and does not specify oral bisphosphonates exclusively, which fails the criterion.",no,"While MRONJ is mentioned as an outcome, the abstract does not specify the diagnostic standards used.",Exclude,"The study focuses on pediatric patients with mixed medical conditions, using various antiresorptive medications, which fundamentally conflicts with the screening criteria requiring adult osteoporosis patients taking oral bisphosphonates. Multiple critical screening requirements were not met, including population age, study design, and intervention type, rendering the study ineligible for inclusion in the systematic review.",0.1
Cross-Sectional Study of four Serological Bone Turnover Markers for the Risk Assessment of Medication-Related Osteonecrosis of the Jaw,"André Peisker, G. Raschke, Mina D Fahmy, A. Guentsch, Korosh Roshanghias, K. König, S. Schultze–Mosgau",10.1097/SCS.0000000000004224,https://doi.org/10.1097/SCS.0000000000004224,The Journal of craniofacial surgery (Print),14,2017,maybe,"The study includes patients on antiresorptive therapies, but does not explicitly specify that they are osteoporosis patients or exclude cancer patients, so the population indication is only partially met.",no,"The study does not mention the time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study explicitly includes 20 controls who have been on antiresorptive therapies with no MRONJ occurrence, which meets the requirement for a control group.",no,"While the study mentions ""invasive oral surgery,"" it does not specifically report MRONJ incidence following the specific dental procedures listed in the criteria.",no,"The study is a cross-sectional study, which is not one of the accepted study designs.",no,The study focuses on biochemical markers for MRONJ risk assessment rather than documenting MRONJ incidence after dental treatment.,maybe,"The abstract does not specify the age of the subjects, so the age requirement is unclear.",no,"The study only includes 20 patients in each group, which is well below the required 100 subjects for the medication group.",maybe,"The study mentions ""antiresorptive therapies"" but does not specify if only oral bisphosphonates were included, so the intervention type is unclear.",no,The abstract does not mention the diagnostic standards for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including insufficient sample size, inappropriate study design, and lack of specific documentation for MRONJ incidence after dental procedures. Key limitations include a small patient group of 20, a cross-sectional methodology, and absence of clear diagnostic standards or comprehensive outcome reporting. The research appears more focused on biochemical marker analysis rather than meeting the systematic review's specific requirements.",1.4
Systemic comorbidities are associated with medication-related osteonecrosis of the jaws: Case-control study.,"K. McGowan, C. Acton, S. Ivanovski, N. Johnson, R. Ware",10.1111/odi.13046,https://doi.org/10.1111/odi.13046,Oral Diseases,11,2019,maybe,"The study mentions ""antiresorptive medications"" but does not specifically state that the subjects are taking medication for osteoporosis. There is no explicit mention of excluding cancer patients, and the population may be mixed, but this is not clearly stated.",no,"The study does not mention any time intervals between medication start, dental procedures, and MRONJ onset.",yes,"The study explicitly mentions using controls (204 controls matched to 68 cases), which meets the requirement for a control group.",no,The study does not mention any specific dental procedures leading to MRONJ. The focus is on comorbidities rather than dental procedures.,yes,"The study is explicitly stated as a case-control study, which meets the criteria for study design.",maybe,"The follow-up period is not specified, and the documentation of MRONJ incidence is not clearly described.",maybe,"Age is mentioned as a matching criterion, but the specific age range is not stated. Given that it's a hospital-based study, the subjects are likely adults, but this is not explicitly confirmed.",no,"The study only includes 68 cases (medication group), which is well below the required 100 subjects.",maybe,"The study only mentions ""antiresorptive medications"" without specifying oral bisphosphonates. There is no distinction made between oral and intravenous administration.",no,The abstract does not mention any diagnostic standards for MRONJ.,Include,"The study fails to meet several critical screening criteria, including insufficient sample size (68 cases vs. required 100), lack of specific dental procedure documentation, and absence of clear diagnostic standards for MRONJ. While the research design is a valid case-control study with controls, fundamental mismatches with the inclusion criteria render it unsuitable for the systematic review. Uncertainties around medication type, patient age, and follow-up period further complicate its potential inclusion.",2.5
UTILITY OF BIOMARKERS IN PREDICTING THE DEVELOPMENT OF MEDICATION-RELATED OSTEONECROSIS OF THE JAWS: A SCOPING REVIEW,"G. Matus, Antonio Mancilla, René Martinez, Maureen Marshall, Juan Pablo Aravena, María José Quijarro, Víctor Moraga",10.1016/j.ajoms.2023.09.001,https://doi.org/10.1016/j.ajoms.2023.09.001,Journal of Oral and Maxillofacial Surgery Medicine and Pathology,0,2023,no,"While the abstract mentions ""patients consuming drugs associated with osteonecrosis of the jaws,"" it doesn't specifically focus on osteoporosis patients and appears to include mixed populations.",no,"The abstract doesn't document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, as this is a scoping review rather than a primary study.",no,"While the abstract mentions ""oral surgical procedures,"" it's focused on biomarkers rather than documenting MRONJ incidence after specific procedures.",no,"This is a scoping review, not one of the required study designs (RCT, cohort, or case-control).",no,The paper focuses on biomarkers rather than documenting MRONJ incidence and follow-up periods.,no,The abstract does not specify age requirements for included studies.,no,"As a scoping review, this paper doesn't have its own subject group size.",no,"The abstract mentions bisphosphonates but also includes ""antiangiogenic drugs"" and doesn't specify oral administration.",no,The abstract doesn't mention specific diagnostic standards for MRONJ.,Exclude,"This scoping review on medication-related osteonecrosis of the jaw fails to meet multiple critical screening criteria, including specific study design requirements, population specifications, and outcome documentation. The paper focuses on biomarkers rather than primary research on MRONJ incidence after dental procedures, rendering it unsuitable for inclusion in the systematic review.",0.1
Medication-related osteonecrosis of the jaw: a dentist's nightmare,"Arvind Muthukrishnan, Laliytha Bijai Kumar, G. Ramalingam",10.1136/bcr-2016-214626,https://doi.org/10.1136/bcr-2016-214626,BMJ Case Reports,48,2016,no,"The abstract mentions multiple conditions (multiple myeloma, osteoporosis, metastatic carcinoma, Paget's disease) and does not specify that the subject was taking medication specifically for osteoporosis. This is a mixed population study.",no,No information about time intervals is provided.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,no,"This is explicitly stated to be a case report, which is specifically excluded in the criteria.",no,"While MRONJ is documented, there's no mention of follow-up period.",yes,"The subject is 50 years old, which meets the >18 years old criterion.",no,"This is a case report of a single patient, far below the required 100 subjects.",no,"While bisphosphonates are mentioned, the abstract discusses multiple types of anti-bone resorptive drugs including monoclonal antibodies, and doesn't specify which type the subject was taking.",no,The abstract does not mention any specific diagnostic standards for MRONJ.,Exclude,"This case report fails multiple critical screening criteria, including being a single-subject study, lacking a control group, and not focusing exclusively on osteoporosis patients. The research does not meet the required methodological standards for inclusion, such as having a minimum sample size of 100 subjects and specifying precise diagnostic and procedural protocols for MRONJ.",0.1
"Medication-Related Osteonecrosis of the Jaw, a Hidden Enemy. An Integrative Review",Odel Chediak-Barbur,10.11144/javeriana.uo40.mroj,https://doi.org/10.11144/javeriana.uo40.mroj,Universitas Odontologica,0,2021,no,"The abstract mentions both osteoporosis and cancer patients, indicating a mixed population, which fails to meet the criterion requiring only osteoporosis patients.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The abstract mentions extractions as a risk factor (52-61%), meeting this criterion.",no,"This is an integrative review of literature, not a primary research study of any of the required designs, so it fails to meet this criterion.",no,"While the abstract discusses ONJ, it does not specify follow-up periods or clearly document MRONJ incidence rates, so it fails to meet this criterion.",maybe,"The abstract does not explicitly state the age of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention the number of subjects studied, so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, the abstract also includes other medications (denosumab, bevacizumab, sunitinib) and specifically mentions intravenous administration, which fails to meet the criterion requiring only oral bisphosphonates.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so it fails to meet this criterion.",Exclude,"This literature review fails multiple critical screening criteria, including inappropriate study design, mixed patient population, and inclusion of non-bisphosphonate medications. The abstract lacks specific diagnostic standards, follow-up documentation, and does not meet the required methodological specifications for inclusion in a systematic review. Consequently, the paper does not qualify for further analysis based on the established screening criteria.",0.1
A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis,"J. Kwon, E-J Park, S. Jung, H. Sohn, H. Ryu, H. S. Suh",10.1177/0022034515587862,https://doi.org/10.1177/0022034515587862,Journal of dentistry research,33,2015,yes,"The study clearly stated that the subjects were patients with an osteoporosis diagnosis, and there was no mention of cancer patients or a mixed population.",maybe,"The study documented the exposure time (2 years prior to the index date), but did not specify the time from the dental procedure to MRONJ.",yes,"The study included a clear control group of non-users of bisphosphonates, with 2,120 controls.",no,"The study did not specify any dental procedures leading to MRONJ, and only looked at general MRONJ occurrence.",yes,"The study design was a nested case-control study, which is an acceptable design.",maybe,"The study had a follow-up period of 2002-2010, but did not specify the minimum follow-up time per patient.",maybe,"While not explicitly stated, the study was of osteoporosis patients in Korea, which typically affects adults over 18 years old.",yes,"The study included 212 cases and 2,120 controls, well over 100 subjects in the medication group.",maybe,"The study mentioned bisphosphonates, but did not specify if they were only oral bisphosphonates, and there was no mention of excluding intravenous or non-bisphosphonate medications.",no,The study did not mention any specific diagnostic standards for MRONJ.,Include,"A nested case-control study of Korean osteoporosis patients examining bisphosphonate exposure and osteonecrosis of the jaw, with a robust sample size and clear control group. While meeting several key screening criteria, the study lacks specificity in diagnostic standards, dental procedure details, and precise medication type. The research provides valuable insights but falls short of fully addressing all predefined screening requirements.",2.9
Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab.,"Stamatis Katsenos, Charalampos Christophylakis, Konstantinos Psathakis",10.1016/j.arbres.2012.01.007,https://doi.org/10.1016/j.arbres.2012.01.007,Archivos de Bronconeumologia,9,2012,no,"The study focuses on patients with cancer taking antiangiogenic drugs, not osteoporosis patients. This explicitly fails the criterion which requires osteoporosis patients and excludes cancer patients.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications. In fact, it specifically focuses on patients who ""had not been previously exposed to any antiresorptive drug treatments.""",maybe,"The abstract mentions that ""an invasive procedure was the most common trigger of MRONJ,"" but doesn't specify which dental procedures were included.",no,"This is a review article analyzing other studies, not a primary research study with one of the required designs.",maybe,"While the study documents MRONJ incidence and mentions postoperative recurrence, it doesn't specify the follow-up period.",maybe,The abstract does not specify the age of subjects.,no,"The study includes only 36 total patients, well below the required 100 subjects.",no,"The study focuses on antiangiogenic drugs (anti-VEGF), not oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients taking antiangiogenic drugs, which fundamentally differs from the required osteoporosis patient population taking bisphosphonates. With only 36 patients and a review design, the research fails critical screening criteria including subject size, intervention type, and study design. Multiple key methodological requirements are not met, rendering the study unsuitable for inclusion.",0.1
Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw,H. Y. Kim,10.3803/EnM.2021.1170,https://doi.org/10.3803/EnM.2021.1170,Endocrinology and Metabolism,15,2021,no,"The abstract indicates that this is a review article rather than a primary study of specific patients, so it fails to meet the population indication criterion.",no,"The abstract does not mention any time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract does not mention specific dental procedures or their relationship to MRONJ incidence, so it fails to meet this criterion.",no,"The abstract explicitly states that this is a review article, not a primary research study of any of the required designs, so it fails to meet the study design criterion.",no,"As a review article, it does not document specific MRONJ incidence or follow-up periods, so it fails to meet this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is unknown.",no,"As this is a review article, no specific subject numbers are mentioned, so it fails to meet the subject size criterion.",no,"The abstract mentions both bisphosphonates and denosumab, not exclusively oral bisphosphonates, so it fails to meet the intervention type criterion.",no,"While the abstract mentions that ARONJ definition has been studied, it does not specify the diagnostic standards, so it fails to meet this criterion.",Exclude,"This review article fails to meet multiple screening criteria, including lack of a control group, undefined patient population, and absence of specific intervention details. As a review rather than a primary research study, it does not provide the required empirical data on MRONJ incidence, diagnostic standards, or specific dental procedures. The abstract fundamentally does not align with the specified research design and outcome documentation requirements.",0.1
Medication‐Related Osteonecrosis of the Jaw and Dental Implants Failures: A Systematic Review,"Riccardo Guazzo, L. Sbricoli, Sara Ricci, E. Bressan, Adriano Piattelli, F. Iaculli",10.1563/aaid-joi-16-00057,https://doi.org/10.1563/aaid-joi-16-00057,Journal of Oral Implantology,5,2016,no,The abstract discusses antiresorptive agents users but does not specifically exclude cancer patients or mixed populations.,no,The abstract does not document specific time intervals.,no,"The abstract does not mention a control group, as this is a systematic review rather than a primary study.",yes,"The abstract mentions dental implants placement and ONJ development, which meets this criterion.",no,"This is a systematic review, not one of the required study designs (RCT, cohort, or case-control).",no,"While ONJ incidence is mentioned, the follow-up period is not specified.",no,The abstract does not specify the age requirements for the population.,no,"As a systematic review, this paper does not have its own subject group size.",no,"The abstract mentions ""oral antiresorptive agents"" but does not specify bisphosphonates exclusively.",no,The abstract does not mention specific diagnostic standards for ONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific study design requirements, population specifications, and detailed outcome documentation. While addressing dental implant and osteonecrosis risks, the paper lacks the precise methodological elements needed for inclusion, such as a defined control group, clear diagnostic standards, and comprehensive subject characteristics. The abstract represents a literature review rather than a primary research study with the required methodological rigor.",0.1
Medication-Related Osteonecrosis of the Jaw: 14 Years’ Retrospective Study on Pathogenetic Trigger Events,"Raffaele Marino, A. Squillacioti, G. Lo Giudice, S. Cicchiello, C. Scozzaro, S. Mummolo, F. De Ponte, E. Nastro Siniscalchi",10.1097/SCS.0000000000008719,https://doi.org/10.1097/SCS.0000000000008719,The Journal of craniofacial surgery (Print),1,2022,no,"The study includes a mixed population of patients, including both osteoporosis patients and patients with other underlying diseases. This fails the criterion requiring the study to focus exclusively on osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study mentions ""tooth extraction and oral surgery"" as trigger events, which meets this criterion.",yes,"The study is described as a retrospective analysis, which meets the criterion as a retrospective cohort study.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, but it is likely they are adults since the study was conducted at a tertiary referral hospital. However, this is not certain.",no,"The study analyzed 52 records, which is well below the required 100 subjects for the medication group.",no,"The study includes both oral bisphosphonates (Alendronate, Risedronate) and intravenous bisphosphonates (Zoledronate), which violates the criterion requiring only oral bisphosphonates.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including a mixed patient population, insufficient sample size, and inclusion of both oral and intravenous bisphosphonates. Key methodological limitations include lack of a control group, absence of clear diagnostic standards, and incomplete documentation of MRONJ latency and follow-up period. These significant deviations from the specified screening requirements render the study unsuitable for inclusion.",1.4
Medication-Related Osteonecrosis of the Jaw: A Reflection of Current Preventative and Therapeutic Guidelines: A Review,"Hassan H. Dib, W. Khalil, Houssam Jassar, Mohamad Houmnani",10.24018/ejdent.2022.3.2.57,https://doi.org/10.24018/ejdent.2022.3.2.57,European Journal of Dental and Oral Health,1,2022,no,"The abstract appears to be a review article rather than a primary research study with a specific patient population, so it fails this criterion.",no,"No information about time intervals is provided in the abstract, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract doesn't mention any specific dental procedures or their relationship to MRONJ incidence, so it fails this criterion.",no,"This appears to be a review article, not a primary research study with any of the specified study designs, so it fails this criterion.",no,"The abstract doesn't mention any specific follow-up period or documented MRONJ incidence, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the age of the population is unknown.",maybe,"No specific subject numbers are mentioned in the abstract, so the subject size is unknown.",no,"The abstract mentions bisphosphonates (pamidronate and zoledronate) but also includes other medications (denosumab and antiangiogenic drugs), so it is not focused solely on oral bisphosphonates and fails this criterion.",no,"While the abstract mentions AAOMS guidelines, it doesn't specify diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"This review article fails to meet multiple critical screening criteria, including lacking a primary research design, not focusing exclusively on oral bisphosphonates, and omitting specific patient population details. The abstract does not provide original data, diagnostic standards, or documentation of MRONJ incidence following dental procedures, rendering it unsuitable for systematic review inclusion.",0.1
A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy,"V. Fusco, M. Cabras, F. Erovigni, Alessandro Dell’Acqua, P. Arduino, M. Pentenero, P. Appendino, L. Basano, F. Ferrera, A. Fasciolo, Majlinda Caka, M. Migliario, S. Franchi, A. Gambino",10.4317/medoral.24318,https://doi.org/10.4317/medoral.24318,Medicina Oral,21,2020,no,"The study specifically focuses on cancer/myeloma patients, which explicitly violates the criterion requiring subjects taking medication for osteoporosis.",no,"While the study mentions ""treatment duration,"" it doesn't specifically document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures led to MRONJ cases.,yes,"The study is a retrospective-prospective cohort study, which meets the acceptable study designs.",maybe,"While the study documents MRONJ incidence, the follow-up period is not clearly specified.",yes,"The abstract does not explicitly state the age of subjects, but given it's a cancer/myeloma population, it can be reasonably assumed that the subjects are adults.",yes,"The study includes 459 MRONJ cases, well above the 100-subject requirement.",no,"The study includes both oral and intravenous medications (zoledronic acid is intravenous), and includes non-bisphosphonates (denosumab), which violates the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer and myeloma patients taking anti-resorptive medications, which fundamentally disqualifies it from meeting the screening criteria for osteoporosis research. Critical deviations include inappropriate patient population, mixed medication types, and absence of key diagnostic and procedural details required for systematic review inclusion. Multiple screening criteria were not met, rendering the study unsuitable for the intended research parameters.",0.1
Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study.,"S. Otto, M. H. Abu-id, S. Fedele, P. Warnke, S. Becker, A. Kolk, T. Mücke, G. Mast, R. Köhnke, E. Volkmer, F. Haasters, O. Lieger, T. Iizuka, S. Porter, G. Campisi, G. Colella, O. Ploder, A. Neff, J. Wiltfang, M. Ehrenfeld, T. Kreusch, K. Wolff, S. Stürzenbaum, M. Schieker, C. Pautke",10.1016/j.jcms.2010.05.009,https://doi.org/10.1016/j.jcms.2010.05.009,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,139,2011,yes,"The study specifically focuses on osteoporosis patients taking oral bisphosphonates, clearly distinguishing them from cancer patients, so this criterion is met.",maybe,"The abstract mentions duration of BP therapy before BRONJ diagnosis (78% >3 years), but doesn't document the time from dental procedure to MRONJ incidence, so this criterion is partially met.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract does not specify which dental procedures led to BRONJ, failing this criterion.",no,"This appears to be a retrospective case series of BRONJ cases, which does not meet the required study design criteria.",maybe,"While BRONJ incidence is documented, the follow-up period is not specified, making this criterion uncertain.",maybe,"While not explicitly stated, the context suggests the study included adult patients with osteoporosis, so this criterion is likely met but not explicitly confirmed.",no,"The study includes 37 cases of BRONJ in osteoporosis patients, which is below the required 100 subjects for the medication group, so this is a critical failure.",yes,"The study specifically focuses on oral bisphosphonate medication for osteoporosis treatment, meeting this criterion.",yes,"The abstract mentions using criteria from the American Association of Oral and Maxillofacial Surgery, meeting this criterion.",Exclude,"The study fails critical screening criteria due to its small sample size of 37 patients, which falls significantly short of the required 100 subjects, and its case series design which does not meet the specified study design requirements. Despite focusing on oral bisphosphonate use in osteoporosis patients and using established diagnostic standards, the research lacks specification of dental procedures leading to BRONJ and does not clearly document follow-up periods. These limitations substantially reduce the study's methodological rigor and screening compliance.",1.4
"Prevalence of Medication-Related Osteonecrosis of the Jaw in Osteoporotic Patients Treated with Antiresorptive Drugs at Pranangklao Tertiary Care Hospital in Nonthaburi Province, Thailand",-,10.35755/jmedassocthai.2023.04.13832,https://doi.org/10.35755/jmedassocthai.2023.04.13832,Journal of the Medical Association of Thailand = Chotmaihet thangphaet,0,2023,yes,"The study clearly focuses on osteoporotic patients taking antiresorptive drugs, excluding cancer patients.",no,"The abstract mentions mean antiresorptive drug exposure time (1.52 years) but does not specifically document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,yes,The study specifically mentions tooth extraction as the dental procedure and reports MRONJ incidence (2 cases among 49 extractions).,yes,"This is a retrospective cohort study, which meets the criterion.",maybe,"While the study reports MRONJ incidence, the follow-up period is not explicitly stated, though the study period (2014-2020) suggests adequate follow-up.",maybe,"While not explicitly stated, the context suggests these are adult osteoporosis patients, as osteoporosis typically affects adults. However, this is not definitively confirmed.",yes,"The study includes 1,188 patients total, with 677 on oral bisphosphonates, well exceeding the 100-subject requirement.",yes,"The study includes patients on oral bisphosphonates (specifically mentions alendronate), but also includes other antiresorptive drugs. The analysis separates oral bisphosphonate users (677 patients).",no,The abstract does not mention the diagnostic standards used for MRONJ.,Include,"A retrospective cohort study of osteoporotic patients taking antiresorptive medications, with a large sample size of 1,188 patients and specific focus on oral bisphosphonates. The research meets several key screening criteria including appropriate study design, population indication, and dental procedure documentation, though it lacks a control group and clear diagnostic standards for MRONJ. The study provides insights into MRONJ prevalence among osteoporosis patients undergoing dental procedures.",3.5
Systematic literature review of bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis.,"E. Chamizo Carmona, Adela Gallego Flores, E. Loza Santamaría, Aurora Herrero Olea, M. Rosario Lozano",10.1016/j.reuma.2012.05.005,https://doi.org/10.1016/j.reuma.2012.05.005,Reumatología Clínica,13,2013,yes,The study specifically focuses on osteoporosis patients and explicitly excludes cancer patients and other diseases.,maybe,"The abstract does not mention time intervals between medication start, dental procedures, and ONJ incidence.",no,"The abstract does not explicitly mention a control group, which is a significant limitation.",maybe,"While the study looks at ONJ occurrence, it does not specifically mention the dental procedures listed in the criteria.",yes,"The abstract includes systematic reviews, meta-analyses, and clinical trials, which are acceptable study designs.",maybe,"While ONJ incidence is documented, the follow-up period is not specified.",yes,The abstract explicitly states that the study includes patients over 18 years of age.,maybe,The abstract does not mention the sample size of the included studies.,maybe,"While the study includes oral bisphosphonates, it also includes intravenous bisphosphonates, which is explicitly excluded in the criteria.",maybe,The abstract does not mention specific diagnostic standards for ONJ.,Include,"A systematic review of bisphosphonate use in osteoporosis patients reveals partial alignment with screening criteria, with clear age and population specifications but significant gaps in procedural details and diagnostic standards. The study includes both oral and intravenous bisphosphonates, which conflicts with specific intervention requirements, and lacks explicit documentation of dental procedures, latency periods, and control group comparisons. Multiple screening criteria remain unaddressed or incompletely met, creating uncertainty about the study's comprehensive eligibility.",2.7
Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.,"J. Bagan, A. Peydró, J. Calvo, M. Leopoldo, Y. Jiménez, L. Bagán",10.1111/odi.12447,https://doi.org/10.1111/odi.12447,Oral Diseases,37,2016,yes,"The study clearly focused on osteoporotic patients taking medication, specifically denosumab and previous bisphosphonates, and did not mention cancer patients.",maybe,"The study mentioned the duration of previous bisphosphonate intake but did not clearly document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The study did report MRONJ incidence following dental procedures, specifically mentioning dental extraction in 60% of cases.",no,"The study appears to be a case series, which is explicitly excluded in the criteria.",maybe,"While the study documented MRONJ incidence and treatment outcomes, the follow-up period was not specified.",maybe,"While the context suggests the study focused on adult patients with osteoporosis, this was not definitively confirmed in the abstract.",no,"The study only included 10 cases, which is well below the required 100 subjects for the medication group.",no,"The study primarily focused on denosumab (not a bisphosphonate) and only mentioned previous bisphosphonate intake, which does not meet the criterion requiring oral bisphosphonates as the primary intervention.",maybe,"While the study mentioned ONM stages and clinical characteristics, it did not explicitly state its diagnostic standards for MRONJ.",Exclude,"The study fails key screening criteria due to its small sample size of only 10 cases, case series design, and focus on denosumab rather than oral bisphosphonates. Critical methodological limitations include the absence of a control group and insufficient documentation of diagnostic standards and follow-up periods. These deficiencies render the study non-compliant with the established screening requirements.",0.1
Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis,"Everts-Graber Judith, L. Daniel, Burkard John-Patrik, S. Benoît, Gahl Brigitta, Häuselmann HansJörg, Studer Ueli, Ziswiler Hans-Rudolf, R. Stephan, Lehmann Thomas",10.1002/jbmr.4472,https://doi.org/10.1002/jbmr.4472,Journal of Bone and Mineral Research,59,2021,yes,"The study specifically focuses on osteoporosis patients, excluding cancer patients. The population is clearly defined from ""osteoporosis register of the Swiss Society of Rheumatology.""",no,"The abstract does not document the time intervals between medication start, dental procedures, and ONJ incidence.",no,The study does not explicitly mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not specify which dental procedures were associated with ONJ development.,yes,"This appears to be a retrospective cohort study using registry data, which meets the acceptable study design criteria.",maybe,"While the study documents ONJ incidence, the follow-up period is not explicitly stated, though the study period (2015-2019) suggests adequate follow-up.",yes,"The abstract mentions ""median age 69 years [63 to 76]"", confirming subjects are over 18.",yes,"The study includes 3,068 patients in the treatment groups (9956 total registered patients), well exceeding the 100-subject requirement.",no,"The study includes both oral and intravenous bisphosphonates, which violates the criterion requiring only oral bisphosphonates. Additionally, it includes denosumab (a non-bisphosphonate).",yes,"The abstract explicitly mentions using ""American Association of Oral and Maxillofacial Surgeons case definition of ONJ"" and confirms diagnosis by ""independent and blinded maxillofacial surgeons.""",Include,"A retrospective cohort study of osteoporosis patients reveals significant methodological limitations, including the inclusion of both oral and intravenous bisphosphonates and a non-bisphosphonate medication. Critical screening criteria were not met, particularly regarding intervention type and specific dental procedure documentation, which prevents the study from qualifying for the systematic review. Despite a robust sample size and clear diagnostic standards, the research fails to align with the predefined screening requirements.",2.7
"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.","F. Saad, J. Brown, C. V. Van Poznak, T. Ibrahim, S. Stemmer, A. Stopeck, I. Diel, S. Takahashi, N. Shore, D. Henry, C. Barrios, T. Facon, F. Senecal, K. Fizazi, L. Zhou, A. Daniels, P. Carrière, R. Dansey",10.1093/annonc/mdr435,https://doi.org/10.1093/annonc/mdr435,-,139,2012,no,"The study specifically focuses on patients with bone metastases secondary to solid tumors or myeloma, not osteoporosis patients. This is a clear violation of the inclusion criteria.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and ONJ incidence.",no,"The study does not include a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,"The study mentions tooth extraction (61.8% of ONJ cases) and reports ONJ incidence, meeting this criterion.",yes,"The abstract describes ""three phase III trials"" which are randomized controlled trials, meeting this criterion.",yes,"The study follows patients for at least 6 months (mentions ""every 6 months"" examinations) and documents ONJ incidence and outcomes.",maybe,"The abstract does not explicitly state the age requirement, but given these are cancer patients receiving bone-targeted therapy, they are likely adults. However, this is not explicitly confirmed.",yes,"The study includes 5,723 patients total, well exceeding the 100-subject requirement.",no,"The study uses intravenous zoledronic acid and subcutaneous denosumab, not oral bisphosphonates. This is a clear violation of the inclusion criteria.",maybe,"The abstract mentions that oral adverse events were ""adjudicated by an independent blinded committee of dental experts,"" suggesting some diagnostic standard, though specific criteria aren't detailed.",Exclude,"The study focuses on cancer patients receiving bone-targeted therapies, which fundamentally conflicts with the requirement for an osteoporosis patient population. Additionally, the intervention uses intravenous medications instead of oral bisphosphonates, representing a critical deviation from the specified screening criteria. These core violations render the study ineligible for inclusion in the systematic review.",1.4
Investigation of the Effectiveness of Surgical Treatment on Maxillary Medication-Related Osteonecrosis of the Jaw: A Literature Review,"Kun-Jung Hsu, S. Hsiao, Ping-Ho Chen, Han-Sheng Chen, Chun-Ming Chen",10.3390/jcm10194480,https://doi.org/10.3390/jcm10194480,Journal of Clinical Medicine,3,2021,no,"The abstract mentions ""medication (antiresorptive or antiangiogenic agents) for bone-related complications"" but does not specifically state that the subjects are osteoporosis patients. The population appears to be mixed, which is excluded by the criteria.",maybe,"The abstract mentions ""average time of medication usage was 50.0 ± 20.1 months"" but does not document the specific time intervals required for MRONJ latency.",no,"The abstract does not mention a control group, so no points are added for this criterion.",maybe,"While surgery is mentioned, it is not clear if this refers to the specific dental procedures listed in the criteria.",no,"This is a meta-analysis of case reports and case series, which are explicitly excluded by the criteria.",maybe,"While MRONJ incidence is discussed, the follow-up period is not specified.",yes,"The study focuses on elderly patients with an average age of 70.6 ± 5.5 years, which meets the requirement of subjects being over 18 years old.",maybe,"The abstract mentions analyzing 77 studies, but does not specify the number of subjects in the medication group, so this information is unclear.",no,"The abstract only mentions ""antiresorptive or antiangiogenic agents"" broadly, and does not specifically state that the subjects are taking oral bisphosphonates, which is required by the criteria.",maybe,"The abstract mentions ""third stage (43.6%)"" but does not specify the diagnostic standards used for MRONJ.",Exclude,"The meta-analysis fails multiple screening criteria, including being a case report/series study design, having a mixed patient population, and lacking specificity about medication types and diagnostic standards. Critical exclusion factors include the study's broad population, non-specific intervention details, and absence of a clear control group, rendering it unsuitable for the intended research parameters.",1.4
"Medication Related Osteonecrosis of the Jaw: An Update on Pathophysiology, Risk Factors, and Treatment","L. Rasmusson, J. Abtahi",10.37247/PAMED2ED.2.2020.25,https://doi.org/10.37247/PAMED2ED.2.2020.25,Prime Archives in Medicine,0,2020,no,"The abstract discusses bisphosphonate treatment but does not specifically state that the subjects are osteoporosis patients, so it appears to be a general review of MRONJ cases rather than a study focused on osteoporosis patients.",no,"The abstract does not document specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The abstract does mention relevant procedures (tooth extractions, implant placement) and their relationship to MRONJ, so it meets this criterion.",no,"This is explicitly stated to be a ""narrative review of the literature,"" which is not one of the accepted study designs.",no,"As a narrative review, it doesn't have its own follow-up period or primary data collection, so it does not meet the outcome documentation criterion.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",no,"This is a narrative review of 91 articles, not a primary study with subjects, so it does not meet the subject size criterion.",no,"The abstract mentions both oral and IV bisphosphonates, and does not specify focusing only on oral bisphosphonates, so it does not meet the intervention type criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This narrative review fails multiple critical screening criteria, including lacking a primary study design, not focusing exclusively on oral bisphosphonates for osteoporosis, and missing specific diagnostic standards and follow-up data. The paper does not meet the required methodological standards for inclusion, primarily because it is a literature review rather than an original research study with defined subject parameters.",0.1
Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings.,"K. Walton, T. Grogan, E. Eshaghzadeh, D. Hadaya, D. Elashoff, T. Aghaloo, S. Tetradis",10.1259/dmfr.20180128,https://doi.org/10.1259/dmfr.20180128,Dento maxillo facial radiology,24,2019,no,"The study explicitly includes both osteoporosis and cancer patients, which violates the criterion requiring exclusive focus on osteoporosis patients. This is a critical failure.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The abstract mentions ""recent tooth extraction"" as a context for MRONJ, meeting this criterion.",yes,"The study is described as a retrospective assessment, which meets the criterion as a retrospective cohort study.",maybe,"While MRONJ incidence is documented, the follow-up period is not mentioned.",maybe,"While the abstract mentions ""older females"" in the osteoporosis group, suggesting an adult population, this is not definitively confirmed, so the reasoning is uncertain.",no,"The study includes 70 total MRONJ patients, but doesn't specify how many were in the osteoporosis group. This likely fails the >100 subjects requirement.",no,"The abstract only mentions ""antiresorptive medications"" without specifying oral bisphosphonates, which is too vague to meet the criterion.",maybe,"The study mentions clinical staging and radiographic assessment using CRI, suggesting diagnostic standards were used, though not explicitly detailed.",Exclude,"The study fails key screening criteria by including a mixed population of osteoporosis and cancer patients, lacking a clear specification of oral bisphosphonate medication, and potentially having an insufficient sample size. Critical methodological limitations include the absence of a control group and unclear documentation of medication latency and follow-up period. These deficiencies significantly compromise the study's alignment with the predefined screening requirements.",1.4
Risk of Osteonecrosis of the Jaw in Patients with Postmenopausal Osteoporosis: A Systematic Literature Review,"C. Glória, Villaverde Virginia, D. Petra, Guerra Mercedes, Naranjo Antonio",10.23937/2643-4091/1710010,https://doi.org/10.23937/2643-4091/1710010,Clinical Archives of Bone and Joint Diseases,0,2019,yes,"The abstract clearly specifies that the subjects were ""diagnosed of osteoporosis"" and excludes cancer patients, indicating that this criterion was met.",maybe,"The abstract does not mention the time intervals between medication start, dental procedures, and MRONJ incidence, creating uncertainty about whether this criterion was met.",maybe,"The abstract does not mention whether a control group was included, which creates significant uncertainty about whether this criterion was met.",maybe,"The abstract does not specify which dental procedures were studied, creating uncertainty about whether this criterion was met.",yes,"The abstract explicitly includes ""randomised clinical trials (RCT) and cohort studies,"" indicating that this criterion was met.",maybe,"While the abstract mentions ""osteonecrosis of the jaw,"" it does not specify the follow-up period, creating uncertainty about whether this criterion was met.",maybe,"The abstract mentions ""all ages"" which does not explicitly confirm that the subjects were over 18 years old, creating uncertainty about whether this criterion was met.",maybe,"The abstract states ""no limitation with regard to the number of patients included,"" but does not specify if the studies included more than 100 subjects in the medication group, creating uncertainty about whether this criterion was met.",no,"The abstract mentions ""Dmab"" (Denosumab), which is not an oral bisphosphonate, indicating that this criterion was not met.",maybe,"The abstract does not mention the diagnostic standards for MRONJ, creating uncertainty about whether this criterion was met.",Exclude,"The systematic review focuses on osteoporosis patients taking Denosumab, which immediately disqualifies it from meeting the oral bisphosphonate intervention requirement. Multiple screening criteria remain unaddressed or uncertain, including control group composition, subject age, diagnostic standards, and specific dental procedures. The study's design as a systematic review and use of a non-bisphosphonate medication further complicate its potential inclusion.",1.4
Prophylaxis of medication-related necrosis of the jaws in dental patients – study of 49 cases,"Joanna Jakiel, Dagmara Jenda, M. Rahnama",10.26444/jpccr/94396,https://doi.org/10.26444/jpccr/94396,Journal of Pre-Clinical and Clinical Research,2,2018,no,"The study includes mixed populations (osteoporosis, Paget's disease, hypercalcaemia of malignancy, bone metastases, multiple myeloma), failing the criterion requiring only osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"While the abstract mentions ""treated areas"" and ""mucosal healing,"" it doesn't specifically report MRONJ incidence following the required dental procedures.",maybe,"The study design is not clearly stated, but appears to be an observational study. However, there's insufficient information to determine if it meets the acceptable study design criteria.",maybe,"The study reports a follow-up period of 1-2 years, meeting the 6-month minimum requirement. However, it doesn't clearly document MRONJ incidence after dental treatment.",yes,"The study includes patients aged 54-77 (mean 64), meeting the >18 years criterion.",no,"The study includes only 49 total patients (8 oral BP patients), well below the required 100 subjects.",no,"The study includes both oral and IV bisphosphonates, as well as denosumab. Only 8 patients received oral bisphosphonates, and the study doesn't focus exclusively on oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including a mixed patient population with cancer patients, insufficient sample size, and inclusion of non-bisphosphonate medications. Key methodological limitations include lack of clear diagnostic standards, absence of a control group, and incomplete documentation of dental procedures and MRONJ outcomes. These significant deficiencies render the study unlikely to meet the required screening standards.",1.4
Conservative Management of Medication-Related Osteonecrosis of the Jaws (MRONJ): A Retrospective Cohort Study,"E. Varoni, N. Lombardi, G. Villa, A. Pispero, A. Sardella, G. Lodi",10.3390/antibiotics10020195,https://doi.org/10.3390/antibiotics10020195,Antibiotics,26,2021,no,"The abstract mentions patients with MRONJ from bisphosphonates and anti-resorptive drugs for ""severe osteoporosis, Paget's disease, and bone malignancies,"" which is a mixed population and violates the criterion requiring only osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures led to MRONJ. It focuses on treatment outcomes rather than the procedures that led to MRONJ.,yes,"The study is described as a retrospective examination of medical records, which qualifies as a retrospective cohort study.",yes,"The study does document MRONJ outcomes with follow-up periods (mean 23.86 ± 18.14 months), exceeding the 6-month requirement.",maybe,"The abstract does not explicitly state the age of the subjects, but it is reasonable to assume they are adults since the study is about osteoporosis treatment. However, this is uncertain without explicit confirmation.",no,"The study includes only 35 patients, which is well below the required 100 subjects for the medication group.",no,"While bisphosphonates are mentioned, the abstract does not specify whether they are oral or intravenous, and includes other anti-resorptive drugs.",maybe,"The abstract mentions using the ""University of Connecticut Osteonecrosis Numerical Scale (UCONNS)"" for assessment, which suggests some diagnostic standardization.",Exclude,"The study fails to meet multiple critical screening criteria, including a mixed patient population, insufficient sample size, and lack of clarity on intervention type and dental procedures. Key disqualifying factors include the inclusion of cancer patients, a small sample of 35 patients, and absence of a control group, which significantly compromise the study's alignment with the specified screening requirements.",1.4
Medication-related osteonecrosis: Literature review,"Idrovo Campoverde María Coralía, Bacuilima Ñauta Erika Susana, Pesántez Alvarado Juan Martín, Lafebre Carrasco Milton Fabricio",10.30574/wjarr.2023.18.2.0832,https://doi.org/10.30574/wjarr.2023.18.2.0832,World Journal of Advanced Research and Reviews,0,2023,no,"The abstract discusses MRONJ in general terms and mentions ""antiresorptive and antiangiogenic agents"" but does not specifically focus on osteoporosis patients. It appears to be a broader review, so it fails this criterion.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While the abstract mentions ""osteonecrosis of the jaws,"" it does not specifically discuss incidence following dental procedures, so it fails this criterion.",no,"This is a literature review, not one of the accepted study designs (RCT, cohort, or case-control), so it fails this criterion.",no,"As a literature review, it does not have its own follow-up period or documented MRONJ incidence, so it fails this criterion.",maybe,"The abstract does not specify the age range of the subjects, so the reasoning for this criterion is unknown.",no,"This is a literature review, not a primary study, so it does not have its own subject group, and therefore fails this criterion.",no,"While the abstract mentions antiresorptive agents, it does not specify oral bisphosphonates exclusively. It appears to cover multiple types of medications, so it fails this criterion.",no,"The abstract does not mention any specific diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"This literature review fails to meet multiple critical screening criteria, including specific study design, population characteristics, and intervention type. The abstract lacks detailed information about subject demographics, medication specifics, and diagnostic standards for medication-related osteonecrosis of the jaw. Consequently, the paper does not qualify for inclusion in the systematic review based on the established screening requirements.",0.1
Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020,"G. Campisi, R. Mauceri, F. Bertoldo, G. Bettini, M. Biasotto, G. Colella, U. Consolo, O. Di Fede, G. Favia, V. Fusco, M. Gabriele, A. Lo Casto, L. Lo Muzio, A. Marcianó, M. Mascitti, M. Meleti, M. Mignogna, G. Oteri, V. Panzarella, U. Romeo, A. Santarelli, P. Vescovi, C. Marchetti, A. Bedogni",10.3390/ijerph17165998,https://doi.org/10.3390/ijerph17165998,International Journal of Environmental Research and Public Health,115,2020,no,"The abstract mentions both cancer and osteometabolic patients, indicating a mixed population, which explicitly violates this criterion.",no,"No mention of time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",maybe,"The abstract mentions dental management but doesn't specifically report MRONJ incidence following specific procedures, so the reasoning for this criterion is uncertain.",no,"This appears to be a consensus conference report, not one of the required study designs, so the criterion is not met.",no,"The abstract doesn't mention any specific follow-up period or documented MRONJ incidence rates, so the criterion is not met.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any specific number of subjects, so the reasoning for this criterion is uncertain.",maybe,"While bisphosphonates are mentioned, the abstract also includes other medications (denosumab and antiangiogenic drugs) and doesn't specify oral administration, so the criterion is only partially met.",maybe,"While the abstract mentions ""diagnosis process,"" it doesn't specify diagnostic standards, so the reasoning for this criterion is uncertain.",Exclude,"This consensus conference report fails multiple critical screening criteria, including having a mixed patient population with cancer patients and lacking a specific research study design. The document does not provide clear documentation of MRONJ incidence, subject numbers, or follow-up periods, rendering it unsuitable for systematic review inclusion.",0.1
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.,"T. Nomura, T. Shibahara, T. Uchiyama, N. Yamamoto, T. Shibui, T. Yakushiji, Akira Watanabe, Kyotaro Muramatsu, Satoshi Ogane, M. Murayama, R. Sekine, E. Nakata, Y. Fujimoto",10.2209/TDCPUBLICATION.54.117,https://doi.org/10.2209/TDCPUBLICATION.54.117,The Bulletin of Tokyo Dental College,12,2013,no,The study includes a mixed population - 5 patients with osteoporosis and 8 patients with cancer. This explicitly fails the criterion requiring only osteoporosis patients.,no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,"While the study discusses BRONJ treatment, it doesn't specifically report incidence following the specified dental procedures.",no,"This appears to be a case series, which is explicitly excluded by the criteria.",maybe,"The study does mention an 11-month follow-up period, which meets the 6-month minimum requirement. However, it focuses on treatment outcomes rather than incidence.",maybe,"While not explicitly stated, given the context of osteoporosis and cancer patients, it's likely these are adult patients, but this isn't definitively confirmed.",no,"The study only includes 13 total patients (5 with osteoporosis), which is well below the required 100 subjects.",no,"The study includes both oral bisphosphonates (risedronate, alendronate) and parenteral bisphosphonates (zoledronate), failing the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for BRONJ.,Exclude,"The study fails multiple critical screening criteria, including a mixed patient population with cancer patients, a small sample size of only 13 patients, and a case series design that does not meet the required study methodology. Additionally, the research includes both oral and parenteral bisphosphonates, lacks a control group, and does not specify diagnostic standards for MRONJ, rendering it ineligible for the systematic review.",0.1
Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw?,"C. Klingelhöffer, Manja Klingelhöffer, S. Müller, T. Ettl, U. Wahlmann",10.1259/dmfr.20160065,https://doi.org/10.1259/dmfr.20160065,Dento maxillo facial radiology,34,2016,no,"The study includes patients taking medication for both osteoporosis and malignant conditions, which violates the requirement for a pure osteoporosis population.",no,"The study does not provide information about the time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study explicitly includes a control group of 60 patients without antiresorptive therapy, meeting this criterion.",no,The study focuses on radiographic findings rather than MRONJ incidence following specific dental procedures.,yes,"The study is explicitly stated as a case-control study, which meets the criteria.",no,"The study does not document MRONJ incidence after dental treatment, but rather looks at radiographic findings in patients who already have MRONJ.",maybe,"The abstract does not specify the age of the subjects, creating uncertainty about whether this criterion is met.",no,"The study only includes 60 patients in the antiresorptive therapy group, which is below the required 100 subjects.",maybe,"The abstract only mentions ""antiresorptive therapy"" without specifying if it's oral bisphosphonates or other types of medications, creating uncertainty about whether this criterion is met.",maybe,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including a mixed patient population, insufficient sample size, and lack of focus on MRONJ incidence after dental procedures. Key methodological limitations include unclear diagnostic standards, absence of specific intervention details, and a research design that diverges from the required protocol. These significant deviations render the study non-compliant with the established screening requirements.",1.4
Reporting Criteria for Clinical Trials on Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review and Recommendations,"Camille Gaudet, Stéphane Odet, C. Meyer, B. Chatelain, E. Weber, A. Parmentier, S. Derruau, S. Laurence, C. Mauprivez, Esteban Brenet, H. Kerdjoudj, M. Fénelon, J. Fricain, N. Zwetyenga, D. Hoarau, R. Curien, É. Gérard, A. Louvrier, F. Gindraux",10.3390/cells11244097,https://doi.org/10.3390/cells11244097,Cells,5,2022,no,"While the abstract mentions anti-resorptive agents, it discusses them in general terms and does not specify osteoporosis patients exclusively.",no,"There is no mention of time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, as this is a review article about protocol development rather than an original study.",no,The abstract does not mention specific dental procedures.,no,"This is a review article and protocol development paper, not one of the required study designs (RCT, cohort, or case-control).",no,The paper discusses the lack of standardized outcome documentation but does not present its own follow-up data.,no,The abstract does not specify age requirements for the population.,no,"This is not an original study with subjects, but rather a review of 43 articles.",no,The abstract mentions anti-resorptive agents broadly but does not specify oral bisphosphonates exclusively.,no,"While the paper discusses the need for standardized criteria, it does not present its own diagnostic standards.",Exclude,"This review article fails to meet multiple screening criteria, primarily because it is a protocol development paper rather than an original research study. The document lacks specific patient data, does not specify intervention types, and does not present original research outcomes, rendering it ineligible for inclusion in the systematic review.",0.1
Osteoradionecrosis and medication-related osteonecrosis of the jaw: similarities and differences.,"K. Grisar, Matthias Schol, J. Schoenaers, T. Dormaar, R. Coropciuc, V. Poorten, C. Politis",10.1016/j.ijom.2016.06.016,https://doi.org/10.1016/j.ijom.2016.06.016,International Journal of Oral & Maxillofacial Surgery,33,2016,no,"While the study includes MRONJ patients, it does not specify that they were taking medication for osteoporosis. The population appears to be mixed with no clear indication of the underlying condition, which is a significant concern.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study does mention dental extractions as a precipitating event, meeting this criterion.",yes,"This appears to be a retrospective comparative study, which would qualify under the acceptable study designs.",no,"While the study documents MRONJ cases, the follow-up period is not mentioned in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, so the age of the population is unclear.",no,"The study includes 74 MRONJ patients, which is below the required 100 subjects threshold.",no,The abstract does not specify the type of medication (oral bisphosphonate vs. other) being taken by the MRONJ patients.,no,The abstract does not mention the diagnostic standards used for MRONJ.,Include,"The study fails to meet critical screening criteria, including insufficient sample size, unclear medication type, and lack of specificity regarding patient population and diagnostic standards. Multiple key requirements were not addressed, such as control group presence, precise medication indication, and comprehensive documentation of MRONJ latency and follow-up period. These deficiencies significantly compromise the study's alignment with the established screening criteria.",2.7
Medication‐Related Osteonecrosis of the Jaw Caused by Drugs With Antiangiogenic Effects—What Should the Clinician Be Aware of and What Course of Treatment Can Be Applied? A Systematic Review of Case Series and Case Reports,"Francisca Jennifer Duarte de Oliveira, Moan Jéfter Fernandes Costa, Carla Samily de Oliveira Costa, L. D. de Souza",10.1111/ors.12940,https://doi.org/10.1111/ors.12940,Oral Surgery,0,2024,no,"The abstract explicitly states that ""most of the patients had cancer"" and only 20% were treated for other diseases, failing the criterion requiring subjects to be specifically osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, indicating that this is a systematic review of case reports rather than an original study with a control group.",yes,"The abstract does mention dental extraction as a procedure associated with MRONJ, meeting this criterion.",no,"This is a systematic review of case reports, which explicitly fails the criterion requiring RCT, cohort, or case-control study designs.",no,"While MRONJ incidence is discussed, the follow-up period is not specified.",yes,"The abstract mentions a mean age of 58 years, which meets the criterion of subjects being over 18 years old.",no,"The review includes 32 articles, but this is not an original study with a medication group of subjects, so the subject size criterion is not met.",no,"The abstract focuses on antiangiogenic drugs, particularly bevacizumab (40% of cases), and does not study oral bisphosphonates for osteoporosis, failing the intervention type criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails multiple critical screening criteria, including inappropriate study design, predominantly cancer patient population, and focus on antiangiogenic drugs rather than oral bisphosphonates. Key methodological requirements such as control group, specific diagnostic standards, and precise intervention type are not met, rendering the study unsuitable for inclusion in the systematic review.",0.1
Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients.,"N. Heim, W. Götz, F. Kramer, A. Faron",10.1259/dmfr.20190132,https://doi.org/10.1259/dmfr.20190132,Dento maxillo facial radiology,18,2019,maybe,"The study included patients taking bisphosphonates and denosumab, which is a mixed population. There was no explicit mention that the subjects were chosen from patients taking medication for osteoporosis.",no,"The study did not document the time intervals between the start of medication, dental procedures, and MRONJ incidence.",yes,"The study included a control group of 40 patients not taking anti-resorptive medications, which meets the requirement for this criterion.",no,The study focused on bone density measurements and did not mention any dental procedures or MRONJ incidence following those procedures.,maybe,"The study design was not explicitly stated, so it is unclear if it was a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",no,"The study did not report MRONJ incidence after dental treatment, and there was no mention of a follow-up period.",maybe,"The age of the subjects was not explicitly mentioned, so it is unclear if the population was over 18 years old.",yes,"The study included a total of 101 patients, with 35 in the bisphosphonate group, which meets the minimum requirement of 100 subjects.",maybe,"The study included oral bisphosphonates, but also included denosumab, which is a non-bisphosphonate medication. The specification of oral vs. IV administration was not provided.",no,The study did not mention the diagnostic standards used for MRONJ.,Include,"The study partially meets screening criteria with a control group and adequate sample size, but fails to address key requirements such as dental procedure outcomes, MRONJ diagnostic standards, and specific intervention details. Mixed population, unclear study design, and absence of critical outcome measurements significantly limit its alignment with the screening criteria. The research appears more focused on bone density measurements than the specified MRONJ investigation parameters.",2.5
Medication-related osteonecrosis of the jaw. Introduction of a new modified experimental model.,"Cláudia Curra, C. Cardoso, O. Ferreira, M. Curi, M. Matsumoto, B. Cavenago, P. Santos, J. Santiago",10.1590/S0102-865020160050000003,https://doi.org/10.1590/S0102-865020160050000003,Acta Cirurgica Brasileira,15,2016,no,"The study uses rats, not human patients taking medication for osteoporosis, so it does not meet the population indication requirement.",yes,"The study documents the time intervals between medication administration and extraction, and follows up at 14/28/42 days, which meets the MRONJ latency requirement.",yes,"The study includes a control group of 15 rats not receiving medication, which meets the requirement for a control group.",yes,"The study examines MRONJ following tooth extraction, which meets the procedure and outcome requirement.",yes,"This is an experimental study with a control group, which would qualify as a controlled trial.",yes,"The study clearly documents MRONJ incidence and has follow-up periods, which meets the outcome documentation requirement.",no,"This is an animal study using rats, not human subjects over 18 years old, so it does not meet the age requirement.",no,"The total sample size is 45 rats (30 experimental + 15 control), which is below the required 100 subjects.",no,"The study uses intravenous zoledronic acid, not oral bisphosphonates, so it does not meet the intervention type requirement.",yes,"The study mentions using clinical analysis, microtomography, and histological analysis for MRONJ diagnosis, which meets the diagnostic standard requirement.",Exclude,"This experimental rat study fails key screening criteria by using an animal model instead of human subjects, employing intravenous rather than oral bisphosphonates, and having a sample size below 100. Despite meeting several methodological criteria like having a control group and documenting MRONJ incidence, the fundamental population and intervention requirements are not satisfied.",0.1
A population based study of multiple myeloma patients with medication-related osteonecrosis of the jaw.,"D. Auziņa, A. Slaidina, M. Sevastjanova, R. Erts, A. Lejnieks, S. Lejniece",-,-,Stomatologija,6,2019,no,"The study focuses on multiple myeloma patients, not osteoporosis patients, which is a clear violation of the inclusion criteria.",yes,"The study documents the time interval from medication start to MRONJ manifestation, meeting this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study mentions dental extraction as a triggering factor for MRONJ, meeting this criterion.",yes,"The study is described as a retrospective analysis, which meets the acceptable study design criteria.",maybe,"The study documents MRONJ incidence and appears to have adequate follow-up, though the exact follow-up period isn't specified.",yes,"While not explicitly stated, the context suggests the study included adult patients with multiple myeloma, so the age criterion was likely met.",yes,"The study includes 88 patients in the bisphosphonate group, which meets the requirement of over 100 subjects.",no,"The study specifically mentions ""intravenous nitrogen-containing BPs"" which explicitly violates the criterion requiring oral bisphosphonates.",yes,"The abstract provides a clear diagnostic definition of MRONJ, meeting this criterion.",Exclude,"The study focuses on multiple myeloma patients receiving intravenous bisphosphonates, which fundamentally conflicts with the specified screening criteria for osteoporosis patients taking oral bisphosphonates. Critical violations include the wrong patient population and medication type, rendering the study ineligible for inclusion in the systematic review. Despite meeting some secondary criteria, these core deviations disqualify the research from further consideration.",0.1
Platelet concentrates as an adjunctive therapy for medication-related osteonecrosis of the Jaw: A systematic review and meta-analysis,"M. Fabbro, S. Taschieri, F. Goker",10.4103/GFSC.GFSC_19_18,https://doi.org/10.4103/GFSC.GFSC_19_18,-,6,2018,maybe,"The abstract mentions ""patients under antiresorptive therapy"" but doesn't specifically exclude cancer patients or mixed populations.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract mentions ""control"" in the context of comparing APC treatment, but this isn't a control group of patients not taking anti-resorptive medications.",yes,"The abstract mentions tooth extraction as a procedure, which is one of the specified procedures.",no,"This is a systematic review, not a primary study of the required designs.",yes,"The abstract mentions follow-up ranging from 3 to 94 months, which meets the 6-month requirement.",maybe,The abstract doesn't explicitly state the age of subjects.,maybe,"The review includes 946 patients total, but this is across 18 studies. We can't determine if individual studies had >100 subjects.",no,"The abstract only mentions ""antiresorptive therapy"" broadly, not specifically oral bisphosphonates.",no,The abstract doesn't mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including specific study design requirements, precise intervention type, and comprehensive population specifications. While addressing medication-related osteonecrosis of the jaw, the study lacks the methodological rigor needed to satisfy the predefined inclusion standards. Key deficiencies include absence of clear diagnostic criteria, undefined patient population, and non-compliance with required study design parameters.",1.4
Osseous changes in patients with medication-related osteonecrosis of the jaws.,"Z. Gönen, Canay Yillmaz Asan, G. Zararsiz, E. Kılıç, A. Alkan",10.1259/dmfr.20170172,https://doi.org/10.1259/dmfr.20170172,Dento maxillo facial radiology,15,2018,maybe,"While the study is about MRONJ patients, it does not explicitly state that the subjects are osteoporosis patients or exclude cancer patients, so the population indication is unclear.",no,"The abstract does not mention any time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study included a control group of patients not taking anti-resorptive medications, which is a positive factor according to the screening criteria.",no,The study focuses on osseous changes in MRONJ patients but does not report MRONJ incidence following specific dental procedures.,yes,"The study is a retrospective study, which is one of the accepted study designs according to the screening criteria.",no,The study does not document MRONJ incidence after dental treatment or mention any follow-up period.,maybe,"The age of the subjects was not specified in the abstract, so it is unclear if the population meets the age requirement of over 18 years old.",no,"The study only included 25 patients, which is well below the required 100 subjects for the medication group at the final statistical analysis stage.",maybe,"The abstract only mentions ""antiresorptive agents"" without specifying if they are oral bisphosphonates, so the intervention type is unclear.",no,"While the study uses CBCT imaging, it does not explicitly mention the diagnostic standards for MRONJ.",Exclude,"The study fails to meet multiple critical screening criteria, including insufficient sample size, lack of clear diagnostic standards, and absence of specific dental procedure-related outcomes. While the research provides insights into MRONJ osseous changes, it does not align with the required methodological and population specifications for the screening protocol.",1.4
Medication-related osteonecrosis of the jaw: An update,H. Bansal,10.4103/njms.NJMS_236_20,https://doi.org/10.4103/njms.NJMS_236_20,National Journal of Maxillofacial Surgery,14,2022,no,"The abstract mentions both osteoporosis and multiple myeloma patients, indicating a mixed population, which fails the criterion requiring exclusive focus on osteoporosis patients.",no,No information about time intervals is provided.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract only briefly mentions ""tooth extraction"" as a risk factor but does not report specific MRONJ incidence following procedures.",no,This appears to be a review/update paper rather than a primary research study with any of the specified designs.,no,No specific follow-up period or MRONJ incidence documentation is mentioned.,maybe,"The abstract mentions ""aging population"" but does not specify the age requirements, so it is unclear if this criterion is met.",no,No specific subject numbers are mentioned in the abstract.,no,"The abstract discusses both bisphosphonates and denosumab, and mentions both oral and intravenous treatments, which fails the criterion requiring exclusive focus on oral bisphosphonates.",no,"While the abstract mentions ""staging and treatment guidelines,"" it does not specify diagnostic standards.",Exclude,"This review paper fails multiple critical screening criteria, including mixed patient populations, inclusion of non-bisphosphonate medications, and lack of a primary research design. The abstract does not provide specific details about subject size, diagnostic standards, or MRONJ incidence following dental procedures, rendering it unsuitable for systematic review inclusion.",0.1
Medication-related osteonecrosis of the jaw in cancer patients: Case series and review of the current literature,"Karen Maciel Reyes Castillo, Miguel Ángel Ocampo Benítez, Omar Peña Curiel",10.21142/2523-2754-1003-2022-123,https://doi.org/10.21142/2523-2754-1003-2022-123,Revista Científica Odontológica,1,2022,no,"The study specifically focuses on cancer patients taking bone modifying agents (BMA), which explicitly violates the criterion requiring subjects to be osteoporosis patients only.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The study mentions tooth extraction and tooth loss as procedures leading to MRONJ, which meets this criterion.",no,"This appears to be a case series of 4 patients, which is explicitly excluded by the criteria.",maybe,"While the study documents MRONJ incidence and mentions follow-up, the duration of follow-up is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, though they are likely adults given the context.",no,"The study only includes 4 patients, which is well below the required 100 subjects.",no,"The study mentions bone modifying agents (BMA) but doesn't specify if they are oral bisphosphonates. Moreover, it's in the context of cancer treatment, not osteoporosis.",yes,"The abstract mentions using AAOMS classification for MRONJ diagnosis, which meets this criterion.",Exclude,"The study focuses on cancer patients with bone modifying agents, which deviates from the required osteoporosis patient population and fails multiple critical screening criteria. With only four patients and a case series design, the research does not meet the systematic review's methodological requirements for sample size, study design, and population specificity. Consequently, the paper would be excluded from further review based on these significant methodological limitations.",0.1
Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons,"Jin-Woo Kim, M. Kwak, J. Han, Sung-Tak Lee, H. Y. Kim, Se Hwa Kim, Junho Jung, J. K. Lee, Young-Kyun Lee, Yong-Dae Kwon, D. Kim",10.11005/jbm.2021.28.4.279,https://doi.org/10.11005/jbm.2021.28.4.279,Journal of Bone Metabolism,21,2021,no,"While the abstract mentions osteoporosis patients, it also discusses other conditions (malignant bone metastases, multiple myeloma, Paget's disease) and appears to be a general review rather than a specific study of osteoporosis patients. Therefore, the study fails this criterion.",no,"No information about time intervals is provided, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While MRONJ is discussed, the abstract doesn't mention specific dental procedures or their relationship to MRONJ incidence. Therefore, the study fails this criterion.",no,"This appears to be a position paper/guideline document rather than any of the required study designs, so the study fails this criterion.",no,"No specific follow-up periods or incidence data are mentioned, so the study fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is unknown.",maybe,"No subject numbers are mentioned in the abstract, so the reasoning for this criterion is unknown.",no,"While bisphosphonates are mentioned, the abstract discusses multiple types of medications including denosumab and bevacizumab, not just oral bisphosphonates. Therefore, the study fails this criterion.",maybe,"The abstract mentions that diagnostic standards were developed and revised, but doesn't specify them. Therefore, the study partially meets this criterion.",Exclude,"This position paper fails multiple screening criteria, including specific study design requirements, population selection, and intervention type. The document appears to be a guideline development effort rather than an original research study, lacking the necessary methodological elements such as control groups, specific subject populations, and detailed outcome measurements. Consequently, the abstract does not meet the established screening criteria for inclusion.",0.1
Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.,"Suad Aljohani, R. Gaudin, J. Weiser, M. Tröltzsch, M. Ehrenfeld, G. Kaeppler, R. Smeets, S. Otto",10.1016/j.jcms.2018.05.046,https://doi.org/10.1016/j.jcms.2018.05.046,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,53,2018,no,"The study includes mixed populations (both cancer patients and osteoporosis patients), which explicitly violates this criterion. The abstract mentions ""patients receiving denosumab for the treatment of metastatic bone disease and osteoporosis.""",maybe,"The abstract mentions a mean period of 6 ± 3.4 months for denosumab discontinuation, but doesn't clearly document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,yes,"The study reports MRONJ incidence following dental procedures, specifically mentioning extraction (55.6% of cases).",yes,"The study is a retrospective review, which meets the acceptable study design criteria.",maybe,"The study documents MRONJ incidence and treatment outcomes, but the follow-up period is not explicitly stated.",yes,"The mean patient age was 70 ± 9 years, meeting the >18 years criterion.",no,"The study includes 63 patients, which is below the required 100 subjects for the medication group.",no,"The study focuses on denosumab, not oral bisphosphonates. While some patients had previous bisphosphonate use, this was not the primary intervention being studied.",maybe,The abstract mentions DRONJ stages but doesn't explicitly state the diagnostic standards used.,Exclude,"The study fails key screening criteria due to a mixed patient population including cancer patients, a sample size below 100, and focus on denosumab rather than oral bisphosphonates. Critical methodological limitations include the absence of a control group and lack of clear diagnostic standards for MRONJ. These significant deviations from the specified screening requirements render the study unsuitable for inclusion in the systematic review.",1.4
Risk factors of medication‐related osteonecrosis of the jaw in preventive tooth extraction before bone resorption inhibitor administration: A multicenter nested case–control study,"T. Saito, Atsushi Nishikawa, Yuko Hara‐Saito, Andrea Rei Estacio Salazar, A. Kurokawa, A. Iida, M. Yamaga, H. Kano, Y. Kato, Y. Takata, H. Nishiyama, N. Kitamura, Takahiro Tanaka, R. Takagi",10.1002/osi2.1122,https://doi.org/10.1002/osi2.1122,Oral Science International,1,2021,no,"The study specifically focuses on patients taking medication for malignant tumors, not osteoporosis, which is a clear violation of the inclusion criteria.",yes,The study documents the time interval between tooth extraction and medication start (within 1 year) and follows patients for 1-3 years after medication initiation.,no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study focuses on tooth extraction, which is one of the specified dental procedures.",yes,"The study is described as a ""nested case-control study,"" which meets the acceptable study design criteria.",yes,"The study clearly documents MRONJ incidence and has a follow-up period of at least 1 year, meeting the 6-month minimum requirement.",maybe,"While not explicitly stated, the study is likely focused on adult patients since it involves cancer patients receiving zoledronic acid/denosumab, but this is not certain.",no,"The study includes 58 patients total, with 180 teeth analyzed, which is below the required 100 subjects for the medication group.",no,"The study uses zoledronic acid and/or denosumab, which are not oral bisphosphonates. Zoledronic acid is typically administered intravenously, and denosumab is a monoclonal antibody, not a bisphosphonate.",maybe,"While MRONJ is discussed, the abstract doesn't explicitly mention diagnostic standards.",Exclude,"The study focuses on cancer patients receiving zoledronic acid/denosumab, which critically fails the screening criteria for osteoporosis medication research. Key disqualifying factors include the wrong patient population, non-oral bisphosphonate medication, and insufficient sample size. Multiple screening requirements were not met, rendering the study ineligible for inclusion.",0.1
"Risk factors for medication-related osteonecrosis of the jaws: a case-control study in Queensland, Australia",K. McGowan,-,-,-,0,2019,no,"The study included a mixed population of patients being treated for 39 different systemic diseases, which does not meet the criterion of focusing specifically on osteoporosis patients.",no,"The abstract does not mention documenting the time intervals between medication start, dental procedures, and MRONJ incidence, so this information is not provided.",yes,"The study included a control group of patients not taking anti-resorptive medications, which meets the criterion.",yes,"The study reports on dental procedures including extractions and mentions MRONJ incidence following these procedures, which meets the criterion.",yes,"The paper includes case-control studies, which is one of the accepted study designs.",maybe,"While the study documents MRONJ incidence, the specific follow-up period is not mentioned in the abstract, so this information is unclear.",maybe,"The abstract does not explicitly state the age range of the participants, but given the context of antiresorptive medication use, it is likely that the subjects were adults over 18 years old.",maybe,"The specific number of subjects in the case-control studies is not mentioned in the abstract, so the subject size cannot be determined.",no,"The study included ""antiresorptive and antiangiogenic medications"" broadly, not specifically oral bisphosphonates, which does not meet the criterion.",maybe,"The abstract does not explicitly state the diagnostic standards used for MRONJ, so this information is unclear.",Include,"The study involves a mixed patient population with various systemic diseases and broad medication types, which deviates from the specified screening criteria for osteoporosis patients taking oral bisphosphonates. While the research includes a control group and case-control study design, it fails to meet key requirements such as population specificity and intervention type. Multiple screening criteria remain unclear or unmet, suggesting the study does not align with the predefined inclusion parameters.",2.7
Radiographic bone loss and the risk of medication‐related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients—A retrospective case control study,"Taggreed Wazzan, D. Kashtwari, W. Almaden, Y. Gong, Yiqing Chen, J. Moreb, J. Katz",10.1111/scd.12318,https://doi.org/10.1111/scd.12318,"Special Care in Dentistry: managing special patients, settings, and situations",11,2018,no,"The study specifically focuses on multiple myeloma patients, not osteoporosis patients, which is a clear violation of the inclusion criteria.",no,"The abstract mentions ""duration of bisphosphonate treatments"" but doesn't document specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"While the study looks at MRONJ, it doesn't specifically report incidence following the required dental procedures. Instead, it focuses on periodontal status and bone loss.",yes,"This appears to be a retrospective cohort study, which meets the criteria.",maybe,"While MRONJ is documented, the follow-up period is not specified.",maybe,"While specific ages aren't mentioned, the study involves multiple myeloma patients, who are typically adults. However, this isn't explicitly stated, so the reasoning is uncertain.",no,"The study includes 100 MM patients and 16 MM patients with MRONJ, which is below the required 100 subjects for the medication group.",no,"The study mentions bisphosphonate (BP) treatments, but doesn't specify if they're oral or intravenous. Aredia (zoledronic acid) is mentioned, which is typically intravenous, so the reasoning suggests this is likely a failure.",no,The abstract doesn't explicitly mention diagnostic standards for MRONJ.,Exclude,"The study focuses on multiple myeloma patients taking bisphosphonates, which deviates from the required osteoporosis patient population and fails to meet several critical screening criteria. Insufficient sample size, unclear intervention type, and lack of specified diagnostic standards further disqualify the research from systematic review inclusion. The fundamental mismatch in patient population represents a critical exclusion factor.",1.4
Oral bisphosphonate-induced osteonecrosis complications in patients undergoing tooth extraction: a systematic review and literature updates.,"M. Dioguardi, M. Di Cosola, C. Copelli, S. Cantore, C. Quarta, G. Nitsch, D. Sovereto, F. Spirito, G. A. Caloro, A. Cazzolla, R. Aiuto, E. Cascardi, A. Greco Lucchina, L. Lo Muzio, A. Ballini, F. Mastrangelo",10.26355/eurrev_202307_32996,https://doi.org/10.26355/eurrev_202307_32996,European Review for Medical and Pharmacological Sciences,3,2023,maybe,"The abstract focuses on patients taking oral bisphosphonates, but does not explicitly exclude cancer patients or specify if the population is purely osteoporosis patients, creating uncertainty about the population indication.",maybe,"The abstract mentions that ""duration of exposure to oral bisphosphonates influences the onset of complications"" but does not provide specific time intervals, partially meeting this criterion.",no,"The abstract does not mention a control group, which is a significant limitation.",yes,"The abstract clearly focuses on tooth extraction and MRONJ outcomes, meeting this criterion.",no,"This is a systematic review of other studies, not a primary research study, which fails to meet the criterion as systematic reviews are not included in the acceptable study designs.",no,"While the abstract discusses MRONJ incidence, it does not specify the follow-up period length.",maybe,"The abstract does not explicitly state the age range of the subjects, creating uncertainty about whether the population meets the age requirement.",no,"The abstract does not mention the total number of subjects included in the analysis, which is a critical missing piece of information.",yes,"The abstract specifically focuses on oral bisphosphonates, meeting this criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including lacking a control group, unclear subject demographics, and being a review rather than a primary research study. While addressing oral bisphosphonates and tooth extraction, the abstract lacks specificity in diagnostic standards, patient population, and follow-up period. The fundamental study design disqualifies it from meeting the established screening requirements.",1.4
Medication-Related Osteonecrosis of the Jaw—A Continuing Issue,"Krzysztof Wróbel, Maciej Sikora, M. Chęciński, Maria Jas, D. Chlubek",10.3390/app11177781,https://doi.org/10.3390/app11177781,Applied Sciences,8,2021,no,"While the abstract mentions bisphosphonates, it also discusses other medications (angiogenesis inhibitors and anti-RANKL monoclonal antibodies) and appears to be a general review rather than a study of a specific population, so it fails this criterion.",no,"No mention of time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract mentions ""simplest of procedures in the oral cavity area"" but doesn't specifically detail the required procedures or report MRONJ incidence, so it fails this criterion.",no,"This appears to be a review paper rather than any of the required study designs (RCT, cohort, or case-control), so it fails this criterion.",no,"While MRONJ is discussed, there's no mention of specific incidence rates or follow-up periods, so it fails this criterion.",maybe,"The abstract does not specify the age range of the subjects, so the age of the population is unknown.",maybe,"No specific subject numbers are mentioned in the abstract, so the subject size is unknown.",no,"While bisphosphonates are mentioned, the paper appears to cover multiple medication types and is not focused specifically on oral bisphosphonates, so it fails this criterion.",maybe,"While the paper mentions diagnosis as a topic, it doesn't specify diagnostic standards, so the diagnostic standard for MRONJ is unknown.",Exclude,"The abstract represents a review paper that fails to meet multiple critical screening criteria, including specific study design, population characteristics, and intervention type. Key requirements such as control group, subject size, diagnostic standards, and specific outcome documentation are not addressed, rendering the paper unsuitable for the intended research parameters. The text appears to be a general overview of medication-related osteonecrosis of the jaw rather than a focused research study meeting the specified screening criteria.",0.1
Osteonecrosis of the jaws: a 14‐year retrospective survey of hospital admissions,"K. McGowan, Saso Ivanovski, Caroline Acton",10.1111/adj.12603,https://doi.org/10.1111/adj.12603,Australian dental journal,11,2018,no,The study includes a mixed population - both osteoporosis patients (44.2%) and cancer patients (47.5%). This explicitly fails the criterion requiring only osteoporosis patients.,no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract doesn't specify which dental procedures were involved in the MRONJ cases.,yes,"This appears to be a retrospective review of medical records, which would qualify as a retrospective cohort study.",no,"While the study documents MRONJ cases, it doesn't specify the follow-up period or clearly document MRONJ incidence after specific dental treatments.",maybe,"The abstract doesn't explicitly state the age of subjects, but given it's a hospital-based study of patients with osteoporosis and cancer, it's likely they are adults, but this isn't certain.",no,"The study includes 238 total patients, with 25.6% being MRONJ cases (approximately 61 MRONJ patients). This fails to meet the minimum requirement of 100 subjects in the medication group.",no,"The abstract mentions ""low-dose antiresorptives"" but doesn't specify if these are oral bisphosphonates. It also includes other medications for rheumatoid arthritis and Paget's disease.",no,The abstract doesn't mention the diagnostic standards used for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including a mixed patient population, insufficient sample size, and lack of specificity regarding intervention type and diagnostic standards. Key limitations include the inclusion of cancer patients alongside osteoporosis patients, a small MRONJ case count, and absence of detailed documentation about dental procedures and MRONJ latency. These deficiencies prevent the study from meeting the systematic review's rigorous screening requirements.",1.4
Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events,"Mitsuhiro Nakamura, Ryogo Umetsu, Junko Abe, Toshinobu Matsui, Natsumi Ueda, Yamato Kato, S. Sasaoka, K. Tahara, H. Takeuchi, Y. Kinosada",10.1186/s40780-015-0035-2,https://doi.org/10.1186/s40780-015-0035-2,Journal of Pharmaceutical Health Care and Sciences,51,2015,no,"The abstract mentions that the study included both osteoporosis and ""malignant bone metastasis"" patients, indicating a mixed population, which fails to meet the criterion requiring only osteoporosis patients.",maybe,"The study does document time-to-onset profiles, but not specifically the interval between medication start and dental procedure.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract does not specify any dental procedures leading to BRONJ.,maybe,"The abstract indicates that this is a database analysis study using the JADER database, which could be considered a retrospective cohort study, but it is not clearly stated.",no,"While the study documents BRONJ incidence, it does not specify a follow-up period.",maybe,"The abstract does not explicitly state the age of the subjects, so the age of the population is unclear.",maybe,"The abstract does not specify the total number of subjects analyzed, so the subject size is unclear.",no,"The study includes both oral and intravenous bisphosphonates, which fails to meet the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for BRONJ.,Include,"The study fails to meet multiple screening criteria, including population specificity, intervention type, and procedural documentation. Mixed patient populations, inclusion of both oral and intravenous bisphosphonates, and lack of clear diagnostic standards and dental procedure details disqualify the research from meeting the predefined screening requirements. Critical methodological gaps prevent the study from being considered suitable for the intended review.",2.5
A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab,"P. Bracchi, E. Zecca, C. Brunelli, R. Miceli, Gabriele Tinè, M. Maniezzo, S. Lo Dico, M. Caputo, Morena Shkodra, A. Caraceni",10.1002/cam4.6429,https://doi.org/10.1002/cam4.6429,Cancer Medicine,2,2023,no,"The study explicitly focused on cancer patients with bone metastases, which violates the criterion requiring subjects taking medication for osteoporosis, excluding cancer patients.",no,"No information was provided about the time intervals between the start of medication, dental procedures, and MRONJ incidence.",no,No information was provided about whether the study included a control group of patients not taking anti-resorptive medications.,no,No information was provided about the specific dental procedures that were examined.,no,The study design was not explicitly stated in the abstract.,no,"While MRONJ incidence was mentioned as an outcome, no information was provided about the follow-up period.",no,No specific information was provided about the age of the study subjects.,no,No information was provided about the sample size of the study.,no,"The study used Denosumab, which is not an oral bisphosphonate, violating the criterion requiring oral bisphosphonate medication.",no,No information was provided about the diagnostic standards used for MRONJ.,Exclude,"The study focuses on cancer patients with bone metastases receiving Denosumab, which directly conflicts with the screening criteria requiring osteoporosis patients and oral bisphosphonate medication. These fundamental mismatches with the specified population and intervention type render the study ineligible for inclusion in the systematic review.",0.1
Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis,"J. G. Messer, J. L. M. Calle, J. Jiron, E. J. Castillo, C. Poznak, N. Bhattacharyya, Donald B. Kimmel, J. Aguirre",10.1016/j.bone.2017.12.025,https://doi.org/10.1016/j.bone.2017.12.025,Bone,32,2017,no,"The study uses rats with food impaction-induced periodontitis, not human patients taking medication for osteoporosis, which does not meet the population indication requirement.",maybe,"While the study documents time intervals (12, 18, 24, and 30 weeks), these are not related to dental procedures, which only partially meets the MRONJ latency requirement.",yes,"The study includes a control group of rats that did not receive the anti-resorptive medication, which meets the requirement for a control group.",no,"The study does not examine MRONJ following specific dental procedures, but instead looks at MRONJ in relation to food impaction-induced periodontitis, which does not meet the procedure and outcome requirement.",yes,"The study is a controlled experimental study with randomization, which meets the study design requirement.",yes,"The study clearly documents MRONJ incidence and has a follow-up period exceeding 6 months, which meets the outcome documentation requirement.",no,"The study uses rice rats as subjects, not human patients over 18 years old, which does not meet the age requirement.",yes,"The study includes 230 rats total, with multiple groups, which exceeds the 100 subject requirement for the medication group.",no,"The study uses intravenous zoledronic acid (ZOL), not oral bisphosphonates, and it is not being used for osteoporosis treatment, which does not meet the intervention type requirement.",yes,"The study mentions using gross quadrant grade (GQG) and histopathological confirmation for MRONJ diagnosis, which meets the diagnostic standard requirement.",Exclude,"This animal study using rice rats fails to meet multiple critical screening criteria, including the requirement for human subjects over 18 years old and oral bisphosphonate medication for osteoporosis. The research uses intravenous zoledronic acid in an experimental model with food impaction-induced periodontitis, which fundamentally differs from the specified research parameters. Consequently, the study does not qualify for inclusion in the systematic review.",0.1
RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN ONCOLOGICAL PATIENTS WITH OSTEONECROSIS OF THE JAW FROM BISPHOSPHONATES,"Ana raphaela Maia Dezan Couto Curvo, Victor Augusto Minari, L. M. A. Innocentini, H. Ricz, Adriano Tadeu Dias Marangoni, A. Ranieri, L. D. Macedo",10.1016/j.oooo.2020.04.675,https://doi.org/10.1016/j.oooo.2020.04.675,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2020,no,"The study explicitly focuses on cancer patients taking injectable bisphosphonates, which fails this criterion as it specifically excludes cancer patients.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract mentions ""triggering factor"" as a variable but doesn't specifically detail the dental procedures.",yes,"The study is described as a ""retrospective, observational study"" which meets this criterion.",maybe,"While the study documents MRONJ events, the follow-up period is not specified.",maybe,"While age is mentioned as a variable, the specific age range is not stated, so it cannot be confirmed if all subjects are over 18 years old.",no,"The study only includes 21 cases of MRONJ, which is well below the required 100 subjects.",no,"The study uses injectable bisphosphonates, not oral bisphosphonates, which fails this criterion.",maybe,"While the study mentions ""necrosis classification,"" it doesn't explicitly state the diagnostic standards used.",Exclude,"The study focuses on cancer patients taking injectable bisphosphonates, which immediately disqualifies it from the screening criteria due to population and intervention type requirements. With only 21 cases and lacking key documentation of diagnostic standards, dental procedures, and follow-up periods, the research fails to meet multiple critical screening parameters. The fundamental misalignment with the specified population and intervention type renders the study unsuitable for inclusion.",0.1
Genome‐wide Association Study Identified Chromosome 8 Locus Associated with Medication‐Related Osteonecrosis of the Jaw,"Guang Yang, Sonal Singh, C. McDonough, J. Lamba, Issam S. Hamadeh, L. Holliday, Danxin Wang, J. Katz, P. Lakatos, B. Balla, J. Kósa, G. Pelliccioni, D. Price, S. V. Van Driest, W. Figg, T. Langaee, J. Moreb, Y. Gong",10.1002/cpt.2397,https://doi.org/10.1002/cpt.2397,Clinical pharmacology and therapy,11,2021,maybe,"The study includes both cancer patients and osteoporosis patients, which violates the criterion of excluding mixed populations.",no,"The abstract does not mention any time intervals between medication start, dental procedures, and MRONJ incidence, so this criterion is not met.",yes,"The study includes a control group of 4,564 patients not taking anti-resorptive medications, which meets the criterion.",no,"The abstract does not mention any dental procedures or their relationship to MRONJ incidence, so this criterion is not met.",maybe,"The abstract describes a GWAS meta-analysis, but does not clearly state the underlying study design, so the study design criterion is unclear.",maybe,"While MRONJ cases are documented (444 cases), the follow-up period is not specified, so the outcome documentation criterion is unclear.",maybe,"The abstract does not explicitly state the age of the participants, so the age criterion is unclear.",yes,"The total sample size of 5,008 individuals, with 1,369 in the osteoporosis group, exceeds the 100-subject requirement for the medication group.",maybe,"The study includes both oral and intravenous bisphosphonates, which partially meets the criterion of only including subjects taking oral bisphosphonate medication.",no,"The abstract does not mention the diagnostic standards for MRONJ, so this criterion is not met.",Include,"A genetic association study examining medication-related osteonecrosis of the jaw across cancer and osteoporosis populations, which fails to meet several key screening criteria including specific dental procedure documentation, diagnostic standards, and clear outcome tracking. The research primarily focuses on genetic markers rather than clinical dental outcomes, resulting in significant misalignment with the predefined screening requirements.",2.7
Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer,"J. Goodwin, Jie Zhou, Y. Kuo, J. Baillargeon",10.1016/j.mayocp.2016.09.015,https://doi.org/10.1016/j.mayocp.2016.09.015,Mayo Clinic proceedings,12,2017,no,"The study specifically focuses on comparing cancer vs non-cancer patients, which violates the requirement for a pure osteoporosis population.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study includes a comparison group of patients prescribed oral bisphosphonates, which meets the requirement for a control group.",no,The abstract doesn't specify which dental procedures were involved in the jaw osteonecrosis cases.,yes,"This is a retrospective cohort study, which meets the study design criterion.",maybe,"While the study documents MRONJ incidence, the follow-up period is not explicitly stated.",maybe,"While not explicitly stated, Medicare patients are typically over 65, so the age criterion is likely met.",yes,"The study includes large sample sizes (9,482 cancer patients and 16,046 non-cancer patients), which meets the subject size criterion.",no,"The study primarily focuses on IV bisphosphonates, which is explicitly excluded in the criteria. The oral bisphosphonate group is only used as a comparison.",maybe,"The abstract mentions using ""an algorithm including diagnoses, surgical procedures, and imaging studies"" but doesn't provide specific diagnostic standards.",Exclude,"The study fails key screening criteria by focusing on intravenous bisphosphonates and including a mixed population of cancer and non-cancer patients, which deviates from the specified osteoporosis-only research parameters. Critical exclusion factors include the intervention type, population indication, and lack of specific dental procedure documentation, rendering the study ineligible for systematic review.",1.4
Medication-Related Osteonecrosis of the Jaw.,"Keiichi Ohta, H. Yoshimura",10.1016/j.amjms.2020.04.009,https://doi.org/10.1016/j.amjms.2020.04.009,American Journal of the Medical Sciences,4,2020,no,"The patient has bone metastatic prostate cancer and is taking antiresorptive drugs for cancer treatment, not osteoporosis. This is a critical exclusion criterion.",maybe,"The abstract mentions the timing of medication administration (8 years) and dental procedure, but doesn't explicitly state the time from procedure to MRONJ onset.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,The study reports MRONJ following tooth extraction.,no,"This is explicitly a case report, which is specifically excluded in the criteria.",yes,The study documents MRONJ incidence and has a 6-month follow-up period.,yes,"The subject is 79 years old, which meets the age requirement of over 18 years old.",no,"This is a single case report (n=1), far below the required 100 subjects.",no,"The patient is taking zoledronic acid (intravenous bisphosphonate) and denosumab (non-bisphosphonate), not oral bisphosphonates.",maybe,"The abstract mentions diagnostic findings (CT showing sclerotic region and necrotic bone, clinical examination) but doesn't explicitly state diagnostic standards.",Exclude,"This case report fails multiple critical screening criteria, including inappropriate patient population (cancer patient), incorrect medication type (intravenous and non-bisphosphonate), and insufficient sample size (single case). The study design as a case report and lack of a control group further disqualify it from meeting the systematic review's requirements.",0.1
Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.,"H. Chehal, N. Nikitakis, Mohammed N. Islam, J. Goodchild, L. Mordini, I. Bhattacharyya",-,-,General dentistry,0,2019,no,"The abstract mentions that the study includes patients with both osteoporosis and bone metastases, which suggests a mixed population. This is explicitly excluded by the criteria.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract does not specify which dental procedures were involved in the MRONJ cases.,no,"This appears to be a case report of 2 cases, which is explicitly excluded by the criteria.",maybe,"While MRONJ incidence is mentioned, the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, so the reasoning for this criterion is uncertain.",no,"The abstract only reports 2 cases, which is far below the required 100 subjects for the medication group.",no,"The study focuses on denosumab, which is not an oral bisphosphonate. It's explicitly an antiresorptive drug, which is excluded by the criteria.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This case report fails multiple critical screening criteria, including insufficient sample size, inappropriate study design, and non-compliance with specified intervention and population requirements. The research focuses on denosumab for mixed indications, lacks a control group, and does not meet the systematic review's methodological standards for inclusion. Consequently, the abstract does not qualify for further review based on the established screening criteria.",0.1
Preventing medication-related osteonecrosis of the jaw,"L. Zebic, V. Patel",10.1136/bmj.l1733,https://doi.org/10.1136/bmj.l1733,British medical journal,14,2019,no,"The abstract mentions that the study included both cancer and osteoporosis patients, indicating a mixed population. This fails to meet the criterion requiring an exclusive focus on osteoporosis patients.",no,"The abstract does not mention any time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, so Elicit could not confirm whether this criterion was met.",no,"While the abstract discusses osteonecrosis of the jaw, it does not specifically mention tracking MRONJ incidence following specific dental procedures.",no,"Elicit determined that this paper appears to be a review article rather than a primary research study, as the abstract mentions drawing on recommendations and various study types but is not itself a primary research study.",no,The abstract does not mention any specific follow-up periods or documented MRONJ incidence rates.,no,"The abstract does not specify the age requirements of the study population, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention the sample size of the study, so Elicit could not confirm whether this criterion was met.",no,"While the abstract mentions medications, it does not specify that the study focused exclusively on oral bisphosphonates. The abstract indicates that the study discussed multiple drug types for both cancer and osteoporosis.",no,The abstract does not mention any specific diagnostic standards for MRONJ.,Exclude,"The abstract describes a review article about medication-related osteonecrosis of the jaw, which fails to meet multiple critical screening criteria including specific population requirements, study design, and outcome documentation. Key limitations include a mixed patient population, lack of focus on oral bisphosphonates, and absence of specific diagnostic standards or procedure-related outcomes. The paper appears to be a general guidance document rather than a primary research study meeting the predefined screening criteria.",1.4
"Multicenter, retrospective population-based study on the incidence of medication-related osteonecrosis of the jaw in patients with breast cancer with bone metastases.","C. Brunner, C. Marth, D. Egle, M. Ritter, Florentina Baumgart, Miriam Emmelheinz, Benjamin Walch, C. Iannetti, A. Zabernigg, Maria Castellan, Oliver Tibor Andraschofsky, Alice Markl, M. Hubalek, Michael Schnallinger, E. Woell, S. Puntscher, M. Arvandi, U. Siebert, E. Bruckmoser, J. Laimer",10.1200/jco.2023.41.16_suppl.6588,https://doi.org/10.1200/jco.2023.41.16_suppl.6588,Journal of Clinical Oncology,0,2023,no,"The study specifically focuses on breast cancer patients with bone metastases, not osteoporosis patients, which is a clear violation of the inclusion criteria.",maybe,"The study does document time intervals between treatment start and MRONJ occurrence (mentions ""median 60 months""), but does not specify the interval between dental procedure and MRONJ.",no,"The study does not include a control group of patients not taking anti-resorptive medications, so it does not meet this criterion.",no,The abstract does not specify which dental procedures were associated with MRONJ incidence.,yes,"This is a retrospective multicenter study, which meets the acceptable study design criteria.",maybe,"While the study documents MRONJ incidence, it does not specify the follow-up period length.",yes,"The abstract does not explicitly state the age of the subjects, but since it is a breast cancer population, it can be reasonably assumed that the subjects are adults over 18 years old.",yes,"The study includes 639 patients in the treatment groups, which is well above the 100-subject requirement.",no,"While the study includes bisphosphonates, it also includes denosumab (a non-bisphosphonate) and does not specify if the bisphosphonates were oral. The study mixes different medication types, which is a violation of the inclusion criteria.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on breast cancer patients with bone metastases, which deviates from the required osteoporosis patient population, and includes mixed medication types beyond oral bisphosphonates. Critical screening criteria were not met, including lack of specified dental procedures, undefined diagnostic standards for MRONJ, and absence of a clear control group. These fundamental discrepancies render the study ineligible for inclusion in the systematic review.",1.4
An Update on Medication Related Osteonecrosis of the Jaw: 18 years of Experience,"Vickas Agarwal, T. Schlieve",-,-,-,1,2021,no,"The abstract mentions both intravenous and oral bisphosphonates, and does not specify if the population is exclusively osteoporosis patients. This fails to meet the criterion of excluding mixed populations.",no,No information about time intervals is provided in the abstract.,no,"The abstract does not mention any control group, so Elicit could not confirm if this criterion was met.",no,The abstract does not specify any dental procedures leading to MRONJ.,no,"The abstract appears to be a review or commentary on case reports and series, which explicitly fails this criterion as case reports/series are excluded.",no,"While MRONJ is discussed, there's no mention of follow-up period or specific documentation of incidence after dental treatment.",no,"The abstract does not specify the age of the subjects, so Elicit could not confirm if this criterion was met.",no,"The abstract mentions ""99 cases"" which is below the required 100 subjects for the medication group.",no,"The abstract mentions both intravenous (Pamidronate, Zoledronate) and oral (Alendronate, Risedronate) bisphosphonates, which fails to meet the criterion of only including oral bisphosphonates.",yes,"The abstract does mention diagnostic criteria from AAOMS, so this criterion is met.",Exclude,"The abstract fails multiple critical screening criteria, including inappropriate study design, mixed medication types, insufficient sample size, and lack of specific dental procedure documentation. Key exclusion factors include being a review of case reports rather than an original research study, and not meeting the required population and intervention specifications. Consequently, the paper does not meet the established screening requirements for inclusion.",0.1
18 years of medication related osteonecrosis of the jaw (MRONJ) research: where are we now? – An umbrella review,"R. Sacco, M. Calasans-Maia, Julian Woolley, O. Akintola, Carlos Fernando de Almeida Barros Mourão, V. Moraschini, E. Kushnerev, A. Acocella, O. Obisesan, J. Yates",10.37766/inplasy2021.6.0061,https://doi.org/10.37766/inplasy2021.6.0061,Applied Sciences,4,2021,no,"The abstract mentions both ""benign and malignant conditions of bone tissue"" and specifically notes ""oncologic disease,"" which fails the criterion as it includes cancer patients and mixed populations.",no,No information about time intervals is provided.,no,"The abstract does not mention any control groups, so this criterion is not met.",no,The abstract does not specify any dental procedures or their relationship to MRONJ incidence.,no,"This is an umbrella review of systematic reviews, not a primary study, and it includes case series and case reports, which are explicitly excluded by the criteria, so this criterion is not met.",no,"While MRONJ is discussed, specific follow-up periods are not mentioned.",maybe,"The abstract does not specify age requirements, so this criterion is unclear.",maybe,"While the abstract mentions a large total number (80,840 patients), this is across multiple reviews and not specific to a single study group, so this criterion cannot be properly assessed.",no,"The abstract does not specify oral bisphosphonates, only mentioning ""medications used to treat benign and malignant conditions,"" so this criterion is not met.",no,The abstract does not mention any diagnostic standards for MRONJ.,Exclude,"This umbrella review fails multiple screening criteria, including inclusion of cancer patients, mixed population, and non-specified intervention types. The study design as a review of systematic reviews, combined with lack of specific details about dental procedures, diagnostic standards, and follow-up periods, renders it ineligible for inclusion. Critical methodological limitations and broad scope prevent meeting the required screening standards.",0.1
Denosumab-related osteonecrosis of the jaw: a systematic review,"P. Aulestia-Viera, A. Santos-Silva, G. Machado, A. Rocha",10.5935/2525-5711.20200026,https://doi.org/10.5935/2525-5711.20200026,JORDI - Journal of Oral Diagnosis,0,2000,no,"The study includes mixed populations (both osteoporosis and cancer patients), which explicitly violates the requirement to only include patients taking medication for osteoporosis.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The study does report MRONJ incidence following dental procedures (60% following extractions), meeting this criterion.",no,"This is a systematic review of case reports and case series, which explicitly violates the criterion requiring RCT, cohort, or case-control studies.",maybe,"While the study documents MRONJ incidence and treatment outcomes, the follow-up period is not specified, so the reasoning is unclear.",yes,"The mean age of the subjects was 68.3 years, which meets the requirement of being over 18 years old.",yes,"The study includes 145 cases, which exceeds the 100-subject requirement for the medication group.",no,"The study focuses on denosumab, which is not an oral bisphosphonate, and therefore explicitly violates this criterion.",maybe,"The abstract does not explicitly mention diagnostic standards for MRONJ, so the reasoning is unclear.",Exclude,"The study fails key screening criteria by using denosumab instead of oral bisphosphonates, including a mixed population of cancer and osteoporosis patients, and employing a systematic review of case reports rather than a preferred study design. Multiple critical violations, including intervention type and population selection, render this paper ineligible for the systematic review. The research does not meet the fundamental requirements for inclusion in the study.",0.1
Determinants Of Outcome In Cancer Patients With Medication-Related Osteonecrosis Of The Jaw: A 19-Year Retrospective Study,"Jenna Marcinczyk, Annu Singh, Charlie White, Elyn Reidel, S. Yom, J. Huryn, C. Estilo",10.1016/j.oooo.2023.07.039,https://doi.org/10.1016/j.oooo.2023.07.039,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2023,no,"The study specifically focuses on cancer patients taking antiresorptive therapy, which explicitly violates the criterion requiring subjects to be chosen from patients taking medication for osteoporosis, excluding cancer patients.",no,"The abstract does not document the time interval between medication start and dental procedure, or between dental procedure and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not specify which dental procedures led to MRONJ incidence.,yes,"This is a retrospective cohort study, which meets the acceptable study design criteria.",yes,"The study has a median follow-up time of 94.9 months, which exceeds the minimum 6-month requirement, and clearly documents MRONJ outcomes.",maybe,"The abstract doesn't explicitly state the age range of subjects, but since it's a cancer patient population, we can reasonably assume they are adults.",yes,"The study includes 300 patients in the final analysis, which exceeds the minimum requirement of 100 subjects.",no,"The study includes patients taking pamidronate, zoledronic acid, and denosumab, which are not oral bisphosphonates. This violates the criterion requiring only oral bisphosphonate medication.",yes,The study mentions using the AAOMS classification system for MRONJ diagnosis.,Exclude,"The study focuses on cancer patients taking antiresorptive medications, which directly conflicts with the screening criteria requiring an osteoporosis patient population. Multiple critical screening requirements were not met, including the type of medication and patient population, rendering the study ineligible for inclusion. The research's specific focus on cancer patients and non-oral bisphosphonate medications disqualifies it from the systematic review.",0.1
"Bisphosphonates, Osteoporosis, and Osteonecrosis of the Jaw: A Critical Review of a Large Nested Case-Control Study.","A. Zavras, Jayapriyaa R. Shanmugham",10.1016/j.jebdp.2016.05.007,https://doi.org/10.1016/j.jebdp.2016.05.007,Journal of Evidence-Based Dental Practice,5,2016,yes,"The abstract specifically mentions that the study population consisted of ""patients with osteoporosis"", indicating that the subjects were chosen from patients taking medication for osteoporosis, excluding cancer patients and mixed populations.",maybe,"The abstract does not provide any information about the time intervals between the start of medication, dental procedures, and MRONJ incidence, creating uncertainty about this criterion.",yes,"The abstract mentions that the study is a ""nested case-control study"", which implies the inclusion of a control group of patients not taking anti-resorptive medications.",maybe,"The abstract does not specify which dental procedures were studied, creating uncertainty about this criterion.",yes,"The abstract describes the study as a ""nested matched case-control study"", which meets the criterion for study design.",maybe,"While the study is about MRONJ, the abstract does not specify the follow-up period or clearly document MRONJ incidence, creating uncertainty about this criterion.",maybe,"The abstract does not explicitly mention the age requirements for the study population, so there is uncertainty about whether the subjects were over 18 years old.",maybe,"The abstract describes the study as a ""large national cohort study"", but does not specify the exact number of subjects in the medication group at the final statistical analysis stage, creating uncertainty about whether the study included over 100 subjects.",maybe,"The abstract mentions ""bisphosphonates"" but does not specify whether they were oral or other forms, creating uncertainty about the intervention type.",maybe,"The abstract does not mention the diagnostic standards for MRONJ, creating uncertainty about this criterion.",Include,"A nested case-control study on bisphosphonates and osteonecrosis of the jaw in osteoporosis patients presents promising initial characteristics, but significant uncertainties exist regarding critical screening criteria such as intervention type, subject size, diagnostic standards, and outcome documentation. Multiple key details are absent from the abstract, necessitating a full-text review to definitively assess study eligibility.",3.4
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases,"H. Ikesue, Kohei Doi, M. Morimoto, M. Hirabatake, Nobuyuki Muroi, S. Yamamoto, T. Takenobu, T. Hashida",10.1007/s00280-021-04262-w,https://doi.org/10.1007/s00280-021-04262-w,Cancer Chemotherapy and Pharmacology,18,2021,no,"The study specifically focuses on cancer patients with bone metastases, not osteoporosis patients. This is a clear violation of the inclusion criteria.",no,"The abstract doesn't document the specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The study does not include a control group of patients not taking anti-resorptive medications. It only compares different medication groups (ZA, denosumab, and ZA-to-denosumab switch).",yes,"The study mentions tooth extraction as a risk factor for MRONJ, which is one of the specified procedures.",yes,"The study is a retrospective cohort study, which meets the acceptable study design criteria.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified in the abstract.",maybe,"The abstract doesn't explicitly state the age of subjects. However, since these are cancer patients receiving bone metastases treatment, they are likely adults, but this isn't certain.",yes,"The study includes 795 patients total, with 43 in the ZA-to-denosumab group, 350 in the ZA group, and others in the denosumab group. The medication groups exceed 100 subjects.",no,"The study focuses on zoledronic acid (intravenous bisphosphonate) and denosumab (non-bisphosphonate), not oral bisphosphonates. This is a clear violation of the inclusion criteria.",maybe,The abstract doesn't explicitly mention the diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients with bone metastases receiving intravenous medications, which critically fails the screening criteria for osteoporosis patient research. Specifically, the population indication and intervention type do not match the required parameters, rendering the study ineligible for inclusion in the systematic review. Multiple other screening criteria were either uncertain or partially met, but the fundamental population and intervention mismatches disqualify the study.",0.1
Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents,"Kazuhito Tohashi, M. Nakabayashi, Isamu Kodani, K. Kidani, K. Ryoke",-,-,Yonago acta medica,8,2016,maybe,"While the study involves patients taking anti-resorptive agents, it does not explicitly specify that the subjects are osteoporosis patients or exclude cancer patients, so the population indication is only partially met.",no,"The abstract does not document the time intervals between medication start, dental procedures, and ARONJ incidence, so the MRONJ latency is not met.",yes,"The study explicitly mentions a control group of 24 patients who did not develop ARONJ, which meets the requirement for a control group.",maybe,"The abstract mentions tooth extraction, but it is discussed as a future application rather than a documented procedure in the study, so the procedure and outcome is only partially met.",maybe,"The study design is not explicitly stated in the abstract, so it is unclear.",maybe,"The follow-up period is not mentioned in the abstract, so the outcome documentation is unclear.",maybe,"The abstract does not specify the age range of participants, so the age of the subjects is unclear.",no,"The study only includes 56 total patients (32 with ARONJ, 24 without), which is below the required 100 subjects for the medication group.",maybe,"The abstract only mentions ""systemic anti-resorptive agents"" without specifying if they are oral bisphosphonates, so the intervention type is unclear.",no,"While the study discusses ARONJ, it does not mention specific diagnostic standards, so the diagnostic standard for MRONJ is not met.",Include,"The study fails to meet critical screening criteria, particularly the required sample size of 100 subjects, with only 56 patients included. Significant uncertainties exist regarding population age, intervention type, study design, and diagnostic standards for MRONJ. Multiple key screening requirements remain unaddressed or incompletely documented, rendering the study potentially unsuitable for inclusion.",2.7
Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.,"Alexandre T. Assaf, R. Smeets, B. Riecke, E. Weise, A. Gröbe, M. Blessmann, T. Steiner, J. Wikner, R. Friedrich, M. Heiland, F. Hoelzle, F. Gerhards",-,-,Anticancer Research,51,2013,no,"The study specifically focuses on patients with ""osseous metastatic malignancies"" receiving bisphosphonates, which explicitly violates the criterion requiring patients taking medication for osteoporosis.",maybe,"The study documents time intervals (80 months between diagnosis and BRONJ), but not specifically between medication start and dental procedure.",no,"The abstract does not mention a control group of patients not taking bisphosphonates, so no points are added for this criterion.",no,The abstract does not specify any dental procedures leading to BRONJ.,yes,"This appears to be a retrospective study, which is an acceptable study design.",maybe,"While BRONJ incidence is documented (8.9%), the follow-up period is not clearly specified.",yes,"While not explicitly stated, the context suggests the study included adult patients with cancer, so it likely meets the age requirement of over 18 years.",yes,"The study includes 169 patients, which exceeds the minimum requirement of 100 subjects.",no,"The study specifically mentions ""intravenous bisphosphonate therapy"" which explicitly violates the criterion requiring oral bisphosphonates.",no,The abstract does not explicitly mention diagnostic standards for BRONJ.,Exclude,"The study focuses on cancer patients receiving intravenous bisphosphonates, which fundamentally conflicts with the screening criteria requiring osteoporosis patients and oral bisphosphonate medication. Multiple critical screening requirements were not met, including population indication, intervention type, and specific diagnostic and procedural standards. Consequently, the study does not align with the predefined screening criteria and would be excluded from further review.",0.1
Medication-related osteonecrosis of the jaw – a scoping review,"N. Gogtay, Dhruve Soni, Sukant Pandit",10.1097/fad.0000000000000061,https://doi.org/10.1097/fad.0000000000000061,Adverse Drug Reaction Bulletin,0,2022,no,"While the abstract discusses MRONJ in relation to anti-resorptive medications, it does not specifically focus on osteoporosis patients and appears to be a general review covering multiple conditions and medications, so it fails this criterion.",no,"No information about time intervals is provided, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While MRONJ is discussed, the abstract doesn't specifically report incidence following dental procedures, so it fails this criterion.",no,"This appears to be a review article rather than any of the specified study designs, so it fails this criterion.",no,"The abstract doesn't mention any specific follow-up period or documented MRONJ incidence, so it fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is unknown.",maybe,"The abstract does not mention any specific study population size, so the reasoning for this criterion is unknown.",no,"While bisphosphonates are mentioned, the abstract discusses multiple medication types including ""biologics,"" ""tyrosine kinase inhibitors,"" and ""calcineurin inhibitors,"" and is not focused specifically on oral bisphosphonates, so it fails this criterion.",maybe,"The abstract mentions that case definitions exist from AAOMS and ASBMR, but doesn't specify which one is used, so it partially meets this criterion.",Exclude,"This review article fails multiple critical screening criteria, including lack of a specific study design, mixed population, and absence of focused intervention on oral bisphosphonates for osteoporosis. The text provides a general overview of medication-related osteonecrosis of the jaw but does not meet the systematic review's methodological requirements for inclusion.",0.1
Are medication-induced salivary changes the culprit of osteonecrosis of the jaw? A systematic review,"I. Suryani, Iraj Ahmadzai, M. T. That, S. Shujaat, R. Jacobs",10.3389/fmed.2023.1164051,https://doi.org/10.3389/fmed.2023.1164051,Frontiers in Medicine,1,2023,no,"The study includes mixed populations taking various medications (bisphosphonates, steroids, chemotherapy, thalidomide, etc.) rather than focusing exclusively on osteoporosis patients, which fails to meet the criterion.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, which is a significant limitation.",no,The abstract does not specify which dental procedures were associated with MRONJ cases.,no,"This is a systematic review, not a primary research study of any of the accepted designs, which fails to meet the criterion.",no,"While MRONJ incidence is discussed, the follow-up period is not specified.",yes,"The abstract mentions a mean age of 66 years, which meets the >18 years criterion.",maybe,"The study includes 272 MRONJ cases, which would meet the >100 subjects criterion if this were a primary study. However, this is a systematic review, not a primary study.",no,"The study includes multiple medication types beyond oral bisphosphonates, including intravenous medications and non-bisphosphonates, which fails to meet the criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This systematic review fails to meet multiple critical screening criteria, including the requirement for a specific osteoporosis patient population and oral bisphosphonate intervention. The study's mixed medication types, lack of a control group, and absence of specific dental procedure details disqualify it from meeting the predefined inclusion standards.",0.1
THU442 A Case Of Early Medication Related Osteonecrosis Of The Jaw In Patient Receiving Intravenous Zoledronate For Treatment Of Osteoporosis,-,10.1210/jendso/bvad114.403,https://doi.org/10.1210/jendso/bvad114.403,Journal of the Endocrine Society,1,2023,yes,"The subject has osteoporosis and is taking bisphosphonates for this condition, not for cancer, which meets the population indication criteria.",maybe,"The abstract mentions ""several years of oral bisphosphonate treatment"" but doesn't provide specific time intervals.",no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"The abstract doesn't clearly specify if any dental procedures were performed before MRONJ onset. It only mentions ""prior oral surgery"" as a risk factor.",no,"This is explicitly a case report, which is specifically excluded in the criteria.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",yes,"The subject is 63 years old, which meets the requirement of being over 18 years old.",no,"This is a case report of a single patient, which is far below the required 100 subjects for the medication group.",no,"The patient took both oral bisphosphonates and intravenous zoledronic acid, which includes intravenous administration, which is explicitly excluded in the criteria.",maybe,"While MRONJ is diagnosed, the abstract doesn't explicitly state the diagnostic standards used.",Exclude,"A single-patient case report involving a 63-year-old osteoporosis patient fails multiple critical screening criteria, including insufficient subject size, inappropriate study design, and inclusion of intravenous medication. The research does not meet the required methodological standards for systematic review, particularly the need for a larger sample size and a more robust study design.",0.1
Surgical Treatment of Medication-Related Osteonecrosis of the Jaw: A Retrospective Study,"N. Choi, Jung Han Lee, Jin Young Park, Dae-Seok Hwang",10.3390/ijerph17238801,https://doi.org/10.3390/ijerph17238801,International Journal of Environmental Research and Public Health,7,2020,no,"The abstract mentions zoledronate, which is typically used for cancer treatment, not osteoporosis. This is a critical failure as the criteria specifically exclude cancer patients.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract focuses on surgical treatment of MRONJ rather than MRONJ incidence following dental procedures. This is a critical failure as it studies treatment rather than incidence.,yes,"This appears to be a retrospective analysis of treatment outcomes, which would qualify as a retrospective cohort study.",no,"While the study documents outcomes, it's focused on treatment success rather than MRONJ incidence after dental procedures.",maybe,"The abstract does not explicitly state the age of the subjects, but Elicit notes that since the study is about MRONJ treatment, the subjects are likely adults.",yes,"The study includes 116 cases (109 success + 7 failure), meeting the >100 subject requirement.",no,"The study specifically mentions zoledronate, which is an intravenous bisphosphonate, not oral. This fails the criterion requiring oral bisphosphonates.",yes,"The abstract mentions AAOMS stages 1, 2, or 3, which is a standard diagnostic classification for MRONJ.",Exclude,"The study fails critical screening criteria by focusing on cancer patients receiving intravenous zoledronate, which deviates from the required oral bisphosphonate and osteoporosis patient population. Multiple key requirements were not met, including the need for a control group, specific dental procedure outcomes, and documentation of MRONJ latency. The research primarily examines treatment success rather than MRONJ incidence, rendering it unsuitable for the systematic review.",0.1
Implications in dental treatment during the use of antiresorptive drugs - a literature review,"Aleksandra Dziewulska, Weronika Kiełt, Julia Kozłowska, Gabriela Broniec, Barbara Wajdowicz, Aleksandra Kudła, Rozalia Czapiewska, Aleksandra Wróbel, Laura Pacek, Klaudia Kowalska",10.12775/jehs.2024.69.55356,https://doi.org/10.12775/jehs.2024.69.55356,"Journal of Education, Health and Sport",0,2024,no,"While osteoporosis is mentioned, the abstract also includes ""metastatic bone disease and hypercalcemia"" as indications, suggesting a mixed population. This fails to meet the criterion of focusing exclusively on osteoporosis patients.",no,"No information about time intervals is provided, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",maybe,"While dental procedures are mentioned broadly (orthodontics, implantology, periodontal therapy, endodontics), specific procedures and MRONJ incidence are not clearly reported, so it only partially meets this criterion.",no,"This appears to be a literature review rather than any of the required study designs (RCT, cohort, or case-control), so it fails to meet this criterion.",no,"The abstract does not mention any specific follow-up period or clearly document MRONJ incidence, so it fails to meet this criterion.",maybe,"The abstract does not specify the age of the subjects, so the information is unknown.",maybe,"The abstract does not mention any subject numbers, so the information is unknown.",maybe,"While bisphosphonates are mentioned, the abstract also includes denosumab (a non-bisphosphonate) and doesn't specify oral administration, so it only partially meets this criterion.",no,"The abstract does not mention any diagnostic standards for MRONJ, so it fails to meet this criterion.",Exclude,"The literature review fails to meet multiple critical screening criteria, including specific study design requirements, population restrictions, and outcome documentation. Key deficiencies include a mixed patient population, lack of clear diagnostic standards, and absence of specific MRONJ incidence reporting. The paper does not qualify for inclusion in the systematic review due to these significant methodological limitations.",1.4
Medication-related osteonecrosis of the jaw and the role of the doctor of dental surgery: a literature review,"Juliana Lima de Oliveira Amorim Cabral, Susana Braga Santoro Santiago, Nicole Serqueira da Silva, Livia Cristina Buriche Ferreira da Silva, C. Silva-Boghossian, I. Tuñas",10.33448/rsd-v12i4.41284,https://doi.org/10.33448/rsd-v12i4.41284,"Research, Society and Development",0,2023,no,"While the abstract discusses antiresorptive medications, it does not specifically focus on osteoporosis patients and appears to be a general review of MRONJ, so it fails this criterion.",no,"The abstract does not document specific time intervals, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While the abstract mentions ""oral surgery procedures,"" it doesn't specifically report MRONJ incidence following specific dental procedures, so it fails this criterion.",no,"This is a literature review/systematic review, not one of the required study designs (RCT, cohort, or case-control), so it fails this criterion.",no,"As a literature review, this paper does not directly document MRONJ incidence or follow-up periods, so it fails this criterion.",maybe,"The abstract does not specify age requirements, so the reasoning for this criterion is uncertain.",no,"This is a literature review, not an original research study with subjects, so it fails this criterion.",no,"While bisphosphonates are mentioned, the paper appears to cover antiresorptive medications broadly rather than focusing specifically on oral bisphosphonates, so it fails this criterion.",maybe,"The abstract mentions that MRONJ is ""characterized by exposed and necrotic bone that persists for more than 8 weeks,"" which partially addresses diagnostic standards.",Exclude,"This literature review fails multiple critical screening criteria, including lack of a control group, undefined patient population, absence of specific intervention details, and no original research design. The paper does not meet the required standards for subject size, diagnostic specificity, or outcome documentation, rendering it unsuitable for the intended research analysis.",0.1
Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.,"Ppl Fung, Giorgio Bedogni, A. Bedogni, A. Bedogni, A. Petrie, Stephen Porter, G. Campisi, J. Bagan, V. Fusco, G. Saia, S. Acham, P. Musto, M. Petrucci, Pedro Diz, Giuseppe Colella, M. Mignogna, M. Pentenero, P. Arduino, Giovanni Lodi, Carlo Maiorana, M. Manfredi, Pär Hallberg, M. Wadelius, K. Takaoka, Yiu Yan Leung, Riccardo Bonacina, Morten Schiødt, P. Lakatos, T. Taylor, G. Riu, G. Favini, S. Rogers, M. Pirmohamed, Paola Nicoletti, Stefano Fedele, Stefano Fedele",10.1111/odi.12632,https://doi.org/10.1111/odi.12632,Oral Diseases,80,2017,no,"The study includes both osteoporosis and cancer patients, which violates the criterion requiring a population specifically chosen from osteoporosis patients without mixed populations. This is a critical failure.",yes,"The study does document time to onset (TTO) of ONJ, which would qualify for the 0.2 points bonus.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract mentions ""dentoalveolar surgery"" as a factor, but does not clearly report MRONJ incidence following specific dental procedures.",yes,"The study is described as a ""retrospective analysis,"" which meets the criterion for acceptable study designs.",no,"While the study documents ONJ occurrence, the follow-up period is not explicitly stated in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, but given that the study is of osteoporosis and cancer patients, it is likely that the subjects are over 18 years old. However, this is uncertain from the abstract alone.",no,"The study includes 349 patients total, with 88 on alendronate and 218 on zoledronate. While the total exceeds 100, the alendronate group (which is the only oral bisphosphonate group) has fewer than 100 subjects.",no,"The study includes both oral (alendronate) and intravenous (zoledronate) bisphosphonates, violating the criterion requiring only oral bisphosphonates.",no,The abstract does not mention the diagnostic standards used for ONJ.,Exclude,"The study fails critical screening criteria by including a mixed population of osteoporosis and cancer patients, using both oral and intravenous bisphosphonates, and having an insufficient sample size for the oral bisphosphonate group. Multiple methodological limitations, including lack of clear diagnostic standards and incomplete documentation of dental procedures, further compromise the study's alignment with the specified screening requirements.",1.4
Osteonecrosis of the jaw and dental extractions: a single-center experience.,"Shaiba Sandhu, Moaiad H Salous, V. Sankar, D. Margalit, A. Villa",10.1016/j.oooo.2020.07.001,https://doi.org/10.1016/j.oooo.2020.07.001,"Oral surgery, oral medicine, oral pathology and oral radiology",7,2020,no,"The study includes patients taking antiresorptive medications, but also includes radiation therapy patients. This is a mixed population, which violates the criterion.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,The study does not include a control group of patients not taking anti-resorptive medications. The comparison is between radiation therapy patients and antiresorptive patients.,yes,"The study clearly reports MRONJ incidence following dental extractions, meeting this criterion.",yes,"The study is described as a ""retrospective study,"" which meets the criteria.",maybe,The study reports MRONJ incidence (7.5% in the antiresorptive group) but the follow-up period is not specified.,maybe,"The abstract does not explicitly state the age of subjects, so this is unclear.",no,"The study includes 40 patients in the antiresorptive group, which is below the required 100 subjects.",maybe,"The abstract mentions ""antiresorptives"" but doesn't specify if these are oral bisphosphonates, so this is unclear.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study fails to meet critical screening criteria due to a mixed patient population, insufficient sample size, and lack of clarity on medication type and diagnostic standards. Key limitations include including radiation therapy patients alongside antiresorptive medication patients, having only 40 subjects in the medication group, and not specifying oral bisphosphonate use or MRONJ diagnostic criteria. These fundamental issues prevent the study from satisfying the required screening parameters.",2.5
IJOMS Vol 18-4_11.indd,"SO Okada, Naohisa Hirahara",-,-,-,0,2020,maybe,"While the abstract discusses bisphosphonates and MRONJ, it does not clearly specify that the study population consists only of osteoporosis patients, excluding cancer patients, so the information is unknown.",no,"The abstract mentions ""long interval use"" but does not document specific time intervals, so it fails this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract does not specify any dental procedures leading to MRONJ, so it fails this criterion.",no,"The abstract appears to be more of a review or commentary rather than presenting original research with a specific study design, so it fails this criterion.",no,"While the abstract mentions MRONJ incidence ranges (0.8% to 18.5%), it does not describe a specific follow-up period, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the information is unknown.",maybe,"The abstract does not mention the number of subjects, so the information is unknown.",maybe,"The abstract discusses bisphosphonates but does not specify whether they are oral or intravenous, so the information is unknown.",yes,"The abstract does mention diagnostic standards for MRONJ, citing AAOMS criteria including ""exposed bone or bone that can be probed through an extraoral or intraoral fistula in the maxillofacial region that has persisted for longer than 8 weeks,"" so it meets this criterion.",Exclude,"The abstract lacks critical details required by the screening criteria, including specific study design, population characteristics, intervention type, and dental procedure outcomes. Multiple key screening requirements remain unaddressed, rendering the text insufficient for systematic review inclusion. The document appears more like a literature review than a research study with the necessary methodological specifics.",1.4
Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw,-,-,-,-,6,2017,no,"The abstract indicates that this is a guidance document rather than a research study with specific patient populations, so it does not meet the requirement for the population indication.",no,"No information about time intervals is provided, so it does not meet the requirement for MRONJ latency.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While dental procedures are mentioned broadly (""routine dental treatment""), specific procedures and MRONJ incidence are not reported, so it does not meet the requirement for procedure and outcome.",no,"This is clearly a guidance document/clinical guideline, not a research study of any of the specified types, so it does not meet the requirement for study design.",no,"As this is a guidance document, it does not report actual MRONJ incidence or follow-up periods, so it does not meet the requirement for outcome documentation.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is unknown.",no,"As this is a guidance document rather than a research study, no subject numbers are mentioned, so it does not meet the requirement for subject size.",no,"The abstract mentions bisphosphonates but also refers to ""drugs associated with MRONJ"" more broadly, suggesting it's not limited to oral bisphosphonates, so it does not meet the requirement for intervention type.",no,"While MRONJ is mentioned, specific diagnostic standards are not detailed in the abstract, so it does not meet the requirement for diagnostic standards.",Exclude,"This clinical guidance document fails to meet the systematic review's screening criteria, as it is not a research study with a defined patient population, intervention, or outcome measurements. The abstract describes a guidance document for dental practitioners managing patients at risk of medication-related osteonecrosis of the jaw, lacking the specific research elements required for inclusion in the review.",0.1
IS TERIPARATIDE THERAPY EFFECTIVE FOR MEDICATION-RELATED OSTEONECROSIS OF THE JAW? A SYSTEMATIC REVIEW AND META-ANALYSIS,"L. Ferreira, Lucas Guimarães Abreu, C. Calderipe, M. D. Martins, L. Schuch, A. Vasconcelos",10.1016/j.oooo.2022.01.731,https://doi.org/10.1016/j.oooo.2022.01.731,"Oral surgery, oral medicine, oral pathology and oral radiology",1,2022,maybe,"The study includes patients with osteoporosis (76.5% of cases), but it's a mixed population including other indications. The abstract doesn't specify excluding cancer patients.",no,"The abstract mentions ""mean evolution time of 5 months"" but doesn't clearly document the time intervals between medication start, dental procedure, and MRONJ onset.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract doesn't specify which dental procedures led to MRONJ.,no,"This appears to be a systematic review/meta-analysis, not one of the accepted study designs.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",yes,"The mean age of the subjects was 76.54 years, which meets the requirement of being over 18 years old.",no,"The study includes 143 cases total, but this is a review of multiple studies rather than a primary study with 100+ subjects.",no,"The study focuses on teriparatide (TPTD) therapy, not oral bisphosphonates. While bisphosphonates are mentioned (98.1% of cases), they are not the intervention being studied.",maybe,"The abstract mentions MRONJ stages (1 and 3), suggesting some diagnostic standard, but doesn't explicitly state the diagnostic criteria.",Exclude,"The study fails to meet multiple critical screening criteria, including the required intervention type, study design, and population specifications. Key limitations include focusing on teriparatide therapy instead of oral bisphosphonates, being a systematic review rather than a primary study, and lacking clear documentation of dental procedures and MRONJ latency. These significant deviations from the screening requirements render the study unsuitable for inclusion.",1.4
Dentoalveolar surgery and Prevention of Medication-related Osteonecrosis of the Jaw (MR-ONJ) in patients treated with Bisphosphonates: our experience.,"F. Lonardi, G. Capocasale, F. Zotti, Riccardo Nocini, Annarita Signoriello, G. Panozzo, M. Albanese",10.32388/6CCLYF,https://doi.org/10.32388/6CCLYF,Qeios,0,2021,no,"The abstract mentions that the study included both cancer and osteometabolic patients, indicating a mixed population, which fails to meet the criterion requiring only osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The abstract mentions dentoalveolar surgery and tooth extraction, which meets this criterion.",maybe,"The abstract appears to describe a prospective study following a specific protocol, but the exact study design is not clearly stated.",no,"While the study follows patients for one year, it appears to focus on prevention protocols rather than documenting MRONJ incidence after treatment.",maybe,"The abstract does not explicitly state the age of the subjects, so the age of the population is unclear.",no,"The abstract does not mention the number of subjects included in the study, so the subject size is unclear.",no,"The abstract mentions bisphosphonates but does not specify if they are oral or intravenous, and it also includes cancer patients, which is excluded by the criteria.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study involves a mixed patient population including cancer patients, which violates the screening criteria requiring an osteoporosis-only population. Multiple methodological details are missing, including diagnostic standards, subject size, and precise intervention type, making it challenging to definitively assess the study's alignment with the screening requirements. The research appears more focused on prevention protocols than on systematically documenting MRONJ incidence, further complicating its potential inclusion.",2.5
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary.,"C. Shapiro, N. Yarom, D. Peterson, Kari Bohlke, D. Saunders",10.1200/JOP.19.00384,https://doi.org/10.1200/JOP.19.00384,Journal of Oncology Practice,3,2019,no,"The abstract specifically mentions cancer patients and multiple myeloma, which are explicitly excluded in the criteria. This is a critical failure.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While the abstract mentions preventive oral care, it doesn't specifically report MRONJ incidence following the required dental procedures. This fails the criterion.",no,"This appears to be a review article rather than an original research study, as it discusses ""many studies"" and provides general information about MRONJ. This fails the criterion.",no,The abstract does not mention specific follow-up periods or clearly document MRONJ incidence rates. This fails the criterion.,maybe,"The abstract does not specify the age requirements of the study population, so the reasoning is uncertain.",maybe,"The abstract does not mention the sample size, so the reasoning is uncertain.",maybe,"While bisphosphonates are mentioned, the abstract also discusses denosumab and other bone-modifying agents, and doesn't specify oral administration. This partially meets the criterion.",yes,"The abstract does provide a clear diagnostic standard for MRONJ, defining it as ""exposed bone or bone that can be probed through an intraoral or extraoral fistula (or fistulae) in the maxillofacial region and that does not heal within 8 weeks."" This meets the criterion.",Exclude,"The abstract fails critical screening criteria by focusing on cancer patients and presenting a review-style discussion rather than an original research study. Multiple key requirements are not met, including specific dental procedure outcomes, follow-up documentation, and population selection criteria. The paper's broad overview of medication-related osteonecrosis of the jaw does not align with the systematic review's precise methodological standards.",0.1
Medication-related osteonecrosis of the jaw (MRONJ) treated with piezosurgery – case report and review of literature,"A. Perini, G. Oliveira, F. Seguin",10.21726/RSBO.V15I2.679,https://doi.org/10.21726/RSBO.V15I2.679,RSBO,1,2018,yes,"The subject is taking alendronate for osteoporosis, not cancer, meeting the population indication criterion.",maybe,"The abstract mentions the patient was on medication for ""more than 4 years"" before extraction, but doesn't clearly document the time from procedure to MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The study does report MRONJ following dental extraction, meeting this criterion.",no,"This is explicitly described as a case report, which is specifically excluded in the criteria.",no,"While the outcome is documented, the follow-up period is not specified.",yes,"The subject is 66 years old, meeting the age requirement of over 18 years old.",no,"This is a single case report with only 1 subject, which fails to meet the minimum requirement of 100 subjects.",yes,"The subject is taking oral bisphosphonate (alendronate), meeting the intervention type criterion.",no,The abstract does not explicitly mention diagnostic standards for MRONJ.,Exclude,"This case report fails multiple critical screening criteria, including being a single-subject study with no control group, which disqualifies it from systematic review inclusion. The research design as a case report, combined with insufficient sample size and lack of comprehensive diagnostic and follow-up documentation, renders the study non-compliant with the established screening requirements.",0.1
Medication-Related Osteonecrosis of the Jaw in Women with Breast Cancer: A Narrative Review,"Alina Čebatariūnienė, Niyosha Rasekhi",10.18103/mra.v12i12.6194,https://doi.org/10.18103/mra.v12i12.6194,Medical Research Archives,0,2024,no,"The study focuses on breast cancer patients taking antiresorptive medications, which explicitly violates the criterion requiring subjects to be osteoporosis patients only.",no,"No mention of time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract doesn't specifically mention any of the required dental procedures, so this criterion is not met.",no,"This appears to be a review article rather than a primary research study, which fails the criterion requiring specific study designs.",no,"While MRONJ is discussed, there's no mention of specific follow-up periods or incidence rates, so this criterion is not met.",maybe,"The abstract does not explicitly state the age range of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention the number of subjects, so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, the study also includes Denosumab (a non-bisphosphonate) and appears to focus on both, which violates the criterion requiring only oral bisphosphonates.",maybe,"While the abstract mentions ""clinical and radiographic manifestations,"" it doesn't explicitly state diagnostic standards, so the reasoning for this criterion is uncertain.",Exclude,"The abstract describes a review article focused on breast cancer patients taking antiresorptive medications, which fundamentally conflicts with the screening criteria requiring an osteoporosis patient population. Multiple critical screening requirements are not met, including study design, intervention type, and specific outcome documentation. The paper fails to align with the systematic review's methodological standards and would be excluded from further analysis.",0.1
Removal of a sequestrum by a patient with medication-related osteonecrosis of the jaw.,"M. Davies, A. Power, A. Kanatas",10.1016/j.bjoms.2017.06.019,https://doi.org/10.1016/j.bjoms.2017.06.019,British Journal of Oral and Maxillofacial Surgery,2,2017,no,"The abstract discusses both cancer and osteoporosis patients, and appears to be a general review rather than a specific study of osteoporosis patients. It explicitly mentions that ""Patients being treated for cancer are more likely to develop it than those being treated for osteoporosis alone,"" suggesting a mixed population.",no,"The abstract does not document specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, so no points were added for this criterion.",maybe,"The abstract mentions ""dentoalveolar surgery"" as a risk factor but doesn't specifically report MRONJ incidence following specific dental procedures.",no,This appears to be a review article or position paper rather than a primary research study. It references other studies and guidelines but doesn't present original research.,no,The abstract does not present specific MRONJ incidence data or follow-up periods.,maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any specific subject numbers, so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, the abstract discusses multiple types of antiresorptive and antiangiogenic agents, not exclusively oral bisphosphonates.",yes,"The abstract does mention diagnostic criteria for MRONJ, including exposed bone, duration >8 weeks, and no radiation history.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific study design, population indication, and intervention type requirements. While providing general information about medication-related osteonecrosis of the jaw, the text appears to be a review article that lacks the precise methodological details needed for systematic review inclusion. Key deficiencies include mixed patient populations, absence of specific subject numbers, and lack of clear outcome documentation.",1.4
Retrospective evaluation of pathologic fractures in medication related osteonecrosis of the jaw.,"Goknur Topaloglu Yasan, S. Adiloğlu, O. Koseoglu",10.1016/j.jcms.2021.03.007,https://doi.org/10.1016/j.jcms.2021.03.007,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,4,2021,no,"The study focuses on cancer patients (prostate and renal cell cancer), which explicitly fails this criterion as it excludes cancer patients.",maybe,The abstract mentions median antiresorptive usage of 24 months but doesn't document the specific time intervals required.,no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"While the abstract mentions ""dento-alveolar surgical procedures,"" it doesn't specifically report MRONJ incidence following the required procedures.",no,"The abstract describes this as a ""case series study,"" which explicitly fails this criterion as case series are excluded.",no,"While the study documents pathologic fractures, it doesn't clearly document MRONJ incidence after dental treatment, and the follow-up period is not specified.",yes,"The mean age of the subjects is 62.08 ± 13.6 years, which meets the requirement of being over 18 years old.",yes,"The study includes 116 patients, which meets the requirement of over 100 subjects for the medication group.",no,"The study mentions zoledronic acid (77.8%), which is an intravenous bisphosphonate, not an oral bisphosphonate, and therefore fails this criterion.",no,The abstract does not explicitly mention diagnostic standards for MRONJ.,Exclude,"The study fails critical screening criteria by focusing on cancer patients and using intravenous bisphosphonates, which deviate from the specified population and intervention requirements. Multiple methodological limitations, including a case series design and lack of clear diagnostic standards, further disqualify the research from meeting the systematic review's screening criteria. The paper's fundamental misalignment with the predefined inclusion parameters necessitates its exclusion.",0.1
WHAT ARE THE MAIN CLINICAL FEATURES OF ONCOLOGICAL PATIENTS WITH MRONJ? A SYSTEMATIC REVIEW AND META-ANALYSIS,"C. Calderipe, L. Ferreira, L. Schuch, M. Martins, F. Silveira, L. Abreu, A. Vasconcelos",10.1016/j.oooo.2023.03.083,https://doi.org/10.1016/j.oooo.2023.03.083,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2023,no,"The study specifically focuses on cancer patients taking anti-resorptive drugs, which explicitly violates the criterion requiring subjects to be osteoporosis patients, excluding cancer patients.",no,"The abstract mentions ""duration of ARD use"" but doesn't document the specific time intervals required.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract mentions ""traumatic events"" as the most common etiology but doesn't specifically detail the dental procedures listed in the criteria.",no,"This appears to be a systematic review/meta-analysis rather than one of the specified study designs (RCT, prospective cohort, retrospective cohort, or case-control).",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",yes,"The mean age of the subjects was 66.45±10.5 years, which meets the requirement of being over 18 years old.",yes,"The study includes 1,598 cases, which meets the requirement of having over 100 subjects in the medication group at the final statistical analysis stage.",maybe,"While the study includes bisphosphonates (77.3% of cases), it also includes denosumab (14.4%) and doesn't specify if all bisphosphonates were oral. The abstract doesn't clearly indicate if intravenous forms were excluded.",maybe,The abstract mentions MRONJ staging but doesn't specify the diagnostic standards used.,Exclude,"The study focuses on cancer patients taking anti-resorptive medications, which directly conflicts with the screening criteria requiring osteoporosis patients. Multiple methodological issues exist, including an inappropriate study design, lack of clear dental procedure documentation, and inclusion of non-bisphosphonate medications. These fundamental deviations from the specified screening criteria render the study unsuitable for inclusion in the systematic review.",0.1
Radiological manifestations and clinical findings of patients with oncologic and osteoporotic medication-related osteonecrosis of the jaw,"Jeong Won Shin, Jo-Eun Kim, K. Huh, W. Yi, M. Heo, Sam-Sun Lee, Soon-Chul Choi",10.1038/s41598-024-59500-x,https://doi.org/10.1038/s41598-024-59500-x,Scientific Reports,1,2024,no,"The study includes both osteoporosis patients and cancer patients, which violates the requirement for a pure osteoporosis population.",maybe,The study documents duration of medication usage (58.1 months for osteoporotic group) but doesn't clearly document the time interval between medication start and dental procedure.,no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract doesn't specify which dental procedures led to MRONJ, only mentioning that MRONJ developed ""after using antiresorptive medications.""",maybe,"The study appears to be a retrospective analysis of clinical and radiological features, which could qualify as a retrospective cohort study.",no,"While the study documents MRONJ incidence and outcomes, the follow-up period is not specified.",yes,"The study includes adults (mean age 75.8 years in osteoporotic group), meeting the age requirement.",yes,"The osteoporotic group has 120 patients, which exceeds the minimum requirement of 100 subjects.",maybe,"The abstract only mentions ""antiresorptive medications"" without specifying whether they are oral bisphosphonates, creating uncertainty about meeting this criterion.",no,"While the study mentions clinical and radiological features, it doesn't explicitly state its diagnostic standards for MRONJ.",Exclude,"The study fails critical screening criteria due to its mixed population of osteoporosis and cancer patients, which violates the requirement for a pure osteoporosis population. Uncertainties exist regarding medication type, dental procedures, and diagnostic standards, further compromising its alignment with the specified screening requirements. Despite having an adequate sample size and adult population, the fundamental population composition disqualifies the study from meeting the established criteria.",1.4
Medication-Related Osteonecrosis of the Jaws (MRONJ): Etiological Update,"G. Tenore, G. Palaia, G. Gaimari, O. Brugnoletti, L. Bove, R. L. Giudice, M. Mohsen, U. Romeo",10.14616/SANDS-2014-147152,https://doi.org/10.14616/SANDS-2014-147152,-,11,2014,no,"The abstract mentions both osteoporosis and cancer patients, indicating a mixed population, which explicitly fails this criterion.",no,"The abstract does not document any specific time intervals, so it fails this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While ONJ is discussed, the abstract does not specifically report MRONJ incidence following any dental procedures, so it fails this criterion.",no,"This appears to be a review article rather than any of the specified study designs, as the abstract discusses mechanisms and general information rather than presenting a specific study, which fails this criterion.",no,"The abstract does not present any specific follow-up period or documented MRONJ incidence, so it fails this criterion.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any specific number of subjects, so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, the abstract discusses multiple types of medications including Denosumab and antiangiogenic medications, not just oral bisphosphonates, which fails this criterion.",no,"The abstract does not mention any specific diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"The abstract fails multiple critical screening criteria, including study design, population indication, and intervention type, by presenting a review of medication-related osteonecrosis across mixed patient populations. It lacks specific details about subject size, diagnostic standards, and procedural outcomes, rendering it unsuitable for the specified research parameters. The text appears to be a general overview rather than a focused research study meeting the required methodological standards.",0.1
CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.,"A. Baba, T. Goto, H. Ojiri, M. Takagiwa, Chiho Hiraga, M. Okamura, S. Hasegawa, Yumi Okuyama, Nobuhiro Ogino, H. Yamauchi, Y. Kobashi, S. Yamazoe, Yohei Munetomo, T. Mogami, T. Nomura",10.1259/dmfr.20170323,https://doi.org/10.1259/dmfr.20170323,Dento maxillo facial radiology,52,2018,no,"The study includes both bisphosphonate and denosumab patients, which violates the criterion of excluding mixed populations. It also doesn't specify that all patients were taking medication for osteoporosis.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract doesn't mention any dental procedures leading to MRONJ. It focuses on radiological characteristics rather than procedure-related outcomes.,yes,"This appears to be a retrospective analysis of CT scans, which could qualify as a retrospective cohort study.",no,"While the study documents MRONJ cases, it doesn't mention follow-up period or incidence after dental treatment.",maybe,"The abstract doesn't explicitly state the age of subjects, but since it's studying ARONJ/MRONJ in Japanese patients, it can be reasonably assumed they are adults, though this isn't certain.",no,"The study includes 74 patients total, which is below the required 100 subjects for the medication group.",no,"The study includes both oral and intravenous bisphosphonates, as well as denosumab, which violates the criterion of only including oral bisphosphonates.",maybe,"The abstract mentions ""clinically diagnosed by inclusion criteria of ARONJ/MRONJ"" but doesn't specify the diagnostic standards.",Exclude,"The study fails multiple critical screening criteria, including insufficient sample size, mixed medication population, and lack of specific dental procedure documentation. While providing valuable insights into radiological characteristics of ARONJ/MRONJ, the research does not meet the systematic review's stringent requirements for population, intervention, and outcome reporting. The abstract's focus on imaging features rather than procedure-related outcomes further disqualifies it from meeting the predefined screening standards.",1.4
Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care.,"D. Hadaya, A. Soundia, E. Freymiller, T. Grogan, D. Elashoff, S. Tetradis, T. Aghaloo",10.1016/j.joms.2018.05.025,https://doi.org/10.1016/j.joms.2018.05.025,Journal of oral and maxillofacial surgery,36,2018,maybe,"The study focuses on patients with MRONJ who were taking antiresorptive medications, but it doesn't explicitly specify that these were all osteoporosis patients, and may include other indications.",no,"While the study mentions ""time of antiresorptive treatment,"" it doesn't specifically document the time intervals between medication start, dental procedures, and MRONJ onset.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract does not discuss dental procedures leading to MRONJ, but rather focuses on treatment of existing MRONJ.",yes,"The study is explicitly described as a ""retrospective cohort study,"" which meets the criteria.",no,"The study documents MRONJ outcomes, but these are treatment outcomes rather than incidence following dental procedures. The follow-up period is not explicitly stated.",maybe,"While the age of the subjects is not explicitly stated, the context and setting (University clinic) suggest this is an adult population, but this is not definitively confirmed.",yes,"The study includes 106 patients with 117 MRONJ lesions, meeting the minimum requirement of 100 subjects.",maybe,"The abstract mentions ""antiresorptive medications"" but doesn't specify whether these were exclusively oral bisphosphonates, which is a significant uncertainty.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails to meet several critical screening criteria, particularly around documenting dental procedures leading to MRONJ and specifying diagnostic standards. While the research includes an adequate sample size and uses a retrospective cohort design, significant uncertainties exist regarding medication type, patient population, and outcome documentation. The fundamental focus on MRONJ treatment rather than incidence following dental procedures represents a substantial deviation from the screening requirements.",1.4
Enhancing the Oral Rehabilitation and Quality of Life of Bisphosphonate-Treated Patients: The Role of Dental Implants,"Abdulaziz M Altalhi, Albatoul A Alsubaihi, Meshaael M Aldosary, L. Alotaibi, Nourah M Aldosariy, A. K. Alwegaisi, Jalal Y Alghadeer, Abdullah H Aljowayed",10.7759/cureus.46654,https://doi.org/10.7759/cureus.46654,Cureus,1,2023,maybe,"The abstract focuses on patients receiving bisphosphonate therapy, but doesn't explicitly exclude cancer patients or specify if it's purely for osteoporosis, so this is uncertain.",maybe,"The abstract mentions timing of implant placement ""before, during, or after BP treatment"" but doesn't document specific time intervals, so this is partially met.",yes,"The abstract mentions comparison to ""healthy patients,"" suggesting a control group exists.",yes,"The study does focus on dental implant procedures and BRONJ incidence, meeting this criterion.",no,"This is actually a systematic review, not a primary research study, which is a critical failure as it doesn't meet the required study design criteria.",maybe,"While the study examines BRONJ incidence, the follow-up period isn't specified, so this is uncertain.",maybe,"The abstract doesn't explicitly specify age requirements, so this is uncertain.",maybe,"The abstract doesn't mention sample size, so this is uncertain.",maybe,"The abstract mentions bisphosphonate therapy but doesn't specify if it's oral or intravenous, so this is uncertain.",maybe,"The abstract mentions BRONJ but doesn't specify diagnostic standards, so this is uncertain.",Exclude,"A systematic review examining bisphosphonate-related osteonecrosis of the jaw fails to meet critical screening criteria, particularly the requirement for a primary research study design. Multiple key screening elements remain uncertain, including population age, intervention specifics, and diagnostic standards, rendering the study non-compliant with the established screening requirements.",1.4
Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan,"Fang-Chun Liu, K. Luk, Yung-Chih Chen",10.1007/s00198-023-06818-3,https://doi.org/10.1007/s00198-023-06818-3,Osteoporosis International,10,2023,yes,"The study specifically focuses on osteoporotic patients, excluding cancer patients and mixed populations, which meets the population indication criterion.",no,"The study documents time intervals (2-year use, subsequent years), but does not specifically document the interval between medication start and dental procedures.",no,"The study does not include a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,The abstract does not specify which dental procedures were associated with ONJ incidence.,yes,"The study is a retrospective cohort study, which meets the acceptable study design criteria.",yes,"The study has a long follow-up period (up to 8 years) and clearly documents ONJ incidence, meeting this criterion.",yes,"The study includes patients aged over 40 years, which meets the requirement of subjects being over 18 years old.",yes,"The study includes 5,139 patients in the bisphosphonate group after initial screening, which exceeds the 100-subject requirement.",maybe,"The study includes bisphosphonates, but also includes denosumab (a non-bisphosphonate) as a comparison group. The bisphosphonate group is oral (implied by context), but this isn't explicitly stated.",no,The abstract does not mention specific diagnostic standards for MRONJ/ONJ.,Include,"A retrospective cohort study of osteoporotic patients comparing denosumab and bisphosphonates reveals significant methodological limitations for MRONJ research. While the study includes a large patient population and meets several screening criteria, it lacks critical details such as specific dental procedures, diagnostic standards for MRONJ, and a non-medicated control group. The research provides insights into medication-related jaw necrosis but falls short of comprehensive screening requirements.",2.7
SYSTEMATIC REVIEW OF CONE BEAM COMPUTED TOMOGRAPHY USE IN DIAGNOSIS OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW,"G. B. Badabaan, S. Singer, A. Creanga, M. Strickland",10.1016/j.oooo.2020.03.032,https://doi.org/10.1016/j.oooo.2020.03.032,"Oral surgery, oral medicine, oral pathology and oral radiology",2,2020,no,"The study included a mixed population of oncologic (52.4%) and osteoporosis (23.8%) cases, which does not meet the requirement for exclusively osteoporosis patients.",no,"There is no mention of the time intervals between medication start, dental procedures, and MRONJ, so no points were added for this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"The study mentions extraction as a precipitating event (75%), but this is reviewing other studies rather than reporting primary outcomes, so this criterion is not applicable.",no,"This is a review article analyzing other studies, not a primary research study of any of the required designs, so it does not meet this criterion.",no,"As a review article, the study does not have its own follow-up period, so this criterion is not applicable.",yes,"The mean age of the subjects was 58.5 years, which meets the requirement of being over 18 years old.",no,"The total number of cases analyzed was 168, but only 23.8% (approximately 40) were osteoporosis cases, which does not meet the requirement of over 100 subjects for the medication group.",maybe,"The study mentions ""antiresorptive medications"" and ""oral route (45%)"" but does not specify if all oral medications were bisphosphonates, so it is unclear if this criterion is met.",no,"The study mentions CBCT findings and staging, but this is a review of diagnostic methods rather than a primary study, so this criterion is not applicable.",Exclude,"This review article fails multiple screening criteria, including having a mixed patient population with cancer and osteoporosis cases, insufficient sample size for osteoporosis patients, and not being a primary research study. The lack of a control group, unclear intervention specifics, and absence of a defined follow-up period further disqualify it from meeting the systematic review requirements.",0.1
Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates,"Hogul Jeong, Jaejoon Hwang, Jeong-hee Lee, Young Hyun Kim, Ji Yeon Na, Sang-Sun Han",10.5624/isd.2017.47.1.45,https://doi.org/10.5624/isd.2017.47.1.45,Imaging Science in Dentistry,44,2017,yes,"The study specifically focuses on patients with osteoporosis taking oral bisphosphonates, with no mention of cancer patients or mixed populations.",no,"The abstract mentions ""duration of administration"" but doesn't explicitly document the time interval between medication start and dental procedure, or between procedure and BRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,The study specifically examines tooth extraction and reports BRONJ incidence following this procedure.,yes,This appears to be a retrospective cohort study based on clinical record review.,yes,The study clearly documents BRONJ incidence (3.44%) and mentions a healing period of more than 6 months.,yes,"While specific age ranges aren't mentioned, the study refers to ""osteoporotic patients"" which typically implies an adult population over 18 years old.",yes,"The study includes 320 patients in the medication group, well above the minimum requirement of 100.",yes,The study explicitly focuses on oral bisphosphonates for osteoporosis treatment.,maybe,"The abstract mentions ""radiographic investigation was carried out to obtain a more definitive diagnosis"" but doesn't explicitly detail the diagnostic standards.",Include,"A retrospective cohort study of 320 osteoporotic patients taking oral bisphosphonates, examining bisphosphonate-related osteonecrosis of the jaw (BRONJ) after tooth extraction, with a clear focus on specific patient populations and dental procedures. The research meets most screening criteria, including appropriate subject size, intervention type, and outcome documentation, though it lacks a control group and has some limitations in diagnostic standard details. The study provides valuable insights into BRONJ incidence and associated risk factors in patients with osteoporosis.",4.3
Clinical and radiologic treatment outcomes of implant presence tirggered-MRONJ: Systematic review of literature.,"M. Nisi, Stefano Gennai, Filippo Graziani, Antonio Barone, R. Izzetti",10.1111/odi.15066,https://doi.org/10.1111/odi.15066,Oral Diseases,1,2024,no,"The study includes a mixed population of 70% osteoporosis patients and 30% oncologic disease patients, which violates the criterion of only including patients taking medication for osteoporosis.",maybe,"The abstract mentions ""46.5 ± 33.2 months following implant placement"" but does not document the time from medication start.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,"The study focuses on implant-related MRONJ, which is one of the specified procedures.",no,"This is a systematic review, not a primary research study of the required designs (randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study).",maybe,"The study documents MRONJ incidence and treatment outcomes, but the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, but since the study is about osteoporosis patients, they are likely over 18 years old.",no,"The study includes a total of 111 patients, with 70% (77.7) being osteoporosis patients, which is below the required 100 subjects for the medication group.",no,"The abstract only mentions ""antiresorptive drugs"" generally, without specifying oral bisphosphonates, which is too vague to meet the criterion.",maybe,The abstract mentions staging (Stage II and III) but does not explicitly describe the diagnostic standards for MRONJ.,Exclude,"The systematic review fails multiple critical screening criteria, including a mixed patient population with cancer patients, insufficient sample size for osteoporosis patients, and a study design that does not meet the required methodological standards. Key disqualifying factors include the lack of specificity about medication type, absence of a control group, and the inclusion of patients with oncologic conditions, which fundamentally compromise the study's alignment with the predefined screening requirements.",1.4
Recurrence - Related Factors of Medication Related Osteonecrosis of the Jaw (MRONJ) ; a Retrospective study,"Kyoungseok Choi, Chulyoung Park, Ji Hyun Kim, Hye Jin Kim, J. Ryu, M. Kook, Hong-Ju Park, H. Oh, Seunggon Jung",10.22974/jkda.2023.61.12.002,https://doi.org/10.22974/jkda.2023.61.12.002,The Journal of The Korean Dental Association,0,2023,maybe,"The abstract does not explicitly state that the subjects are osteoporosis patients, and does not specify the exclusion of cancer patients, so the population indication is unknown.",maybe,"The abstract mentions ""duration of administration"" but does not provide specific time intervals, so the MRONJ latency is unknown.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study discusses surgical treatment and tooth extraction, which meets this criterion.",yes,"The abstract indicates that this appears to be a retrospective analysis of surgical outcomes, which could qualify as a retrospective cohort study.",maybe,"The study documents MRONJ recurrence rates and discusses post-operative outcomes, but does not specify the follow-up period length, so the outcome documentation is partially met.",maybe,"The abstract does not specify the age of the subjects, so the age of the population is unknown.",maybe,"The abstract does not mention the number of subjects, so the subject size is unknown.",maybe,"The abstract only mentions ""related medications"" without specifying oral bisphosphonates, so the intervention type is unknown.",maybe,"The abstract mentions ""alveolar bone necrosis"" but does not specify the diagnostic standards for MRONJ, so the diagnostic standard is unknown.",Include,"The abstract lacks critical details about population characteristics, medication specifics, and study design, making it challenging to definitively assess compliance with most screening criteria. While the study appears to be a retrospective analysis of MRONJ surgical outcomes, significant information gaps exist regarding patient demographics, intervention type, and diagnostic standards. Multiple key screening requirements remain unaddressed or incompletely documented.",2.7
Patients' osteometabolic control improves the management of medication-related osteonecrosis of the jaw.,"G. Colapinto, R. Volpi, G. Forino, V. Tricarico, M. De Benedittis, R. Cortelazzi, T. Testori, M. Del Fabbro",10.1016/j.oooo.2017.10.015,https://doi.org/10.1016/j.oooo.2017.10.015,"Oral surgery, oral medicine, oral pathology and oral radiology",9,2018,no,"The study includes a mixed population of both osteoporosis (53) and cancer patients (42), which explicitly violates this criterion.",yes,"The study documents a 3-month drug holiday before and after intervention, meeting this criterion.",yes,"The study explicitly includes a control group of 94 patients, meeting this criterion.",maybe,"While the study mentions ""surgically treated region,"" it doesn't specify which dental procedures were performed.",yes,"This is a prospective study with a control group, meeting this criterion.",yes,The study has a follow-up period of approximately 28 months and clearly documents ONJ outcomes.,maybe,"The abstract doesn't explicitly state the age of subjects. While it's likely they're adults given the conditions, this isn't confirmed.",no,"The medication group has 95 patients total, but only 53 are osteoporosis patients, which is below the required 100 subjects.",maybe,"The abstract only mentions ""anti-resorptive therapy"" without specifying if it's oral bisphosphonates. This is unclear.",no,"While the study discusses ONJ, it doesn't mention specific diagnostic standards.",Exclude,"The study fails key screening criteria due to a mixed patient population including cancer patients, insufficient sample size for osteoporosis patients, and lack of specific diagnostic standards for MRONJ. While the research demonstrates a prospective design with a control group, critical methodological limitations prevent it from meeting the required screening standards. The inclusion of cancer patients and unclear intervention type further compromise the study's alignment with the specified criteria.",1.4
[Risk assessment of medication-related osteonecrosis of the jaw in general dental practice].,"Anna Zurányi, Enikő Vasziné Szabó, Z. Tóth",10.1556/650.2019.31204,https://doi.org/10.1556/650.2019.31204,Orvosi Hetilap,10,2019,no,"The abstract discusses antiresorptive therapy but does not specifically focus on osteoporosis patients, mentioning ""oncological disease"" as a major risk factor, suggesting a mixed population.",no,The abstract does not document specific time intervals.,no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"The abstract mentions relevant procedures (dentoalveolar surgery, periodontal inflammation) but does not report specific MRONJ incidence rates.",no,This appears to be a literature review of risk factors rather than an original research study with one of the required designs.,no,The abstract does not mention follow-up periods or specific MRONJ incidence rates.,maybe,"The abstract does not explicitly specify age requirements, so the reasoning is uncertain.",maybe,"The abstract does not mention sample size, so the reasoning is uncertain.",no,"The abstract refers to ""antiresorptive therapy"" broadly and mentions intravenous treatment, which is explicitly excluded by the criteria.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The abstract describes a literature review on medication-related osteonecrosis of the jaw risk factors, which fundamentally fails to meet multiple critical screening criteria including study design, population specificity, and intervention type. Key disqualifying factors include a mixed patient population, broad antiresorptive therapy discussion, and lack of specific diagnostic standards or outcome documentation. The paper does not align with the required research parameters for inclusion.",1.4
Major aspects of the use of bisphosphonates for dental implants in patients with or without osteoporosis:,"Filipe Antônio Munhoz, Fabio Alarcon Idalgo, Silvio Antonio dos Santos Pereira, Alexandre Gomes Nunes, Elias Naim Kassis, Alvaro José Cicareli",10.54448/mdnt23s14,https://doi.org/10.54448/mdnt23s14,MedNEXT Journal of Medical and Health Sciences,0,2023,no,"The abstract mentions patients with osteoporosis, but also discusses patients ""with or without osteoporosis"", suggesting a mixed population. This fails to meet the criterion of focusing exclusively on osteoporosis patients.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"The abstract mentions dental implants but doesn't clearly report MRONJ incidence following specific procedures, so it partially meets this criterion.",no,"This is actually a systematic review, not a primary research study of the types specified in the criteria. This is a critical failure as systematic reviews are not included in the acceptable study designs.",no,"While MRONJ is discussed, the abstract doesn't clearly document incidence rates or specify follow-up periods.",maybe,"The abstract does not explicitly state the age of the subjects, so the reasoning is uncertain.",maybe,"The abstract does not specify the number of subjects in the included studies, so the reasoning is uncertain.",maybe,"The abstract mentions bisphosphonates, specifically alendronate sodium, but doesn't specify if it's exclusively oral administration, so it partially meets this criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review fails to meet multiple critical screening criteria, including study design, population specificity, and diagnostic standards for MRONJ. Key deficiencies include a mixed patient population, lack of clear diagnostic criteria, and absence of specific outcome documentation. The paper's methodological limitations render it unsuitable for inclusion in the systematic review.",1.4
Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw,"Hyo-jeong Son, Jin-Woo Kim, Sun-Jong Kim",10.1186/s40902-019-0210-8,https://doi.org/10.1186/s40902-019-0210-8,Maxillofacial plastic and reconstructive surgery,15,2019,no,"The study fails this criterion as it includes a mixed population - while some patients had osteoporosis, others had rheumatic arthritis, multiple myeloma, or cancer therapy history.",maybe,"The abstract mentions ""duration of intake"" but doesn't clearly document the specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study does report MRONJ incidence following relevant dental procedures (extraction, implant surgery, denture use).",no,"This appears to be a retrospective case series, which is explicitly excluded by the criteria.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified in the abstract.",yes,"The study includes patients with a mean age of 73.98 (range 45-97), which meets the requirement of subjects being over 18 years old.",no,"The study includes 86 patients total, which is below the required 100 subjects for the medication group.",maybe,"The abstract mentions bisphosphonates but doesn't specify if they were all oral. It also includes patients on other medications, making this criterion unclear.",no,"While the study mentions using ""clinical symptoms and radiographic images,"" it doesn't explicitly state diagnostic standards for MRONJ.",Exclude,"The study fails multiple critical screening criteria, including a mixed patient population with cancer patients, a sample size below 100, and a retrospective case series design that does not meet methodological requirements. While the research documents medication-related osteonecrosis of the jaw across various dental procedures, significant methodological limitations prevent it from meeting the established screening standards.",1.4
Clinical analysis of medication related osteonecrosis of the jaws: A growing severe complication in China,"Qizhang Wang, Ji-Yuan Liu, Shuqun Qi, Xuejuan Liao, D. Liu, Jian Pan",10.1016/j.jds.2017.12.003,https://doi.org/10.1016/j.jds.2017.12.003,Journal of Dental Sciences,14,2018,no,"The abstract does not specify that the subjects were taking medication for osteoporosis. It only mentions MRONJ patients generally, without clarifying the underlying condition.",no,"No information is provided about the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The study mentions tooth extraction as a risk factor, but does not clearly report MRONJ incidence following specific dental procedures.",maybe,"This appears to be a retrospective analysis of cases, but it's not clearly specified if it's a case-control study or just a case series.",maybe,"While the study documents outcomes, the follow-up period is not specified.",maybe,"While the abstract does not explicitly state the age of the subjects, the mention of ""advanced age"" as a risk factor suggests the population was likely adults, but this is not definitively confirmed.",no,"The study includes 201 ONJ patients, with 14.71% being MRONJ cases (approximately 29 MRONJ patients). This is well below the required 100 subjects.",no,The abstract does not specify the type of medication patients were taking. There is no mention of oral bisphosphonates.,no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study fails to meet multiple critical screening criteria, including insufficient sample size, lack of specification about medication type, absence of a control group, and unclear diagnostic standards for MRONJ. While the research provides insights into medication-related osteonecrosis of the jaw, it does not satisfy the comprehensive requirements for systematic review inclusion. Key methodological limitations prevent the study from qualifying under the established screening framework.",2.5
Risk factors associated with prognosis of patients with medication‐related osteonecrosis of the jaw,"Yoshiaki Tadokoro, T. Hasegawa, D. Takeda, Aki Murakami, Nanae Yatagai, Satomi Arimoro, E. Iwata, Izumi Saito, Junya Kusumoto, M. Akashi",10.1002/hed.27574,https://doi.org/10.1002/hed.27574,Head and Neck,1,2023,no,"The abstract mentions ""antiresorptive and/or antiangiogenic agents"" but does not specifically state these are for osteoporosis treatment. Elicit notes that the population appears to be a mixed population study, rather than specifically osteoporosis patients.",no,"The abstract does not provide any information about time intervals, so Elicit could not determine if this criterion was met.",no,"The abstract does not mention any control group, so Elicit could not confirm whether this criterion was met.",no,"While MRONJ is the focus, the abstract does not specify which dental procedures were studied, so Elicit could not determine if this criterion was met.",no,"The study design is not explicitly stated in the abstract, so Elicit could not determine if this criterion was met.",no,"While MRONJ is discussed, the abstract does not mention the follow-up period or specific documentation of incidence, so Elicit could not confirm if this criterion was met.",no,"The abstract does not provide any specific information about the age of the subjects, so Elicit could not determine if this criterion was met.",no,"The abstract does not provide any information about the sample size, so Elicit could not determine if this criterion was met.",no,"The abstract mentions ""antiresorptive and/or antiangiogenic agents"" but does not specify oral bisphosphonates. Elicit notes that the intervention appears to be broader than just oral bisphosphonates.",no,"The abstract does not mention any diagnostic standards for MRONJ, so Elicit could not confirm if this criterion was met.",Exclude,"The abstract lacks critical details about population, intervention, and study design, suggesting a mixed population study of medication-related osteonecrosis of the jaw that does not meet specific screening criteria. Multiple key requirements remain unaddressed, including subject age, specific medication type, sample size, and diagnostic standards, which significantly reduces the likelihood of study inclusion.",1.4
Medication-Related Osteonecrosis of the Jaws: A Literature Review,"Gyeong-Mi Kim, S. Moon, Jae-Seek You, Gyeong-Yun Kim, Ji-Su Oh",10.14476/jomp.2022.47.1.1,https://doi.org/10.14476/jomp.2022.47.1.1,Journal of Oral Medicine and Pain,0,2022,maybe,"While the title suggests the study is about medication-related osteonecrosis, Elicit could not confirm if it specifically focused on osteoporosis patients, as the provided abstract did not contain any actual content, only section headers.",no,"Elicit could not determine if the study documented the time interval between the start of medication and dental procedure, and between the dental procedure and MRONJ incidence, as the provided abstract did not contain any actual content, only section headers.",no,"Elicit could not determine if the study included a control group of patients not taking anti-resorptive medications, as the provided abstract did not contain any actual content, only section headers.",no,"Elicit could not determine the procedures and outcomes reported, as the provided abstract did not contain any actual content, only section headers.",no,"Elicit could not determine the study design, as the provided abstract did not contain any actual content, only section headers.",no,"Elicit could not determine if the study clearly documented MRONJ incidence after dental treatment and had a follow-up period of at least 6 months, as the provided abstract did not contain any actual content, only section headers.",no,"Elicit could not determine the age of the subjects, as the provided abstract did not contain any actual content, only section headers.",no,"Elicit could not determine the subject size, as the provided abstract did not contain any actual content, only section headers.",no,"Elicit could not determine the intervention type, as the provided abstract did not contain any actual content, only section headers.",no,"Elicit could not determine the diagnostic standards for MRONJ, as the provided abstract did not contain any actual content, only section headers.",Exclude,"Insufficient information is available to assess the screening criteria, as only section headers are present without actual abstract content. The lack of substantive details prevents verification of critical requirements such as population characteristics, study design, intervention type, and outcome documentation. Consequently, the paper cannot be definitively included or excluded based on the current information.",1.4
Three-dimensional clinical assessment for MRONJ risk in oncologic patients following tooth extractions,"Catalina Moreno Rabie, Rocharles Cavalcante Fontenele, Nicolly Oliveira Santos, Fernanda Nogueira Reis, T. Van den Wyngaert, R. Jacobs",10.1259/dmfr.20230238,https://doi.org/10.1259/dmfr.20230238,Dento maxillo facial radiology,2,2023,no,"The study specifically focuses on ""oncologic patients"" taking anti-resorptive drugs, which explicitly violates the criterion excluding cancer patients.",maybe,"The abstract mentions ""drug holidays"" but doesn't clearly document the time intervals between medication start, procedure, and MRONJ incidence.",yes,"The study explicitly includes a control group (n=50) matched for age, gender, and tooth extraction, which meets the criterion for including a control group.",yes,The study specifically looks at tooth extractions and reports MRONJ incidence.,yes,"The study is a retrospective case-control study, which is one of the accepted study designs.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified in the abstract.",maybe,"The abstract doesn't explicitly state the age requirement, though given it's a study of oncologic patients, they are likely adults. There is some uncertainty about whether the age criterion is met.",yes,"The study group has 47 patients (87 extractions), which meets the >100 subjects criterion when considering the number of procedures.",no,"The study includes both bisphosphonates and denosumab (a non-bisphosphonate), and doesn't specify if the bisphosphonates were oral. This violates the criterion requiring only oral bisphosphonates.",maybe,"The abstract doesn't explicitly mention diagnostic standards for MRONJ, though it does describe radiographic findings.",Exclude,"The study involves oncologic patients taking anti-resorptive medications, which directly conflicts with the screening criteria excluding cancer patients. Multiple methodological issues, including the inclusion of non-bisphosphonate medications and unclear diagnostic standards, further disqualify the research from meeting the specified screening requirements. Critical deviations from the predefined criteria render this study unsuitable for inclusion.",1.4
Osteometabolic profile: a possible tool in decision making for implant rehabilitation in patients under antiresorptive drugs,"G. Colapinto, F. Goker, M. Del Fabbro, T. Testori",10.32388/BCIX7F,https://doi.org/10.32388/BCIX7F,-,0,2021,maybe,"The abstract doesn't explicitly state that patients are taking medication for osteoporosis. It only mentions patients ""under risk of developing MRONJ"" which is insufficient.",maybe,"The abstract mentions ""within six months after implant insertions"" but doesn't document the time from medication start to procedure.",yes,"The study includes two groups: G1 (normal osteometabolic profile) and G2 (altered osteometabolic profile). While not explicitly stated as a control group, G1 serves as a comparison group.",yes,The study clearly reports MRONJ incidence following implant placement.,yes,"This appears to be a comparative study, likely a prospective cohort study based on the description.",yes,The study documents MRONJ incidence and has a follow-up period of at least 6 months.,maybe,"The abstract doesn't specify the age range of participants, so the age of the subjects is unclear.",yes,"The total sample size is 146 patients (92 in G1, 54 in G2), meeting the >100 subject requirement.",maybe,"The abstract doesn't specify the type of medication patients are taking, which is a critical missing piece of information.",no,The abstract doesn't mention specific diagnostic standards for MRONJ.,Include,"The study presents a comparative analysis of patients with different osteometabolic profiles undergoing implant-supported prosthesis, with significant MRONJ incidence in the altered profile group. While meeting several screening criteria like subject size and procedure documentation, critical information about medication type, patient age, and specific osteoporosis indication remains unclear. The research provides insights into MRONJ risk but lacks comprehensive details required for definitive screening assessment.",2.9
Anti-resorptive therapy in the osteometabolic patient affected by periodontitis. A joint position paper of the Italian Society of Orthopaedics and Traumatology (SIOT) and the Italian Society of Periodontology and Implantology (SIdP),"L. Landi, P. T. Leali, L. Barbato, A. Carrassi, N. Discepoli, P. Muti, G. Oteri, M. Rigoni, E. Romanini, C. Ruggiero, U. Tarantino, E. Varoni, N. Sforza, M. Brandi",10.1186/s10195-023-00713-7,https://doi.org/10.1186/s10195-023-00713-7,Journal of Orthopaedics and Traumatology,3,2023,yes,"The abstract specifically focuses on osteoporotic patients taking anti-resorptive therapy, excluding cancer patients, which meets the population indication criterion.",no,"The abstract does not document specific time intervals between the start of medication and dental procedure, and between the dental procedure and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The abstract mentions relevant procedures (tooth extraction, surgical dental procedures) and MRONJ as an outcome, which meets this criterion.",no,"This appears to be a consensus report/guideline rather than a primary research study, and it does not fit any of the required study designs, so it fails this criterion.",maybe,"While the abstract mentions MRONJ incidence (0.9%), it does not specify the follow-up period, so it only partially meets this criterion.",yes,"While the age of the subjects is not explicitly stated, the abstract refers to ""aging patients"", suggesting the population is over 18 years old.",no,"The abstract does not mention the sample size, which is a significant limitation.",maybe,"The abstract mentions ""anti-resorptive (AR) therapy"" but does not specify if it is oral bisphosphonates exclusively, so it only partially meets this criterion.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"This consensus report fails to meet key screening criteria, particularly the requirement for a primary research study design with a defined methodology. While addressing osteoporotic patients and medication-related jaw necrosis, the document lacks critical elements such as specific diagnostic standards, clear sample size, and a structured research approach. The abstract provides clinical guidance but does not qualify as a research study suitable for systematic review.",1.4
Anti-resorptive therapy and MRONJ. A survey of the Italian Society of Periodontology and Implantology.,"L. Landi, G. Oteri, L. Barbato, N. Discepoli, A. Carrassi, M. Rigoni, F. Cairo, R. Cavalcanti, A. Crea, R. Gianserra, N. M. Sforza",10.1111/odi.14907,https://doi.org/10.1111/odi.14907,Oral Diseases,1,2024,maybe,"The abstract mentions ""patients under anti-resorptive therapy for osteometabolic disorders"" but does not specifically exclude cancer patients or mixed populations.",no,No information about time intervals is provided.,no,"The abstract does not mention any control group, as this is a survey of practitioners rather than a clinical study.",no,"While the abstract mentions tooth extractions and implant surgery, this is in the context of practitioners' experiences, not as a study of outcomes.",no,"This is a survey study, which is not one of the accepted study designs (RCT, cohort, or case-control).",no,"While MRONJ cases are mentioned (63.2% of respondents encountered MRONJ patients), there is no systematic documentation of incidence or follow-up periods.",maybe,The abstract does not specify the age ranges of the patients.,no,"This is a survey of 451 practitioners, not a study of patients, and the actual patient numbers are not reported.",no,"The abstract only mentions ""anti-resorptive agents"" generally, without specifying oral bisphosphonates.",no,The abstract does not mention any diagnostic standards for MRONJ.,Exclude,"This survey of dental practitioners fails to meet the systematic review's screening criteria, lacking a clinical study design, specific patient population details, and comprehensive documentation of MRONJ outcomes. The research primarily explores practitioners' knowledge and experiences rather than providing a rigorous clinical investigation of medication-related jaw necrosis, rendering it unsuitable for inclusion in the review.",0.1
Risk Factors and Indices of Osteomyelitis of the Jaw in Osteoporosis Patients: Results from a Hospital-Based Cohort Study in Japan,"T. Yamazaki, M. Yamori, Shiro Tanaka, Keiichi Yamamoto, Eriko Sumi, Megumi Nishimoto-Sano, K. Asai, Katsu Takahashi, T. Nakayama, K. Bessho",10.1371/journal.pone.0079376,https://doi.org/10.1371/journal.pone.0079376,PLoS ONE,5,2013,yes,"The study specifically focuses on ""patients taking medications for osteoporosis"" and excludes cancer patients (except in interaction analysis), meeting this criterion.",no,"No information is provided about time intervals between medication start, dental procedures, and OMJ incidence.",no,"The abstract does not explicitly mention a control group of patients not taking anti-resorptive medications. While it is a retrospective cohort study, Elicit could not confirm if there was a proper control group.",no,"The abstract does not mention any specific dental procedures leading to OMJ, which is a critical missing element.",yes,"The abstract explicitly states this is a ""retrospective cohort study,"" which meets the criterion.",maybe,"While the study documents OMJ incidence, the follow-up period is not specified in the abstract.",maybe,"The study is focused on osteoporosis patients, which typically implies an adult population. However, Elicit noted that the age was not explicitly stated, so there is some uncertainty.",no,"The abstract does not specify the total number of subjects, which is a significant missing piece of information.",yes,"The study specifically mentions ""oral BPs"" (bisphosphonates) for osteoporosis treatment, meeting this criterion.",no,"The abstract refers to ""osteomyelitis of the jaw (OMJ)"" but does not specify diagnostic standards, which is a significant omission.",Include,"A retrospective cohort study on osteoporosis patients taking oral bisphosphonates reveals significant risk factors for osteomyelitis of the jaw, but lacks critical details about dental procedures, diagnostic standards, and follow-up periods. While the research provides insights into potential risk indices, it does not fully meet the comprehensive screening criteria for a definitive MRONJ investigation.",2.7
The importance of treating dental caries in the prevention of medication related osteonecrosis of the Jaw,"Mehmet Salık, E. Bakır",10.51271/jdse-0021,https://doi.org/10.51271/jdse-0021,Journal of Dental Sciences and Education,0,2023,no,"The abstract mentions both cancer patients and bone metabolism diseases, indicating a mixed population, which fails to meet the criterion requiring only osteoporosis patients.",no,"The abstract does not document any time intervals, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",yes,"The abstract mentions tooth extraction as a predisposing factor, which is one of the specified procedures, so it meets this criterion.",no,"This appears to be a review paper rather than an original research study with any of the specified designs, so it fails to meet the study design criterion.",no,"The abstract does not mention any specific follow-up period or clearly document MRONJ incidence, so it fails to meet this criterion.",maybe,"The abstract does not specify the age of the subjects, so the age of the population is unknown.",maybe,"The abstract does not mention the number of subjects, so the subject size is unknown.",no,"While bisphosphonates are mentioned, the abstract also includes denosumab (a non-bisphosphonate) and doesn't specify oral administration, so it fails to meet the criterion requiring only oral bisphosphonate medication.",no,"The abstract does not mention any diagnostic standards for MRONJ, so it fails to meet this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including study design, population specificity, and intervention type. It represents a review paper discussing medication-related osteonecrosis of the jaw, but lacks the required methodological rigor such as a control group, clear diagnostic standards, and specific outcome documentation. The mixed population and inclusion of non-bisphosphonate medications further disqualify it from meeting the established screening requirements.",0.1
Medication‐related to osteonecrosis of the jaw affect dental implant success? A systematic review,"M. D. P. R. Sanchez, Lamis Meorin Nogueira, R. M. Pinheiro, M. Haddad, Diana Lucia Bettin Yanez, Francy Osorio, J. Gale",10.1111/clr.478_13509,https://doi.org/10.1111/clr.478_13509,Clinical Oral Implants Research,0,2019,maybe,"The study focuses on patients taking bisphosphonates, but does not explicitly exclude cancer patients or specify if it's purely osteoporosis patients, so the population indication criterion is only partially met.",maybe,"The study documents the time interval between implant placement and MRONJ development (mean 42 months), but does not clearly document the time from medication start to procedure, so the MRONJ latency criterion is only partially met.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study focuses on dental implants, which is one of the specified procedures, and reports MRONJ incidence, so the procedure and outcome criterion is met.",no,"This is a systematic review, not a primary study of any of the specified designs, so the study design criterion is not met.",maybe,"The study reports MRONJ incidence after dental treatment, but the follow-up period is not explicitly stated, so the outcome documentation criterion is only partially met.",maybe,"The abstract does not explicitly state the age of the subjects, so the age criterion is unclear.",no,"The abstract mentions 106 cases of osteonecrosis across 8 studies, but does not specify the total number of patients in the medication group. Since this is a systematic review rather than a primary study, the subject size criterion is not met.",no,"The study includes both oral and intravenous bisphosphonates, which violates the criterion of only including oral bisphosphonates.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so the diagnostic standard criterion is not met.",Exclude,"The systematic review fails to meet multiple critical screening criteria, including lack of a clear control group, unspecified patient age, and inclusion of both oral and intravenous bisphosphonates. While the study addresses dental implant-related osteonecrosis, it does not conform to the required methodological standards for inclusion, particularly regarding study design and diagnostic specificity.",1.4
Associated systemic diseases and etiologies of medication-related osteonecrosis of the jaw: a retrospective study of 265 surgical cases,"Hoon-Je Chang, Minjoo Kim, K. Ahn",10.1186/s40902-023-00377-7,https://doi.org/10.1186/s40902-023-00377-7,Maxillofacial plastic and reconstructive surgery,5,2023,no,"The study includes a mixed population of patients with osteoporosis (n=127) and various cancers (breast cancer, multiple myeloma, prostate cancer), which fails the criterion as it specifically excludes cancer patients and requires a pure osteoporosis population.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study reports MRONJ incidence following specific dental procedures (extraction, implants, prosthesis irritation), so this criterion is met.",yes,"This is a retrospective review of surgical cases, which could be considered a retrospective cohort study, so this criterion is met.",maybe,"While the study documents MRONJ cases, it doesn't specify the follow-up period, so it is unclear if this criterion is met.",yes,"The study includes adults with average ages of 67.7 and 69.8 years for males and females respectively, which meets the criterion of age over 18 years old.",yes,"The study includes 127 osteoporosis patients, which meets the criterion of over 100 subjects in the medication group.",maybe,"The abstract does not specify whether the osteoporosis patients were taking oral bisphosphonates, as it only mentions ""bone targeting agents"" which could include various medications, so it is unclear if this criterion is met.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so this criterion is not met.",Exclude,"The study fails key screening criteria due to a mixed patient population including cancer patients, which violates the requirement for a pure osteoporosis cohort. Unclear medication specifics, lack of diagnostic standards, and absence of a control group further compromise the study's alignment with the screening requirements. Multiple critical methodological gaps prevent the study from meeting the established screening criteria.",1.4
The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.,"D. Yuh, Ting-Han Chang, Ren-Yeong Huang, W. Chien, F. Lin, E. Fu",10.1016/j.jdent.2014.05.001,https://doi.org/10.1016/j.jdent.2014.05.001,E -journal of dentistry,14,2014,no,"The study includes a mixed population of patients with osteoporosis, cancer, and diabetes, rather than focusing exclusively on osteoporosis patients, which does not meet the criterion.",no,"The abstract does not mention documenting the time intervals between medication start, dental procedure, and MRONJ incidence, which does not meet the criterion.",yes,"The study explicitly mentions including a qualified control group of patients not taking anti-resorptive medications, which meets the criterion.",yes,"The study specifically looks at tooth extraction and periodontal therapy as dental procedures, which meets the criterion.",yes,"The study is a retrospective cohort study using national database data, which meets the criterion for study design.",maybe,"While the study documents ONJ incidence, the follow-up period (2006-2008) is mentioned but not the specific follow-up duration for individual patients, which is unclear.",maybe,"The abstract does not explicitly state the age requirement, but the fact that it is a national-scale study of osteoporosis patients suggests the population is likely adults over 18 years old.",yes,"The study includes 958,136 subjects total, which exceeds the 100-subject requirement for the medication group.",no,"The study includes both oral and intravenous bisphosphonates, while the criteria specify only oral bisphosphonates, which does not meet the criterion.",yes,"The abstract mentions using three criteria modified from the definition proposed by the American Association of Oral and Maxillofacial Surgeons, which meets the criterion for diagnostic standard.",Include,"A comprehensive national-scale cohort study examining bisphosphonate-related osteonecrosis of the jaw reveals significant methodological limitations, including a mixed patient population and inclusion of both oral and intravenous bisphosphonates. While the research demonstrates robust sample size and appropriate diagnostic standards, critical screening criteria related to population specificity and intervention type were not fully met, potentially compromising the study's alignment with strict research parameters.",2.7
Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years.,"T. Mücke, H. Deppe, J. Hein, K. Wolff, D. Mitchell, M. Kesting, M. Retz, J. Gschwend, M. Thalgott",10.1016/j.jcms.2016.07.026,https://doi.org/10.1016/j.jcms.2016.07.026,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,44,2016,no,"The study specifically focuses on prostate cancer patients, not osteoporosis patients, which is a clear violation of the inclusion criteria.",no,"The abstract doesn't document the specific time intervals between medication start, dental procedures, and BRONJ incidence, so no points are added for this criterion.",no,"The study does not include a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,"The study reports BRONJ incidence following dental extractions, which is one of the specified procedures.",yes,"This is a prospective randomized study, which meets the acceptable study design criteria.",maybe,"The study has a follow-up period and clearly documents BRONJ incidence, though the exact follow-up duration isn't specified, so the reasoning is that it partially meets this criterion.",yes,"While not explicitly stated, the reasoning is that since the subjects are prostate cancer patients, they can be reasonably assumed to be over 18 years old.",yes,"The study includes 253 patients total, which exceeds the minimum requirement of 100 subjects.",no,"The study uses intravenous zoledronic acid, not oral bisphosphonates, which is a clear violation of the inclusion criteria.",maybe,"The abstract doesn't explicitly mention the diagnostic standards for BRONJ (though it uses the term BRONJ rather than MRONJ), so the reasoning is unclear.",Exclude,"The study focuses on prostate cancer patients receiving intravenous zoledronic acid, which fundamentally conflicts with the screening criteria requiring osteoporosis patients and oral bisphosphonates. Critical exclusion factors include the wrong patient population and intervention type, rendering the study ineligible for the systematic review despite meeting some secondary criteria like sample size and study design.",0.1
Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report,"J. K. Lee, Kyung-Wook Kim, Jin-Young Choi, S. Moon, Su-Gwan Kim, Chul-Hwan Kim, Hyeon-Min Kim, Yong-Dae Kwon, Yong-Deok Kim, Dong-Keun Lee, S. Min, I. Park, Young-Wook Park, M. Kook, Hong-Ju Park, J. Baek, Jun-Woo Park, T. Kwon",10.5125/jkaoms.2013.39.1.9,https://doi.org/10.5125/jkaoms.2013.39.1.9,Journal of the Korean Association of Oral and Maxillofacial Surgeons,50,2013,maybe,"The abstract doesn't explicitly state that all patients were taking medication for osteoporosis. It only mentions ""BP therapy"" without specifying the indication, which is a significant uncertainty.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and BRONJ incidence.",no,"The abstract does not mention a control group of patients not taking bisphosphonates, so no points were added for this criterion.",no,The abstract doesn't specify which dental procedures led to BRONJ cases.,maybe,"This appears to be a retrospective survey/case collection study, which could qualify as a retrospective cohort study, though the design isn't explicitly stated.",no,"While BRONJ incidence is documented, the follow-up period is not specified.",yes,"The study includes patients with ages ranging from 38-88 years, meeting the >18 years criterion.",yes,"The study includes 254 BRONJ cases, which exceeds the 100-subject requirement.",maybe,"The study includes both oral (majority) and intravenous (21.8%) bisphosphonates, which partially fails the criterion as it should only include oral bisphosphonates.",no,The abstract doesn't mention the diagnostic standards used for BRONJ.,Include,"The study presents a nationwide survey of bisphosphonate-related osteonecrosis of the jaw with a substantial sample size, but lacks critical details about diagnostic standards, specific dental procedures, and precise medication indications. While meeting some screening criteria like age range and subject size, the research includes both oral and intravenous bisphosphonates and fails to provide comprehensive information about patient selection and follow-up protocols.",2.8
"Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma","Petra Rugani, C. Walter, B. Kirnbauer, S. Acham, Yvonne Begus-Nahrman, N. Jakse",10.3390/dj4040032,https://doi.org/10.3390/dj4040032,Dental journal,31,2016,no,"The study specifically focuses on cancer patients (breast cancer, prostate cancer, and multiple myeloma) receiving antiresorptive therapy, which explicitly fails the criterion requiring subjects to be osteoporosis patients, not cancer patients.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,no,"This appears to be a systematic review/meta-analysis of 69 articles, not one of the specified study designs.",no,"While the study documents MRONJ prevalence, it does not mention follow-up period duration.",maybe,"The abstract does not explicitly state the age of subjects, though cancer patients are typically adults.",yes,"The study includes 29,437 patients total, well exceeding the 100-subject requirement.",no,"The abstract specifically mentions ""parenteral antiresorptive therapy"" (intravenous), which explicitly fails the criterion requiring oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients receiving parenteral antiresorptive therapy, which critically fails the screening criteria requiring osteoporosis patients and oral bisphosphonate medication. Multiple key methodological requirements were not met, including diagnostic standards, specific dental procedures, and follow-up documentation, rendering the study unsuitable for inclusion in the review.",0.1
Clinical and panoramic radiographic features of osteomyelitis of the jaw: A comparison between antiresorptive medication-related and medication-unrelated conditions,"J. Shin, Jo-Eun Kim, K. Huh, W. Yi, M. Heo, Sam-Sun Lee, Soon-Chul Choi",10.5624/isd.2019.49.4.287,https://doi.org/10.5624/isd.2019.49.4.287,Imaging Science in Dentistry,14,2019,no,"The abstract doesn't specify that patients were taking medication specifically for osteoporosis. It only mentions ""antiresorptive medication use"" which could include other conditions. This is a significant limitation.",no,"The abstract doesn't mention any time intervals between medication start, dental procedures, and MRONJ incidence.",maybe,"The study does compare medication-related OM (m-OM) vs conventional OM (c-OM), but it's not explicitly stated that the c-OM group didn't take any medications. This criterion is unclear from the abstract.",maybe,The study mentions extraction sockets but doesn't clearly establish the relationship between dental procedures and MRONJ incidence.,yes,"The study is described as a retrospective review, which meets this criterion.",no,"While the study documents imaging features, it doesn't clearly specify follow-up periods or MRONJ incidence rates.",yes,"The study meets this criterion as the average age is 66.8±14.9 years, clearly over 18.",yes,"The study includes 364 total patients, with 44.2% (approximately 161 patients) in the medication group, meeting the >100 subjects criterion.",no,"The abstract only mentions ""antiresorptive medication"" without specifying oral bisphosphonates. This is a significant limitation as it could include other types of medications.",no,"While the study discusses osteomyelitis and imaging features, it doesn't explicitly mention diagnostic standards for MRONJ specifically.",Include,"The study partially meets screening criteria with an appropriate age range and retrospective design, but lacks specificity regarding osteoporosis medication, oral bisphosphonates, and clear MRONJ diagnostic standards. Significant limitations include unclear patient population, absence of precise medication type, and incomplete documentation of dental procedure outcomes and follow-up periods. The research appears more focused on osteomyelitis than medication-related osteonecrosis of the jaw, creating substantial screening challenges.",2.7
Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.,"J. Laimer, Martin Hechenberger, D. Müller, Benjamin Walch, A. Kolk, D. Schnabl, M. Schomaker, E. Bruckmoser",10.2217/fon-2020-1240,https://doi.org/10.2217/fon-2020-1240,Future Oncology,1,2021,no,"The study specifically focuses on patients with ""solid tumors with osseous metastases or multiple myeloma"", which explicitly fails the criterion as it excludes cancer patients.",no,"The abstract doesn't document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"While the study mentions dental procedures (extractions and surgery), it appears to be focused on screening before treatment rather than reporting MRONJ incidence after procedures.",yes,"The study is described as prospective, which meets this criterion.",no,"The study doesn't appear to document MRONJ incidence after dental treatment, as it's focused on pre-treatment screening. No follow-up period is mentioned.",maybe,"The abstract does not explicitly state the age of the subjects, but given it's a cancer patient population, they are likely adults. However, this is not explicitly confirmed.",yes,"The study includes 119 subjects, which meets the criterion of over 100 subjects.",maybe,"The abstract only mentions ""antiresorptive therapy"" generally and doesn't specify oral bisphosphonates, so it's unclear if other types of medications are included.",no,The abstract doesn't mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients with osseous metastases, which immediately disqualifies it from meeting the population indication criteria. Multiple screening requirements were not met, including lack of clear diagnostic standards, absence of MRONJ incidence documentation, and no specification of oral bisphosphonate medication. The research appears to be a pre-treatment screening study rather than an outcome-focused investigation, further compromising its alignment with the screening criteria.",1.4
Medication-Related Osteonecrosis of the Jaw: Update and Future Possibilities,"J. Borke, J. Elo, H. Sun, Shirley Y. Kang",10.1080/19424396.2018.12222022,https://doi.org/10.1080/19424396.2018.12222022,Journal - California Dental Association,0,2018,no,"The abstract mentions that the study included both osteoporosis and cancer patients, which fails the criterion as it includes a mixed population.",no,"The abstract does not provide any information about the time intervals between the start of medication, dental procedures, and MRONJ incidence, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention any control group, so Elicit could not confirm whether this criterion was met.",no,"While the abstract discusses MRONJ, it does not mention any specific dental procedures or their relationship to MRONJ incidence, so Elicit could not confirm whether this criterion was met.",no,"The abstract indicates that this is a review article rather than an original research study, which fails the criterion as it does not meet the required study designs.",no,"The abstract does not mention any specific follow-up period or documentation of MRONJ incidence, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not specify the age requirements of the study population, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not provide any information about the sample size of the study, so Elicit could not confirm whether this criterion was met.",no,"The abstract only mentions ""antiresorptive and antiangiogenic medications"" broadly, without specifying oral bisphosphonates, which is too general to meet the criterion.",no,"The abstract does not mention any diagnostic standards for MRONJ, so Elicit could not confirm whether this criterion was met.",Exclude,"This review article fails multiple screening criteria, including the requirement for a specific study design and a focused population of osteoporosis patients. The manuscript discusses medication-related osteonecrosis of the jaw across mixed patient populations and lacks the detailed methodological specifications needed for systematic review inclusion.",0.1
Comparison of the Effect of Oral Versus Intravenous Bisphosphonate Administration on Osteoclastogenesis in Advanced-Stage Medication-Related Osteonecrosis of the Jaw Patients,"Hye-Won Kim, Min-woo Lee, Jung-Hwan Lee, M. Kim",10.3390/jcm10132988,https://doi.org/10.3390/jcm10132988,Journal of Clinical Medicine,2,2021,yes,"The study specifically focuses on osteoporosis patients, excluding cancer patients.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract mentions ""surgery for the treatment of stage III MRONJ"" but doesn't clearly specify if this was following one of the required dental procedures.",yes,"The study is described as a retrospective study, which is an acceptable design.",maybe,"While MRONJ is documented, the follow-up period is not specified.",yes,"The abstract does not explicitly state the age of subjects, but since they are osteoporosis patients, it can be reasonably assumed that they are over 18 years old.",no,"The study only includes 20 total subjects (10 oral BP, 10 IV BP), which is well below the required 100 subjects per group.",no,"The study includes both oral and intravenous bisphosphonates, which violates the criterion requiring only oral bisphosphonates.",maybe,"The abstract mentions ""stage III MRONJ"" but doesn't explicitly describe the diagnostic standards used.",Exclude,"The study fails to meet critical screening criteria, particularly the required sample size of 100 subjects per group, with only 20 total participants. Additionally, the research includes both oral and intravenous bisphosphonates, which violates the specified intervention type, and lacks clear documentation of dental procedures and follow-up periods. These significant methodological limitations substantially reduce the study's alignment with the predefined screening requirements.",1.4
Prognosis of Medication-Related Osteonecrosis of the Jaw with Surgical Treatment,"E. Kobayashi, Haruka Takahashi, Kensuke Igarashi, Hiroki Katagiri, M. Haga-Tsujimura, I. Ogura, K. Nakahara, A. Tanaka",10.2485/jhtb.31.39,https://doi.org/10.2485/jhtb.31.39,Journal of Hard Tissue Biology,0,2022,no,"The study includes a mixed population of both osteoporosis patients (40) and cancer patients (46), which explicitly fails the criterion requiring only osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract focuses on surgical treatment of MRONJ rather than dental procedures leading to MRONJ, and it doesn't report MRONJ incidence following specific dental procedures.",yes,"The study is described as retrospective, which meets the criterion as a retrospective cohort study.",no,"While the study documents outcomes of surgical treatment, it doesn't clearly document MRONJ incidence after dental treatment or specify a follow-up period.",yes,"The study includes adults (average age 78.8 years for osteoporosis patients, 67.7 years for cancer patients), which meets the criterion for population age.",no,"The osteoporosis group has only 40 patients, which is below the required 100 subjects, and therefore fails this criterion.",maybe,"The abstract does not specify whether the patients were taking oral bisphosphonates or other medications, so this information is missing.",maybe,"While the study mentions staging (Stage 2, Stage 3), it doesn't explicitly describe the diagnostic standards used for MRONJ.",Exclude,"The study fails critical screening criteria due to a mixed patient population including cancer patients and an insufficient sample size of osteoporosis patients. Key methodological limitations include lack of clarity on medication type, diagnostic standards, and specific dental procedures leading to MRONJ. The research does not meet the required systematic review standards for inclusion.",1.4
A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates,"Hanna Sobczak-Jaskow, B. Kochańska, B. Drogoszewska",10.3390/medicina59061073,https://doi.org/10.3390/medicina59061073,Medicina,4,2023,no,"The study specifically focuses on oncological patients, which is explicitly excluded in the criteria.",no,"No information about time intervals between medication start, dental procedures, and MRONJ incidence is provided.",yes,"The study includes a control group of 32 persons without oncological history and without antiresorptive therapy, which meets the requirement for a control group.",no,"The abstract does not mention any specific dental procedures leading to MRONJ, and instead focuses on oral cavity status and saliva composition.",yes,"The study is a retrospective case-control study, which meets the criteria for study design.",maybe,"While MRONJ is documented, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, so there is uncertainty about whether the population meets the age requirement.",no,"The study includes only 49 patients total (29 with MRONJ, 20 without), which is well below the required 100 subjects for the medication group.",maybe,"While the study mentions bisphosphonates, it does not specify whether they are oral or intravenous, creating uncertainty about the intervention type.",yes,"The abstract mentions assessment of MRONJ localization and stage, indicating that diagnostic standards were used.",Exclude,"The study fails key screening criteria due to its focus on oncological patients and small sample size of 49 participants, which does not meet the required 100-subject threshold. Critical exclusion criteria were triggered, particularly the population indication and subject size requirements, rendering the study ineligible for systematic review. Multiple other screening criteria were either unclear or not met, further disqualifying the research from inclusion.",1.4
Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws.,"C. Klingelhöffer, F. Zeman, J. Meier, T. Reichert, T. Ettl",10.1016/j.jcms.2016.08.001,https://doi.org/10.1016/j.jcms.2016.08.001,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,48,2016,maybe,"The study focuses on patients with MRONJ who were taking antiresorptive therapy, but it does not explicitly exclude cancer patients or specify if it is purely osteoporosis patients, creating uncertainty.",maybe,"The abstract mentions ""preoperative duration"" but does not document the specific time intervals required.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The study focuses on surgical treatment of existing MRONJ rather than MRONJ incidence following dental procedures, which is a critical mismatch with the inclusion criteria.",yes,"The study is described as a ""prospective design"", which meets the criteria for study design.",no,"While the study has a follow-up period (55 weeks), it documents surgical outcomes rather than MRONJ incidence after dental procedures.",maybe,"The abstract does not explicitly state the age of the subjects, but it is likely that they are adults since the study is about MRONJ in patients taking antiresorptive therapy.",no,"The study includes 40 patients with 76 surgical interventions, which is below the required 100 subjects threshold.",no,"The abstract only mentions ""antiresorptive therapy"" without specifying if it is oral bisphosphonates or other types of medications.",maybe,"The abstract mentions MRONJ staging (I, II, III) but does not explicitly state the diagnostic standards used.",Exclude,"The study fails to meet multiple critical screening criteria, including insufficient sample size, unclear medication type, and a focus on surgical treatment of existing MRONJ rather than incidence after dental procedures. Key methodological requirements such as diagnostic standards, population specification, and outcome documentation are not fully addressed, rendering the study non-compliant with the established screening protocol.",1.4
Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw Dental Clinical Guidance,Michele West,-,-,-,3,2017,no,"While the abstract mentions patients prescribed bisphosphonates, it appears to be a guidance document rather than a research study with specific patient populations, so this criterion is not met.",no,"No information about time intervals is provided, so this criterion is not met.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While dental procedures are mentioned generally (""routine dental treatment""), specific procedures and MRONJ incidence are not reported, so this criterion is not met.",no,"This is clearly a guidance document, not a research study of any of the specified types, so this criterion is not met.",no,"As this is a guidance document, it does not report specific MRONJ incidence or follow-up periods, so this criterion is not met.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is unknown.",no,"No subject numbers are mentioned as this appears to be a guidance document rather than a research study, so this criterion is not met.",no,"The abstract mentions bisphosphonates but appears to be about general guidance rather than a specific study of oral bisphosphonate patients, so this criterion is not met.",no,"While MRONJ is mentioned, specific diagnostic standards are not detailed in the abstract, so this criterion is not met.",Exclude,"This guidance document fails to meet the systematic review's screening criteria, as it is not a research study with a defined patient population, intervention, or outcome measurements. The abstract lacks essential research elements such as control groups, subject size, specific intervention details, and documented MRONJ incidence, rendering it unsuitable for inclusion in the review.",0.1
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.,"P. Vestergaard, Kristoffer Schwartz, L. Rejnmark, L. Mosekilde, E. Pinholt",10.1016/j.joms.2011.02.093,https://doi.org/10.1016/j.joms.2011.02.093,Journal of oral and maxillofacial surgery,33,2012,yes,"The study specifically focuses on patients taking medication for osteoporosis, excluding other conditions. The control group is clearly defined as not taking osteoporosis medications.",no,"No information is provided about the time intervals between medication start, dental procedures, and jaw events.",yes,"The study explicitly includes a control group of ""a random sample of the Danish population"" who had not been prescribed oral BPs, which meets the criterion and adds 0.2 points.",no,The abstract doesn't mention any specific dental procedures leading to the jaw events.,yes,"This is a historical cohort study, which meets the acceptable study design criteria.",maybe,"While the study documents jaw events, it's unclear if there's a specific follow-up period of at least 6 months.",maybe,"The abstract doesn't explicitly state the age requirement, but given it's a general population study of osteoporosis patients, it's likely these are adult patients. However, this is uncertain.",yes,"The study includes 103,562 index subjects (medication group), well exceeding the 100-subject requirement.",yes,The study specifically focuses on oral bisphosphonates (alendronate and etidronate) for osteoporosis treatment.,no,"The abstract mentions ""inflammatory jaw events"" including osteomyelitis, osteitis, periostitis, or sequestrum, but doesn't specifically mention MRONJ or its diagnostic standards.",Include,"A large-scale historical cohort study examining inflammatory jaw events in osteoporosis patients taking oral bisphosphonates, with a robust sample size and appropriate control group. While meeting several key screening criteria, the research lacks specific details about MRONJ diagnostic standards, dental procedure outcomes, and precise follow-up periods. The study's broader focus on inflammatory jaw events rather than MRONJ specifically creates potential limitations for systematic review inclusion.",2.7
Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction,"C. Moreno-Rabié, Laurence Lapauw, H. Gaêta-Araujo, André Ferreira-Leite, W. Coucke, T. Van den Wyngaert, R. Jacobs",10.1038/s41598-022-15254-y,https://doi.org/10.1038/s41598-022-15254-y,Scientific Reports,14,2022,no,"The study specifically focuses on oncologic patients, which is explicitly excluded by the criteria. This is a critical failure.",maybe,"The abstract mentions ""longer ARD treatment"" but doesn't clearly document the specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking ARDs, so no points are added for this criterion.",yes,"The study clearly focuses on tooth extraction and MRONJ incidence, meeting this criterion.",yes,"The study is described as a ""retrospective longitudinal cohort study,"" which meets the criteria.",maybe,"The study documents MRONJ incidence after dental treatment, but the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, but since they are oncologic patients, they are likely adults. However, this is uncertain without explicit confirmation.",no,"The study includes 77 patients with 218 extractions, which is below the required 100 subjects for the medication group.",maybe,"The abstract only mentions ""antiresorptive drugs (ARDs)"" generally, without specifying if they are oral bisphosphonates. This is unclear and potentially includes other types of ARDs.",no,"While the study documents MRONJ cases, it doesn't explicitly state its diagnostic standards.",Exclude,"The study fails critical screening criteria by focusing on oncologic patients, which is explicitly excluded, and having a sample size below the required 100 subjects. Uncertainty exists around the specific type of antiresorptive drugs and lack of clarity on diagnostic standards and follow-up period. These significant deviations from the screening requirements render the study unsuitable for inclusion.",1.4
The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw.,"G. Topaloglu, O. Koseoglu, Ç. Karaca, K. Kosemehmetoglu",10.1016/j.jcms.2017.05.003,https://doi.org/10.1016/j.jcms.2017.05.003,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,10,2017,maybe,"The abstract mentions patients with a ""history of bisphosphonate use"" but does not explicitly state they were taking it for osteoporosis. It also does not exclude cancer patients, so the population indication is uncertain.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study specifically looks at tooth extraction procedures and MRONJ incidence, which meets the procedure and outcome criteria.",yes,"The study is described as a ""prospective study,"" which meets the criteria for study design.",maybe,"While the study documents MRONJ incidence (6% in 3 patients), the follow-up period is not specified, so the outcome documentation is uncertain.",yes,"The mean age of the subjects is 57.4 ± 12.1 years, which meets the requirement of being over 18 years old.",no,"The study only includes 50 patients, which is well below the required 100 subjects for the medication group at the final statistical analysis stage.",maybe,"The abstract mentions bisphosphonate use but does not specify if it is oral or intravenous, so the intervention type is uncertain.",yes,"The study mentions using CTX values and histopathological findings for diagnosis, including Stage 0 MRONJ classification, which meets the diagnostic standard for MRONJ.",Include,"The study involves 50 patients with bisphosphonate use undergoing tooth extraction, but falls short of key screening requirements, particularly the minimum sample size of 100 subjects. While the research design and diagnostic approach are sound, critical uncertainties exist regarding patient population specifics, medication type, and follow-up period. The small sample size and lack of a control group significantly limit the study's screening compliance.",2.7
Osteonecrosis of the jaw in patients treated with oral and intravenous bisphosphonates: experience in Sweden.,"F. Hallmer, T. Bjørnland, Anders Nicklasson, J. Becktor, G. Andersson",10.1016/j.oooo.2014.05.006,https://doi.org/10.1016/j.oooo.2014.05.006,"Oral surgery, oral medicine, oral pathology and oral radiology",28,2014,no,"The study includes both osteoporosis and cancer patients, which violates the requirement for a non-mixed population.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract mentions ""inciting factors"" but does not specifically detail which dental procedures were involved.",yes,"This appears to be a retrospective cohort study based on patient records, which meets the criterion.",maybe,"The study documents BRONJ incidence and treatment outcomes, but the follow-up period is not specified.",yes,"While not explicitly stated, the study is of osteoporosis patients, so it can be reasonably assumed that the subjects are over 18 years old.",maybe,"The study identified 341 patients total, with 55 having BRONJ. However, the number of patients in the osteoporosis group specifically is not known, creating uncertainty about meeting the 100-subject requirement.",no,"The study includes both oral and intravenous bisphosphonates, and specifically separates these groups, which violates the requirement for only oral bisphosphonates.",maybe,"The abstract mentions searching for specific conditions including ""unspecified inflammation, osteomyelitis, osteonecrosis due to drugs, and other osteonecrosis"" but does not clearly state the diagnostic standards for BRONJ.",Include,"The study fails key screening criteria by including a mixed population of osteoporosis and cancer patients, and utilizing both oral and intravenous bisphosphonates. Multiple uncertain elements exist regarding diagnostic standards, dental procedures, and follow-up periods, which further complicate its alignment with the specified screening requirements. The presence of these critical deviations significantly reduces the study's suitability for inclusion.",2.5
Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.,"Jorge Chaurand-Lara, Laura Pacheco-Ruiz, José L. Trejo-Campos, Jose Alfredo Facio-Umaña, Josué Mora-Pérez",10.24875/CIRU.18000661,https://doi.org/10.24875/CIRU.18000661,Cirugía y Cirujanos,5,2019,no,"The study focuses on patients with ""metastatic bone disease due to solid tumors"" rather than osteoporosis patients, which is a critical exclusion criterion.",maybe,"The study does document time intervals for medication use before MRONJ (25 months for zoledronic acid, 16 months for denosumab), but doesn't specify the time from dental procedure to MRONJ.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract doesn't mention any specific dental procedures leading to MRONJ.,yes,"The abstract explicitly states it's a ""retrospective cohort study,"" which meets this criterion.",maybe,"While the study documents MRONJ incidence (3.5%), it doesn't specify the follow-up period.",yes,"The abstract doesn't explicitly state the age of subjects, but given it's a study of patients with metastatic bone disease, we can reasonably assume they are adults.",yes,"The study includes 802 patients total (699 bisphosphonates + 103 denosumab), which exceeds the 100-subject requirement.",no,"The study includes both bisphosphonates and denosumab (a non-bisphosphonate), and doesn't specify if the bisphosphonates were oral.",no,The abstract doesn't mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on patients with metastatic bone disease, which critically fails the screening criteria requiring an osteoporosis patient population. Multiple other screening criteria were not met, including lack of specified diagnostic standards for MRONJ, absence of dental procedure details, and inclusion of non-bisphosphonate medications. These fundamental deviations render the study unsuitable for the systematic review.",1.4
Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment,"Seung-hun Lee, So-Young Choi, M. Bae, T. Kwon",10.1186/s40902-021-00310-w,https://doi.org/10.1186/s40902-021-00310-w,Maxillofacial plastic and reconstructive surgery,4,2021,no,"The study includes both osteoporosis patients and cancer patients, which violates the criterion requiring a pure osteoporosis population.",maybe,"The study documents duration of bisphosphonate medication but does not clearly document the time interval between medication start and dental procedure, or between procedure and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract does not specify which dental procedures led to MRONJ, only mentioning ""surgeries"" in general.",yes,"The study is described as a retrospective study, which is an acceptable design.",maybe,"While the study documents MRONJ outcomes, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, but since the study is on osteoporosis patients, it can be reasonably assumed that the subjects are adults over 18 years old.",yes,"The study includes 251 oral bisphosphonate patients, which exceeds the minimum requirement of 100 subjects.",no,"The study includes both oral and intravenous bisphosphonates, and specifically compares them, which violates the criterion requiring only oral bisphosphonates.",maybe,The abstract does not explicitly mention the diagnostic standards used for MRONJ.,Exclude,"The study fails critical screening criteria by including a mixed population of osteoporosis and cancer patients, and by examining both oral and intravenous bisphosphonates. Multiple key methodological details remain uncertain, including diagnostic standards, specific dental procedures, and follow-up period. These significant deviations from the required screening parameters render the study unsuitable for inclusion.",1.4
The impact of surgical intervention and antibiotics on MRONJ stage II and III - Retrospective study.,"M. Zirk, M. Kreppel, Johannes Buller, Julij Pristup, F. Peters, T. Dreiseidler, M. Zinser, J. Zöller",10.1016/j.jcms.2017.05.027,https://doi.org/10.1016/j.jcms.2017.05.027,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,33,2017,no,"The abstract mentions both ""metastatic bone disease and osteoporosis"" as indications for bisphosphonates, indicating a mixed population, which fails to meet the criterion requiring only osteoporosis patients.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract focuses on surgical interventions for MRONJ treatment rather than dental procedures leading to MRONJ. It doesn't report MRONJ incidence following specific dental procedures.,yes,"The study is described as a ""retrospective study,"" which meets the criterion.",no,"While the study has a follow-up period of 12 months, it focuses on treatment outcomes rather than MRONJ incidence after dental procedures.",maybe,"The abstract doesn't explicitly state the age of subjects, though given it's a study of MRONJ patients, they are likely adults.",yes,"The study includes 143 patients, which meets the criterion of >100 subjects.",maybe,"The abstract doesn't specify whether the bisphosphonates were oral or intravenous, and doesn't exclude non-bisphosphonate medications.",maybe,"The abstract mentions MRONJ stages II and III, suggesting some diagnostic standard, though it doesn't explicitly detail the criteria.",Exclude,"The study involves a mixed patient population with metastatic bone disease and osteoporosis, which deviates from the specified screening criteria requiring only osteoporosis patients. While the research includes a sufficient sample size and follows a retrospective design, it fails to meet key requirements such as documenting dental procedure-related MRONJ incidence and clearly specifying medication type. The focus on treatment outcomes rather than procedure-related MRONJ development further disqualifies the study from meeting the established screening criteria.",1.4
Medication-related osteonecrosis of the jaw: A multifaceted diagnostic challenge. Mini review.,"Roxana Bonachea, J. Katz",-,-,American Journal of Dentistry,0,2022,no,"While the abstract mentions bisphosphonates, it also discusses other medications (RANKL ligand inhibitors and antiangiogenic drugs) and appears to be a general review rather than a study of a specific population, so it fails this criterion.",no,"No specific time intervals are documented in the abstract, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",maybe,"While dental procedures are mentioned (extractions, bone manipulations), this is in the context of risk factors rather than reporting specific outcomes, so it partially meets this criterion.",no,"This appears to be a ""mini review"" rather than any of the required study designs, so it fails this criterion.",no,"While MRONJ is discussed, this is a review paper and doesn't document specific incidence rates or follow-up periods, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the age requirement is unknown.",maybe,"No specific subject numbers are mentioned in the abstract, so the subject size requirement is unknown.",no,"The abstract discusses multiple types of medications, not just oral bisphosphonates, so it fails this criterion.",maybe,"The abstract mentions that conventional radiographs are not sufficient and that three-dimensional modalities are important, but it doesn't specify exact diagnostic standards, so it partially meets this criterion.",Exclude,"This mini review fails multiple critical screening criteria, including the required study design, specific medication focus, and outcome documentation. The paper discusses medication-related osteonecrosis of the jaw broadly but lacks the precise methodological elements needed for systematic review inclusion. Consequently, the abstract does not meet the established screening requirements for the research study.",0.1
Characteristic Multimodal Imaging of Medication-Related Osteonecrosis of the Jaw: Comparison Between Oral and Parenteral Routes of Medication Administration,"I. Ogura, Yoshihiko Sasaki, A. Kameta, Mikiko Sue, Takaaki Oda",10.12659/PJR.902513,https://doi.org/10.12659/PJR.902513,Polish Journal of Radiology,18,2017,no,"The abstract does not specify whether patients were taking medication for osteoporosis or cancer. It only mentions ""medication-related"" osteonecrosis, which could include cancer patients. This is a major limitation.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract does not mention any dental procedures leading to MRONJ. It focuses on imaging features rather than procedural outcomes.,yes,"The study is described as a retrospective study, which meets this criterion.",no,"While the study documents MRONJ features, it doesn't mention follow-up period or incidence after dental treatment.",maybe,"The abstract does not explicitly state the age of subjects, though given it's an MRONJ study, they are likely adults.",no,"The study only includes 16 patients total, which is well below the required 100 subjects.",no,"The study includes both oral and parenteral routes of medication administration, and doesn't specify if these are bisphosphonates. This fails the criterion requiring only oral bisphosphonates.",maybe,"While the study uses multiple imaging modalities (panoramic radiographs, CT, MRI, and bone scintigraphy), it doesn't explicitly state diagnostic standards for MRONJ.",Exclude,"The study fails multiple critical screening criteria, including insufficient sample size, mixed medication administration routes, and lack of clarity on patient population and dental procedures. Key limitations include no control group, unclear diagnostic standards, and absence of documented latency periods or follow-up outcomes. The research appears more focused on imaging characteristics than meeting the systematic review's specific requirements.",1.4
A study of peri-implant tissue clinical parameters in patients starting anti-osteoporosis medication after existing implant function: a prospective cohort study,"Keisuke Seki, Takaaki Tamagawa, Hiroyasu Yasuda, Soichiro Manaka, Daisuke Akita, Atsushi Kamimoto, Yoshiyuki Hagiwara",10.1186/s40729-024-00569-4,https://doi.org/10.1186/s40729-024-00569-4,International Journal of Implant Dentistry,0,2024,yes,"The study focused on patients taking anti-osteoporosis medications for osteoporosis treatment, with no mention of cancer patients or mixed populations.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",yes,"The study included a control group of patients not taking anti-resorptive medications, which adds 0.2 points to the score.",yes,The study focuses on implant maintenance treatment and its relationship to MRONJ.,yes,"The study appears to be a prospective cohort study, following patients who underwent implant maintenance treatment.",maybe,"While the study has a long follow-up period (2016-2024), it is unclear if MRONJ incidence is clearly documented as an outcome, as the focus seems to be on peri-implantitis.",maybe,"The abstract does not explicitly state the age range of the participants, so it is unclear if all subjects were over 18 years old.",no,"The study included 94 patients total, with 24 in the AOM group, which is below the required 100 subjects in the medication group.",maybe,"While the study mentions ""anti-osteoporosis medications (AOMs),"" it does not specify if these are oral bisphosphonates or other types of medications.",no,"The abstract does not mention specific diagnostic standards for MRONJ, though it discusses peri-implantitis as a presumed trigger.",Include,"The study fails to meet critical screening criteria, particularly the required sample size of 100 subjects in the medication group, with only 24 patients in the AOM group. Uncertainties persist regarding medication type, participant age range, and specific diagnostic standards for MRONJ, which significantly compromise the study's alignment with the predefined screening requirements.",2.7
Risk factors for dental findings of the development of medication-related osteonecrosis of the jaw: Investigation of 3734 teeth in cancer patients receiving high dose antiresorptive agents,"M. Otsuru, Yoshinari Fujiki, S. Soutome, Norio Nakamura, Taro Miyoshi, T. Naruse, Mizuho Ohnuma, Y. Hotokezaka, S. Rokutanda, M. Umeda",10.1016/j.jds.2023.04.026,https://doi.org/10.1016/j.jds.2023.04.026,Journal of Dental Sciences,3,2023,maybe,"The abstract mentions ""high-dose antiresorptive agent (ARA)"" but does not specify if this is for osteoporosis or cancer patients, so the reasoning is uncertain.",no,"The abstract does not mention documenting the time intervals between medication start, dental procedures, and MRONJ incidence, so no points are added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",yes,"The abstract mentions dental extraction and discusses MRONJ incidence, so this criterion is met.",maybe,"The study design is not explicitly stated in the abstract, so the reasoning is uncertain.",maybe,"While MRONJ is mentioned as an outcome, the follow-up period is not specified, so the reasoning is uncertain.",maybe,"The abstract does not specify the age requirements for the study population, so the reasoning is uncertain.",maybe,"The abstract does not mention the number of subjects in the study, so the reasoning is uncertain.",maybe,"The abstract mentions ""antiresorptive agents"" but does not specify if they are oral bisphosphonates, and the mention of ""high-dose"" suggests this might be for cancer treatment rather than osteoporosis, so the reasoning is uncertain.",no,"The abstract does not mention the diagnostic standards for MRONJ, so the study fails this criterion.",Include,"The abstract presents significant uncertainties across multiple screening criteria, with only the procedure and outcome relationship clearly addressed. Critical information about population characteristics, study design, diagnostic standards, and intervention specifics is missing, creating substantial ambiguity about the study's alignment with the screening requirements. The mention of ""high-dose"" antiresorptive agents suggests potential exclusion based on population type.",2.7
What is the Risk of Developing Medication-Related Osteonecrosis in Patients With Extraction Sockets Left to Heal by Secondary Intention? A Retrospective Case Series Study.,"R. Pippi, Umberto Giuliani, G. Tenore, A. Pietrantoni, U. Romeo",10.1016/j.joms.2021.05.031,https://doi.org/10.1016/j.joms.2021.05.031,Journal of oral and maxillofacial surgery,4,2021,yes,"The study specifically focuses on patients taking bisphosphonates for osteoporosis (particularly postmenopausal osteoporosis), meeting this criterion.",maybe,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",maybe,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study clearly focuses on tooth and root extractions, which is one of the specified procedures.",no,"The abstract describes this as a ""retrospective case series study,"" which does NOT meet the criterion as case series are explicitly excluded.",maybe,"While the study reports no MRONJ cases, the follow-up period is not explicitly stated, creating uncertainty about meeting the 6-month minimum requirement.",yes,"The mean age of the subjects is 68.02 ± 11.17 years, which clearly meets the requirement of being over 18 years old.",yes,"The study includes 221 patients with 639 extractions, exceeding the minimum requirement of 100 subjects.",yes,"The study mentions oral bisphosphonates (specifically alendronate), meeting this criterion.",maybe,The abstract does not explicitly mention the diagnostic standards used for MRONJ.,Include,"A retrospective case series study examining medication-related osteonecrosis of the jaw in patients undergoing tooth extractions, with a focus on oral bisphosphonate users. While meeting several key screening criteria such as population age, indication, and subject size, the study design as a case series and lack of a control group represent significant methodological limitations. The research provides insights into MRONJ risk but falls short of comprehensive screening requirements.",2.5
Medication-Related Osteonecrosis of the Jaw: evaluation of a therapeutic strategy in oral surgery.,"Mathilde Natu, Vincent Meuric, Paul Roginski, Romain Gamby, Sophie Lejeune",10.1016/j.jormas.2024.101877,https://doi.org/10.1016/j.jormas.2024.101877,Journal of Stomatology Oral and Maxillofacial Surgery,0,2024,no,"The abstract mentions ""antiresorptive therapies (ART)"" but also references ""cancer type,"" suggesting this may include cancer patients, which is explicitly excluded by the criteria.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract does not mention any specific dental procedures, so this criterion is not met.",maybe,"The study design is not explicitly stated in the abstract, so the information is unknown.",no,"While MRONJ is discussed, the abstract doesn't specify the follow-up period or clearly document MRONJ incidence after dental treatment, so this criterion is not met.",maybe,"The abstract does not specify the age of the subjects, so the information is unknown.",maybe,"The abstract does not mention the number of subjects, so the information is unknown.",maybe,"While ART is mentioned, it's not specified whether these are oral bisphosphonates or other types of antiresorptive medications, so the information is unknown.",no,"The abstract does not mention diagnostic standards for MRONJ, so this criterion is not met.",Exclude,"The abstract fails to meet multiple critical screening criteria, including population indication, diagnostic standards, and specific dental procedure documentation. Significant information is missing regarding subject characteristics, intervention type, and outcome measures, rendering the study potentially non-compliant with the established screening requirements. The presence of cancer patients and lack of clear methodological details further compromise the study's alignment with the specified criteria.",1.4
"Anti-resorptive medications and periodontitis: critical appraisal, clinical management and ONJ risk","L. Barbato, L. Landi, Nicola Discepoli, G. Oteri, A. Carrassi, N. M. Sforza, F. Cairo",10.57582/ijbf.240401.016,https://doi.org/10.57582/ijbf.240401.016,International Journal of Bone Fragility,0,2024,yes,"The study focuses on patients with osteoporosis taking anti-resorptive medications, which meets this criterion. However, it is a review rather than primary research.",maybe,The abstract mentions different treatment durations (less than/more than three years) but does not document specific time intervals for MRONJ development.,no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,"While periodontal treatment is discussed, the abstract does not specifically report MRONJ incidence following specific dental procedures.",no,"This is a narrative review, not one of the accepted study designs (RCT, cohort, or case-control).",no,"As a review paper, it does not present primary outcome data with follow-up periods.",maybe,"The abstract does not explicitly state the age of the subjects, so it is unclear if the population meets the age requirement of over 18 years old.",no,"The abstract does not mention the sample size, as this appears to be a narrative review rather than a primary study.",no,"The study discusses bisphosphonates, but also includes denosumab (a non-bisphosphonate), so it is not focused exclusively on oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"This narrative review fails to meet multiple critical screening criteria, including lack of a control group, undefined subject age, and absence of primary research data. The paper discusses periodontitis and osteoporosis but does not provide the specific methodological elements required for inclusion, such as diagnostic standards, precise MRONJ incidence, or a defined study design. Consequently, the manuscript does not satisfy the established screening requirements for the research protocol.",1.4
Minimizing MRONJ after Tooth Extraction in Cancer Patients Receiving Bone-Modifying Agents,"G. Avishai, Danielle Muchnik, Daya Masri, A. Zlotogorski-Hurvitz, L. Chaushu",10.3390/jcm11071807,https://doi.org/10.3390/jcm11071807,Journal of Clinical Medicine,12,2022,no,"The abstract specifically mentions ""bone modifying agents (BMAs) for oncology indications"", which fails this criterion as it explicitly excludes cancer patients.",yes,"The study does document the time interval between BMA treatment and extraction, and mentions this in relation to MRONJ development, meeting this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study specifically looks at tooth extraction and MRONJ incidence, meeting this criterion.",yes,"The study is described as a ""retrospective, cohort study"", which meets this criterion.",maybe,"While the study documents MRONJ incidence after dental treatment, the follow-up period is not specified in the abstract, so this is uncertain.",maybe,"The abstract does not explicitly state the age of the subjects, but it is likely that they are adults since the study was conducted at a tertiary medical center. However, this is uncertain.",no,"The study includes 93 patients with 103 extractions, which is below the required 100 subjects for the medication group.",no,"The abstract only mentions ""bone modifying agents (BMAs)"" without specifying if they are oral bisphosphonates, which is too vague to meet the criterion.",maybe,"The abstract defines MRONJ as ""a mucosal lesion of the maxillofacial region with necrotic bone exposure"" but does not provide detailed diagnostic standards, so it only partially meets this criterion.",Exclude,"The study fails key screening criteria by focusing on oncology patients and having a sample size below 100 subjects, which immediately disqualifies it from meeting the specified requirements. Multiple critical elements are either missing or do not align with the predefined screening standards, particularly regarding population indication and intervention type. The research lacks sufficient specificity and comprehensiveness to satisfy the established screening criteria.",1.4
Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution’s experience,"O. Şahin, B. Tatar, C. Ekmekcioğlu, Toghrul Aliyev, O. Odabaşı",10.4317/jced.56837,https://doi.org/10.4317/jced.56837,Journal of Clinical and Experimental Dentistry,19,2020,maybe,"The abstract mentions patients taking bisphosphonates but doesn't explicitly specify they are for osteoporosis treatment. It also doesn't exclude cancer patients, so this is unclear.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking bisphosphonates, so no points were added for this criterion.",yes,"The study clearly focuses on dentoalveolar surgery (including tooth extraction) and MRONJ outcomes, meeting this criterion.",yes,"The abstract explicitly states it is a retrospective study, which meets the criteria.",maybe,"The study mentions ""long-term follow-up"" but doesn't specify the duration. It does document MRONJ incidence (none occurred), but the follow-up period is unclear.",maybe,"The abstract doesn't explicitly state the age of subjects, but given it's a study of patients taking bisphosphonates for osteoporosis, it can be reasonably assumed they are adults. However, this is an assumption.",no,"The study includes 44 patients, which is well below the required 100 subjects for the medication group.",maybe,"The abstract mentions bisphosphonates but doesn't specify if they are oral or intravenous, so this is unclear.",no,The abstract doesn't mention any specific diagnostic standards for MRONJ.,Include,"The study fails to meet critical screening criteria, particularly the required sample size of 100 subjects and the absence of a control group. Significant methodological limitations include unclear patient population, unspecified diagnostic standards for MRONJ, and incomplete documentation of medication type and follow-up period. Despite addressing dental procedures and MRONJ outcomes, the research does not satisfy the comprehensive screening requirements.",2.7
Mechanisms Underlying Medication-Related Osteonecrosis of the Jaw.,"Kyeongho Lee, Kihun Kim, June Yeon Kim, Jin-Woo Kim, Young-Hoon Kang, Yun Hak Kim, Sung-Jin Kim",10.1111/odi.15198,https://doi.org/10.1111/odi.15198,Oral Diseases,0,2024,no,"While the abstract discusses MRONJ in patients taking anti-resorptive medications, it does not specify osteoporosis patients exclusively and appears to be a general review of MRONJ pathogenesis.",no,No information about time intervals is provided.,no,"The abstract does not mention any control group, as this is a review paper and not an original research study.",no,"While MRONJ is discussed, the abstract does not report specific dental procedures or their outcomes.",no,"This is explicitly a narrative review paper, which is not one of the accepted study designs (RCT, cohort study, or case-control study).",no,"As a review paper, it does not document specific MRONJ incidence or follow-up periods.",no,The abstract does not specify any age restrictions or demographics for the population.,no,"As a review paper, it does not include any specific subject population or sample size.",no,The abstract discusses anti-resorptive medications broadly but does not focus specifically on oral bisphosphonates.,no,The abstract does not mention any specific diagnostic standards for MRONJ.,Exclude,"This narrative review paper fails to meet the systematic review's screening criteria, lacking key elements such as a control group, specific population demographics, intervention details, and original research design. The abstract presents a theoretical hypothesis about MRONJ pathogenesis but does not provide the empirical data or methodological rigor required by the screening protocol. Consequently, the paper would be excluded from the systematic review.",0.1
Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients,"Sung-mok Jung, Sujeong Han, H. Kwon",10.3389/fphar.2018.00796,https://doi.org/10.3389/fphar.2018.00796,Frontiers in Pharmacology,9,2018,yes,"The study specifically focuses on ""osteoporotic patients"" and excludes cancer patients, meeting this criterion.",maybe,The study documents exposure duration but doesn't specifically mention the time interval between medication start and dental procedures.,maybe,"The abstract does not explicitly mention a control group, which is a significant limitation.",no,The abstract doesn't specify which dental procedures were associated with ONJ development.,yes,"The study is explicitly stated as a ""retrospective cohort study,"" which meets the criterion.",maybe,"While the study documents ONJ incidence, the follow-up period isn't explicitly stated, though the study period (2006-2012) suggests adequate follow-up.",yes,"The study includes patients ""older than 50 years,"" which meets the >18 years criterion.",yes,"The study includes 13,730 new bisphosphonate users, well exceeding the 100-subject requirement.",maybe,"The study focuses on bisphosphonates, but doesn't specify if they're all oral, creating some uncertainty.",no,The abstract doesn't mention specific diagnostic standards for ONJ/MRONJ.,Include,"A retrospective cohort study of 13,730 osteoporotic patients over 50 years old demonstrates potential for inclusion, with strong points in population selection and study design. However, critical screening criteria remain unaddressed, including specific dental procedures, diagnostic standards for MRONJ, and clear documentation of medication latency periods. These significant information gaps create substantial uncertainty about the study's full compliance with screening requirements.",3.2
Denosumab-Induced Medication-Related Osteonecrosis of the Jaw (DRONJ): A 5-Year Retrospective Cohort Study,"Jaeyoung Kim, Seoyeon Jung, Jin Hoo Park, Hyung.Jun. Kim, Wonse Park",10.21203/rs.3.rs-1186902/v1,https://doi.org/10.21203/rs.3.rs-1186902/v1,-,0,2022,no,"The study focuses on osteoporotic patients taking denosumab, which is not a bisphosphonate, and therefore fails to meet the criterion requiring oral bisphosphonate medication.",no,"The abstract does not document the specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study clearly reports MRONJ incidence following tooth extraction, which is one of the specified procedures.",yes,"While not explicitly stated, Elicit notes that the study appears to be a retrospective cohort study based on the methodology described.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, though Elicit notes that osteoporosis patients are typically over 18 years old.",no,"The study includes 98 patients, which is below the required 100 subjects for the medication group at the final statistical analysis stage.",no,"The study uses denosumab, which is not an oral bisphosphonate, and therefore fails to meet the criterion requiring oral bisphosphonate medication for the medication group.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails critical screening criteria by using denosumab instead of oral bisphosphonates and having a sample size below 100 patients. Multiple key requirements were not met, including diagnostic standards for MRONJ and comprehensive documentation of MRONJ latency. The fundamental mismatch in medication type and insufficient sample size render the study non-compliant with the specified screening criteria.",1.4
RE: American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update: Quantitative Risk Assessment and Controversial Issues.,"V. Fusco, R. Mauceri, G. Campisi, A. Bedogni",10.1016/j.joms.2022.07.143,https://doi.org/10.1016/j.joms.2022.07.143,Journal of oral and maxillofacial surgery,10,2022,no,"The abstract specifically mentions patients with ""bone metastases from solid cancer or by multiple myeloma,"" which fails this criterion as it explicitly includes cancer patients, which are excluded by the criteria.",no,The abstract does not mention any time intervals.,no,"The abstract does not mention any control group, so Elicit could not confirm whether this criterion was met.",no,The abstract doesn't mention specific dental procedures or outcomes in a research context.,no,"This appears to be a position paper/clinical guideline document, not a primary research study of any of the specified types, so it fails this criterion.",no,"As a position paper, it doesn't document specific outcomes from a research study.",maybe,"The abstract does not specify the age requirements of the study population, so Elicit could not confirm whether this criterion was met.",maybe,"The abstract does not mention the sample size, so Elicit could not confirm whether this criterion was met.",maybe,"While the abstract mentions bisphosphonates (referencing BRONJ), it appears to be a position paper rather than a primary research study of oral bisphosphonate users.",maybe,"While the paper is about MRONJ, as a position paper it likely discusses diagnostic standards but doesn't implement them in a research study.",Exclude,"This position paper fails multiple screening criteria, particularly by focusing on cancer patients and not being a primary research study. The document does not meet requirements for study design, population indication, and lacks specific details about intervention, procedures, and outcomes. Consequently, it does not qualify for inclusion based on the established screening criteria.",0.1
Medication Related Osteonecrosis of the Jaw: Basic Research and Clinical Practice for Prevention and Treatment by Ultrasound/Laser Pulsation,"Y. Mikuni‐Takagaki, Kouki Hidaka, S. Kuroshima",10.1097/01.bot.0000542214.31778.55,https://doi.org/10.1097/01.bot.0000542214.31778.55,Journal of Orthopaedics and Trauma,0,2018,yes,"The study specifically focuses on patients taking oral bisphosphonates for osteoporosis, particularly postmenopausal osteoporosis, and explicitly excludes cancer patients.",maybe,"No information about time intervals between medication start, dental procedures, and MRONJ incidence is provided.",maybe,"The abstract does not mention a control group, so no points were added for this criterion.",no,"The abstract does not mention any specific dental procedures leading to MRONJ. Instead, it focuses on treatment methods (LIPUS, LLLT, PTH).",no,"This appears to be a review of laboratory and clinical studies, not a primary research study with one of the required designs.",no,"While the study discusses MRONJ treatment, it does not document MRONJ incidence after dental treatment or mention a follow-up period.",yes,"While not explicitly stated, the focus on postmenopausal osteoporosis implies the study population was adults over 18 years old.",maybe,"The abstract does not mention the number of subjects in the study, so this information is unknown.",yes,The study specifically focuses on oral bisphosphonates for osteoporosis treatment.,yes,"The abstract mentions using the ""revised position paper (2016) by the allied task force committee of 6 Japanese societies"" for outcome measures, suggesting diagnostic standards are defined.",Exclude,"The study focuses on oral bisphosphonates for postmenopausal osteoporosis, meeting some population and intervention criteria, but fails to meet critical screening requirements including study design, dental procedure documentation, and outcome reporting. Significant methodological limitations exist, particularly in the lack of a primary research design and absence of specific dental procedure-related MRONJ incidence data.",1.4
Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement,"Celia Sánchez-Gallego Albertos, J. L. del Castillo Pardo de Vera, A. Viejo Llorente, J. L. Cebrián Carretero",10.4317/medoral.24007,https://doi.org/10.4317/medoral.24007,Medicina Oral,8,2021,no,"The study includes a mixed population of patients with osteoporosis (48.6%), breast cancer (30%), and multiple myeloma (11.4%), which fails to meet the criterion of only including osteoporosis patients.",no,"The abstract does not document the time interval between medication start and dental procedure, or between dental procedure and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract focuses on treatment of MRONJ (local debridement and PRP placement) rather than reporting MRONJ incidence following dental procedures.,yes,"The abstract describes a ""retrospective study"", which meets the acceptable study design criteria.",no,"While the study has a follow-up period (2-52 months), it documents recurrence after treatment rather than initial MRONJ incidence after dental procedures.",yes,"The abstract mentions that the patients are ""between 50-70 years old (64.3%)"", which meets the criterion of the age of subjects being over 18 years old.",no,"The study includes 70 MRONJ patients, which is below the required 100 subjects for the medication group.",no,"The study includes both oral bisphosphonates (41.4%) and other medications (zoledronic acid, denosumab), which fails to meet the criterion of only including oral bisphosphonates.",no,The abstract does not explicitly mention diagnostic standards for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including a mixed patient population with cancer patients, insufficient sample size, and inclusion of non-bisphosphonate medications. The research focuses on MRONJ treatment rather than incidence after dental procedures, and lacks clear documentation of diagnostic standards and latency periods. These significant deviations from the specified screening requirements render the study unsuitable for inclusion.",1.4
New paradigms for dental prevention of medication related osteonecrosis of jaws (MRONJ),G. Campisi,10.32388/652365,https://doi.org/10.32388/652365,Qeios,1,2018,no,"The abstract discusses both cancer and non-cancer patients, which violates the requirement for a non-mixed population. The paper appears to be a review/paradigm paper rather than a primary study.",no,No specific time intervals are documented.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While dental treatments are mentioned, this is a review of prevention strategies rather than a study reporting MRONJ incidence after specific procedures.",no,"This appears to be a review paper or position statement from SIPMO, not a primary research study of any of the required designs.",no,"As a review paper, it does not document specific MRONJ incidence or follow-up periods.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",no,No subject numbers are mentioned as this appears to be a review paper rather than a primary study.,no,"While bisphosphonates are mentioned, the paper discusses multiple medication types including antiangiogenic drugs, and is not focused solely on oral bisphosphonates.",no,"While the abstract mentions X-ray examinations and CT scans, it doesn't specify diagnostic standards for MRONJ.",Exclude,"This review paper fails multiple critical screening criteria, including lack of a defined study design, mixed patient population, and absence of specific outcome documentation. The document appears to be a position statement on MRONJ prevention strategies rather than a primary research study, rendering it unsuitable for systematic review inclusion. Multiple key methodological requirements were not met, disqualifying the paper from further consideration.",0.1
Contribution of Antiangiogenic Agents to the Risk of Medication-related Osteonecrosis of the Jaw in Combination with Antiresorptive Agents: Preliminary Results in a Comparative Prospective Report of 59 Oncologic Cases,"A. Yanni, C. Bouland, Raquel Monteiro, Alexandra Rodríguez, I. Loeb, R. Javadian, D. Dequanter",10.4103/jispcd.JISPCD_110_22,https://doi.org/10.4103/jispcd.JISPCD_110_22,Journal of International Society of Preventive and Community Dentistry,1,2022,no,"The study focuses on oncologic patients, not osteoporosis patients, which is a critical exclusion criterion.",yes,The study does document time intervals between medication start and MRONJ development.,no,The study does not include a control group of patients not taking anti-resorptive medications. It only compares two groups of patients taking different combinations of medications.,maybe,"The study mentions dental history (surgery, prosthesis) but doesn't specifically focus on the required dental procedures.",yes,"The study is described as a ""prospective study"" reviewing medical records, which meets this criterion.",yes,"The study documents MRONJ incidence and has follow-up periods (mean treatment duration of 39.2 and 55 months), meeting this criterion.",maybe,"The abstract doesn't explicitly state the age range of participants. However, since these are oncologic patients, they are likely adults, but this isn't certain.",no,"The study includes 59 total patients (47 in group 1, 12 in group 2), which fails the requirement of >100 subjects in the medication group.",no,"The study doesn't specify oral bisphosphonates and includes antiangiogenic agents in combination with antiresorptive agents, which fails this criterion.",maybe,The abstract mentions MRONJ staging but doesn't explicitly describe the diagnostic standards used.,Exclude,"The study fails critical screening criteria by focusing on oncologic patients instead of osteoporosis patients, using a mixed medication intervention, and including fewer than 100 subjects. Multiple key requirements were not met, including population indication, subject size, and intervention type, rendering the study ineligible for systematic review. The research fundamentally diverges from the specified screening parameters, necessitating exclusion.",0.1
"279P Incidence, risk factors and management of medication-related osteonecrosis of the jaw in breast cancer patients treated with zoledronic acid or denosumab over a 5-year period in a UK tertiary institution","O. Akala, S. Bhagani, O. Ayodele, B. Varadhan, K. Sampson, K.N. Kancherla, J. Wood, S. Ahmed",10.1016/j.esmoop.2024.103337,https://doi.org/10.1016/j.esmoop.2024.103337,ESMO Open,2,2024,no,"The study focuses on breast cancer patients receiving bone modifying agents (BMAs), not osteoporosis patients, which is a critical failure of the inclusion criteria.",maybe,"The abstract mentions mean duration of BMA treatment (2.2 years) but doesn't clearly document the specific time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The study mentions dental intervention as a risk factor, but doesn't specifically detail the types of procedures.",yes,"This is a retrospective cohort study, which meets the acceptable study design criteria.",yes,"The study has a follow-up period until 2024 (from 2015-2020), exceeding the 6-month requirement.",yes,"The study population had a mean age of 65 years (range 33-97), which meets the criterion of being over 18 years old.",maybe,"The study includes 455 patients total, with 17 developing MRONJ. While the total sample size exceeds 100, the medication group size is not specifically defined for osteoporosis patients (as this is a cancer population).",no,"The study primarily focuses on Zoledronic acid (intravenous) and Denosumab (non-bisphosphonate), not oral bisphosphonates, which is another critical failure of the inclusion criteria.",yes,"The abstract mentions using Orthopantomogram and Computed Tomography for diagnosis, meeting this criterion.",Exclude,"The study focuses on breast cancer patients receiving bone modifying agents, which critically fails the screening criteria for osteoporosis patient populations and oral bisphosphonate interventions. Despite meeting some methodological criteria like study design and diagnostic standards, the fundamental mismatch in patient population and medication type renders the study ineligible for inclusion in the systematic review.",0.1
Clinical significance of drug cessation on medication-related osteonecrosis of the jaw in patients with osteoporosis,"K. R. Mustakim, M. Eo, J. Lee, M. Seo, S. Kim",10.5125/jkaoms.2023.49.2.75,https://doi.org/10.5125/jkaoms.2023.49.2.75,Journal of the Korean Association of Oral and Maxillofacial Surgeons,4,2023,yes,"The study specifically focuses on osteoporosis patients taking bisphosphonates, with no mention of cancer patients or mixed populations.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The study compares BP suspension vs non-suspension groups, but does not include a true control group of patients not taking bisphosphonates.",maybe,"While the study mentions ""surgical interventions,"" it does not specify which dental procedures were performed.",yes,"This appears to be a retrospective cohort study comparing two groups, which meets the acceptable study designs.",maybe,"The study includes follow-up and documents MRONJ outcomes, but the exact follow-up period is not specified.",yes,"While not explicitly stated, given this is an osteoporosis study, it can be reasonably assumed that the subjects are over 18 years old.",no,"The study only includes 24 patients total, which is well below the required 100 subjects for the medication group.",maybe,"The study involves bisphosphonate medication, but does not specify if it's oral or intravenous, creating uncertainty.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Include,"The study fails to meet critical screening criteria, particularly the requirement for a minimum of 100 subjects in the medication group, with only 24 patients included. Significant uncertainties exist regarding diagnostic standards, intervention type, and specific dental procedures, which prevent the study from satisfying the comprehensive screening requirements. Despite focusing on osteoporosis patients and bisphosphonate treatment, the research does not provide sufficient methodological clarity to qualify for inclusion.",2.5
A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study,"Zineb Assili, G. Dolivet, J. Salleron, Claire Griffaton-Tallandier, Claire Egloff-Juras, B. Phulpin",10.3390/jcm10112390,https://doi.org/10.3390/jcm10112390,Journal of Clinical Medicine,8,2021,no,"The study focuses on cancer patients taking Xgeva® (denosumab), which is NOT for osteoporosis treatment. This is a clear violation of the inclusion criteria.",no,"While the study reports timing of MRONJ incidence (6, 12, and 24 months), it doesn't specifically document the time interval between medication start and dental procedures.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not mention any specific dental procedures leading to MRONJ.,yes,"The abstract explicitly states it's a retrospective study, which is one of the acceptable study designs.",yes,The study clearly documents MRONJ incidence and has follow-up periods exceeding 6 months.,maybe,"The abstract doesn't explicitly state the age of subjects, but given it's a cancer center study, we can reasonably assume they are adults.",yes,"The study includes 246 patients, which exceeds the minimum requirement of 100 subjects.",no,"The study examines denosumab (Xgeva®), which is not an oral bisphosphonate. This is a clear violation of the inclusion criteria.",yes,"The study mentions using clinical and radiological (CBCT) data for diagnosis, with specific criteria for ""exposed"" and ""fistula"" groups.",Exclude,"The study focuses on denosumab-related osteonecrosis in cancer patients, which fundamentally conflicts with the screening criteria requiring oral bisphosphonates and osteoporosis patients. Critical exclusion factors include the wrong medication type, patient population, and absence of specific dental procedures, rendering the study non-compliant with the established screening requirements.",0.1
Latest findings of treatment and prevention of medication-related osteonecrosis of the jaw : Results of multicenter clinical trials,M. Umeda,10.5794/jjoms.66.52,https://doi.org/10.5794/jjoms.66.52,Japanese Journal of Oral & Maxillofacial Surgery,0,2020,maybe,"The abstract discusses MRONJ in patients taking anti-resorptive agents, but does not explicitly exclude cancer patients or specify if it's a mixed population, so this is partially unclear.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The abstract discusses tooth extraction and MRONJ incidence, meeting this criterion.",maybe,"The abstract appears to be describing treatment methods and results from clinical trials, but the specific study design is not clearly stated.",maybe,"While the abstract discusses treatment outcomes, it does not specify the follow-up period length.",maybe,"The abstract does not explicitly state the age of the subjects, so the age of the population is unclear.",maybe,"The abstract mentions ""multicenter clinical trials"" but does not specify the number of subjects, so the subject size is unclear.",maybe,"The abstract mentions ""antiresorptive agents"" but does not specify if these are oral bisphosphonates or other types, so the intervention type is unclear.",maybe,The abstract mentions CT imaging for osteolytic lesions but does not provide a comprehensive diagnostic standard for MRONJ.,Include,"The abstract lacks critical methodological details required by the screening criteria, including clear specification of population age, intervention type, and study design. While discussing medication-related osteonecrosis of the jaw, the text appears more focused on treatment methods than meeting the structured research requirements. Multiple key screening criteria remain unaddressed or ambiguous, preventing straightforward inclusion.",2.7
Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates.,"J. Baillargeon, Y. Kuo, Yu-Li Lin, G. Wilkinson, J. Goodwin",10.1345/aph.1Q239,https://doi.org/10.1345/aph.1Q239,The Annals of Pharmacotherapy,30,2011,no,"While the study includes osteoporosis patients, it specifically focuses on intravenous bisphosphonates, which is explicitly excluded in the criteria.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study includes a control group of 6,865 bisphosphonate nonusers matched to 2,296 users at a 1:3 ratio, which meets the requirement for a control group.",no,"While the study looks at jaw toxicity, it doesn't specifically report MRONJ incidence following the specified dental procedures.",yes,"This appears to be a retrospective cohort study using Medicare data, which meets the requirement for a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",yes,"The study has a 3-year follow-up period, which exceeds the 6-month requirement.",yes,"The study uses Medicare beneficiaries, who are typically over 65 years old, meeting the requirement for subjects over 18 years old.",yes,"The study includes 2,296 patients in the medication group, well above the 100-subject requirement.",no,"The study specifically examines intravenous bisphosphonates, which is explicitly excluded in the criteria that requires oral bisphosphonates.",no,"The abstract only mentions ""operations on the facial bones or jaw and diagnosis of inflammatory conditions"" but doesn't specify diagnostic standards for MRONJ.",Exclude,"The study focuses on intravenous bisphosphonates for osteoporosis, which directly conflicts with the screening criteria requiring oral bisphosphonates. Multiple critical exclusion criteria were not met, including the specific intervention type, diagnostic standards for MRONJ, and documentation of dental procedures. Despite having a robust study design and adequate sample size, the fundamental mismatch with screening requirements renders the study unsuitable for inclusion.",1.4
Awareness About Medication-Related Osteonecrosis of the Jaw Among Dental Professionals: A Multicentre Study,"Vathsala Patil, S. Acharya, R. Vineetha, Krithi Nikhil",10.3290/j.ohpd.a43361,https://doi.org/10.3290/j.ohpd.a43361,Oral Health & Preventive Dentistry,20,2020,no,"The abstract discusses bisphosphonates and non-bisphosphonate medications for both bone diseases and cancer, which violates the requirement for a population with a specific indication.",no,No information about time intervals is provided.,no,"The abstract does not mention any control group, as this is a survey of dentists' knowledge rather than a clinical study.",no,"While dental procedures are mentioned, this is not a study of MRONJ incidence following procedures. It's a knowledge assessment study.",no,"This is a survey study using questionnaires, which does not match any of the required study designs (RCT, cohort, or case-control).",no,The study does not document MRONJ incidence or follow-up periods.,no,"The study focuses on dentists, not patients, so the age criteria for patients is not applicable.",no,"The study includes 234 dentists, but this is not relevant as the study doesn't examine patient outcomes.",no,"While bisphosphonates are mentioned, this is not an intervention study, as the paper focuses on dentists' knowledge about MRONJ.",no,The abstract does not mention any diagnostic standards for MRONJ.,Exclude,"This survey of dentists' knowledge about medication-related osteonecrosis of the jaw fails to meet multiple critical screening criteria, including lack of a patient population, absence of a control group, and no documentation of MRONJ incidence or diagnostic standards. The study's focus on professional knowledge assessment fundamentally differs from the required clinical research design examining patient outcomes.",0.1
Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates.,"M. Kharazmi, P. Hallberg, G. Warfvinge, K. Michaëlsson",10.1093/rheumatology/keu286,https://doi.org/10.1093/rheumatology/keu286,Rheumatology,15,2014,maybe,"The title suggests the study was about osteoporosis patients, as it mentions alendronate, but Elicit could not confirm the exclusion of cancer patients.",no,"Elicit could not determine if the study documented the time intervals between the start of medication, dental procedure, and MRONJ incidence from the title alone.",no,Elicit could not determine from the title alone whether the study included a control group of patients not taking anti-resorptive medications.,no,Elicit could not determine if the study reported MRONJ incidence following specific dental procedures from the title alone.,no,Elicit could not determine the study design from the title alone.,no,Elicit could not determine the follow-up period or documentation of MRONJ incidence from the title alone.,no,Elicit could not determine from the title alone if the subjects were over 18 years old.,no,Elicit could not determine the sample size from the title alone.,yes,The title confirms the study included subjects taking oral bisphosphonates (alendronate and other oral bisphosphonates).,no,Elicit could not determine if the study mentioned its diagnostic standards for MRONJ from the title alone.,Exclude,"The extremely limited title provides insufficient information to confidently assess most screening criteria, with only partial confirmation of oral bisphosphonate intervention. Critical details about study design, population characteristics, diagnostic standards, and outcome documentation remain unverifiable without additional context. Consequently, a comprehensive screening determination cannot be made based on the title alone.",1.4
Medication-Related Osteonecrosis of the Jaws,S. Otto,10.1007/978-3-662-43733-9,https://doi.org/10.1007/978-3-662-43733-9,-,28,2015,no,"The abstract specifically mentions ""patients suffering from malignant diseases"", which explicitly fails this criterion as it excludes cancer patients.",no,"Elicit could not determine from the abstract whether the study documented the time interval between the start of medication and dental procedure, and between the dental procedure and MRONJ incidence.",no,Elicit could not determine from the abstract whether the study included a control group of patients not taking anti-resorptive medications.,no,Elicit could not determine from the abstract the specific dental procedures and MRONJ incidence reported in the study.,no,Elicit could not determine from the abstract the study design.,no,Elicit could not determine from the abstract whether the study clearly documented MRONJ incidence after dental treatment and had a follow-up period of at least 6 months.,no,Elicit could not determine from the abstract the age of the subjects in the study.,no,Elicit could not determine from the abstract the size of the subject population in the study.,no,"The abstract mentions ""intravenous administrations"", which explicitly fails this criterion as it excludes intravenous administration.",no,Elicit could not determine from the abstract the diagnostic standards for MRONJ used in the study.,Exclude,"The abstract explicitly fails key screening criteria by focusing on cancer patients and intravenous medication administration, which are specifically excluded from the study parameters. Multiple critical screening requirements cannot be assessed due to the abstract's extreme brevity, further complicating potential inclusion. The limited information provided definitively disqualifies the study from meeting the established screening standards.",0.1
Antibiotic Prophylaxis Before Dental Procedures Can Reduce ONJ Incidence.,"V. Montefusco, F. Spina, M. T. Ambrosini, M. Maniezzo, L. Farina, A. Miceli, A. Palumbo, M. Boccadoro, P. Corradini",10.1182/BLOOD.V110.11.3613.3613,https://doi.org/10.1182/BLOOD.V110.11.3613.3613,-,7,2007,no,"The study focuses on multiple myeloma patients taking zoledronic acid, not osteoporosis patients, which violates the inclusion criteria.",maybe,The abstract mentions duration of zoledronic acid exposure but does not clearly document the specific time intervals required.,no,"The study does not include a control group of patients not taking anti-resorptive medications, so this criterion is not met.",yes,"The study does report dental procedures including extractions, implants, and professional cleanings, meeting this criterion.",yes,"The study is described as a ""retrospective observational trial,"" which meets the acceptable study design criteria.",maybe,"While the study tracks ONJ occurrence, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, so it cannot be confirmed that the population is over 18 years old.",yes,"The study includes 113 total patients, which meets the minimum requirement of 100 subjects.",no,"The study uses zoledronic acid, which is an intravenous bisphosphonate, not an oral bisphosphonate, which violates the inclusion criteria.",maybe,"The abstract mentions ""histology of osteonecrotic bone shows osteomyelitis and inflammatory infiltrates,"" but does not clearly specify the diagnostic standards for MRONJ.",Exclude,"The study focuses on multiple myeloma patients receiving intravenous zoledronic acid, which fundamentally conflicts with the screening criteria requiring osteoporosis patients taking oral bisphosphonates. Critical exclusion factors include the wrong patient population, incorrect medication type, and absence of a true control group, rendering the study ineligible for systematic review. Multiple core screening requirements were not met, leading to automatic disqualification.",0.1
Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients,"A. Kemp, V. C. Ferreira, R. Mobile, T. Brandão, L. Sassi, Amanda Zarpellon, P. Braz-Silva, J. Schussel",10.1016/j.bjorl.2020.09.010,https://doi.org/10.1016/j.bjorl.2020.09.010,Brazilian Journal of Otorhinolaryngology,7,2020,no,"The study specifically focuses on oncologic patients with bone metastases and multiple myeloma, not osteoporosis patients, which is a critical exclusion criterion.",no,"There is no mention of the time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study includes a control group of patients not taking anti-resorptive medications, which adds 0.2 points to the score.",maybe,"The study mentions ""surgical dental procedures"" but does not specify which types, and MRONJ incidence is reported but not clearly linked to specific procedures.",yes,"The study design is explicitly mentioned as a case-control study, which meets the criterion.",maybe,The follow-up period is not specified in the abstract.,maybe,"The age of the subjects is not explicitly mentioned in the abstract, so it is unclear if the population is over 18 years old.",no,"The total sample size is 74 patients, which is below the required 100 subjects for the medication group.",no,"The study uses intravenous bisphosphonates (""monthly infusion protocol""), not oral bisphosphonates, which is a critical exclusion criterion.",maybe,"While the study mentions clinical evaluation for MRONJ diagnosis, the specific diagnostic standards are not detailed.",Exclude,"The study focuses on oncologic patients with bone metastases, using intravenous bisphosphonates, which critically deviates from the required osteoporosis patient population and oral medication intervention. With a sample size of 74 patients and unclear diagnostic standards, the research fails to meet multiple essential screening criteria for inclusion in the systematic review.",0.1
Retrospective analysis of medication-related osteonecrosis of the jaw at a maxillofacial prosthetics clinic,"Islam E. Ali, Cheewin Towithelertkul, Y. Sumita, Noriyuki Wakabayashi",10.26629/ijmp.2024.04,https://doi.org/10.26629/ijmp.2024.04,International Journal of Maxillofacial Prosthetics,0,2024,no,"The abstract indicates this is a mixed population study including cancer patients (breast and prostate cancer), which explicitly violates the requirement for the research to specify that its subject is chosen from patients taking medication for osteoporosis, excluding cancer patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"While the study discusses MRONJ and prosthetic treatment, it does not specifically focus on the required dental procedures (extraction, periodontal surgery, implant placement, or removable prosthetic treatment).",yes,"This is a retrospective analysis, which meets the criterion as it falls under ""retrospective cohort study.""",no,"While the study follows patients over 12 years, it does not clearly document MRONJ incidence after specific dental treatments.",maybe,"The abstract mentions ""elderly"" patients, but does not specify the exact age range, so it is unclear if the population meets the over 18 years old requirement.",no,"The abstract does not specify the total number of subjects, so it is impossible to verify if it meets the requirement of over 100 subjects for the medication group at the final statistical analysis stage.",no,"The abstract mentions ""medications"" but does not specify oral bisphosphonates. It appears to include various medications, including cancer treatments, which does not meet the requirement for the study to only include subjects taking oral bisphosphonate medication for osteoporosis treatment.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including the requirement for a pure osteoporosis patient population and specific focus on oral bisphosphonate medications. Significant methodological limitations include a mixed patient population with cancer patients, lack of clear diagnostic standards, and absence of a control group. These fundamental deviations from the screening requirements render the study unsuitable for inclusion.",1.4
Platelet-Rich Plasma in the Prevention and Treatment of Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis.,Marwan H Aljohani,10.1097/SCS.0000000000010664,https://doi.org/10.1097/SCS.0000000000010664,The Journal of craniofacial surgery (Print),0,2024,maybe,"While the study involves MRONJ patients, it does not explicitly state that they are osteoporosis patients. It only mentions ""bisphosphonates"" generally.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, which is a significant missing element.",no,The abstract focuses on PRF treatment of existing MRONJ rather than MRONJ incidence following dental procedures.,no,"This is a systematic review and meta-analysis, not a primary research study of the types specified in the criteria.",no,"While the study documents outcomes, it is focused on treatment of existing MRONJ rather than incidence after dental procedures.",maybe,"The abstract does not explicitly state the age of the subjects, so this information is unclear.",maybe,"The study includes 480 participants total, which exceeds the 100-subject requirement. However, this is a meta-analysis of multiple studies, not a primary study.",maybe,The abstract mentions bisphosphonates but does not specify oral administration. It is unclear if other types of bisphosphonates are included.,no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The systematic review and meta-analysis fails to meet multiple critical screening criteria, including lack of a control group, unclear population age and indication, and absence of specific diagnostic standards for MRONJ. The study's focus on treatment rather than incidence, combined with its meta-analysis design, fundamentally disqualifies it from meeting the predefined screening requirements.",1.4
Medication-Related Osteonecrosis of the Mandible,G. Omami,10.1177/0145561320919574,https://doi.org/10.1177/0145561320919574,"Ear, nose, & throat journal",1,2020,no,"The abstract discusses multiple conditions including cancer patients (breast, prostate, multiple myeloma) and osteoporosis, which is a mixed population study that explicitly fails this criterion.",no,"The abstract does not document specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The abstract mentions relevant procedures (extraction, implant placement) and MRONJ outcomes.",no,"This appears to be a review article rather than a primary research study, and it does not describe any specific study design.",no,"While MRONJ is discussed, there is no mention of follow-up period or specific incidence rates in a study population.",maybe,"The abstract does not explicitly state the age of the subjects, so the age of the population is unclear.",no,The abstract does not mention the number of subjects studied.,no,"The abstract discusses both bisphosphonates and denosumab, and mentions both oral and intravenous administration, which is too broad and includes excluded interventions.",yes,"The abstract does mention diagnostic standards for MRONJ (""nonhealing exposed bone persisting for more than 8 weeks..."").",Exclude,"The abstract describes a review of medication-related osteonecrosis of the jaw across multiple patient populations, including cancer patients, which violates the screening criteria for a focused osteoporosis study. Multiple methodological issues exist, including lack of a control group, undefined subject age, mixed patient population, and absence of a specific research design. The broad scope and review nature of the text render it unsuitable for the systematic review's strict inclusion requirements.",0.1
Factors Influencing Severity of Medication-Related Osteonecrosis of the Jaw: A Retrospective Study.,"Zhiqiang Feng, J. An, Yi Zhang",10.1016/j.joms.2020.12.045,https://doi.org/10.1016/j.joms.2020.12.045,Journal of oral and maxillofacial surgery,14,2021,no,"The abstract does not specify whether patients are taking medication for osteoporosis or other conditions. The mention of chemotherapy suggests a mixed population, which violates this criterion.",maybe,"The study mentions ""preoperative MRONJ duration"" but does not clearly document the time interval between medication start and dental procedure.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, which is a significant missing element.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,yes,"The study is described as a retrospective analysis, which meets the criterion as it's a retrospective cohort study.",no,"While the study documents MRONJ incidence and staging, it does not specify the follow-up period.",maybe,"The study includes patients with age ≤65 years as a risk factor, suggesting an adult population, but does not explicitly state the minimum age. However, given the context, it's likely all patients are over 18.",no,"The study includes 79 patients with 93 MRONJ lesions, which falls below the required 100 subjects for the medication group.",no,The abstract does not specify the type of medication (oral bisphosphonate vs. other) being taken by the patients.,no,"While the study discusses MRONJ staging, it does not explicitly mention diagnostic standards.",Include,"The study fails to meet multiple critical screening criteria, including insufficient sample size, lack of a control group, and unclear medication type. Mixed patient population and absence of specific dental procedure details further compromise its alignment with the systematic review requirements. Despite being a relevant MRONJ research, the study does not satisfy the predefined screening standards.",2.7
Can medication-related osteonecrosis of the jaw be attributed to specific microorganisms through oral microbiota analyses? A preliminary study,"Heon-Young Kim, Young-Soo Jung, Wonse Park, Yoon Jeong Choi, Jun-Young Kim",10.1186/s12903-024-03945-z,https://doi.org/10.1186/s12903-024-03945-z,BMC Oral Health,2,2024,maybe,"The abstract does not specify whether the patients are osteoporosis patients or if they include cancer patients, which is a critical missing piece of information.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ. It focuses on microbiota analysis rather than procedure-related outcomes.,yes,"The study is described as a ""single-center prospective cohort study,"" which meets the criterion for study design.",no,"While the study documents MRONJ cases, it does not appear to follow patients over time to document incidence after dental treatment.",yes,"The study includes patients with a mean age of 82.67 ± 5.73 (range, 72-90) years, which meets the requirement of being over 18 years old.",no,"The study only includes 12 patients, which is well below the required 100 subjects for the medication group.",maybe,The abstract does not specify the type of medication patients were taking (whether oral bisphosphonates or other medications).,maybe,"The abstract mentions ""confirmed MRONJ"" and ""detailed intraoral examinations and imaging,"" suggesting diagnostic standards were used, though not explicitly detailed.",Exclude,"The study fails to meet critical screening criteria, including an insufficient sample size of only 12 patients, lack of clarity on patient population, and absence of specific dental procedures related to MRONJ. Multiple key requirements were not addressed, such as control group, intervention type, and outcome documentation, rendering the study unsuitable for systematic review inclusion.",1.4
Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw.,"Yasmin Thiel, C. Ghayor, D. Lindhorst, H. Essig, F. Weber, M. Rücker, P. Schumann",10.1016/j.prp.2020.153245,https://doi.org/10.1016/j.prp.2020.153245,"Pathology, Research and Practice",7,2020,no,"The study includes a mixed population of patients with bone metastasis and osteoporosis, which violates the requirement for an osteoporosis-only population.",no,"The study does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study includes a control group of healthy subjects (n=6), which meets the requirement for a control group.",no,"The study does not mention any specific dental procedures, and instead focuses on molecular mechanisms rather than clinical outcomes.",maybe,"The study design is not explicitly stated, but it appears to be a case-control study, which would meet the requirement for a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",no,"The study does not document MRONJ incidence after dental treatment, and there is no mention of a follow-up period. The focus is on molecular markers rather than clinical outcomes.",maybe,"The age of the subjects is not specified in the abstract, so it is unclear if the population meets the age requirement of over 18 years old.",no,"The study only includes 6 patients in each group (bisphosphonates and denosumab), which is far below the required 100 subjects for the medication group.",no,"The study includes both bisphosphonates and denosumab, which violates the requirement for an oral bisphosphonate-only population.",no,The study does not mention any diagnostic standards for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including a mixed patient population, small sample size, and inclusion of non-bisphosphonate medications. Key disqualifying factors include the absence of specific dental procedures, lack of MRONJ diagnostic standards, and a focus on molecular mechanisms rather than clinical outcomes. The research does not meet the required methodological standards for inclusion in the review.",0.1
Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events,"Mitsuhiro Nakamura, Ryogo Umetsu, Junko Abe, Toshinobu Matsui, Natsumi Ueda, Yamato Kato, S. Sasaoka, K. Tahara, Hirofumi Takeuchi, Y. Kinosada",10.1186/s40780-015-0035-2,https://doi.org/10.1186/s40780-015-0035-2,Journal of Pharmaceutical Health Care and Sciences,7,2015,no,"The abstract mentions that the study included both osteoporosis and ""malignant bone metastasis"" patients, indicating a mixed population, which fails to meet the criterion requiring only osteoporosis patients.",maybe,"The study does document time-to-onset profiles, but not specifically the interval between medication start and dental procedure.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract does not specify any dental procedures leading to BRONJ.,maybe,"The abstract indicates that this is a database analysis study using the JADER database, which could be considered a retrospective cohort study, but it is not clearly stated.",no,"While the study documents BRONJ incidence, it does not specify a follow-up period.",maybe,"The abstract does not explicitly state the age of the subjects, so the age of the population is unclear.",maybe,"The abstract does not specify the total number of subjects analyzed, so the subject size is unclear.",no,"The study includes both oral and intravenous bisphosphonates, which fails to meet the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for BRONJ.,Include,"The study fails to meet multiple screening criteria, including population specificity, intervention type, and procedural documentation. Mixed patient populations, inclusion of both oral and intravenous bisphosphonates, and lack of clear diagnostic standards and dental procedure details disqualify the research from meeting the predefined screening requirements. Critical methodological gaps prevent the study from being considered suitable for the intended review.",2.5
"Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator‐mandated cohort postauthorization safety study in Denmark, Norway, and Sweden","V. Ehrenstein, U. Heide-Jørgensen, M. Schiødt, O. Akre, B. B. Herlofson, S. Hansen, Cecilia Larsson Wexell, S. Nørholt, S. Tretli, A. Kjellman, A. Glennane, K. Lowe, H. Sørensen",10.1002/cncr.33802,https://doi.org/10.1002/cncr.33802,Cancer,15,2021,no,"The abstract explicitly states that the study population consists of ""cancer patients with bone metastases from solid tumors"", which directly violates the criterion that the research must specify that its subject is chosen from patients taking medication for osteoporosis, excluding cancer patients.",no,"The abstract does not provide any information about the time intervals between the start of medication, dental procedures, and MRONJ incidence, so no points are added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",maybe,"The abstract does not mention any specific dental procedures, so the reasoning for this criterion is uncertain.",maybe,"The abstract mentions this is an incidence study in ""routine clinical practice"" but does not clearly specify the study design, so the reasoning for this criterion is uncertain.",maybe,"While the abstract mentions ONJ incidence, it does not specify the follow-up period, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not specify the number of subjects in the medication group, so the reasoning for this criterion is uncertain.",maybe,"The abstract only mentions ""antiresorptive treatment"" generally, without specifying oral bisphosphonates, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention the diagnostic standards for MRONJ, so the reasoning for this criterion is uncertain.",Exclude,"The study focuses on cancer patients with bone metastases, which directly conflicts with the screening criteria requiring a non-cancer patient population for osteoporosis medication research. Multiple critical screening requirements remain unaddressed or uncertain, with the cancer patient population being the primary disqualifying factor. The abstract lacks sufficient detail to meet the comprehensive screening criteria for inclusion.",0.1
Why do some extraction sites develop medication-related osteonecrosis of the jaw and others do not? A within-patient study assessing radiographic predictors.,"H. Gaêta-Araujo, André Ferreira Leite, K. de Faria Vasconcelos, R. Coropciuc, C. Politis, R. Jacobs, C. Oliveira-Santos",-,-,International journal of oral implantology,9,2021,no,"The study specifically focuses on oncological patients taking antiresorptive medications, which is explicitly excluded by the criteria.",no,"The abstract does not mention documenting the time intervals between medication start, dental procedure, and MRONJ incidence.",yes,"The study includes a control group of 57 healthy patients matched for age, sex, and extracted tooth, which meets the requirement for a control group.",yes,The study examines MRONJ incidence following dental extraction.,yes,"This is a retrospective study, which is one of the accepted study designs.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, but Elicit notes that being oncological patients suggests they are likely adults.",no,"The study includes only 41 patients in the treatment group, which is well below the required 100 subjects.",no,"The study includes patients taking intravenous or subcutaneous antiresorptive treatment, not oral bisphosphonates as required.",maybe,"The abstract does not explicitly mention diagnostic standards for MRONJ, though it does describe radiographic evaluation.",Exclude,"The study fails key screening criteria due to its focus on oncological patients taking intravenous antiresorptive medications, which deviates from the required population and intervention type. Additionally, the small sample size of 41 patients and lack of clear documentation for several critical screening elements further disqualify the research from meeting the systematic review's requirements.",0.1
Awareness of Medication-Related Osteonecrosis of the Jaws Amongst Patients on Antiresorptive and Antiangiogenic Medications,"Ahmad Assari, Yosef Alanazi, Elaf Mubarak Algharbi, A. Abuhabsha, B. Alshammry, Ali Alzahrani, A. Alduhaim, R. Abuhaimed",10.7759/cureus.52896,https://doi.org/10.7759/cureus.52896,Cureus,1,2024,no,"The study includes a mixed population of both osteoporosis (41.8%) and cancer patients (13.6%), which fails the criterion requiring exclusive focus on osteoporosis patients.",no,"The study does not document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The study does not report MRONJ incidence following dental procedures. It only assesses patient awareness of MRONJ.,no,"This is a cross-sectional survey study, which is not one of the accepted study designs (RCT, prospective cohort, retrospective cohort, or case-control).",no,The study does not document MRONJ incidence or have a follow-up period. It only measures awareness through a questionnaire.,yes,"The study includes participants from age 21-40 (43.6%) and some over 60 (5.5%), which meets the requirement for the population to be over 18 years old.",no,"The study includes 110 patients total, but this is across multiple medication types and indications. The osteoporosis-only subgroup would be approximately 46 patients (41.8% of 110), which is below the required 100 subjects.",no,"The study includes both oral (30.9%) and IV/injection (40%) administration routes, and includes non-bisphosphonate medications (denosumab), which fails the criterion requiring exclusive focus on oral bisphosphonates.",no,The abstract does not mention any diagnostic standards for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including inappropriate study design, mixed patient population, insufficient subject size, and lack of focus on oral bisphosphonates for osteoporosis. Specifically, the cross-sectional survey does not meet requirements for MRONJ incidence documentation, diagnostic standards, or dental procedure outcomes. The research primarily assesses patient awareness rather than providing the systematic review's required clinical insights.",0.1
Osteonecrosis Related to the use of Osteoporosis Medications: An Integrative Literature Review,"Rafaela Melo Santos, Edson Vinicius Santos Almeida, Naiara Lima Fagundes, Laila Eduarda Silva Pires, Luiz Eduardo de Góes Ladeia",10.9734/jammr/2024/v36i65453,https://doi.org/10.9734/jammr/2024/v36i65453,Journal of Advances in Medicine and Medical Research,0,2024,yes,"The abstract specifically focuses on patients taking bisphosphonates for osteoporosis treatment, excluding other conditions.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, as this is a literature review and not a primary study with control groups.",no,"While the abstract mentions ONJ, it doesn't specifically report incidence following the required dental procedures.",no,"This is an integrative literature review, which is NOT one of the accepted study designs (RCT, prospective cohort, retrospective cohort, or case-control).",no,"As a literature review, it doesn't have its own follow-up period or primary outcome documentation.",maybe,"While the abstract mentions ""advanced age"" as a risk factor, it doesn't explicitly specify that subjects are over 18. However, given the context of osteoporosis treatment, this is likely met.",no,"As this is a literature review, it doesn't have its own subject group size, so this criterion cannot be evaluated.",yes,"The abstract specifically mentions oral bisphosphonates for osteoporosis treatment, meeting this criterion.",no,The abstract does not mention specific diagnostic standards for MRONJ/ONJ.,Exclude,"This literature review fails to meet critical screening criteria, particularly the required study design of a randomized controlled trial, prospective cohort, retrospective cohort, or case-control study. While addressing bisphosphonates and osteoporosis, the abstract lacks specific documentation of control groups, subject size, diagnostic standards, and precise outcome measurements. The integrative review approach fundamentally disqualifies it from meeting the systematic review's methodological requirements.",0.1
OSTEONECROSIS OF THE JAW (ONJ) IN CANCER AND MYELOMA PATIENTS. A 16-YEAR EXPERIENCE OF “RETE ONCOLOGICA PIEMONTE–VALLE D’AOSTA” CANCER NETWORK,"M. Cabras, A. Gambino, F. Erovigni, Francesco Della Ferrera, R. Freilone, M. Pentenero, A. Fasciolo, M. Di Maio, G. Ramieri, M. Migliario, P. Appendino, V. Fusco",10.32388/YIVAW8,https://doi.org/10.32388/YIVAW8,Qeios,2,2021,no,"The study focuses on cancer/myeloma patients, not osteoporosis patients, which violates the inclusion criteria.",maybe,"The study documents time intervals between treatment and MRONJ occurrence (12-36 months), but not specifically for dental procedures.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures were involved in MRONJ cases.,yes,"The study is a retrospective survey, which is an acceptable study design.",maybe,"The study has a long follow-up period (16 years) and documents MRONJ incidence, but not specifically after dental procedures.",yes,"The study includes patients with a mean age of 68 (range 38-90), which meets the requirement of subjects being over 18 years old.",yes,"The study includes 691 patients, which is well above the 100-subject requirement.",no,"The study includes zoledronate (71.9%) and denosumab (5.3%), which are not oral bisphosphonates, violating the intervention criterion.",maybe,The abstract does not explicitly mention diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer and myeloma patients taking intravenous medications, which fundamentally conflicts with the screening criteria requiring osteoporosis patients on oral bisphosphonates. Critical exclusion factors include the wrong patient population, non-oral medication types, and absence of specific dental procedure documentation. These significant deviations render the study ineligible for the systematic review.",0.1
5PSQ-026 Medication-related osteonecrosis of the jaws andCDK4/6 inhibitors,"L. Domínguez Senín, D. Morales Pancorbo, MY Rodríguez Garcés, M. Rodriguez Jorge, M. Santos-Rubio, J. Bayo Calero",10.1136/ejhpharm-2023-eahp.250,https://doi.org/10.1136/ejhpharm-2023-eahp.250,Section 5: Patient safety and quality assurance,0,2023,no,"The study specifically focuses on cancer patients (breast, prostate, and lung cancer) taking denosumab, which explicitly violates the criterion requiring subjects to be osteoporosis patients.",maybe,"The study does document the time interval from start of medication to MRONJ incidence (mean 23 months), but not the time from dental procedure to MRONJ.",no,"The study does not include a control group of patients not taking anti-resorptive medications. It only compares patients with and without CDK4/6 inhibitors, both groups taking denosumab.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,yes,"The study is described as a ""retrospective observational study,"" which meets the criteria as a retrospective cohort study.",maybe,"While the study documents MRONJ incidence, it doesn't specify the follow-up period length.",maybe,"The abstract does not explicitly state the age of subjects. While cancer patients are typically adults, we cannot assume all subjects are over 18.",yes,"The study includes 363 patients total, with 267 in one group and 96 in the other, meeting the >100 subjects requirement.",no,"The study uses denosumab, which is not an oral bisphosphonate but rather a monoclonal antibody. This explicitly violates the criterion requiring oral bisphosphonates.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on cancer patients taking denosumab, which deviates from the required osteoporosis patient population and oral bisphosphonate intervention. Critical screening criteria were not met, including the absence of a control group, lack of dental procedure documentation, and use of a non-bisphosphonate medication. These fundamental discrepancies render the study ineligible for inclusion in the systematic review.",0.1
Preventive dental management of osteonecrosis of the jaws related to zoledronic acid treatment.,"JA Coello-Suanzes, V. Rollón-Ugalde, A. Castaño-Seiquer, E. Lledo-Villar, J. Herce-López, P. Infante-Cossio, Á. Rollón-Mayordomo",10.1111/odi.12842,https://doi.org/10.1111/odi.12842,Oral Diseases,9,2018,no,"The study specifically mentions patients with cancer, which is explicitly excluded in the criteria.",maybe,"The study documents the timing between medication start and dental procedures, as it compares groups based on when dental treatment was performed relative to ZA therapy.",no,"The study does not include a control group of patients not taking anti-resorptive medications, as both groups (A and B) are taking zoledronic acid.",yes,"The study does report MRONJ incidence following dental procedures, specifically mentioning dental extractions.",yes,"The study appears to be a prospective cohort study, which meets the criteria.",yes,"The study has a 6-year follow-up period, which exceeds the minimum requirement of 6 months.",maybe,"The abstract does not explicitly state the age range of the participants, so the age of the subjects is unclear.",yes,"The study includes 255 patients total, which exceeds the minimum requirement of 100 subjects in the medication group.",no,"The study uses intravenous zoledronic acid, which is explicitly excluded in the criteria (must be oral bisphosphonates).",no,The abstract does not explicitly mention the diagnostic standards used for BRONJ.,Exclude,"The study fails critical screening criteria by focusing on cancer patients and using intravenous zoledronic acid instead of oral bisphosphonates. Despite meeting some methodological requirements like sample size and follow-up period, the fundamental population and intervention characteristics disqualify the research from inclusion. The core exclusion criteria render the study non-compliant with the systematic review's specified parameters.",0.1
The effect of bisphosphonate discontinuation on the incidence of postoperative medication-related osteonecrosis of the jaw after tooth extraction,"Sang-Hoon Kang, Se-Jin Park, Moon-Key Kim",10.5125/jkaoms.2020.46.1.78,https://doi.org/10.5125/jkaoms.2020.46.1.78,Journal of the Korean Association of Oral and Maxillofacial Surgeons,23,2020,yes,"The study clearly focuses on patients taking bisphosphonates for osteoporosis, with no mention of cancer patients or mixed populations.",maybe,"The study documents the time interval between medication discontinuation and extraction (39.0±35.5 months), but doesn't clearly document the time from extraction to MRONJ incidence.",no,"The study compares BP-continuation vs BP-discontinuation groups, but does not include a true control group of patients not taking bisphosphonates.",yes,The study clearly reports MRONJ incidence following tooth extraction.,yes,"While not explicitly stated, this appears to be a retrospective or prospective cohort study comparing two groups.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of subjects, but given it's about bisphosphonate treatment for osteoporosis, it's likely adults. However, this is uncertain without explicit confirmation.",yes,"The study includes 179 patients in the BP-continuation group and 286 in the BP-discontinuation group, exceeding the 100-subject requirement.",maybe,"The study specifically focuses on bisphosphonate medication, though it doesn't explicitly specify oral administration. However, given the context of routine discontinuation, it's likely oral bisphosphonates.",no,The abstract doesn't mention specific diagnostic standards for MRONJ.,Include,"A study examining bisphosphonate treatment and medication-related osteonecrosis of the jaw (MRONJ) in patients undergoing tooth extraction, with a robust sample size and clear focus on osteoporosis patients. While meeting several key screening criteria, the research lacks a true control group and does not explicitly detail diagnostic standards or follow-up period, creating some uncertainty in its comprehensive assessment.",3.5
A primary prevention strategy: oral hygiene and correct lifestyles  among patients at risk of developing drug-related osteonecrosis of the Jaw,"Giovanna Mosaico, C. Casu",10.32388/BGMWYJ,https://doi.org/10.32388/BGMWYJ,Qeios,1,2021,no,"The abstract discusses both osteoporosis and bone cancer metastases patients, indicating a mixed population, which fails to meet the criterion requiring only osteoporosis patients.",no,"No specific time intervals are mentioned, so the criterion is not met.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While dental procedures are mentioned (tooth extraction, bone surgery), this appears to be in the context of prevention rather than reporting specific outcomes, so the criterion is not met.",no,"This appears to be a review article or treatise rather than a primary research study, as indicated by phrases like ""This treatise describes..."", so the criterion is not met.",no,"The abstract does not describe specific MRONJ incidence or follow-up periods, so the criterion is not met.",maybe,"The abstract does not explicitly specify age requirements, so the reasoning is uncertain.",maybe,"The abstract does not mention any specific number of subjects, so the reasoning is uncertain.",maybe,"While bisphosphonates are mentioned, the abstract also discusses denosumab and doesn't specify oral administration, so the criterion is only partially met.",no,"The abstract does not mention specific diagnostic standards for MRONJ, so the criterion is not met.",Exclude,"The abstract describes a review article on MRONJ prevention strategies, which fails to meet multiple critical screening criteria including study design, population specificity, and outcome documentation. As a non-primary research study with a mixed patient population and lack of specific diagnostic standards, the paper does not qualify for inclusion based on the established screening requirements.",0.1
Medication-related osteonecrosis of the jaw: Evidence for infection versus oversuppression.,"K. Fleisher, F. Muggia, R. Glickman",10.1200/JCO.2019.37.15_SUPPL.E18268,https://doi.org/10.1200/JCO.2019.37.15_SUPPL.E18268,Journal of Clinical Oncology,0,2019,no,"The study included a mixed population of both cancer patients (40) and osteoporosis patients (14), which violates the criterion requiring only osteoporosis patients.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract doesn't specify which dental procedures led to MRONJ, only mentioning ""surgical management"" of existing MRONJ.",yes,"The study is described as a ""retrospective cohort study,"" which meets this criterion.",yes,"The study has a follow-up period (average 10 months) and documents MRONJ outcomes, meeting this criterion.",maybe,"While not explicitly stated, the context suggests the study included adult patients (osteoporosis and cancer patients), but this was not definitively confirmed.",no,"The total sample size was 54 patients, with only 14 in the osteoporosis group, which is well below the required 100 subjects.",no,"The abstract mentions ""antiresorptive therapy"" but does not specify if it's oral bisphosphonates exclusively, and it appears to include various types of antiresorptive medications.",yes,"The abstract mentions diagnostic methods including ""nuclear imaging, computed tomography and/or cone beam computed tomography"" for identifying infected and necrotic bone.",Exclude,"The study fails key screening criteria due to a mixed patient population including cancer patients, a small sample size of only 14 osteoporosis patients, and lack of specificity regarding oral bisphosphonate medication. Critical methodological limitations include absence of a control group, unclear dental procedure documentation, and insufficient subject size for meaningful statistical analysis. These significant deviations from the required screening standards render the study unsuitable for inclusion.",1.4
Prediction of medication-related osteonecrosis of the jaws using machine learning methods from estrogen receptor 1 polymorphisms and clinical information,"Seo-Yong Choi, Jin-Woo Kim, Sang-Hyeon Oh, Seung-min Cheon, Jeong Yee, Sun-Jong Kim, H. Gwak, J. Chung",10.3389/fmed.2023.1140620,https://doi.org/10.3389/fmed.2023.1140620,Frontiers in Medicine,2,2023,yes,"The study specifically focuses on patients taking bisphosphonates for osteoporosis, with no mention of cancer patients or mixed populations.",no,"The study mentions ""treatment duration"" but doesn't specifically document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures were involved in MRONJ occurrence.,yes,The study appears to be a retrospective cohort study analyzing genetic factors and MRONJ occurrence.,maybe,"While MRONJ incidence is documented, the follow-up period is not specified in the abstract.",yes,"The study includes women with osteoporosis, and mentions age ≥72 years as a risk factor, indicating the population is over 18 years old.",yes,"The study includes 125 patients in the medication group, which meets the minimum requirement of 100 subjects.",maybe,"The abstract mentions ""bisphosphonates"" but doesn't specify if they are oral or intravenous, creating some uncertainty.",no,The abstract does not explicitly mention the diagnostic standards used for MRONJ.,Include,"A genetic study on osteoporotic women taking bisphosphonates reveals significant associations between ESR1 polymorphisms and medication-related osteonecrosis of the jaw, but lacks critical details about dental procedures, diagnostic standards, and intervention specifics. While meeting some basic screening criteria like population age and sample size, the research fails to provide comprehensive documentation of key methodological elements required for a definitive assessment.",2.7
Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) – A primary prevention strategy,"Abdulrhman Al Abdullateef, Muhanad Alhareky",10.1016/j.jsps.2020.05.004,https://doi.org/10.1016/j.jsps.2020.05.004,Saudi Pharmaceutical Journal,8,2020,no,The study includes mixed populations - both cancer patients and osteoporotic individuals. This explicitly violates the criterion requiring only osteoporosis patients.,no,"The study does not document time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The study does not report MRONJ incidence following specific dental procedures. It's focused on awareness assessment rather than outcomes.,no,"This is a prospective survey study, which doesn't match any of the required study designs (RCT, prospective cohort, retrospective cohort, or case-control).",no,The study does not document MRONJ incidence or have a follow-up period. It's a cross-sectional survey about awareness.,maybe,"While the study includes adults (mentions males and females), it doesn't explicitly state that all subjects are over 18. However, given the context, this is likely met.",no,"The study only includes 68 patients total, which is well below the required 100 subjects for the medication group.",no,"The study includes multiple medication types (Bisphosphonate, Denosumab, and anti-Angiogenic agents), not just oral bisphosphonates. This violates the criterion requiring only oral bisphosphonates.",no,The abstract does not mention any diagnostic standards for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including having a mixed patient population, insufficient sample size, and a survey design that does not match required study types. It lacks documentation of MRONJ incidence, diagnostic standards, and specific dental procedure outcomes, rendering it unsuitable for the systematic review. The research primarily focuses on patient awareness rather than meeting the specified methodological requirements.",0.1
"Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study","Yuqiong Zhou, Yejia Yu, Yueqi Shi, Meng-yu Li, Chi Yang, Shaoyi Wang",10.1155/2020/5847429,https://doi.org/10.1155/2020/5847429,BioMed Research International,11,2020,no,"The study includes patients with mixed medication use (bisphosphonates, chemotherapeutic agents, targeted drugs, and immunosuppressive agents), which fails to meet the criterion of focusing specifically on osteoporosis patients. This is a critical failure.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract doesn't mention any specific dental procedures leading to MRONJ, which is a critical failure.",yes,"The study is described as a retrospective study, which meets this criterion.",no,"While the study documents MRONJ outcomes, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, but Elicit notes that since it is a study of MRONJ patients, they are likely adults. However, this is uncertain without explicit confirmation.",no,"The study includes only 60 patients total, which is well below the required 100 subjects for the medication group.",no,"The study includes multiple types of medications beyond oral bisphosphonates, including chemotherapeutic agents and targeted drugs, which fails to meet the criterion of focusing only on oral bisphosphonates.",maybe,"The study mentions MRONJ staging (stage 2 and 3), suggesting some diagnostic standard, though specific criteria aren't detailed in the abstract.",Exclude,"The study fails to meet multiple critical screening criteria, including a mixed patient population with cancer patients, multiple medication types beyond oral bisphosphonates, and a small sample size of only 60 patients. Key disqualifying factors include the absence of specific dental procedures, lack of clear latency documentation, and deviation from the required focus on osteoporosis patients taking oral bisphosphonates. These significant departures from the inclusion criteria render the study unsuitable for the intended research parameters.",1.4
The Case of Lower Jaw Resection due to Medication-Induced Osteonecrosis Mronj,"Tsolov, G. Yordanov, T. Dushkova",10.20431/2456-0030.0501004,https://doi.org/10.20431/2456-0030.0501004,-,0,2020,no,"The abstract focuses on cancer patients and does not specify osteoporosis patients, which is a critical failure as it explicitly violates the exclusion of cancer patients criterion.",no,The abstract mentions timing for denosumab (14 doses) but not in the context of a specific study protocol.,maybe,"The abstract mentions a ""placebo group"" in the context of cancer patients, but it is unclear if this refers to a control group for the main study population.",no,"While dental extraction is mentioned, it is only in passing and not as part of a specific study protocol.",no,"The abstract appears to be a review article rather than any of the specified study designs, which is a critical failure.",no,The abstract does not describe any specific follow-up period or documentation of MRONJ incidence in a study population.,maybe,The abstract does not specify the age of the subjects.,maybe,The abstract does not mention the total number of subjects in any study group.,no,"While the abstract discusses bisphosphonates (zoledronate), it also focuses heavily on denosumab (a non-bisphosphonate) and appears to be a review of multiple medication types rather than a focused study on oral bisphosphonates.",no,The abstract does not mention any diagnostic standards for MRONJ.,Exclude,"The abstract fails multiple critical screening criteria, particularly by focusing on cancer patients and multiple medication types instead of a targeted osteoporosis population. It lacks key methodological details such as study design, subject size, and diagnostic standards, and appears to be a review article rather than a primary research study. The fundamental misalignment with the specified inclusion criteria renders the abstract unsuitable for further consideration.",0.1
"A Multi-Center Observation Study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in Patients with Osteoporosis, and Other Non-Malignant Bone Diseases, in Northwestern Italy over 16 Years","Dora Karimi, P. Arduino, A. Gambino, F. Erovigni, Alessandro Dell’Acqua, F. Pera, Massimo Carossa, M. Pentenero, P. Appendino, Francesco Della Ferrera, A. Fasciolo, Majlinda Caka, Mario Migliario, Matteo Brucoli, S. Franchi, Alessandro Pezzimenti, V. Fusco",10.3390/biomedicines12102179,https://doi.org/10.3390/biomedicines12102179,Biomedicines,0,2024,no,"The study includes patients with osteoporosis (87%) but also includes other conditions (13% including rheumatoid arthritis, Paget's disease, etc.). This mixed population violates the criterion.",maybe,"While the abstract mentions ""duration of therapy (when available)"" and ""onset time of disease,"" it doesn't clearly document the specific time intervals required.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not specify which dental procedures were associated with MRONJ cases.,yes,"This appears to be a retrospective cohort study analyzing cases from referral centers, which meets the criterion.",no,"While the study documents MRONJ cases over time, it doesn't specify the follow-up period or clearly document MRONJ incidence after specific dental treatments.",maybe,"The abstract doesn't explicitly state the age of subjects, but given it's focused on osteoporosis patients, we can reasonably assume they are adults. However, this is an assumption.",no,"The study includes 198 cases, which is below the required 100 subjects for the medication group at final analysis.",no,"The study includes both bisphosphonates (74%) and denosumab (6%), with 20% receiving a sequence of different drugs. This violates the criterion of only including oral bisphosphonates.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Include,"The study fails to meet multiple screening criteria, including population specificity, intervention type, and sample size requirements. While examining MRONJ cases in patients with osteoporosis and other bone diseases, the research includes mixed populations, non-bisphosphonate medications, and lacks clear documentation of diagnostic standards and dental procedures. The retrospective cohort study does not fully align with the predefined screening criteria for a comprehensive MRONJ investigation.",2.5
Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition,"M. Migliario, G. Mergoni, P. Vescovi, I. Martino, M. Alessio, L. Benzi, F. Renó, V. Fusco",10.3390/dj5010013,https://doi.org/10.3390/dj5010013,Dental journal,15,2017,yes,"The abstract clearly focuses on osteoporosis patients taking alendronate (a bisphosphonate), without mixing with cancer patients, so this criterion is met.",no,No specific time intervals are documented in the abstract.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,The abstract does not specify any dental procedures leading to MRONJ.,no,"This is explicitly a case report, which is specifically excluded in the criteria.",no,"While MRONJ is documented, there's no mention of follow-up period.",maybe,"While the abstract discusses osteoporosis patients, it doesn't explicitly state the age requirement. However, osteoporosis typically affects adults over 18, so the reasoning is that the age criterion is likely met.",no,"This is a case report of a single patient, which fails to meet the minimum requirement of 100 subjects.",yes,"The study mentions alendronate, which is an oral bisphosphonate, meeting this criterion.",maybe,"The abstract discusses MRONJ definition and mentions the AAOMS 2014 definition, partially meeting this criterion.",Exclude,"This case report fails multiple critical screening criteria, including being a single-patient study instead of a required cohort with over 100 subjects, and lacking specific documentation of dental procedures and follow-up periods. The paper's focus on a single osteoporosis patient taking alendronate does not meet the comprehensive research design requirements for inclusion in the study.",0.1
Surgical Management of Medication-Related Osteonecrosis of the Jaw Patients Related to Dental Implants.,"M. Nisi, R. Izzetti, S. Gennai, P. Bellini, F. Graziani, M. Gabriele",10.1097/SCS.0000000000006283,https://doi.org/10.1097/SCS.0000000000006283,The Journal of craniofacial surgery (Print),9,2020,no,"The study included a mixed population of ""osteoporotic and oncologic patients"", which explicitly violates the requirement for the research to specify that its subject is chosen from patients taking medication for osteoporosis, excluding cancer patients.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ onset.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The study focuses on peri-implant MRONJ, which is one of the specified procedures.",no,"The study is described as a case series, which is explicitly excluded in the criteria.",yes,"The study has a 12-month follow-up period, which exceeds the 6-month requirement.",maybe,"While the context suggests the study included adult patients, this was not definitively confirmed in the abstract.",no,"The study only included 15 patients total, which is well below the required 100 subjects for the medication group at the final statistical analysis stage.",maybe,"The abstract only mentions ""anti-resorptive/antiangiogenic drugs"" generally, without specifying oral bisphosphonates, so this criterion is not clearly met.",maybe,"The abstract mentions ""clinical diagnosis"" and ""MRONJ staging"" but does not specify the diagnostic standards, so this criterion is only partially met.",Exclude,"The study fails critical screening criteria due to its mixed patient population including oncologic patients, case series design, and extremely small sample size of only 15 patients. Multiple methodological limitations, including lack of a control group and unclear medication specifics, render the research unsuitable for systematic review inclusion. The paper's design and population fundamentally conflict with the predefined screening requirements.",0.1
Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.,"Ling-Ying Wei, S. Kok, Yen-Ching Lee, Wei-Yih Chiu, J. Wang, Shih-Jung Cheng, Hao-Hueng Chang, Jang-Jaer Lee",10.1016/j.jfma.2020.11.017,https://doi.org/10.1016/j.jfma.2020.11.017,Journal of the Formosan Medical Association = Taiwan yi zhi,7,2020,no,"The study specifically focuses on cancer patients (multiple myeloma, breast cancer, prostate cancer) taking zoledronic acid, not osteoporosis patients, which is a critical exclusion criterion.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract doesn't mention any specific dental procedures leading to MRONJ.,yes,"This is a retrospective cohort study, which is one of the accepted study designs.",maybe,"The study documents MRONJ outcomes with a 24-month follow-up period, but doesn't specify the timing of dental procedures.",maybe,"While not explicitly stated, the population appears to be adult cancer patients, so this criterion is likely met.",yes,"The study includes 133 patients with 150 MRONJ lesions, exceeding the 100-subject requirement.",no,"The study uses zoledronic acid, which is an intravenous bisphosphonate, not oral bisphosphonates as required.",no,The abstract doesn't explicitly mention diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients taking intravenous zoledronic acid, which fundamentally conflicts with the screening criteria requiring osteoporosis patients on oral bisphosphonates. Critical exclusion factors include the wrong patient population, medication type, and absence of specific dental procedure documentation. Multiple core screening requirements were not met, rendering the study ineligible for inclusion.",0.1
The progress of medication-related osteonecrosis of the jaw with conservative initial treatment: A 12-year retrospective study of 129 patients,"N. Kaibuchi, K. Hoshi, A. Yamazaki, Noriko Miyamoto-Sangu, Y. Akagi, T. Okamoto",10.1016/j.bonr.2021.101072,https://doi.org/10.1016/j.bonr.2021.101072,Bone Reports,16,2021,no,"The study includes both osteoporosis and cancer patients, which violates the requirement for a pure osteoporosis population.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The abstract mentions ""teeth extraction or others"" as triggers for MRONJ, meeting this criterion.",yes,"This is a retrospective study, which is one of the accepted study designs.",yes,"The study clearly documents MRONJ outcomes with follow-up periods of 12, 36, and 60 months, exceeding the 6-month requirement.",yes,"While not explicitly stated, the context of osteoporosis treatment suggests this appears to be an adult population.",yes,"The study includes 129 patients total, with 57 having osteoporosis, which meets the requirement of >100 subjects, though just barely for the osteoporosis subgroup.",no,"The study includes both bisphosphonates and denosumab, which violates the requirement for only oral bisphosphonates.",maybe,"The abstract mentions following ""the position paper of the American Association of Oral and Maxillofacial Surgeons"" for treatment, but doesn't explicitly state diagnostic standards.",Include,"The study fails key screening criteria by including a mixed population of osteoporosis and cancer patients, and by incorporating non-bisphosphonate medications like denosumab. Despite meeting several other criteria such as study design and outcome documentation, the fundamental violations of population and intervention type render the research unsuitable for inclusion. The lack of a control group and unclear diagnostic standards further compromise the study's alignment with the specified screening requirements.",2.5
Clinical and Radiographic Features of Peri-Implant Medication-Related Osteonecrosis of the Jaw: A Retrospective Study.,"Hyeon-Gyu Jo, Wonse Park, In-Ho Cha, Young-Soo Jung, Da Yun Lee, Jun-Young Kim",10.1111/cid.13412,https://doi.org/10.1111/cid.13412,Clinical Implant Dentistry and Related Research,0,2024,no,"The study focuses on patients taking anti-resorptive drugs (ARDs), but doesn't specifically mention osteoporosis. It appears to be a mixed population study, which is excluded by the criteria.",maybe,"The abstract mentions ""time of ARD therapy"" but doesn't clearly document the specific time intervals required, so the reasoning is uncertain.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study focuses on implant placement and its relationship to MRONJ, which meets this criterion.",yes,"The study is described as retrospective, which meets the criteria as a retrospective cohort study.",maybe,"The study period is 2018-2022 (4 years), which exceeds the 6-month minimum follow-up requirement. However, individual patient follow-up periods aren't specified, so the reasoning is partially met.",maybe,"While not explicitly stated, the context suggests adult patients, but this isn't definitively confirmed, so the reasoning is uncertain.",no,"The study includes 75 patients, which is below the required 100 subjects for the medication group.",no,"The abstract only mentions ""anti-resorptive drugs"" generally, without specifying oral bisphosphonates. This is too broad and doesn't meet the criteria.",maybe,"While the study discusses PI-MRONJ, it doesn't explicitly mention diagnostic standards, so the reasoning is uncertain.",Include,"The study fails to meet several critical screening criteria, including insufficient sample size (75 patients), lack of specificity regarding osteoporosis patients, and absence of a control group. While the research design is retrospective and addresses implant-related MRONJ, key methodological requirements are not satisfied, significantly reducing its potential for inclusion. Multiple uncertain elements and non-compliance with specified screening standards further compromise the study's eligibility.",2.5
[Risk assessment in patients undergoing osseous antiresorptive therapy in dentistry. An update].,"Jan Borm, S. Moser, M. Locher, G. Damerau, B. Stadlinger, K. Grätz, C. Jacobsen",-,-,Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia,6,2013,no,"The abstract mentions both osteoporosis and cancer patients, indicating a mixed population, which fails to meet the criterion requiring exclusive focus on osteoporosis patients.",no,"No mention of time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract mentions oral implantation but doesn't specifically report MRONJ incidence following specific dental procedures, so it fails to meet the criterion requiring reporting of MRONJ incidence after dental procedures.",no,"This appears to be a review article/guideline paper, not one of the required study designs (RCT, cohort, or case-control), so it fails to meet the study design criterion.",no,"The paper appears to be a review/guideline rather than reporting specific MRONJ incidence with follow-up periods, so it fails to meet the criterion requiring clear documentation of MRONJ incidence and a follow-up period of at least 6 months.",maybe,"The abstract does not explicitly specify age requirements, so the reasoning for this criterion is uncertain.",no,"The abstract does not mention any specific number of subjects, and it appears to be a review/guideline paper rather than an original research study, so it fails to meet the criterion requiring over 100 subjects in the medication group.",no,"The abstract discusses both oral and intravenous bisphosphonates, and appears to be a general review rather than focusing specifically on oral bisphosphonates, so it fails to meet the criterion requiring only oral bisphosphonate medication.",maybe,"While the paper discusses BRONJ, it doesn't explicitly mention diagnostic standards in the abstract, so the reasoning for this criterion is uncertain.",Exclude,"This review article fails multiple screening criteria, including lack of a specific study design, mixed patient population, and absence of original research data. The paper appears to be a clinical guideline focused on bisphosphonate-related osteonecrosis, rather than a research study meeting the systematic review's methodological requirements. Consequently, it does not qualify for inclusion based on the predefined screening criteria.",0.1
10-Year Institutional Retrospective Case-Control Study of Medication-Related Osteonecrosis of the Jaw,"Pardis Barati Mahvar, Amna Imran, R. Enciso, Andrew Sanapanya, M. Khalifeh, P. Sedghizadeh, Laurel Henderson",10.1080/19424396.2019.12220864,https://doi.org/10.1080/19424396.2019.12220864,Journal - California Dental Association,0,2019,maybe,"The abstract mentions ""antiresorptive therapy"" (ART) but does not specify that the subjects were chosen from patients taking medication for osteoporosis, and does not explicitly exclude cancer patients or mixed populations.",no,"The abstract does not provide any information about the time intervals between the start of medication, dental procedures, and MRONJ incidence.",yes,"The study included a control group of patients not taking anti-resorptive medications, which is relevant to the criterion.",no,The abstract does not mention any specific dental procedures that led to MRONJ.,yes,"The abstract explicitly states that the study design was a ""retrospective case-control study"", which meets the criterion.",maybe,"The abstract documents MRONJ incidence, but does not specify the follow-up period, so it is unclear if it meets the requirement of at least 6 months.",maybe,"The abstract did not provide any information about the age of the subjects, so it is unclear if the population meets the age requirement of over 18 years old.",yes,"The study included 223 MRONJ patients and 615 non-MRONJ patients, which exceeds the requirement of over 100 subjects for the medication group.",maybe,"The abstract only mentions ""antiresorptive therapy"" generally and does not specify that the subjects were taking oral bisphosphonate medication for osteoporosis treatment.",no,The abstract does not mention any diagnostic standards for MRONJ.,Include,"A retrospective case-control study examining medication-related osteonecrosis of the jaw presents promising sample sizes and study design, but lacks critical details about patient population, intervention specifics, and diagnostic standards. Significant information gaps exist regarding patient age, medication type, dental procedures, and follow-up period, creating uncertainty about the study's comprehensive eligibility.",2.9
Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.,"G. Favia, A. Tempesta, L. Limongelli, V. Crincoli, E. Maiorano",10.3290/j.qi.a35263,https://doi.org/10.3290/j.qi.a35263,Quintessence International,7,2016,yes,"The study specifically focuses on osteoporosis patients, excluding cancer patients.",no,"The abstract mentions ""long-term"" treatment but doesn't document specific time intervals.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract doesn't specify which dental procedures led to MRONJ.,no,"This appears to be a case series of 8 patients, which is explicitly excluded in the criteria.",maybe,"While outcomes are documented, the follow-up period is not specified.",yes,"While not explicitly stated, the subjects are described as ""female patients"" with osteoporosis, implying an adult population.",no,"The study only includes 8 patients, which is well below the required 100 subjects.",no,"The study includes patients who switched from oral bisphosphonates to intravenous zoledronic acid, which fails the criterion as it includes intravenous medication and mixed treatment types.",no,"While MRONJ is diagnosed, the abstract doesn't specify the diagnostic standards used.",Exclude,"The study fails multiple critical screening criteria, including an insufficient sample size of only 8 patients, a case series design, and mixed intervention types involving intravenous medication. Key methodological limitations include the absence of a control group, lack of specified dental procedures, and unclear diagnostic standards for MRONJ. These deficiencies render the study unsuitable for inclusion in the systematic review.",0.1
Surgical Therapy in Patients With Medication-Related Osteonecrosis of the Jaw Is Associated With Disease Resolution and Improved Quality of Life: A Prospective Cohort Study.,"M. El-Rabbany, N. Blanas, S. Sutherland, D. Lam, P. Shah, A. Azarpazhooh",10.1016/j.joms.2022.01.012,https://doi.org/10.1016/j.joms.2022.01.012,Journal of oral and maxillofacial surgery,5,2022,no,"The abstract does not specify whether the patients were taking medication for osteoporosis or other conditions, which is a critical missing piece of information.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, which is a significant limitation.",no,"The abstract does not mention any specific dental procedures leading to MRONJ. Instead, it focuses on comparing operative vs. nonoperative treatment of existing MRONJ.",yes,"The abstract explicitly states this is a ""prospective cohort study,"" which meets this criterion.",yes,"The study does have a 6-month follow-up period and documents MRONJ outcomes, meeting this criterion.",maybe,"The abstract does not explicitly state the age of subjects, though given it's a study of MRONJ patients, they are likely adults. However, this is uncertain without explicit confirmation.",no,"The study includes 60 total patients (40 operative, 20 nonoperative), which is below the required 100 subjects for the medication group.",no,"The abstract does not specify the type of medication patients were taking, so it cannot be confirmed if they were taking oral bisphosphonates.",no,"While the study mentions MRONJ, it does not explicitly state its diagnostic standards.",Include,"The study fails to meet multiple critical screening criteria, including insufficient sample size, lack of a control group, and unclear medication type. While the research design is a prospective cohort study, key details about patient population, dental procedures, and diagnostic standards are missing. The abstract provides insufficient information to confirm alignment with the comprehensive screening requirements.",2.5
Medication-related osteonecrosis of the jaw using periodontitis-induced rat before tooth extraction,"Kyeong-Mee Park, Ji-Sook Cheong, N. Pang, K. Kim, Jung-Seok Lee, W. Park",10.1186/s12903-023-03200-x,https://doi.org/10.1186/s12903-023-03200-x,BMC Oral Health,3,2023,no,"The study uses ovariectomized rats with induced osteoporosis, not human patients taking medication for osteoporosis, so it does not meet the population indication requirement.",yes,"The study documents the time interval (8 weeks) between tooth extraction and MRONJ assessment, which meets the MRONJ latency requirement.",yes,"The study includes a control group (CONT group) receiving saline, which meets the requirement for a control group.",yes,"The study examines MRONJ following tooth extraction, which meets the procedure and outcome requirement.",maybe,"While this is a controlled experimental study, it's an animal study rather than one of the specified human study designs, so it only partially meets the study design requirement.",yes,"The study clearly documents MRONJ incidence and has a follow-up period of 8 weeks, which meets the outcome documentation requirement.",no,"This is an animal study using rats, not human subjects over 18 years old, so it does not meet the age requirement.",no,"The study only includes 24 rats total (12 per group), well below the required 100 subjects, so it does not meet the subject size requirement.",no,"The study uses zoledronic acid (ZA), which is an intravenous bisphosphonate, not oral bisphosphonates, so it does not meet the intervention type requirement.",maybe,"While the study documents MRONJ through histological and radiological findings, it's not clear if these meet standard diagnostic criteria, so it only partially meets the diagnostic standard for MRONJ requirement.",Exclude,"This animal study using rats fails to meet multiple critical screening criteria, including human subject requirements, population size, and intervention type. Specifically, the research uses an intravenous bisphosphonate in an experimental rat model with only 24 subjects, which fundamentally disqualifies it from the systematic review's inclusion standards. The study's methodology and subject population do not align with the specified research parameters.",0.1
Bisphosphonate-Related Osteonecrosis of the Jaw.,"Hsin-I Chien, Lee-Wei Chen, Wen-Chung Liu, Cheng-Ta Lin, Yen-Yi Ho, Wei-Hsuan Tsai, Kuo‐Chung Yang",10.1097/SAP.0000000000002650,https://doi.org/10.1097/SAP.0000000000002650,Annals of Plastic Surgery,5,2020,no,"The study includes a mixed population of cancer patients (multiple myeloma and breast cancer) and osteoporosis patients, which violates the requirement for only osteoporosis patients.",maybe,"The study documents drug duration (25.86 ± 27.23 months for cancer, 58.33 ± 23.87 months for osteoporosis) but doesn't clearly document the time interval between medication start and dental procedure, so it partially meets this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"While the abstract mentions that ""most patients with BRONJ undergo dental procedures,"" it doesn't specifically report MRONJ incidence following the required dental procedures.",no,"This appears to be a case series, which is explicitly excluded in the criteria.",yes,"The study has follow-up periods (22.71 ± 14.46 months for cancer, 28.08 ± 36.35 months for osteoporosis), exceeding the 6-month requirement, so this criterion is met.",yes,"The study includes patients with average ages of 63.57 ± 14.54 years (cancer) and 79.5 ± 9.31 years (osteoporosis), all over 18 years old, so this criterion is met.",no,"The study only includes 13 total patients (4 cancer + 3 cancer + 6 osteoporosis), well below the required 100 subjects.",maybe,"While the study mentions antiresorptive agents and bisphosphonates, it doesn't specify that only oral bisphosphonates were used, so the reasoning is unclear.",yes,"The study mentions using the American Association of Oral and Maxillofacial Surgeons classification for staging, so this criterion is met.",Exclude,"The study fails key screening criteria due to its small sample size of 13 patients, mixed population including cancer patients, and case series design. Critical methodological limitations include lack of a control group, insufficient subject numbers, and absence of specific dental procedure outcomes. These fundamental issues disqualify the research from meeting the systematic review's rigorous screening requirements.",1.4
"Complementarity of Photo-Biomodulation, Surgical Treatment, and Antibiotherapy for Medication-Related Osteonecrosis of the Jaws (MRONJ)","D. Nica, Mircea Riviș, C. Roi, C. Todea, Virgil-Florin Duma, C. Sinescu",10.3390/medicina57020145,https://doi.org/10.3390/medicina57020145,Medicina,16,2021,no,"The abstract mentions patients ""previously exposed to antiresorptive or anti-angiogenic therapy"" but does not specifically state they were taking medication for osteoporosis. It appears to be a mixed population including both antiresorptive and anti-angiogenic therapy patients, which fails this criterion.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract does not specify which dental procedures were performed, only mentioning ""surgical treatment"" generally.",maybe,"The abstract does not clearly state the study design, so it is unclear if it is one of the accepted study designs.",maybe,"While the study documents MRONJ outcomes, the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, so the age of the population is unclear.",yes,"The study includes 241 total patients, with 108 in the surgical group, which meets the criterion of over 100 subjects.",no,"The abstract does not specify oral bisphosphonates, only mentioning ""antiresorptive or anti-angiogenic therapy"" which is too broad and includes non-bisphosphonate medications, failing this criterion.",maybe,"The abstract mentions different stages of MRONJ (0, 1, 2, 3) but does not explicitly state the diagnostic standards used.",Include,"The study involves a mixed population of patients on antiresorptive and anti-angiogenic therapies, which deviates from the specific requirement of oral bisphosphonate users for osteoporosis. Critical screening criteria were not met, including lack of a control group, unclear study design, and absence of specific dental procedure details. The research fails to align with the precise methodological requirements for the intended review.",2.5
Anatomical factors in medication-related osteonecrosis of the jaws,"J. A. Correia, A. Lóio, I. Furtado, A. Capelo, C. Caldas, N. Santos, F. Salvado",10.1080/07853890.2021.1897445,https://doi.org/10.1080/07853890.2021.1897445,Annals medicus,1,2021,no,"The abstract mentions ""antiresorptive and antiangiogenic drugs"" but doesn't specifically state these are for osteoporosis treatment. It appears to be a mixed population including both antiresorptive and antiangiogenic drugs, which fails this criterion.",maybe,"The abstract mentions ""length of antiresorptive or antiangiogenic medication"" but doesn't document specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,maybe,"The abstract mentions ""dentoalveolar surgery"" and ""dental prosthesis"" but doesn't clearly report MRONJ incidence following specific dental procedures.",yes,"This is a retrospective study, which meets the criterion.",maybe,"While the study documents MRONJ cases, it doesn't clearly specify the follow-up period.",yes,"The mean age of the subjects is 68.12 ± 11.02 years, which meets the >18 years criterion.",yes,"The study includes 147 patients, which meets the >100 subjects requirement.",no,"The abstract mentions ""antiresorptive and antiangiogenic drugs"" but doesn't specify oral bisphosphonates. This is too broad and fails this criterion.",maybe,"While the study mentions ""MRONJ diagnosis,"" it doesn't explicitly state the diagnostic standards used.",Include,"The study involves a mixed population of patients taking antiresorptive and antiangiogenic drugs, which fails the specific requirement for osteoporosis medication. While the research includes a sufficient sample size and appropriate study design, it lacks clear specification of oral bisphosphonate intervention and does not meet several critical screening criteria. The broad medication classification and absence of precise diagnostic standards prevent the study from fully aligning with the systematic review requirements.",2.5
"Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.","A. yuan, A. Munz, S. Reinert, S. Hoefert",10.1016/j.oooo.2019.08.018,https://doi.org/10.1016/j.oooo.2019.08.018,"Oral surgery, oral medicine, oral pathology and oral radiology",12,2020,no,"The study includes patients taking bisphosphonates and denosumab, but does not specify if they are specifically for osteoporosis treatment. It appears to be a mixed population including various conditions.",no,"No information about time intervals between medication start, dental procedures, and MRONJ incidence is provided.",maybe,"The abstract mentions ""healthy individuals"" but does not clearly describe a control group in the traditional sense, so the reasoning for this criterion is unclear from the abstract.",no,The abstract does not mention any dental procedures or MRONJ incidence following procedures. It focuses on histological analysis of existing MRONJ cases.,no,"This appears to be a histological analysis study, which does not fit into any of the specified study design categories.",no,The study does not document MRONJ incidence after dental treatment or follow-up periods. It is a cross-sectional histological analysis.,no,"The abstract does not specify the age of the subjects, so this information is missing.",maybe,"The study includes 105 patients total, but does not specify how many were in the medication group, so this information is unclear.",no,"The study includes both bisphosphonates and denosumab, which does not meet the criterion of only oral bisphosphonates. Additionally, the route of administration is not specified.",no,"While the study examines MRONJ, it focuses on histological features rather than diagnostic standards.",Exclude,"This histological study examining medication-related osteonecrosis of the jaw fails to meet multiple critical screening criteria, including lack of a clear control group, unspecified patient age, mixed medication population, and absence of dental procedure outcomes. The research focuses on microscopic tissue analysis rather than clinical MRONJ incidence, rendering it incompatible with the systematic review's requirements.",1.4
Antiresorptive medication in oncology: the clinical and dental profile of patients in a reference center,"V. C. Ferreira, A. Kemp, J. Vendruscolo, L. Sassi, J. Schussel",10.5125/jkaoms.2021.47.1.20,https://doi.org/10.5125/jkaoms.2021.47.1.20,Journal of the Korean Association of Oral and Maxillofacial Surgeons,0,2021,no,"The study specifically focuses on patients taking antiresorptive medications for cancer treatment, not osteoporosis, which is a critical exclusion criterion.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract doesn't specify which dental procedures were performed or their relationship to MRONJ incidence.,no,"The study is described as an ""observational cross-sectional study"" which doesn't clearly fit into the accepted study designs (RCT, prospective cohort, retrospective cohort, or case-control).",no,"While MRONJ incidence is reported (10%), the follow-up period is not specified.",yes,"The study includes patients with a mean age of 61 years, which meets the requirement of being over 18 years old.",no,"The study includes 90 patients total, which is below the required 100 subjects for the medication group.",no,"The study specifically mentions using intravenous bisphosphonate (zoledronic acid), which is explicitly excluded in the criteria.",no,The abstract doesn't explicitly mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on cancer patients taking intravenous bisphosphonates, which critically deviates from the required osteoporosis patient population and oral bisphosphonate intervention. With a sample size below 100 and a cross-sectional design that doesn't match accepted study types, the research fails to meet multiple essential screening criteria for inclusion.",0.1
[ALGORITHM FOR TREATMENT PATIENTS WITH MEDICAL OSTEONEKROSIS OF JAWS BY CORRECTING ORAL MICROBIOTAL DISORDERS].,"T. Ivanyushko, K. Polyakov, L. Arazashvili, A. Simonova",-,-,Georgian medical news,0,2021,no,"The study specifically focuses on cancer patients taking Zometa for tumor metastasis, which is explicitly excluded in the criteria.",no,"The study does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study includes a control group of 10 healthy individuals, which meets the requirement for a control group.",no,"While the study mentions surgical treatment, it is not specifically for the dental procedures listed in the criteria, and the focus is on microbiota analysis and treatment outcomes rather than MRONJ incidence after dental treatment.",maybe,"The study design is not explicitly stated in the abstract, so it is unclear if it meets the requirement for a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",maybe,"The study has a 6-month follow-up period and documents relapse rates, but it does not clearly document the initial MRONJ incidence after dental treatment.",yes,"The subjects in the study are aged 55-76 years, which meets the requirement for the population to be over 18 years old.",no,"The study only includes 22 patients with MRONJ, which is below the required 100 subjects for the medication group.",no,"The study uses intravenous Zometa (zoledronic acid), not oral bisphosphonates, and the medication is for cancer treatment, not osteoporosis.",no,The study does not mention its diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients taking intravenous Zometa, which fundamentally conflicts with the screening criteria requiring osteoporosis patients on oral bisphosphonates. With a small sample size of 22 patients and a cancer-specific treatment context, the research fails to meet multiple critical screening requirements. Consequently, the study does not qualify for inclusion in the systematic review.",0.1
Dental management in Oncology patient: osteonecrosis related osteonecrosis of the Jaw (MRONJ),P. Noemi,10.31579/2690-4861/058,https://doi.org/10.31579/2690-4861/058,-,0,2020,no,"The abstract focuses on ""oncological patients"" taking antiresorptives, which explicitly violates the criterion of excluding cancer patients.",no,No specific time intervals are documented.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,The abstract does not report specific MRONJ incidence following dental procedures. It only discusses general treatment approaches.,no,This appears to be a review or commentary paper rather than any of the specified study designs. It discusses recommendations and consensus but doesn't present original research.,no,The abstract does not document specific MRONJ incidence or follow-up periods.,maybe,"The abstract does not specify the age of the subjects, so the age criterion is unknown.",maybe,"The abstract does not mention any specific number of subjects, so the subject size criterion is unknown.",no,"While the abstract mentions bisphosphonates (BPs), it also discusses other antiresorptive drugs and antiangiogenic drugs, making it a mixed intervention study.",no,"While MRONJ is discussed, specific diagnostic standards are not mentioned.",Exclude,"The abstract fails multiple screening criteria, particularly by focusing on oncological patients and discussing mixed antiresorptive medications, which violates the specified population and intervention requirements. Lacking a control group, specific subject size, diagnostic standards, and clear outcome documentation, the paper does not meet the essential methodological standards for the intended research review.",0.1
Diagnosis and management of antiresorptive-related osteonecrosis of the jaw.,S. Ruggiero,-,-,General dentistry,1,2013,maybe,"While the abstract discusses antiresorptive medications for bone remodeling and metabolism, it does not specifically focus on osteoporosis patients or exclude cancer patients, so it only partially meets this criterion.",maybe,"The abstract mentions ""duration of exposure"" but does not document specific time intervals, so it only partially meets this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract mentions ""dentoalveolar trauma"" but does not specifically detail the dental procedures listed in the criteria, so it only partially meets this criterion.",no,"The abstract mentions ""retrospective, prospective, and case-controlled studies"" but appears to be a review article rather than a primary research study, so it does not meet this criterion.",maybe,"While the abstract discusses MRONJ, it does not specify follow-up periods or clearly document incidence rates, so it only partially meets this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention the sample size of the study, so the reasoning for this criterion is uncertain.",maybe,"The abstract discusses ""antiresorptive medications"" broadly but does not specify oral bisphosphonates exclusively, so it only partially meets this criterion.",maybe,"The abstract mentions that studies have ""defined the diagnosis"" but does not specify the diagnostic standards used, so it only partially meets this criterion.",Include,"The abstract appears to be a literature review that lacks specific methodological details required by the screening criteria, with significant gaps in documenting control groups, precise population characteristics, and specific intervention types. Multiple screening criteria are only partially met or remain uncertain, suggesting the text does not qualify as a primary research study meeting the comprehensive requirements. The broad, general nature of the discussion prevents definitive alignment with the detailed screening standards.",2.5
Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression,"A. Badros, M. Meddeb, D. Weikel, S. Philip, Todd Milliron, R. Lapidus, L. Hester, O. Goloubeva, T. Meiller, E. Mongodin",10.3389/fonc.2021.704722,https://doi.org/10.3389/fonc.2021.704722,Frontiers in Oncology,10,2021,no,"The study specifically focuses on multiple myeloma patients, not osteoporosis patients. This is a clear violation of the inclusion criteria.",maybe,"The study documents time from MM diagnosis to BRONJ development (median 5.7 years), but doesn't clearly document the time from medication start to dental procedure.",no,The abstract does not mention a control group of patients not taking bisphosphonates.,no,"While the study mentions periodontal disease as a risk factor, it doesn't specifically report MRONJ incidence following specific dental procedures.",yes,"The study is described as a ""single center observational prospective study,"" which meets the criteria for acceptable study designs.",yes,"The study has an 18-month follow-up period, which meets the 6-month minimum requirement.",maybe,"While not explicitly stated, the population consists of multiple myeloma patients, who are typically adults over 18. However, this is not explicitly confirmed.",yes,"The study includes 110 patients, which meets the requirement of >100 subjects.",maybe,"The abstract mentions ""bisphosphate (BP) therapy"" but doesn't specify if it's oral or intravenous. This is unclear.",no,The abstract doesn't explicitly mention diagnostic standards for BRONJ (which is the same as MRONJ).,Exclude,"The study focuses on multiple myeloma patients taking bisphosphonates, which critically fails the screening criteria requiring an osteoporosis patient population. Multiple other screening criteria were not met, including lack of a control group, unclear intervention type, and absence of specific dental procedure documentation. The research does not align with the systematic review's predefined inclusion requirements.",1.4
Risk profile for antiangiogenic agent-related osteonecrosis of the jaws,"R. Caminha, G. Chicrala, Luiz Alberto Valente Soares Júnior, P. S. Santos",10.31744/einstein_journal/2019RW4628,https://doi.org/10.31744/einstein_journal/2019RW4628,Einstein,10,2019,no,"The study focuses on patients taking antiangiogenic agents for cancer treatment, not osteoporosis, which is a clear violation of the inclusion criteria.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,The abstract does not specify any particular dental procedures leading to osteonecrosis.,no,"The paper is explicitly described as case reports, which is specifically excluded in the criteria.",maybe,"While the abstract mentions osteonecrosis, it does not specify a follow-up period.",maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",no,"The abstract mentions 19 case reports, which is well below the required 100 subjects for the medication group.",no,"The study examines antiangiogenic agents, not oral bisphosphonates, which is a clear violation of the inclusion criteria.",yes,"The abstract does mention a diagnostic standard for osteonecrosis (""exposure of necrotic bone in the oral cavity that does not heal over a period of 8 weeks"").",Exclude,"The study focuses on antiangiogenic agents for cancer patients, which fundamentally differs from the required osteoporosis and bisphosphonate medication criteria. Multiple critical screening requirements are unmet, including study design, population type, intervention, and sample size. The research does not align with the systematic review's specified parameters and would be excluded from further consideration.",0.1
Medication-Related Osteonecrosis of Jaw,Jang-Jaer Lee,10.1142/9789811220814_0010,https://doi.org/10.1142/9789811220814_0010,Osteoporosis of the Spine,0,2021,no,"While the abstract mentions osteoporosis, it appears to be a book chapter or review rather than a primary research study with specific patient populations, so Elicit could not confirm whether this criterion was met.",no,"There is no mention of time intervals, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention any control group, so Elicit could not confirm whether this criterion was met.",no,"While MRONJ is discussed, there's no specific mention of dental procedures or their relationship to MRONJ incidence, so Elicit could not confirm whether this criterion was met.",no,"This appears to be a book chapter or review article, not a primary research study with any of the required study designs, so Elicit determined that this criterion was not met.",no,"No specific documentation of MRONJ incidence or follow-up periods is mentioned, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not specify the age requirements of the study population, so Elicit could not confirm whether this criterion was met.",no,"The abstract does not mention the number of subjects in the study, so Elicit could not confirm whether this criterion was met.",no,"While ""Agents for Anti-Bone Resorption"" is mentioned, there's no specific focus on oral bisphosphonates, so Elicit could not confirm whether this criterion was met.",no,"While MRONJ is discussed, specific diagnostic standards are not mentioned in the abstract, so Elicit could not confirm whether this criterion was met.",Exclude,"This book chapter or review article fails to meet multiple critical screening criteria, particularly the requirement for a primary research study design. The abstract lacks specific details about patient populations, intervention types, control groups, and outcome measurements necessary for systematic review inclusion. Consequently, the document does not provide sufficient methodological information to qualify for further analysis.",0.1
CURATIVE RATES OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW FOLLOWING APPLICATION OF THE SICMF-SIPMO SURGICAL TREATMENT ALGORITHM,"G. Bettini, G. Saia, E. Perra, L. Tognin, Piero Franco, G. Bedogni, A. Bedogni",10.32388/LVB61W,https://doi.org/10.32388/LVB61W,Qeios,3,2021,no,"The study includes both cancer and osteoporosis patients, which violates the criterion requiring a population specifically taking medication for osteoporosis. This is a critical failure.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract does not mention any specific dental procedures leading to MRONJ, only discussing treatment of existing MRONJ. This is a critical failure.",yes,"The study is described as a ""10-years longitudinal cohort study,"" which meets the acceptable study design criteria.",maybe,"While the study has a 12-month follow-up period (meeting the 6-month minimum), it focuses on treatment outcomes rather than MRONJ incidence after dental procedures.",maybe,"The abstract does not explicitly state the age of the subjects, but Elicit notes that since it is a study of MRONJ patients, they are likely adults. However, this is uncertain without explicit confirmation.",no,"The study includes 70 patients at 12-month follow-up, which is below the required 100 subjects for the medication group.",maybe,"The abstract does not specify the type of anti-resorptive medication used, only mentioning ""medication-related"" osteonecrosis. This is a significant uncertainty.",yes,"The study mentions using ""SICMF-SIPMO clinico-radiological diagnostic criteria,"" meeting this criterion.",Exclude,"The study fails critical screening criteria by including a mixed population of cancer and osteoporosis patients, lacking specific dental procedure details, and having a sample size below the required threshold. Multiple methodological limitations, including unclear medication type and absence of a control group, further compromise the study's alignment with systematic review requirements. The research does not meet the essential screening standards for inclusion.",1.4
Identification of Potentially Pathogenic Variants Associated with Recurrence in Medication-Related Osteonecrosis of the Jaw (MRONJ) Patients Using Whole-Exome Sequencing,"Songmi Kim, Seyoung Mun, Wonseok Shin, Kyudong Han, Moon-Young Kim",10.3390/jcm11082145,https://doi.org/10.3390/jcm11082145,Journal of Clinical Medicine,5,2022,no,"The abstract mentions that the study included both osteoporosis and cancer patients, indicating a mixed population, which fails to meet the criterion requiring an exclusive focus on osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"While the abstract mentions ""tooth extraction and dental trauma"" as causes of MRONJ, it does not report MRONJ incidence following specific dental procedures.",no,"This appears to be a genetic study using whole-exome sequencing, not one of the specified study designs (RCT, cohort, or case-control).",no,The study does not appear to track MRONJ incidence over time or document follow-up periods.,yes,"While the abstract does not explicitly state that all subjects are over 18 years old, it can be reasonably inferred from the context that the study focused on women with postmenopausal osteoporosis, which typically occurs in adults over 18.",no,"The study only included 10 MRONJ patients, which is well below the required 100 subjects for the medication group at the final statistical analysis stage.",maybe,"The abstract mentions bisphosphonates but does not specify whether they are oral or intravenous, so the intervention type is uncertain.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including a mixed patient population, extremely small sample size of only 10 patients, and a genetic research design that does not match the required clinical study types. Key deficiencies include lack of specific diagnostic standards, absence of clear dental procedure outcomes, and no documentation of MRONJ latency or follow-up periods. The research appears to be a genetic variant identification study rather than a clinical investigation of medication-related osteonecrosis of the jaw.",0.1
Medication-related osteonecrosis of the jaw in patients with bone metastases from solid tumors: analysis of the Istituto Oncologico Veneto case series,"Selma Ahcene-Djaballah, S. zovato, C. Bacci, G. Bettini, M. Maruzzo, F. Di Sarra, A. M. Ferrara, A. Brunello, V. Guarneri, E. Lamberti, C. Falci, V. Zagonel",10.32388/4AKYSB,https://doi.org/10.32388/4AKYSB,Qeios,0,2021,no,"The study focuses on patients with bone metastases from solid tumors, not osteoporosis patients, which clearly fails this critical criterion.",maybe,"The abstract mentions ""time to onset (TTO)"" but does not clearly document both intervals required for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",maybe,"While the abstract mentions ""dental prevention,"" it does not specifically detail the dental procedures studied.",yes,"The abstract explicitly states that the study is a retrospective study, which meets this criterion.",maybe,"The study appears to document MRONJ incidence, but the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, so it is unclear if the population meets the age requirement of over 18 years old.",yes,"The study includes 1211 patients, which exceeds the minimum requirement of 100 subjects for the medication group.",maybe,"The abstract only mentions ""bone antiresorptive agents (BAA)"" generally, without specifying if they are oral bisphosphonates, so it is unclear if this criterion is met.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients with bone metastases, which fundamentally disqualifies it from meeting the screening criteria for osteoporosis-related research. Critical exclusion factors include the wrong patient population and unspecified medication type, rendering the study non-compliant with the systematic review's requirements. Multiple other screening criteria remain unaddressed or unclear, further supporting exclusion.",1.4
THE ROLE OF CONSERVATIVE MANAGEMENT IN PATIENTS WITH MEDICATION-RELATED OSTEONECROSIS OF JAW: A MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE,"A. Pischek, Annu Singh, D. Shem, J. Randazzo, S. Yom, J. Huryn, C. Estilo",10.1016/j.oooo.2021.08.051,https://doi.org/10.1016/j.oooo.2021.08.051,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2022,no,"The study specifically focuses on oncologic patients taking medications for bone metastasis or multiple myeloma, not osteoporosis patients, which is a clear violation of the inclusion criteria.",maybe,"The study does document the time interval between medication start and MRONJ diagnosis (median 28 months), but not specifically for dental procedures.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract does not specify which dental procedures led to MRONJ. It only mentions ""spontaneous MRONJ"" in 47% of cases.",yes,"This is a retrospective cohort study, which meets the acceptable study design criteria.",yes,The study has a follow-up period of at least 12 months (median 27.5 months) and documents MRONJ outcomes.,yes,"While not explicitly stated, the study is from a cancer center with adult cancer patients, so it can be reasonably assumed that the subjects are over 18 years old.",yes,"The study includes 110 patients, which exceeds the minimum requirement of 100 subjects.",no,"The study includes patients taking pamidronate, zoledronic acid, and denosumab, which are not specifically oral bisphosphonates for osteoporosis treatment.",no,The abstract does not explicitly mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on oncologic patients with medication-related osteonecrosis of the jaw, which fundamentally differs from the required osteoporosis patient population. Critical screening criteria were not met, including medication type, patient indication, and specific dental procedure documentation. Multiple core requirements were violated, rendering the study ineligible for systematic review inclusion.",0.1
Incidence and Risk of Anti-Resorptive Agent-Related Osteonecrosis of the Jaw after Tooth Extraction: A Retrospective Study,"R. Shimizu, S. Sukegawa, Yuka Sukegawa, K. Hasegawa, S. Ono, Tomoya Nakamura, Ai Fujimura, Ayaka Fujisawa, K. Nakano, Kiyofumi Takabatake, Hotaka Kawai, H. Nagatsuka, Y. Furuki",10.3390/healthcare10071332,https://doi.org/10.3390/healthcare10071332,Healthcare,1,2022,no,"The study includes a mixed population of patients with bone metastases, osteoporosis, and multiple myeloma, which fails to meet the criterion requiring only osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study specifically looks at tooth extraction, which is one of the specified dental procedures.",yes,"The study is described as a retrospective analysis, which meets the criterion as a retrospective cohort study.",maybe,"The study reports ARONJ incidence (3.2%) after dental treatment, but the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, but given that the study is of patients with bone metastases, osteoporosis, and multiple myeloma, it is likely that the subjects are adults. However, this is uncertain without explicit confirmation.",yes,"The study includes 302 patients with 505 target sites, which exceeds the minimum requirement of 100 subjects.",no,"The study includes both bisphosphonates and denosumab (a non-bisphosphonate), and does not specify if the bisphosphonates are oral, which fails to meet the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for ARONJ (MRONJ).,Exclude,"The study fails critical screening criteria due to a mixed patient population including cancer patients and the inclusion of non-bisphosphonate medications. While the research meets some methodological requirements like sample size and study design, the fundamental deviations from the specified population and intervention types render it unsuitable for the systematic review. Key diagnostic and procedural details are also insufficiently documented, further compromising its eligibility.",1.4
"Comment on ""Medication-Related Osteonecrosis of the Jaw (MRONJ)"" by Elie M. Ferneini in the Section ""Simply Put: JOMS Information for Patients"".","A. Bedogni, V. Fusco, O. D. Fede, G. Bettini, V. Panzarella, R. Mauceri, G. Saia, G. Campisi",10.1016/j.joms.2021.09.021,https://doi.org/10.1016/j.joms.2021.09.021,Journal of oral and maxillofacial surgery,4,2021,no,"While the abstract mentions osteoporosis patients, it also mentions cancer patients (multiple myeloma) and appears to be a general discussion rather than a specific study population, so it fails this criterion.",no,"No time intervals are documented in the abstract, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While MRONJ is discussed, no specific dental procedures or outcomes are detailed, so it fails this criterion.",no,"This appears to be a letter to the editor or commentary rather than any of the required study designs, so it fails this criterion.",no,"No follow-up period or specific MRONJ incidence is documented in the abstract, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the age criterion is unknown.",maybe,"No subject numbers are mentioned in the abstract, so the subject size criterion is unknown.",maybe,"The abstract mentions bisphosphonates but does not specify oral administration exclusively, so it partially meets this criterion.",no,"No diagnostic standards for MRONJ are mentioned in the abstract, so it fails this criterion.",Exclude,"This commentary piece fails multiple critical screening criteria, including lacking a specific study design, mixed patient population, and absence of detailed diagnostic standards or outcome documentation. The text appears to be a letter to the editor discussing medication-related osteonecrosis of the jaw rather than an original research study, rendering it ineligible for systematic review inclusion.",0.1
Comparison of Different Antibiotic Regimes for Preventive Tooth Extractions in Patients with Antiresorptive Intake—A Retrospective Cohort Study,"O. Ristow, T. Rückschloss, Gregor Schnug, J. Moratin, Moritz Bleymehl, Sven Zittel, Maximilian Pilz, C. Sekundo, C. Mertens, M. Engel, Jürgen Hoffmann, Maximilian Smielowski",10.3390/antibiotics12060997,https://doi.org/10.3390/antibiotics12060997,Antibiotics,4,2023,maybe,"The abstract mentions ""antiresorptive therapy"" but does not specifically state these are osteoporosis patients. It also does not explicitly exclude cancer patients, creating uncertainty about the population indication.",no,"The abstract does not document the time interval between medication start and dental procedure, or between procedure and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,The study clearly focuses on tooth extraction and reports MRONJ incidence following this procedure.,yes,"The abstract explicitly states it's a ""retrospective analysis,"" which meets the criteria for study design.",no,"The study has a 12-week follow-up period, which is less than the required 6 months.",maybe,"The abstract does not explicitly state the age of the subjects, but it is likely they are adults since the study is about patients receiving antiresorptive treatment. However, this is uncertain without explicit confirmation.",yes,"The study includes 760 patients total, which exceeds the 100-subject requirement for the medication group.",maybe,"The abstract only mentions ""antiresorptive therapy"" without specifying if it's oral bisphosphonates, creating uncertainty about the intervention type.",no,"While MRONJ is mentioned as an outcome, the abstract does not specify the diagnostic standards used.",Include,"A retrospective study of 760 patients undergoing tooth extraction during antiresorptive therapy reveals significant uncertainties regarding patient population, medication type, and diagnostic standards. While the research meets some screening criteria like study design and sample size, critical gaps exist in control group representation, patient age confirmation, and comprehensive outcome documentation. The study's short follow-up period and lack of explicit diagnostic criteria further complicate its alignment with comprehensive screening requirements.",2.9
Prevention of Medication-related Osteonecrosis of the Jaw (MR-ONJ) after dentoalveolar surgery in cancer patients: one year experience.,"G. Capocasale, F. Lonardi, Annarita Signoriello, G. Panozzo, F. Zotti, Riccardo Nocini, M. Albanese",10.32388/TTPEZS,https://doi.org/10.32388/TTPEZS,Qeios,0,2021,no,"The study specifically focuses on cancer patients, which is explicitly excluded by the criteria.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,The study mentions tooth extraction as a procedure and MRONJ as an outcome.,yes,"The study is described as a ""retrospective analysis"" which meets the criteria for acceptable study designs.",yes,The study has a one-year follow-up period (2019) which meets the 6-month minimum requirement.,maybe,"The abstract does not explicitly state the age of the subjects, but Elicit notes that since they are cancer patients, they are likely adults.",no,"The study only includes 15 patients, which is well below the required 100 subjects.",no,"The abstract mentions ""antiresorptive-antiangiogenic drugs, with or without Bisphosphonates"" which is too broad and includes non-bisphosphonate medications.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails critical screening criteria by focusing on cancer patients, having an insufficient sample size of only 15 subjects, and including non-bisphosphonate medications. Multiple other criteria were either not met or remained unclear, rendering the study ineligible for inclusion in the systematic review. The research fundamentally diverges from the specified population, intervention, and methodological requirements.",0.1
Medication related osteonecrosis of the jaw a current,"Domah, Raunaq, Pravinchandra",-,-,-,0,2019,no,"The abstract indicates that this is a review article rather than a primary research study with a specific patient population, so it fails this criterion.",no,"No information about time intervals is provided in the abstract, so it fails this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract discusses MRONJ but does not specifically report incidence following dental procedures, so it fails this criterion.",no,"The abstract indicates that this is a review article rather than one of the required study designs, so it fails this criterion.",no,"As a review article, the abstract does not document specific MRONJ incidence or follow-up periods, so it fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning is uncertain.",no,"As this is a review article, no specific subject numbers are mentioned, so it fails this criterion.",no,"The abstract discusses multiple types of antiresorptive medications, not just oral bisphosphonates, so it fails this criterion.",yes,"The abstract mentions diagnostic criteria for MRONJ, but this is in the context of reviewing existing literature rather than implementing these criteria in a study, so it technically meets this criterion but not in the intended way.",Exclude,"This review article fails to meet multiple critical screening criteria, including lack of a defined study population, absence of a control group, and no specific documentation of MRONJ incidence following dental procedures. The paper provides a literature review of medication-related osteonecrosis of the jaw but does not constitute a primary research study with the required methodological elements for systematic review inclusion.",0.1
Bisphosphonate-Related Osteonecrosis of the Jaws – Diagnosis and Management,"P. Pechalova, E. Poriazova, N. Pavlov, A. Bakardjiev",10.5772/53858,https://doi.org/10.5772/53858,-,4,2013,maybe,"The abstract mentions patients taking alendronate for established osteoporosis, which meets this criterion. However, it also discusses mixed populations including Paget's disease patients, so it only partially meets this criterion.",no,"The abstract does not document any time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract does not specify any dental procedures or report MRONJ incidence following specific procedures, so it fails this criterion.",no,"The abstract appears to be a review or commentary of existing literature rather than an original research study, so it fails this criterion.",no,"The abstract does not provide any information about follow-up periods or clearly documented MRONJ incidence, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the information is unknown.",maybe,"The abstract does not provide any information about the sample size, so the information is unknown.",maybe,"The abstract discusses both oral (alendronate) and intravenous bisphosphonates, but appears to focus on oral bisphosphonates. However, it's not clear if the study exclusively includes oral bisphosphonate patients, so it only partially meets this criterion.",no,"The abstract does not mention any diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including lack of a clear study design, absence of diagnostic standards, and no documentation of specific dental procedures or MRONJ incidence. While discussing bisphosphonate-related osteonecrosis, the text appears to be a literature review rather than an original research study, rendering it unsuitable for systematic review inclusion.",1.4
The role of interdisciplinary cooperation in the prevention of medication-related osteonecrosis of the jaw (MRONJ),"Monika Teślak, Izabela Chlebus, Iwona Ordyniec-Kwaśnica",10.31373/ejtcm/120581,https://doi.org/10.31373/ejtcm/120581,-,0,2020,maybe,"The abstract mentions patients treated with zoledronic or pamidronic acid, but does not specify if they were taking it for osteoporosis or cancer, so the population indication is unknown.",no,"No information about time intervals is provided, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract doesn't mention any specific dental procedures leading to MRONJ, so the study fails this criterion.",no,"The abstract appears to be describing a case series, which is explicitly excluded in the criteria, so the study fails this criterion.",no,"While MRONJ is mentioned, there's no information about follow-up period or clear documentation of incidence, so the study fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the age of the population is unknown.",no,"The abstract mentions ""36 patients"" which is below the required 100 subjects, so the study fails this criterion.",no,"The abstract mentions zoledronic and pamidronic acid, which are intravenous bisphosphonates, not oral bisphosphonates, so the study fails this criterion.",no,"While the abstract mentions ""painful exposure of the maxilla and mandible,"" it doesn't provide specific diagnostic standards, so the study fails this criterion.",Exclude,"The abstract describes a case series of 36 patients with medication-related jaw osteonecrosis, which fails multiple critical screening criteria including insufficient sample size, inappropriate study design, and lack of specific diagnostic and procedural details. The paper does not meet the required standards for inclusion in a systematic review, particularly regarding population size, intervention type, and comprehensive outcome documentation.",0.1
Medication-related osteonecrosis of the jaw triggered by endodontic failure in oncologic patients.,"A. Tempesta, S. Capodiferro, Simona Di Nanna, S. D’Agostino, M. Dolci, A. Scarano, G. Gambarini, E. Maiorano, G. Favia, L. Limongelli",10.1111/odi.14449,https://doi.org/10.1111/odi.14449,Oral Diseases,8,2022,no,"The study specifically focuses on ""oncologic patients"" taking antiresorptive and antiangiogenic drugs, which explicitly violates the criterion requiring patients taking medication for osteoporosis, excluding cancer patients.",no,"The abstract mentions that endodontic treatment was performed ""at least six months before the starting of antiresorptive/antiangiogenic therapies,"" but doesn't document the time from dental procedure to MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,"The study focuses on endodontic treatment failure rather than the specified dental procedures (extraction, periodontal surgery, implant placement, or removable prosthetic treatment).",yes,"This appears to be a cohort study, which would meet this criterion.",maybe,"The study does document MRONJ incidence and mentions follow-up, but the specific follow-up period is not clearly stated.",maybe,"The abstract does not explicitly state the age of the subjects, so it is unclear if this criterion is met.",no,"The study only includes 18 patients, which is well below the required 100 subjects.",no,"The abstract mentions ""antiresorptive and antiangiogenic drugs"" but does not specify oral bisphosphonates, so it appears to include a broader range of medications.",maybe,"While the study mentions surgical treatment and clinical/radiological follow-up, it doesn't explicitly state its diagnostic standards for MRONJ.",Exclude,"The study fails key screening criteria by focusing on oncologic patients instead of osteoporosis patients, using a small sample size of 18 subjects, and examining endodontic treatment rather than specified dental procedures. Multiple critical exclusion factors, including wrong patient population, insufficient sample size, and non-standard intervention type, disqualify this research from meeting the systematic review requirements.",0.1
Update on Medication Related Osteonecrosis of the Jaws,B. Boyd,10.32481/djph.2023.04.009,https://doi.org/10.32481/djph.2023.04.009,Delaware journal of public health,1,2023,no,"While the abstract mentions osteoporosis patients, it also discusses cancer patients and mixed populations, which violates the criterion requiring exclusive focus on osteoporosis patients.",no,No time intervals are documented in the abstract.,no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While ONJ/MRONJ is discussed, specific dental procedures are not mentioned.",no,"This appears to be a review or commentary rather than any of the required study designs, as it discusses the evolution of terms and general concepts rather than presenting original research.",no,No specific follow-up period or incidence rates are mentioned in the abstract.,maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is unknown.",maybe,"The abstract does not mention any specific sample size, so the reasoning for this criterion is unknown.",maybe,"While bisphosphonates are mentioned, the abstract discusses multiple types of medications and doesn't specify oral bisphosphonates exclusively, so it only partially meets this criterion.",no,No diagnostic standards for MRONJ are mentioned in the abstract.,Exclude,"The abstract fails to meet multiple critical screening criteria, including specific study design requirements, population exclusivity, and detailed outcome documentation. While discussing medication-related osteonecrosis of the jaw, the text appears to be a conceptual review rather than an original research study with the necessary methodological rigor. Consequently, the abstract does not satisfy the comprehensive screening requirements for inclusion.",0.1
Optical bone density as a prognostic risk factor for the development of medication-related osteonecrosis of the jaw in patients with bone metastases,"N. Vinogradova, L. Solomatina, M. Kharitonova, K. L'vov, D. Borzunov",10.18019/1028-4427-2020-26-4-539-543,https://doi.org/10.18019/1028-4427-2020-26-4-539-543,-,2,2020,no,"The abstract mentions ""osteomodifying agents (bisphosphonates, denosumab)"" but does not specify if all patients were taking these for osteoporosis. Elicit notes that it appears to be a mixed population study, which fails this criterion.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"The abstract does not specify which dental procedures led to MRONJ, so it fails this criterion.",yes,"The study is described as a ""retrospective analysis,"" which meets the criterion as a retrospective cohort study.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified, so it is unclear if this criterion is met.",maybe,"The abstract does not explicitly state the age of the subjects, but Elicit notes that since it is a study of MRONJ patients, they are likely adults.",no,"The study only includes 52 patients, which is well below the required 100 subjects, so it fails this criterion.",no,"The study includes both bisphosphonates and denosumab, not exclusively oral bisphosphonates, so it fails this criterion.",yes,"The study uses multispiral computed tomography and bone type classification according to Misch, which constitutes a diagnostic standard.",Include,"The study fails key screening criteria including insufficient sample size (52 patients), mixed medication population, and lack of specification for dental procedures leading to MRONJ. Critical shortcomings include no control group, unclear patient age, and absence of detailed documentation about medication and procedure timelines. Despite meeting some methodological criteria, the research does not comprehensively address the required screening standards.",2.5
A clinical retrospective study of implant as a risk factor for medication-related osteonecrosis of the jaw: surgery vs loading?,"Yong-Dae Kwon, Hyunmi Jo, Jae-eun Kim, Jooyoung Ohe",10.1186/s40902-023-00398-2,https://doi.org/10.1186/s40902-023-00398-2,Maxillofacial plastic and reconstructive surgery,4,2023,maybe,"The study focuses on patients taking bisphosphonates, but it's not explicitly stated these are for osteoporosis treatment. The population appears to be specifically those with dental implant-associated MRONJ.",yes,The study documents the time interval between medication start and dental procedure (61.37 months average medication use) and between dental procedure and MRONJ incidence (51.03 months average).,no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,The study clearly reports MRONJ incidence following dental implant placement.,no,"This appears to be a retrospective case series, which is explicitly excluded by the criteria.",maybe,"The study documents MRONJ incidence and appears to have adequate follow-up, but the specific follow-up period isn't mentioned.",yes,"While not explicitly stated, the abstract refers to ""older patients,"" suggesting the subjects are over 18 years old.",no,"The study only includes 33 patients, which is well below the required 100 subjects.",maybe,"The study mentions bisphosphonates as the most commonly used drug, but doesn't specify if all patients were taking oral bisphosphonates exclusively.",maybe,"While the study mentions using cone-beam computed tomography for evaluation, it doesn't explicitly state diagnostic standards for MRONJ.",Exclude,"The study fails key screening criteria due to its small sample size of 33 patients, which falls significantly short of the required 100 subjects, and its retrospective case series design, which is explicitly excluded. While the research provides insights into medication-related osteonecrosis of the jaw, it lacks a control group and does not clearly specify that all patients were taking oral bisphosphonates exclusively for osteoporosis treatment.",1.4
Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment,"Seung-Hun Lee, So-Young Choi, M. Bae, T. Kwon",10.1186/s40902-021-00310-w,https://doi.org/10.1186/s40902-021-00310-w,Maxillofacial plastic and reconstructive surgery,0,2021,no,"The study includes both osteoporosis patients and cancer patients, which violates the criterion requiring a pure osteoporosis population.",maybe,"The study documents duration of bisphosphonate medication but does not clearly document the time interval between medication start and dental procedure, or between procedure and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract does not specify which dental procedures led to MRONJ, only mentioning ""surgeries"" in general.",yes,"The study is described as a retrospective study, which is an acceptable design.",maybe,"While the study documents MRONJ outcomes, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly state the age of the subjects, but since the study is on osteoporosis patients, it can be reasonably assumed that the subjects are adults over 18 years old.",yes,"The study includes 251 oral bisphosphonate patients, which exceeds the minimum requirement of 100 subjects.",no,"The study includes both oral and intravenous bisphosphonates, and specifically compares them, which violates the criterion requiring only oral bisphosphonates.",maybe,The abstract does not explicitly mention the diagnostic standards used for MRONJ.,Exclude,"The study fails critical screening criteria by including a mixed population of osteoporosis and cancer patients, and by examining both oral and intravenous bisphosphonates. Multiple key methodological details remain uncertain, including diagnostic standards, specific dental procedures, and follow-up period. These significant deviations from the required screening parameters render the study unsuitable for inclusion.",1.4
Contemporary Concept for Prevention and treatment of MRONJ (Medication Related Osteonecrosis of Jaw),"Jung-Hyun Park, Sun-Jong Kim",10.22974/jkda.2016.54.4.003,https://doi.org/10.22974/jkda.2016.54.4.003,The Journal of The Korean Dental Association,1,2016,no,"The abstract mentions that bisphosphonates are used for both osteoporosis and bone metastasis of malignancy, but does not specify which population was studied. This appears to be a mixed population study, which fails this criterion.",no,"No information about time intervals is provided, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract does not mention any specific dental procedures leading to MRONJ, so this criterion is failed.",no,"The abstract explicitly states this is a ""case series,"" which is specifically excluded in the criteria, so this criterion is failed.",no,"While MRONJ is discussed, there's no mention of a follow-up period or clear documentation of incidence, so this criterion is failed.",maybe,"The abstract does not specify the age of the subjects, so the reasoning for this criterion is unknown.",no,"The abstract describes this as a ""case series"" and does not specify the number of subjects. Given it's a case series, it likely has fewer than 100 subjects, which fails this criterion.",maybe,"While bisphosphonates are mentioned, the abstract does not specify whether they are oral or intravenous, so the reasoning for this criterion is unknown.",yes,"The abstract does mention a diagnostic standard for MRONJ (""exposed necrotic bone in the jaw, which has persisted for more than 8 weeks""), so this criterion is met.",Exclude,"This case series fails multiple critical screening criteria, including study design, population specification, and subject size requirements. The research lacks clear documentation of dental procedures, follow-up periods, and does not meet the specified methodological standards for inclusion. Consequently, the study does not qualify for further review based on the established screening criteria.",0.1
Potential role of comprehensive dental care in preventing medication related osteonecrosis of the jaw (MRONJ): a single centre study,"Kamila Alblazi, Syed Nabil, Nor Rafeah Tumian, S. S. M. Yunus, R. Ramli",10.1186/s12903-024-05081-0,https://doi.org/10.1186/s12903-024-05081-0,BMC Oral Health,0,2024,no,"The abstract mentions ""antiresorptive and antiangiogenic drugs"" but does not specifically state that the research is limited to patients taking medication for osteoporosis, suggesting a mixed population. This indicates the study fails this criterion.",no,"The abstract does not provide any information about the time intervals between the start of medication, dental procedure, and MRONJ incidence, so no points are added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",maybe,"The abstract mentions dental extraction as a risk factor and discusses comprehensive dental care, so this criterion is partially met.",maybe,"The abstract does not explicitly state the study design, so the study design criterion is unknown.",maybe,"While the abstract discusses MRONJ, it does not clearly indicate the follow-up period or specific documentation of MRONJ incidence, so this criterion is unknown.",maybe,"The abstract does not provide any specific information about the age of the subjects, so the age criterion is unknown.",maybe,"The abstract does not provide any information about the sample size of the medication group, so the subject size criterion is unknown.",no,"The abstract only mentions ""antiresorptive and antiangiogenic drugs"" broadly, and does not specifically state that the study includes only subjects taking oral bisphosphonate medication for osteoporosis treatment. This indicates the study fails this criterion.",no,"The abstract does not mention any diagnostic standards for MRONJ, so this criterion is not met.",Include,"The abstract fails to meet several critical screening criteria, including specific population indication, intervention type, and diagnostic standards for MRONJ. Multiple key details are missing or unclear, such as subject age, sample size, and study design, which prevents a comprehensive assessment of the research's alignment with the specified requirements. The broad mention of antiresorptive and antiangiogenic drugs suggests a mixed population that does not strictly adhere to the defined screening parameters.",2.5
Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients.,"Bridget Boston, D. Ipe, B. Căpitănescu, Andrei Gresita, S. Hamlet, R. Love, M. Hadjiargyrou, Chien-Ling Huang, I. Nusem, R. Miroiu, A. Popa-Wagner, P. Warnke, E. Petcu",10.1111/jgs.18414,https://doi.org/10.1111/jgs.18414,Journal of The American Geriatrics Society,4,2023,no,"The abstract discusses both osteoporosis and cancer patients, indicating a mixed population. This fails to meet the criterion requiring exclusive focus on osteoporosis patients.",no,No information about time intervals is provided.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While dental therapy is mentioned, specific procedures (extraction, periodontal surgery, etc.) are not detailed.",no,"This appears to be a literature review rather than any of the specified study designs (RCT, cohort, or case-control).",no,The abstract doesn't describe specific follow-up periods or incidence rates.,maybe,"While the abstract mentions ""older patients,"" it doesn't explicitly specify age >18. However, given the context of osteoporosis treatment, it can be reasonably inferred that the population is adults.",no,The abstract does not specify the number of subjects in any study. It appears to be a review article rather than a primary research study.,no,"The abstract discusses ""anti-resorptive, anti-angiogenic or immunomodulators"" broadly, not specifically oral bisphosphonates.",no,The abstract provides a basic clinical definition of MRONJ but doesn't detail specific diagnostic standards.,Exclude,"The abstract represents a literature review that fails to meet multiple critical screening criteria, including lack of a control group, mixed patient population, and absence of specific intervention details. Key methodological requirements such as subject size, diagnostic standards, and precise outcome documentation are not addressed, rendering the study unsuitable for systematic review inclusion. The broad, review-style approach and mixed patient population fundamentally disqualify the paper from meeting the established screening criteria.",0.1
Medication-related osteonecrosis of the jaws (MRONJ) and the time to event: A retrospective study,"Cameron Y. S. Lee, Cameron Y. S. Lee, J. Suzuki",10.15761/docr.1000131,https://doi.org/10.15761/docr.1000131,-,0,2015,yes,"The study specifically focuses on patients prescribed oral antiresorptive medications, with no mention of cancer patients or mixed populations.",yes,"The study documents the time interval between medication start and MRONJ incidence (mean time to event of 55.8 months), which adds 0.2 points to the score.",yes,"The study included a control group of patients not taking anti-resorptive medications, which adds 0.2 points to the score.",yes,"The study specifically looks at MRONJ following dentoalveolar surgery, including tooth extraction and dental implant surgery.",yes,"The study is explicitly stated as a ""retrospective cohort study"".",yes,The study clearly documents MRONJ incidence and has a follow-up period of approximately 7 years (2006-2013).,maybe,"The abstract does not explicitly state the age of the subjects, but since the study focuses on patients taking antiresorptive medications for osteoporosis, it is likely that the subjects are adults, though this is not certain.",yes,"The study includes 388 patients, which is well above the 100-subject requirement.",maybe,"The study mentions ""oral antiresorptive medications"" and specifically mentions Fosamax (a bisphosphonate), but does not explicitly state that all patients were on oral bisphosphonates.",no,The abstract does not mention the diagnostic standards used for ONJ.,Include,"A retrospective cohort study of 388 patients taking oral antiresorptive medications demonstrates strong alignment with most screening criteria, including appropriate study design, large sample size, and clear documentation of dental procedures and MRONJ outcomes. While the study meets most key requirements, some uncertainties exist regarding diagnostic standards, precise medication types, and explicit age confirmation, which slightly temper its overall screening performance.",4.3
Antiresorptive agent-related osteonecrosis of the jaw risk in cancer patients before bone-modifying agent therapy: A retrospective study of 511 patients.,"C. Kanno, Momoyo Kojima, Yu Tezuka, Sadanoshin Yaginuma, Yoshiaki Kanaya, T. Kaneko",10.1016/j.bone.2023.116892,https://doi.org/10.1016/j.bone.2023.116892,Bone,1,2023,no,"The study focuses on patients taking bone-modifying agents (BMAs) for advanced cancer, not osteoporosis, which does not meet the population indication requirement.",maybe,"The study mentions the timing of extraction before BMA therapy, but does not clearly document the time to ARONJ incidence, so it only partially meets this requirement.",yes,"The study explicitly includes a non-extraction group as a control, which meets the requirement for a control group.",yes,"The study specifically examines tooth extraction and subsequent ARONJ incidence, which meets the procedure and outcome requirement.",yes,"The study design is explicitly mentioned as a retrospective study, which meets the study design requirement.",maybe,"The follow-up period is not specified in the abstract, and while ARONJ incidence is documented, the timing details are lacking, so it is unclear if this requirement is met.",maybe,"The age of the subjects is not explicitly mentioned in the abstract, so it is unclear if the population meets the age requirement.",yes,"The study includes 511 patients total, with 135 in the extraction group, which exceeds the 100-subject requirement for the medication group.",no,"The study uses bone-modifying agents (BMAs) for cancer treatment, not oral bisphosphonates for osteoporosis, which does not meet the intervention type requirement.",maybe,"While ARONJ is mentioned, the specific diagnostic standards are not detailed in the abstract, so it is unclear if this requirement is met.",Exclude,"The study focuses on cancer patients receiving bone-modifying agents, which critically disqualifies it from the systematic review due to population and intervention type mismatches. Despite meeting several methodological criteria like control group, subject size, and study design, the fundamental deviation from osteoporosis patient and oral bisphosphonate requirements necessitates exclusion. The research's specific focus on cancer-related bone-modifying agents renders it inappropriate for the intended review.",0.1
Incidence and treatment of MR-ONJ in a cohort of oncological patients.,"G. Setti, G. Garuti, Francesco Diamante, U. Consolo, P. Bellini",10.32388/O4EIE8,https://doi.org/10.32388/O4EIE8,Qeios,0,2021,no,"The study focuses on patients with ""onco-hematological"" diseases, not osteoporosis patients. This is a clear violation of the inclusion criteria.",no,"The abstract does not document the specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,maybe,"While dental procedures are mentioned, the abstract doesn't specifically report MRONJ incidence following the required dental procedures.",yes,"This appears to be a prospective cohort study with follow-up, which meets the criteria.",yes,"The study has a 12-month follow-up period, which meets the 6-month minimum requirement, and documents MRONJ incidence.",maybe,"The abstract does not explicitly state the age of subjects, though given it's an oncological population, they are likely adults.",yes,"The study includes 313 patients total, which exceeds the minimum requirement of 100 subjects.",no,"The abstract mentions ""antiresorptive drugs"" but does not specify oral bisphosphonates. It appears to include a broader range of medications including ""target therapy agents.""",maybe,"The abstract mentions ""staging"" but does not explicitly describe diagnostic standards for MRONJ.",Exclude,"The study focuses on oncological patients taking antiresorptive medications, which deviates from the required osteoporosis patient population and medication type. Critical screening criteria were not met, particularly regarding patient indication and intervention specifics, rendering the study ineligible for inclusion in the systematic review. Multiple uncertainties and violations of key screening requirements further support exclusion.",1.4
Analysis of Factors Associated with the Postoperative Healing of Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis,"Young-Ho Shim, Sang-Hwan Jung, Obida Boboeva, Sung-Tak Lee, Jin-Wook Kim, T. Kwon, So-Young Choi",10.3390/jcm10163651,https://doi.org/10.3390/jcm10163651,Journal of Clinical Medicine,3,2021,yes,"The study clearly focused on osteoporosis patients, excluding cancer patients, so this criterion was met.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The study focuses on surgical treatment of MRONJ rather than MRONJ incidence following dental procedures, which is a fundamental mismatch with the criterion.",yes,"This is a retrospective study, which is one of the accepted study designs, so this criterion was met.",no,"While the study documents outcomes, it is focused on post-surgical healing rather than MRONJ incidence after dental treatment, and the follow-up period is not specified, so this criterion was not met.",maybe,"While not explicitly stated, the context suggests the study included adult patients with osteoporosis, but this was not definitively confirmed.",yes,"The study included 400 patients, well above the minimum requirement of 100, so this criterion was met.",no,"The abstract mentions ""intravenously administered drugs"" and does not specify oral bisphosphonates exclusively, so this criterion was not met.",no,"The abstract does not explicitly mention diagnostic standards for MRONJ, so this criterion was not met.",Exclude,"The study fails to meet several critical screening criteria, including the requirement for oral bisphosphonates, documentation of MRONJ diagnostic standards, and focus on MRONJ incidence after dental procedures. While the research includes a large sample size of osteoporosis patients and uses an acceptable retrospective study design, fundamental misalignments with the specified screening requirements significantly reduce its suitability. The paper's primary focus on surgical treatment of existing MRONJ rather than incidence prevention represents a core deviation from the intended research parameters.",1.4
What Affects Healing Rates in Patients Treated for Medication-Related Osteonecrosis of the Jaw? The Role of Operative Therapy and Other Clinical Factors.,"M. Fujimori, Y. Toriyabe, Noriyuki Sakakibara, Masanori Nojima, Shujiroh Makino",10.1016/j.joms.2024.06.176,https://doi.org/10.1016/j.joms.2024.06.176,Journal of oral and maxillofacial surgery,1,2024,no,"While the abstract mentioned MRONJ, there was no specific information about whether the subjects were osteoporosis patients or if there was a mixed population.",no,"No information was provided about the time intervals between the start of medication, dental procedures, and MRONJ incidence.",no,No information was provided about whether the study included a control group of patients not taking anti-resorptive medications.,no,"While MRONJ was discussed, there was no specific mention of dental procedures leading to MRONJ.",no,The abstract did not specify the study design.,no,"The abstract mentioned ""healing rate"" but did not specify the follow-up period or clearly document MRONJ incidence.",no,No information was provided about the age of the study subjects.,no,No information was provided about the sample size of the study.,no,There was no specific mention of oral bisphosphonate medication or any other medication type.,no,There was no mention of the diagnostic standards used for MRONJ.,Exclude,"The abstract lacks critical details required by the screening criteria, including population characteristics, intervention specifics, study design, and diagnostic standards. Insufficient information prevents confirmation of any of the ten specified screening requirements, suggesting the study does not meet the predefined inclusion criteria. The brief text appears to focus on MRONJ treatment rather than the targeted research parameters.",1.4
Risk assessment of bisphosphonate-related osteonecrosis of the jaw based on CBCT scans,"Ferenc Koppány, Á. Joób-Fancsaly, Z. Németh, A. Belik, M. Vaszilkó, Edvárd Márton Varmuzsa, K. Csomó",10.1556/650.2020.31732,https://doi.org/10.1556/650.2020.31732,Orvosi Hetilap,3,2020,yes,"The study specifically focuses on patients with osteoporosis taking oral bisphosphonates, excluding mixed populations, which meets the population indication criteria.",no,"The abstract does not document the time intervals between medication start, dental procedure, and BRONJ incidence.",yes,"The study explicitly includes a control group of patients with osteoporosis who had not received any medications known to cause BRONJ, which meets the requirement for a control group.",yes,"The study mentions oral surgery as the dental procedure, though specific types are not detailed.",maybe,"While this appears to be a comparative study, the exact design (whether prospective, retrospective, or case-control) is not clearly stated in the abstract.",maybe,"While BRONJ incidence is documented, the follow-up period is not specified in the abstract.",maybe,"The abstract does not explicitly mention the age requirements for the study population, so it is unclear if all subjects were over 18 years old.",maybe,"The abstract does not mention the total number of subjects in either group, so it is impossible to verify if the study included over 100 subjects in the medication group.",yes,"The study specifically focuses on oral bisphosphonate medication for osteoporosis treatment, which meets the intervention type criteria.",maybe,The abstract does not explicitly mention the diagnostic standards for BRONJ.,Include,"The study partially meets screening criteria with a clear focus on oral bisphosphonate treatment for osteoporosis and inclusion of a control group, but lacks explicit documentation of critical elements like sample size, study design, and diagnostic standards. Significant uncertainties exist regarding age requirements, follow-up period, and comprehensive outcome documentation, which limit the study's alignment with systematic review screening criteria.",3.2
"Differences Between Medication-Related Osteonecrosis of the Jaw Caused by Bisphosphonates and Denosumab: Histological, Molecular Biological, and Clinical Studies","Taro Miyoshi, M. Otsuru, Kota Morishita, K. Omori, Kei-ichiro Miura, S. Hayashida, S. Rokutanda, Yuki Matsushita, Masahiro Umeda, Tomohiro Yamada",10.7759/cureus.62855,https://doi.org/10.7759/cureus.62855,Cureus,2,2024,no,"The study includes both bisphosphonate and denosumab patients, which violates the requirement for a pure osteoporosis population without mixed populations.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract doesn't specify which dental procedures were involved in the MRONJ cases.,yes,"The abstract mentions a ""retrospective study,"" which meets the criteria.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of subjects, though given it's about osteoporosis treatment, they are likely adults.",yes,"The study includes 298 patients total (30 BP + 13 DMB + 255 others), meeting the >100 subject requirement for the medication group.",no,"The study includes both oral bisphosphonates and denosumab (a non-bisphosphonate), violating the requirement for only oral bisphosphonates.",maybe,"While the study includes histological examination and various measurements, it doesn't explicitly state diagnostic standards for MRONJ.",Include,"The study fails key screening criteria by including a mixed population of bisphosphonate and denosumab patients, lacking specification of dental procedures, and not clearly documenting diagnostic standards or follow-up periods. While the research involves a substantial patient sample and uses a retrospective design, it does not meet the precise requirements for a focused osteoporosis medication-related osteonecrosis of the jaw investigation. Critical methodological gaps prevent the study from satisfying the comprehensive screening criteria.",2.5
Multiple myeloma masquerading as medication-related osteonecrosis of the jaw: a case study,"Y. Danskin, Dalal Alhajji, S. Yom, C. Estilo",10.1016/j.oooo.2019.07.032,https://doi.org/10.1016/j.oooo.2019.07.032,-,0,2020,no,"The study focuses on a cancer patient (multiple myeloma) taking zoledronic acid, which explicitly violates the criterion requiring subjects with osteoporosis only.",maybe,"The abstract mentions the timing of zoledronic acid treatment (2013-2016) but doesn't clearly document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"The study mentions a fixed partial denture (FPD) removal, which could be considered a dental procedure, but it's not clearly presented as a cause of MRONJ.",no,"This is explicitly stated as a case report, which is specifically excluded in the criteria.",maybe,"While MRONJ is discussed, the follow-up period is not clearly stated.",yes,"The subject is 67 years old, which meets the criterion of being over 18 years old.",no,"This is a case report of a single patient, far below the required 100 subjects.",no,"The study uses zoledronic acid, which is an intravenous bisphosphonate, not an oral bisphosphonate as required.",maybe,"While the abstract discusses diagnostic challenges, it doesn't clearly state the diagnostic standards used.",Exclude,"This case report of a multiple myeloma patient fails multiple critical screening criteria, including inappropriate population type, intervention method, and study design. The single-patient case study does not meet the required sample size, uses intravenous bisphosphonates instead of oral medications, and focuses on a cancer patient rather than an osteoporosis population. These fundamental deviations render the study non-compliant with the systematic review's screening requirements.",0.1
Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer,"Loreto Domínguez Senín, D. M. Pancorbo, María Yeray Rodríguez Garcés, M. Santos-Rubio, Juan Bayo Calero",10.3390/curroncol31010016,https://doi.org/10.3390/curroncol31010016,Current Oncology,2,2024,no,"The study focuses on breast cancer patients taking denosumab, not osteoporosis patients. This is a clear violation of the inclusion criteria.",maybe,"The study does document time to MRONJ occurrence (16.8 months and 15.4 months for the two groups), but not the time from medication start to dental procedure.",no,"The study does not include a control group of patients not taking anti-resorptive medications. It only compares patients with and without CDK4/6 inhibitors, both groups taking denosumab.",no,The abstract does not specify whether the MRONJ cases were related to any of the specified dental procedures.,yes,"The study is described as a ""multicentre, retrospective, observational study,"" which meets the acceptable study design criteria.",yes,"The study reports MRONJ incidence and has a follow-up period of 11 years (2011-2022), meeting the 6-month minimum requirement.",maybe,"The abstract doesn't explicitly state the age of subjects, but since these are breast cancer patients, we can reasonably assume they are adults. However, this is an assumption.",yes,"The study includes 243 total patients, with 120 in one group and 95 in the other, meeting the >100 subjects criterion.",no,"The study examines denosumab, which is not an oral bisphosphonate. This is a clear violation of the inclusion criteria.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on breast cancer patients taking denosumab, which deviates from the required osteoporosis patient population and oral bisphosphonate intervention. Critical screening criteria were not met, including population indication, medication type, and lack of a non-medication control group. These fundamental differences render the study ineligible for inclusion in the systematic review.",0.1
Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis,"Christian Gross, Manuel Weber, Kay Creutzburg, Patrick Möbius, R. Preidl, K. Amann, F. Wehrhan",10.1186/s12967-017-1230-8,https://doi.org/10.1186/s12967-017-1230-8,Journal of Translational Medicine,0,2017,maybe,"While the study involves patients with MRONJ from bisphosphonate therapy, it does not explicitly state that these are osteoporosis patients. The inclusion of comparison groups with OM and ORN may indicate a mixed population.",no,"The study does not mention any time intervals between medication start, dental procedures, and MRONJ incidence.",yes,"The study includes a control group of 10 patients, which meets the requirement for a control group.",no,The study does not report MRONJ incidence following dental procedures. The focus is on tissue analysis rather than clinical outcomes.,no,"This is a retrospective tissue analysis study, not one of the specified study designs (randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study). It appears to be more of a laboratory/pathology study.",no,"The study does not document MRONJ incidence after dental treatment, and there is no mention of a follow-up period.",maybe,"The age of the subjects is not specified in the abstract, so it is unclear if the population is over 18 years old.",no,"The study only includes 30 MRONJ patients, which is below the required 100 subjects for the medication group.",maybe,"While bisphosphonates are mentioned, it is not specified if they are oral or intravenous. The study appears to be analyzing tissue samples rather than following medication groups.",maybe,"The study mentions ""non-healing exposed bone in the maxillofacial region"" as a diagnostic criterion for MRONJ, but does not provide detailed diagnostic criteria.",Exclude,"This pathology study examining osteoclast characteristics in MRONJ fails to meet multiple critical screening criteria, including insufficient subject size, lack of clear dental procedure outcomes, and absence of a comprehensive clinical study design. The research focuses on tissue analysis rather than clinical incidence, with only 30 MRONJ patients and no documentation of dental treatment-related MRONJ occurrence. Consequently, the study does not align with the specified screening requirements for a clinical investigation of medication-related osteonecrosis of the jaw.",1.4
Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single Center Retrospective Cohort Study,"R. Mauceri, Martina Coppini, G. Campisi",10.3390/oral2040026,https://doi.org/10.3390/oral2040026,Oral,2,2022,no,"The study focused on breast cancer patients taking bone-modifying agents for cancer treatment-induced bone loss, not osteoporosis patients, which violates the inclusion criteria.",no,"While the abstract mentions some time intervals (48 months, 60 months, 20 months, 16 months), these are not clearly documented as the specific intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract does not specify which dental procedures were performed before MRONJ occurrence.,yes,"The study is described as a retrospective study, which meets the criterion for study design.",maybe,"While MRONJ cases are documented, the follow-up period is not clearly specified.",yes,"The mean age of the subjects was 66.6 years, which meets the requirement of being over 18 years old.",no,"The study only included 14 patients, which is well below the required 100 subjects for the medication group.",no,"The study included both oral bisphosphonates (risedronate) and non-bisphosphonates (Prolia®, Xgev®), and included intravenous administration, which violates the criterion requiring only oral bisphosphonates.",no,The abstract does not mention specific diagnostic standards for MRONJ.,Exclude,"The study fails key screening criteria by focusing on breast cancer patients instead of osteoporosis patients, and includes only 14 subjects, which is significantly below the required 100-subject threshold. Multiple methodological limitations, including mixed medication types and lack of clear diagnostic standards, further disqualify the research from meeting the systematic review's inclusion requirements.",0.1
What Do Prescribers of Bone Modifying Agents Know about Medication-Related Osteonecrosis of the Jaw? Is Current Prevention Enough?,"M. Golu, I. Pașcanu, C. Togănel, C. Petrovan, A. Coșarcă, Despina Luciana Bereczki Temistocle, A. Ormenișan",10.3390/app12189224,https://doi.org/10.3390/app12189224,Applied Sciences,2,2022,no,"The abstract discusses both osteoporosis and cancer patients, mentioning ""patients with osteoporosis or malignancies."" This fails the criterion requiring exclusive focus on osteoporosis patients.",no,"The abstract does not document any time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While dental procedures are mentioned as risk factors, the study does not report MRONJ incidence following specific dental procedures.",no,"This appears to be a survey study of physicians using a questionnaire, which does not match any of the required study designs (RCT, cohort, or case-control).",no,The study does not document MRONJ incidence or follow-up periods as it is a survey of physician knowledge rather than a clinical study.,maybe,"The abstract does not explicitly specify age requirements, so the reasoning for this criterion is uncertain.",no,The abstract does not mention any subject numbers as this appears to be a survey study of physicians rather than a clinical study of patients.,no,"While bisphosphonates are mentioned, the study discusses multiple types of bone remodeling agents (BMAs) including denosumab and tyrosine kinase inhibitors, not exclusively oral bisphosphonates.",no,The abstract does not mention any specific diagnostic standards for MRONJ.,Exclude,"The study fails multiple screening criteria by being a physician survey rather than a clinical patient study, including mixed patient populations, and not reporting specific MRONJ incidence or diagnostic standards. Critical requirements such as subject size, intervention type, study design, and outcome documentation are not met, rendering the paper unsuitable for the intended research parameters.",0.1
Medication-related osteonecrosis of jaws revisited through the bone inherited disorders: what do we know?,"M. Fénelon, J. Fricain",10.1051/MBCB/2021015,https://doi.org/10.1051/MBCB/2021015,Journal of Oral Medicine and Oral Surgery,0,2021,no,"While the abstract mentions patients receiving anti-resorptive treatments, it does not specifically state they are osteoporosis patients, and it appears to be a general discussion of MRONJ rather than a study focused on osteoporosis patients.",no,"The abstract does not provide any information about time intervals between the start of medication, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While the abstract mentions ""bone complications,"" it does not specifically discuss any of the required dental procedures.",no,The abstract appears to be a general discussion or review rather than any of the specified study designs.,no,The abstract does not mention any specific follow-up period or documented MRONJ incidence.,maybe,"The abstract does not specify the age of the subjects, so the age requirement is unknown.",maybe,"The abstract does not mention any sample size, so the subject size requirement is unknown.",no,"The abstract mentions both bisphosphonates and Denosumab, which includes non-bisphosphonate medication (Denosumab), violating the criterion requiring only oral bisphosphonates.",no,The abstract does not mention any diagnostic standards for MRONJ.,Exclude,"The abstract fails to meet multiple critical screening criteria, including specific population requirements, intervention type, study design, and outcome documentation. Key deficiencies include the lack of a control group, unspecified subject age, mixed medication types, and absence of detailed diagnostic and procedural information. The text appears to be a general discussion rather than a research study meeting the specified screening requirements.",0.1
"Dentists’ Awareness of Medication-Related Osteonecrosis of the Jaw (Risk Factors, Drugs, and Prevention) in the Republic of Croatia","Sven Bival, Lucija Šimović, Anamarija Blažun, L. Bergman, D. Vražić, M. Granić",10.15644/asc57/2/3,https://doi.org/10.15644/asc57/2/3,Acta Stomatologica Croatica,1,2023,no,The study does not include patients taking medication for osteoporosis. It is a survey about knowledge of antiresorptive medications.,no,No information about time intervals is provided as this is not a clinical study.,no,"The abstract does not mention any control group, as this is a survey of dental professionals rather than a clinical study.",no,The study does not report MRONJ incidence following dental procedures. It only surveys knowledge about these topics.,no,"This is a survey study, which does not match any of the required study designs (RCT, cohort, or case-control).",no,The study does not document MRONJ incidence or follow-up periods.,no,"The study focuses on dental professionals, not patients, so the age criteria cannot be evaluated.",no,"While the study has 458 participants, these are dental professionals, not medication-taking patients.",no,The study discusses bisphosphonates but does not include patients taking them. It is about knowledge of these medications.,no,"While MRONJ is discussed, the study does not mention diagnostic standards as it is not a clinical study.",Exclude,"This survey of dental professionals' knowledge about antiresorptive medications fails to meet the systematic review's screening criteria, which require a clinical study of patients taking bisphosphonates. The research does not include patient subjects, lacks a control group, and does not document MRONJ incidence or follow dental procedures, rendering it ineligible for inclusion.",0.1
Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management,"M. Tani, K. Hatano, Akihiro Yoshimura, Y. Horibe, Yutong Liu, N. Sassi, Toshiki Oka, Yohei Okuda, A. Yamamoto, T. Uemura, G. Yamamichi, Y. Ishizuya, Y. Yamamoto, Taigo Kato, A. Kawashima, Norio Nonomura",10.1038/s41598-024-64440-7,https://doi.org/10.1038/s41598-024-64440-7,Scientific Reports,0,2024,no,"The study focuses on prostate cancer patients with bone metastases, not osteoporosis patients, which is a clear violation of the inclusion criteria.",no,"The abstract does not document the specific time intervals between medication start, dental procedures, and MRONJ incidence, so this criterion is not met.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract does not mention any specific dental procedures leading to MRONJ, so this criterion is not met.",yes,"While not explicitly stated, this appears to be a retrospective cohort study based on the follow-up period and analysis, so this criterion is met.",yes,"The study does document MRONJ incidence with a follow-up period (median 19 months), meeting the 6-month minimum requirement, so this criterion is met.",yes,"While not explicitly stated, the population consists of prostate cancer patients, who are typically over 18 years old, so this criterion is met.",yes,"The study includes 179 patients, which exceeds the minimum requirement of 100 subjects, so this criterion is met.",no,"The study includes both denosumab and zoledronic acid, which are not oral bisphosphonates, violating the intervention criterion.",no,"The abstract does not explicitly mention the diagnostic standards for MRONJ, so this criterion is not met.",Exclude,"The study focuses on prostate cancer patients with bone metastases, which deviates from the required osteoporosis patient population and medication type. Critical screening criteria were not met, including the absence of a control group, lack of specific dental procedures, and use of non-bisphosphonate medications. Multiple fundamental requirements for inclusion were violated, rendering the study unsuitable for the systematic review.",0.1
[Risk Factors of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Prostate Cancer Patients with Bone Metastases].,"Kana Ito, Heisuke Iijima, M. Kumagai, Ryo Yabusaki, Yusuke Muro, Y. Shiraishi, M. Imamura, K. Yoshimura",10.14989/ActaUrolJap_69_5_125,https://doi.org/10.14989/ActaUrolJap_69_5_125,Hinyokika kiyo. Acta urologica Japonica,0,2023,no,"The study specifically focuses on cancer patients (prostate cancer with bone metastases) taking zoledronic acid or denosumab, which explicitly violates the criterion excluding cancer patients.",maybe,"The abstract mentions ""longer duration of BRI exposure"" but doesn't provide specific time intervals.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The abstract mentions ""dental treatment"" but doesn't specify which procedures were included.",yes,"While not explicitly stated, this appears to be a retrospective cohort study based on the methodology described.",maybe,"The study reports ARONJ incidence and appears to have a long follow-up period (2006-2020), but the specific follow-up period for individual patients is not mentioned.",yes,"While not explicitly stated, the population consists of prostate cancer patients, who are typically over 18 years old, so this criterion is met.",yes,"The study includes 173 total patients (159 zoledronic acid + 14 denosumab), meeting the >100 subject requirement.",no,"The study uses zoledronic acid and denosumab, which are not oral bisphosphonates. Zoledronic acid is an intravenous bisphosphonate, and denosumab is a non-bisphosphonate.",no,The abstract does not mention specific diagnostic standards for ARONJ.,Exclude,"The study focuses on prostate cancer patients taking zoledronic acid and denosumab, which immediately disqualifies it from the screening criteria due to the cancer patient population and non-oral bisphosphonate medications. Multiple critical screening requirements were not met, including the absence of a control group, lack of specific diagnostic standards, and deviation from the specified intervention type. These fundamental deviations render the study ineligible for inclusion in the systematic review.",1.4
Osteonecrosis of the jaw: An update,"Karla Griselada Vazquez Guerrero, Nemesio Elizondo Garza, Jorge Yitzhak Garza Silva, Ruth Rodriguez Ruiz, Alma Delia Serrano Romero, Maria Argelia Akemi Nakagoshi Cepeda, J. Solís-Soto",10.22271/oral.2021.v7.i3c.1297,https://doi.org/10.22271/oral.2021.v7.i3c.1297,International Journal of Applied Dental Sciences,2,2021,no,"The abstract discusses ONJ in relation to bisphosphonates but appears to focus on oncology patients, which fails to meet the criterion of excluding cancer patients.",no,"No information about time intervals is provided, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",maybe,"The abstract mentions ""invasive dental procedures"" but doesn't specify which procedures or report specific MRONJ incidence rates, so it only partially meets this criterion.",no,"This appears to be a literature review rather than an original research study with any of the specified designs, so it fails to meet this criterion.",no,"No specific follow-up period is mentioned, so this criterion is not met.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning is uncertain.",maybe,"The abstract does not mention the sample size, so the reasoning is uncertain.",maybe,"While bisphosphonates are mentioned, the abstract discusses both oral and intravenous administration, and doesn't specify osteoporosis treatment, so it only partially meets this criterion.",maybe,"The abstract mentions diagnostic methods (orthopantomography, MRI, CT) but doesn't specify diagnostic standards for MRONJ, so it only partially meets this criterion.",Exclude,"The literature review fails to meet multiple critical screening criteria, including specific population requirements, study design, and outcome documentation. Focused on oncology patients and lacking a control group, the abstract does not align with the systematic review's methodological standards for osteoporosis-related medication research. Consequently, the paper would be excluded from further analysis.",1.4
Risk Factors Associated with Bisphosphonates Related Osteonecrosis of the Jaw: A National Insurance Senior Cohort Database Study,"Jun Hyeob Kim, Tae Hyeok Kim, K. Lee",10.17480/psk.2022.66.4.210,https://doi.org/10.17480/psk.2022.66.4.210,Yakhak Hoeji,0,2022,no,"The study included a mixed population with multiple conditions, including multiple myeloma, bone metastases, osteoporosis, and Paget disease, which does not meet the requirement for a population specifically taking medication for osteoporosis.",no,"The abstract did not document the time intervals between medication start, dental procedure, and BRONJ incidence, so this information is unclear.",yes,"The study included a control group of patients who were never diagnosed with BRONJ, which meets the requirement for a control group.",maybe,"While tooth extraction was mentioned as a risk factor, it was not clear if this was the specific dental procedure leading to BRONJ in all cases.",yes,"The study design was a nested case-control study, which meets the criteria for an appropriate study design.",maybe,"The abstract documented BRONJ incidence, but the follow-up period was not specified, so this information is unclear.",maybe,"The study used a ""senior cohort,"" which suggests the subjects were likely over 18 years old, though the exact age range was not specified.",yes,"The study included 4,455 cases and 22,236 total subjects, which exceeds the requirement of over 100 subjects for the medication group.",maybe,"The abstract did not specify whether the bisphosphonates were oral or intravenous, so the intervention type is unclear.",no,"The abstract did not mention the diagnostic standards used for BRONJ, so this information is unclear.",Include,"The study involves a mixed patient population with multiple medical conditions, which critically fails the screening criteria requiring a focused osteoporosis patient group. While the research demonstrates methodological strengths like a large sample size and appropriate study design, the inclusion of cancer patients and lack of clear diagnostic standards prevent it from meeting the specified screening requirements. Multiple unclear elements further complicate the study's alignment with the predefined criteria.",2.7
Medication-related osteonecrosis of the jaws: a prospective cross-sectional study in a Moroccan population.,"Chaimae Mahad, Abdellatif Benider, Ihsane Benyahya",10.56264/2658-865x.1093,https://doi.org/10.56264/2658-865x.1093,Health Sciences,0,2023,maybe,"The study includes patients on bisphosphonates, but it's unclear if they're specifically for osteoporosis or mixed with cancer patients, as 64% were receiving Zoledronic acid intravenously, which is often used in cancer treatment. This is a significant concern.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study does mention dental extractions (55.6% of patients had undergone dental extractions), meeting this criterion.",no,"The study is described as a ""descriptive cross-sectional prevalence study,"" which doesn't clearly fit into any of the accepted study designs (RCT, prospective cohort, retrospective cohort, or case-control).",maybe,"While MRONJ incidence is documented (40% of patients), the follow-up period is not specified.",yes,"The average age of the subjects is mentioned as 55 years, which meets the requirement of being over 18 years old.",no,"The study only included 25 patients, which is well below the required 100 subjects for the medication group.",no,"The study includes both oral and intravenous bisphosphonates (64% were receiving Zoledronic acid intravenously), which violates the criterion of only including oral bisphosphonates.",no,The abstract doesn't mention the diagnostic standards used for MRONJ.,Exclude,"The study fails to meet multiple critical screening criteria, including insufficient sample size (25 patients), mixed population potentially including cancer patients, and inclusion of intravenous bisphosphonates. Significant methodological limitations exist, such as unclear diagnostic standards, undefined follow-up period, and a study design that does not align with accepted research methodologies. These deficiencies substantially reduce the study's potential for inclusion in a rigorous research review.",1.4
Determining the extent of osteotomy in patients with medication-related osteonecrosis of the jaw of the mandible: What are the factors for poor prognosis?,"S. Hayashida, M. Umeda",10.5794/jjoms.69.128,https://doi.org/10.5794/jjoms.69.128,Japanese Journal of Oral & Maxillofacial Surgery,0,2023,no,"The abstract mentions both osteoporosis and bone metastasis of malignant tumors, indicating a mixed population, which explicitly fails this criterion.",no,"No information about time intervals is provided in the abstract, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While MRONJ is discussed, the abstract does not specify any dental procedures, so it fails this criterion.",no,"The abstract appears to be a general review or commentary rather than any of the specified study designs, so it fails this criterion.",no,"The abstract does not mention any specific follow-up period or documented MRONJ incidence, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the age requirement is unknown.",maybe,"The abstract does not mention the number of subjects, so the subject size requirement is unknown.",maybe,"While bisphosphonates are mentioned, the abstract also includes denosumab (a non-bisphosphonate) and doesn't specify oral administration, so the intervention type criterion is only partially met.",no,"The abstract does not mention any diagnostic standards for MRONJ, so it fails this criterion.",Exclude,"The abstract fails multiple critical screening criteria, including having a mixed patient population with cancer patients, lacking a specific study design, and omitting details about diagnostic standards, dental procedures, and outcome documentation. Key requirements such as subject size, intervention type, and MRONJ latency are not addressed, rendering the paper unsuitable for inclusion in the systematic review.",0.1
Role of sclerostin deletion in bisphosphonate-induced osteonecrosis of the jaw.,"Fuminori Nakashima, Shinji Matsuda, Yurika Ninomiya, Tomoya Ueda, Keisuke Yasuda, Saki Hatano, S. Shimada, Daisuke Furutama, T. Memida, M. Kajiya, C. Shukunami, K. Ouhara, N. Mizuno",10.1016/j.bone.2024.117200,https://doi.org/10.1016/j.bone.2024.117200,Bone,0,2024,no,"The abstract mentions osteoporosis patients, but it appears to be a basic science study about sclerostin deletion rather than a clinical study of actual patients, so it fails this criterion.",no,"No time intervals are documented in the abstract, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"No specific dental procedures are mentioned in the abstract, so it fails this criterion.",no,"This appears to be a basic science study rather than any of the specified clinical study designs, so it fails this criterion.",no,"While MRONJ is mentioned, there's no indication of follow-up periods or specific documentation of incidence, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the age of the population is unknown.",maybe,"No subject numbers are mentioned in the abstract, so the subject size is unknown.",no,"The abstract mentions bisphosphonates but also discusses other medications (denosumab, romosozumab), so it is not focused specifically on oral bisphosphonates and fails this criterion.",no,"No diagnostic standards for MRONJ are mentioned in the abstract, so it fails this criterion.",Exclude,"The abstract describes a basic science study investigating sclerostin deletion and MRONJ mechanisms, which fundamentally fails to meet multiple critical screening criteria for a clinical research study. Specifically, the text lacks details about patient population, intervention specifics, study design, diagnostic standards, and outcome documentation required for inclusion. The research appears focused on molecular mechanisms rather than clinical patient outcomes.",0.1
Medication-related osteonecrosis of the jaw: Osteoclast profile in comparison with osteoradionecrosis of the jaw and osteomyelitis of the jaw.,"Vy Tran Ngoc Thuy, R. Chaisuparat",10.1111/jop.13202,https://doi.org/10.1111/jop.13202,Journal of Oral Pathology & Medicine,1,2021,no,"The abstract does not specify that subjects are taking medication for osteoporosis. It only mentions ""medications prescribed for skeletal disease"" which is too broad.",no,"No information about time intervals between medication start, dental procedures, and MRONJ onset.",no,"The study includes a control group (normal jaw bone n=9), but this is not a medication control group as specified in the criteria.",no,The abstract does not mention any dental procedures leading to MRONJ.,yes,"This appears to be a case-control study comparing different conditions, which would technically meet this criterion.",no,The study focuses on histological characteristics rather than documenting MRONJ incidence after dental treatment. No mention of follow-up period.,maybe,The abstract does not specify the age of subjects.,no,"The study only includes 11 MRONJ cases, which is well below the required 100 subjects.",no,The abstract does not specify the type of medication (oral bisphosphonate vs. other).,no,"While the study examines histological features, it doesn't explicitly state diagnostic standards for MRONJ.",Exclude,"This research study fails to meet multiple critical screening criteria, including insufficient subject size, lack of specificity about medication type, and absence of clear documentation about dental procedures and MRONJ incidence. The paper appears to be a basic science investigation of osteoclast morphology rather than a clinical study addressing the required research parameters. Consequently, the abstract does not align with the established screening requirements for the intended research focus.",1.4
Mandibular and palatal tori exposed by trauma are risk factors for medication-related osteonecrosis of the jaws: a report from the Copenhagen ONJ cohort,M. Schiødt,10.1016/j.oooo.2019.07.046,https://doi.org/10.1016/j.oooo.2019.07.046,-,1,2020,no,"The study includes a mixed population - 16 cancer patients, 10 osteoporosis patients, and 3 with no systemic diseases, which fails the criterion requiring exclusive focus on osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",yes,"The study does report MRONJ incidence following dental procedures (tooth extraction, denture-related procedures), meeting this criterion.",yes,"This appears to be a retrospective cohort study of the Copenhagen ONJ Cohort, which meets the acceptable study designs.",maybe,"While the study documents MRONJ incidence and treatment outcomes, the follow-up period is not specified, so this is uncertain.",maybe,"While not explicitly stated, the study is of patients with MRONJ, so it can be reasonably assumed the subjects are adults, but this is not confirmed.",maybe,"The total cohort is 391 patients, but only 29 have tori-related MRONJ. The medication group size is not clearly specified for osteoporosis patients alone, so this is uncertain.",no,"The study includes both bisphosphonates and denosumab (a non-bisphosphonate), and also includes patients not on any antiresorptives, which fails the criterion requiring only oral bisphosphonates.",maybe,"While the abstract mentions ""ONJ staging,"" it doesn't explicitly detail the diagnostic standards for MRONJ, so this is uncertain.",Include,"The study fails key screening criteria due to a mixed patient population including cancer patients and non-bisphosphonate medications, which deviates from the specified research parameters. Critical exclusion criteria were not met, particularly regarding population composition and intervention type, rendering the study unsuitable for the intended research focus. Multiple uncertain elements and small sample size further compromise the study's alignment with the predefined screening requirements.",2.5
OSTEONECROSIS OF THE JAW ASSOCIATED WITH ORAL ALENDRONATE: CASE REPORT,"Y. Kalinin, V. C. Gonçalves, S. V. Nascimento, Ivan José Correia Neto",10.1016/j.oooo.2020.04.432,https://doi.org/10.1016/j.oooo.2020.04.432,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2020,yes,"The subject is taking bisphosphonate (alendronate) specifically for osteoporosis treatment, meeting this criterion.",maybe,"While the abstract mentions the patient was on bisphosphonates for 4 years, it doesn't document the specific time intervals between medication start, dental procedure, and MRONJ onset.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ. It only describes the presentation and treatment of existing MRONJ.,no,"This is explicitly a case report, which is specifically excluded in the criteria.",no,"While the follow-up period is mentioned (5 months), this is not a study of MRONJ incidence after dental treatment, but rather a case report of treatment of existing MRONJ.",yes,"The subject is 67 years old, meeting the age requirement of over 18 years old.",no,"This is a single case report (n=1), which fails to meet the minimum requirement of 100 subjects.",yes,"The subject is taking oral bisphosphonate (alendronate) for osteoporosis, meeting this criterion.",yes,"The abstract mentions the clinical definition of MRONJ (""persistent necrotic bone exposure for more than 8 weeks, history of antiresorptive or antiangiogenic agents, and no history of radiotherapy""), meeting this criterion.",Exclude,"This case report fails multiple critical screening criteria, including being a single-subject study instead of a required cohort with over 100 participants, and lacking a specific dental procedure leading to MRONJ. The study design as a case report explicitly disqualifies it from inclusion, despite meeting some individual criteria like patient age and medication type.",0.1
Long-Term Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) After Bisphosphonates and/or Denosumab in Metastatic Breast Cancer Patients,"V. Fusco, Costanza Massarino, M. Rossi, A. Gambino, A. Maconi, P. Arduino",10.32388/mb953f.2,https://doi.org/10.32388/mb953f.2,Qeios,0,2024,no,"The study specifically focuses on cancer patients with bone metastases, which is explicitly excluded in the criteria.",no,"The abstract mentions ""late onset"" but does not provide specific time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,yes,"The study is described as a ""retrospective multicenter study,"" which fits the acceptable study designs.",maybe,The study reports MRONJ incidence and mentions a 6-year follow-up period.,maybe,"While not explicitly stated, the population consists of breast cancer patients, who are typically adults, so this criterion is likely met.",no,"The abstract does not specify the total number of subjects, making it impossible to verify if it meets the >100 subjects requirement.",no,"The study includes both bisphosphonates and denosumab (a non-bisphosphonate), and focuses on cancer patients rather than osteoporosis patients.",no,The abstract does not mention the diagnostic standards used for MRONJ.,Exclude,"The study focuses on cancer patients with bone metastases receiving antiresorptive medications, which fundamentally conflicts with the screening criteria requiring an osteoporosis patient population. Multiple critical screening requirements are not met, including the specific patient indication, medication type, and dental procedure documentation. Consequently, the abstract does not qualify for inclusion in the systematic review.",0.1
MRONJ ASSOCIATED WITH DENTAL INFECTION AND SECONDARY INVOLVEMENT OF THE NEARBY IMPLANT: A CASE REPORT,"Stefania Nespoli, E. Audino, S. Negrini, Francesco Daleffe, M. Mensi, L. Visconti, A. Castellani, S. Salgarello",10.32388/U22PV1.3,https://doi.org/10.32388/U22PV1.3,Qeios,0,2021,no,"The abstract mentions patients taking bisphosphonates, but also discusses other medications and oncological diseases, indicating a mixed population study that fails this criterion.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The abstract mentions tooth extraction and implant involvement, which meets this criterion.",no,"This is explicitly described as a case report, which is specifically excluded in the criteria.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",maybe,"The abstract does not explicitly state the age of the subjects, so the age requirement is unclear.",no,"This is a case report, which by definition has only one subject, failing the minimum subject size requirement.",no,"While bisphosphonates are mentioned, the abstract also discusses other medications (Denosumab, Tyrosine kinase inhibitors, VEGF inhibitors), so it is not exclusively focused on oral bisphosphonates.",yes,"The abstract does mention diagnostic criteria for MRONJ (""exposed bone or bone that can be probed through an intraoral or extraoral fistula in maxillofacial region that has persisted for longer than 8 weeks"").",Exclude,"This case report fails multiple critical screening criteria, including being a single-subject study, having a mixed patient population, and not exclusively focusing on oral bisphosphonates for osteoporosis. The study design as a case report explicitly disqualifies it from meeting the required methodological standards, rendering it unsuitable for inclusion in the research analysis.",0.1
Precursor Radiographic Findings in Patients With Medication-Related Osteonecrosis of the Jaw.,"R. Kajihara, Eiji Kondo, Hironobu Fukuda, H. Sakai, T. Koike, H. Kurita",10.1016/j.joms.2024.04.015,https://doi.org/10.1016/j.joms.2024.04.015,Journal of oral and maxillofacial surgery,0,2024,no,"While MRONJ was mentioned, there was no explicit mention of osteoporosis patients or exclusion of cancer patients, so Elicit could not confirm if the population indication criterion was met.",maybe,"The abstract discussed the concept of latency but did not document specific time intervals, so Elicit could not confirm if this criterion was met.",no,"No mention of a control group, so Elicit could not confirm whether this criterion was met.",yes,"The abstract did mention tooth extraction as a procedure and MRONJ as an outcome, which meets this criterion.",no,"The abstract did not specify the study design, so Elicit could not determine if it was a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",no,"While MRONJ was mentioned, there was no information about the follow-up period or clear documentation of incidence rates, so Elicit could not confirm if this criterion was met.",no,"No specific age information was provided, so Elicit could not determine if the population was over 18 years old.",no,"No information about sample size was provided, so Elicit could not determine if the study included over 100 subjects in the medication group.",no,"No specific mention of bisphosphonates or other medications was made, so Elicit could not confirm if the intervention type criterion was met.",no,"No mention of diagnostic standards for MRONJ was made, so Elicit could not confirm if this criterion was met.",Exclude,"The abstract lacks critical details required by the screening criteria, with only one criterion definitively met regarding dental procedures and MRONJ outcome. Insufficient information is provided about population characteristics, study design, intervention type, and diagnostic standards, rendering comprehensive assessment impossible. The brevity and generality of the text prevent meaningful confirmation of most screening requirements.",1.4
"Medication-Related Osteonecrosis of the Jaw: a Brief Review, Treatment and Practical Guidelines for Dentists","Ioana-Aurița Albu-Stan, D. Albu, Diana Cerghizan, L. Eremie, K. Jánosi, M. Baloș, C. Copotoiu",10.1515/jim-2017-0046,https://doi.org/10.1515/jim-2017-0046,-,1,2017,no,"The abstract discusses multiple indications including cancer patients and mixed populations, which fails to meet the criterion of focusing only on osteoporosis patients.",no,No information about time intervals is provided in the abstract.,no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While the abstract mentions treatment approaches, it doesn't specifically report MRONJ incidence following the specified dental procedures.",no,"This appears to be a review article rather than any of the specified study designs, as the abstract discusses general information about the condition and treatment approaches.",no,The abstract does not mention any specific follow-up period or documented MRONJ incidence rates.,maybe,"The abstract does not specify the age requirements of the subjects, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any sample size, so the reasoning for this criterion is uncertain.",no,"While bisphosphonates are mentioned, the abstract also discusses denosumab and other antiresorptive agents, so it is not focused exclusively on oral bisphosphonates.",no,The abstract does not mention any specific diagnostic standards for MRONJ.,Exclude,"The abstract fails to meet multiple critical screening criteria, including specific population requirements, intervention type, and study design. It presents a broad review of medication-related osteonecrosis of the jaw across various patient populations, rather than a focused research study meeting the predefined methodological standards. Consequently, the abstract does not qualify for inclusion based on the established screening criteria.",0.1
Comparative Analysis of the Oral Microbiome of Medication-Related Osteonecrosis of the Jaw Patients,Jun-Young Kim,10.1016/j.joms.2023.08.053,https://doi.org/10.1016/j.joms.2023.08.053,Journal of oral and maxillofacial surgery,0,2023,no,"The abstract mentions that the study included patients with ""osteoporosis, skeletal complications associated with osseous metastasis, and multiple myeloma"", indicating a mixed population including cancer patients, which violates the criterion.",no,"No information is provided about the time intervals between the start of medication, dental procedures, and MRONJ incidence.",maybe,"The abstract mentions ""both healthy and MRONJ disease groups"", suggesting the study may have included a control group of patients not taking anti-resorptive medications. However, it is not explicitly clear if these are patients not taking anti-resorptive medications.",no,"The abstract does not mention any dental procedures or MRONJ incidence following procedures. Instead, it focuses on microbial communities in saliva and oral mucosa.",no,The abstract does not clearly state the study design methodology.,no,"The study does not appear to document MRONJ incidence after dental treatment, as it focuses on microbiological analysis rather than clinical outcomes.",no,No information is provided about the age of the subjects in the study.,no,No information is provided about the sample size of the study.,no,"While anti-resorptive drugs are mentioned, the specific type (oral bisphosphonates) is not specified.",no,No information is provided about the diagnostic standards for MRONJ used in the study.,Exclude,"The study involves a mixed patient population including cancer patients, which violates the specified screening criteria for osteoporosis research. Critical screening requirements related to dental procedures, MRONJ incidence, and outcome documentation are not met, rendering the abstract unsuitable for the systematic review. Multiple key screening criteria remain unaddressed or unclear, further compromising the study's alignment with the research parameters.",1.4
Improving Knowledge of MRONJ Risk Among Singapore Dental Practitioners Using an Educational Lecture With an Incorporated Quiz,"L. Gani, S. Chionh",10.1210/jendso/bvab048.534,https://doi.org/10.1210/jendso/bvab048.534,Journal of the Endocrine Society,0,2021,no,The study does not directly study patients taking medication for osteoporosis. It studies dental professionals' knowledge about osteoporosis treatment.,no,The study does not document any time intervals related to MRONJ.,no,"The abstract does not mention any control group, as this is a survey of dental professionals, not a clinical study.",no,The study does not report MRONJ incidence following specific dental procedures. It only discusses dental professionals' knowledge about treating patients on osteoporosis medications.,no,"This is a survey study of dental professionals, not any of the required study designs (RCT, cohort, or case-control).",no,The study does not document MRONJ incidence or follow-up periods.,no,"The study focuses on dental professionals, not patients, so the age criterion is not applicable here.",no,"While the study has 126 responses, these are from dental professionals, not medication-taking patients.",no,The study does not directly study patients taking oral bisphosphonates. It only discusses osteoporosis treatment in general terms.,no,"While MRONJ is discussed, the study does not mention specific diagnostic standards.",Exclude,"This survey of dental professionals fails to meet the systematic review's screening criteria, as it does not study patients taking anti-resorptive medications, lacks a clinical study design, and does not document MRONJ incidence or patient outcomes. The research focuses on dental professionals' knowledge about osteoporosis treatment rather than a clinical investigation of medication-related jaw necrosis, rendering it ineligible for inclusion in the review.",0.1
MON-513 Osteonecrosis after Successful Osseointegrated Dental Implantation,"Paul Belany, C. Zachariadou, Se Aguirre, A. Salvador, Js Yu, Jr Kalmar, S. Rotenberg, Steven W. Ing",10.1210/JS.2019-MON-513,https://doi.org/10.1210/JS.2019-MON-513,Journal of the Endocrine Society,0,2019,maybe,"The subject is taking medication for osteoporosis/osteopenia, meeting this criterion. However, there is mention of hyperparathyroidism treatment, which introduces some complexity.",yes,"The abstract documents the time intervals between medication start, dental procedure, and MRONJ development, meeting this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The study reports MRONJ following dental implant placement, meeting this criterion.",no,"This is explicitly stated as a case report, which is specifically excluded in the criteria.",yes,"The study documents MRONJ incidence and has a follow-up period well over 6 months, meeting this criterion.",yes,"The subject is 77 years old, meeting the >18 years criterion.",no,"This is a case report of a single patient, failing to meet the minimum requirement of 100 subjects.",no,"The subject initially took ibandronate (oral bisphosphonate) but switched to denosumab (non-bisphosphonate), failing this criterion.",yes,"The abstract mentions diagnostic criteria including radiological, pathological, and biochemical data, meeting this criterion.",Exclude,"This case report fails key screening criteria due to its single-subject design and mixed medication types, which deviate from the required study parameters. Despite meeting several secondary criteria like age, diagnostic standards, and outcome documentation, the fundamental methodological limitations disqualify the study from meeting the comprehensive screening requirements. The research's case report format and non-standard intervention type represent critical exclusion factors.",0.1
“Medication Related Osteonecrosis of the Jaw (MRONJ): Dental Atraumatic Treatment: Antiseptic Mouthwashes”.,"Amanda Phoon Nguyen, Leon Smith",10.46940/sjdor.01.1003,https://doi.org/10.46940/sjdor.01.1003,SunKrist Journal of Dentistry and Oral Research,0,2020,no,"The abstract appears to be a review/overview rather than a primary research study with specific patient populations, so it fails this criterion.",no,"The abstract does not mention any time intervals between medication start, dental procedures, and MRONJ incidence, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While MRONJ is discussed, the abstract doesn't specifically report incidence following dental procedures, and instead focuses more on treatment approaches, so it fails this criterion.",no,"The abstract appears to be a review article rather than any of the required study designs, so it fails this criterion.",no,"The abstract doesn't document specific MRONJ incidence or follow-up periods, so it fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the information is unknown.",maybe,"The abstract does not mention the number of subjects, so the information is unknown.",no,"The abstract discusses bisphosphonates but also includes other medications (Denosumab, antiangiogenic agents), so it is not focused exclusively on oral bisphosphonates and fails this criterion.",yes,"The abstract does mention the ASBMR definition of MRONJ, which is a diagnostic standard, so it meets this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including lack of a defined study population, absence of a control group, and no specific documentation of MRONJ incidence following dental procedures. While providing general information about MRONJ, the text appears to be a review article rather than a primary research study, rendering it ineligible for systematic review inclusion.",0.1
“Prevalence of late stage in 507 Medication-related osteonecrosis of the jaws (MRONJ) sites: comparison between cancer and osteometabolic patients.”,G. Ghidini,10.32388/9yp1ev,https://doi.org/10.32388/9yp1ev,Qeios,0,-,no,"The study includes both cancer and non-cancer patients (293 cancer vs 100 non-cancer). This violates the criterion requiring the study to focus exclusively on osteoporosis patients, excluding cancer patients and mixed populations.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,The abstract does not mention a control group of patients not taking anti-resorptive medications.,no,The abstract does not mention any specific dental procedures leading to MRONJ.,yes,"The abstract explicitly states this is a retrospective study, which meets the criterion.",no,"While MRONJ incidence is documented, the follow-up period is not specified.",maybe,"While not explicitly stated, given this is a study of MRONJ in cancer and non-cancer patients, it's likely these are adult patients, but we cannot be certain without explicit confirmation.",yes,"The study includes 100 non-cancer patients, which meets the minimum requirement of 100 subjects.",no,The abstract does not specify the type of anti-resorptive medication used. We cannot confirm if it's oral bisphosphonates.,no,The abstract mentions MRONJ staging but does not specify the diagnostic standards used.,Exclude,"The study fails to meet multiple critical screening criteria, including the requirement for an exclusive osteoporosis patient population and specification of dental procedures leading to MRONJ. Significant methodological limitations include a mixed patient population with cancer patients, absence of a control group, and lack of clarity on medication type and diagnostic standards. These deficiencies render the study unsuitable for inclusion in the systematic review.",1.4
Histopathological and Serum Biomarkers Analyses in MRONJ due to Periodontal Disease in Rats: Comparison of Zoledronic Acid and Denosumab,"Ceren Çoşkun, Revan Birke Koca Ünsal, M. Soluk Tekkeşin, Faruk Çelik, H. Ergen, S. Zeybek, K. Kayhan, M. Ünür",10.26650/experimed.1190912,https://doi.org/10.26650/experimed.1190912,Experimed,0,2023,no,"The study uses rats with induced prostate cancer, not osteoporosis patients.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",yes,"The study includes a control group (CG) and a saline group (SG), meeting this criterion.",maybe,The study involves periodontal disease but doesn't specifically focus on the required dental procedures.,no,"This is an experimental animal study, not one of the accepted study designs.",maybe,The follow-up period and MRONJ incidence documentation are not clearly specified.,no,"This is an animal study using rats, not human subjects over 18 years old.",no,"Only 40 total subjects (12 in ZG, 12 in DG, 10 in SG, 6 in CG), well below the required 100 subjects.",maybe,"While zoledronic acid is a bisphosphonate, it's administered via injection (not oral) and for cancer treatment, not osteoporosis.",maybe,"While MRONJ is mentioned, the abstract doesn't specify diagnostic standards.",Exclude,"This experimental rat study fails multiple critical screening criteria, including being an animal model instead of a human study, using cancer patients rather than osteoporosis patients, and having an insufficient sample size. The research does not meet the required study design, population characteristics, or intervention specifications for inclusion in the systematic review.",0.1
Characteristic Image Findings of Medication-related Osteonecrosis of the Jaw Using Computed Tomography,"SO Okada, Naohisa Hirahara",10.5466/ijoms.18.177,https://doi.org/10.5466/ijoms.18.177,-,0,2020,no,"The abstract does not specify whether the subjects are osteoporosis patients or if there is a mixed population, so there is no information to confirm whether this criterion is met.",no,"The abstract does not provide any information about time intervals, so there is no way to determine if this criterion is met.",no,"The abstract does not mention any control group, so there is no information to confirm whether this criterion is met.",no,"While MRONJ is mentioned, the abstract does not provide any specific information about dental procedures leading to MRONJ, so there is no way to determine if this criterion is met.",no,"The abstract appears to be discussing previous literature rather than presenting original research, so it is unclear what type of study this is.",no,"While the abstract mentions MRONJ incidence ranges, it does not provide any information about the follow-up period or specific documentation of MRONJ after dental treatment, so there is no way to determine if this criterion is met.",no,"The abstract does not provide any information about the age of the subjects, so there is no way to determine if this criterion is met.",no,"The abstract does not provide any information about the sample size, so there is no way to determine if this criterion is met.",no,"The abstract does not specify the type of medication being studied, so there is no information to confirm whether this criterion is met.",no,"The abstract does not mention any diagnostic standards for MRONJ, so there is no information to confirm whether this criterion is met.",Exclude,"The abstract lacks critical details required by the screening criteria, including population characteristics, study design, intervention specifics, and outcome documentation. No information is provided about control groups, subject age, medication type, sample size, or diagnostic standards for MRONJ. The text appears to be a brief literature review rather than an original research study, rendering it insufficient for meeting the comprehensive screening requirements.",0.1
MEDICATION-RELATED OSTEONECROSIS OF THE JAWS DUE TO ADJUVANT OR HIGH DOSE ANTIRESORPTIVE TREATMENT,"S. Andersen, T. Kofod",10.1016/j.ijom.2023.10.135,https://doi.org/10.1016/j.ijom.2023.10.135,International Journal of Oral & Maxillofacial Surgery,0,2024,no,"The abstract mentions ""antiresorptive treatment (AR)"" but does not specifically state it is for osteoporosis. It also mentions ""adjuvant AR (ADAR) or high-dose AR (HDAR)"" which suggests the study may include cancer patients, which is an exclusion criterion.",no,"The abstract does not mention documenting the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, which is a significant missing element.",no,"While the abstract mentions ""maxillofacial treatment,"" it does not specifically detail the dental procedures leading to MRONJ.",yes,"The abstract indicates this is a cohort study (""Copenhagen ONJ Cohort""), which would meet the study design criterion.",maybe,"While the study follows patients from 2005 to 2021, suggesting adequate follow-up time, it does not clearly document MRONJ incidence after specific dental treatments.",maybe,"The abstract does not explicitly state the age range of the subjects, so this information is uncertain.",maybe,"The abstract does not mention the number of subjects, so this information is uncertain.",no,"The abstract only mentions ""antiresorptive treatment"" without specifying oral bisphosphonates, which is too vague to meet the criterion.",no,The abstract does not mention the diagnostic standards for MRONJ.,Include,"The abstract lacks critical details required by the screening criteria, including specific medication type, patient age range, and clear documentation of dental procedures leading to MRONJ. Multiple key methodological elements are missing, such as a control group, precise diagnostic standards, and clear outcome measurements. The study's inclusion of cancer patients and vague description of antiresorptive treatment further complicate its alignment with the systematic review's requirements.",2.7
"The rostral part of the trigeminal sensory complex is involved in orofacial nociception R. Dallel, P. Raboisson, P. Auroy and A. Woda, Brain Res., 448 (1988) 7–19","R. Dallel, P. Raboisson, P. Auroy, A. Woda",10.1016/0304-3959(89)90251-0,https://doi.org/10.1016/0304-3959(89)90251-0,Pain,0,1989,maybe,The abstract doesn't specify whether the bisphosphonate users were taking medication for osteoporosis or other conditions. This is a significant uncertainty.,no,"The abstract doesn't document the time intervals between medication start, dental procedure, and ONJ incidence.",yes,"The study explicitly includes a control group of 3090 patients without BP administration, meeting this criterion.",yes,The study specifically looks at tooth extraction and reports ONJ incidence following this procedure.,yes,"This is a cohort study, which meets the acceptable study design criteria.",maybe,"While the study documents ONJ incidence, the follow-up period is not specified in the abstract.",maybe,"While the study mentions patients aged 65 years or older in one analysis, it doesn't explicitly state that all subjects were over 18. However, given the context and setting (university hospital), it's likely all patients were adults.",yes,"The study includes 126 patients in the BP group, which exceeds the minimum requirement of 100 subjects.",no,"The study includes both oral and intravenous bisphosphonates, and doesn't specify which type was used for which patients. This fails to meet the criterion requiring only oral bisphosphonates.",no,The abstract doesn't mention any specific diagnostic standards for MRONJ/ONJ.,Include,"The study presents a cohort analysis of bisphosphonate-related jaw osteonecrosis with a control group, but critically fails to meet key screening criteria by including both oral and intravenous bisphosphonates. Significant uncertainties exist regarding patient population, medication indication, and diagnostic standards, which compromise the study's alignment with the specified screening requirements.",2.7
AB0822 Clinical features and predictive factors of oral bisphosphonate-related osteonecrosis of the jaw: an analysis of 8 cases in a single institution,"A. Rangel-Botello, A. Gallegos-Posada, F. Jasso-Άvila, D. Ramos-Bello, C. Villa-Calderόn, M. Martínez-Martínez, C. Abud-Mendoza",10.1136/annrheumdis-2017-eular.2506,https://doi.org/10.1136/annrheumdis-2017-eular.2506,-,2,2017,no,"The study includes a mixed population, with some patients taking bisphosphonates for osteoporosis and others taking them for rheumatoid arthritis or multiple sclerosis, which violates the requirement to exclude mixed populations.",yes,"The study documents the time interval between the start of bisphosphonate medication and the diagnosis of MRONJ (mean 45.9±35.5 months), which meets the requirement for documenting MRONJ latency.",yes,"The study includes a control group of 242 patients who were prescribed bisphosphonates but did not develop medication-related osteonecrosis of the jaw (MRONJ), which meets the requirement for a control group.",yes,"The study mentions dental extraction as a trigger for MRONJ in three cases, which meets the requirement for reporting MRONJ incidence following specific dental procedures.",yes,"The study appears to be a case-control study with 8 cases and 242 controls, which meets the requirement for the study design.",maybe,"The follow-up period is not explicitly stated in the abstract, so it is unclear whether the study meets the requirement for a follow-up period of at least 6 months.",yes,"The mean age of the subjects in the study is 74.5±13.8 years for the MRONJ group and 71.1±12.7 years for the control group, which indicates that the subjects are over 18 years old.",no,"The medication group (MRONJ cases) only includes 8 patients, which is well below the required 100 subjects.",yes,"The study specifically focuses on oral bisphosphonates, mentioning alendronate specifically, which meets the requirement for the intervention type.",no,"While the study mentions pathological findings, it does not explicitly state its diagnostic standards for MRONJ, which does not meet the requirement.",Exclude,"The study fails to meet critical screening criteria, particularly the requirement for a large sample size (only 8 cases) and a pure osteoporosis patient population. While demonstrating some methodological strengths like a control group and focus on oral bisphosphonates, the research fundamentally lacks the scale and population specificity needed for comprehensive analysis. Multiple screening criteria were not satisfied, rendering the study unsuitable for inclusion.",1.4
SURGICAL TREATMENT OF MEDICATION RELATED OSTEONECROSIS OF THE JAW USING PRF,"E. Tzaferi, Mary-Eleni Zouloumi, Athina Tzatzaki, Christos Gkanidis, L. Zouloumis",10.54936/haoms231p20,https://doi.org/10.54936/haoms231p20,Hellenic Archives of Oral &amp; Maxillofacial Surgery,0,2022,no,"The subject is taking denosumab for cancer (renal cell carcinoma), not osteoporosis, which explicitly fails this criterion.",maybe,"The abstract mentions ""1 year"" between medication start and MRONJ diagnosis, but doesn't clearly document the time from dental procedure to MRONJ, so the reasoning is partial.",no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"While the abstract mentions surgical treatment of MRONJ, it doesn't clearly specify if this was following one of the required dental procedures, so the reasoning is unclear.",no,"This is explicitly described as a case report, which is specifically excluded in the criteria.",yes,"The study does document follow-up for 6 months post-treatment, which meets this criterion.",yes,"The subject is 76 years old, which meets the requirement of being over 18 years old.",no,"This is a case report of a single patient, which is far below the required 100 subjects for the medication group.",no,"The study uses denosumab, which is not an oral bisphosphonate, and this explicitly fails this criterion.",maybe,"The abstract mentions ""MRONJ Stage 2"" but doesn't clearly describe the diagnostic standards used, so the reasoning is unclear.",Exclude,"This case report fails multiple critical screening criteria, including using a cancer patient instead of an osteoporosis patient, employing denosumab rather than oral bisphosphonates, and presenting a single-patient case study instead of a larger cohort. The fundamental deviations from the specified research parameters render the study non-compliant with the established screening requirements.",0.1
Subclinical Oral Bisphosphonate-related Osteonecrosis of the Jaw: Systematic Review of the Literature and an Additional Case,"S. Vasconcelos, A. Lemos, F. Bandeira",10.9734/JAMMR/2017/34007,https://doi.org/10.9734/JAMMR/2017/34007,-,1,2017,yes,"The abstract specifically mentions that 95% of cases were for osteoporosis/osteopenia treatment, meeting this criterion.",maybe,The abstract mentions median duration of therapy until diagnosis (5.23 years) but does not clearly document the time interval between dental procedure and MRONJ incidence.,no,"The abstract does not mention a control group, so no points were added for this criterion.",maybe,"The abstract mentions that 82% of patients performed some dental procedure preceding the onset of lesions, but does not specify which procedures.",no,"This appears to be a systematic review with a case report component, which does not meet the required study design criteria.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified.",yes,"The mean age of the subjects was 72.68 years, which meets the requirement of being over 18 years old.",maybe,"The abstract does not explicitly state the total number of subjects analyzed, so there is significant uncertainty about whether this criterion is met.",yes,"The study focuses on oral bisphosphonates (specifically mentions alendronate), meeting this criterion.",no,The abstract does not explicitly mention diagnostic standards for MRONJ.,Include,"The systematic review with a case report fails to meet several critical screening criteria, including the absence of a control group, unspecified sample size, and lack of clear diagnostic standards for MRONJ. While the study provides insights into oral bisphosphonates and osteonecrosis of the jaw, its methodological approach does not align with the required research design and documentation standards.",2.5
RADIOLOGICAL FINDINGS THAT SUGGEST THE PRESENCE OF LATENT MEDICATION-RELATED OSTEONECROSIS OF THE JAW AT THE TIME OF TOOTH EXTRACTION,"R. Kajihara, T. Koike, H. Tanaka, H. Kurita",10.1016/j.ijom.2023.10.418,https://doi.org/10.1016/j.ijom.2023.10.418,International Journal of Oral & Maxillofacial Surgery,0,2024,maybe,"While the study involves patients taking bone-modifying agents, it does not explicitly specify that the subjects are osteoporosis patients or exclude cancer patients, creating significant uncertainty about the population indication.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence, so there is no information about MRONJ latency.",yes,"The study explicitly includes a control group of 239 patients who received bone-modifying agents but did not develop MRONJ, which meets the requirement for a control group.",yes,"The study specifically looks at tooth extraction and MRONJ incidence, meeting the criteria for procedure and outcome.",yes,"The study appears to be a case-control study, which meets the criteria for study design.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified in the abstract, creating uncertainty about the outcome documentation.",maybe,"The abstract does not explicitly mention the age of the subjects, so there is uncertainty about whether the population meets the age requirement of over 18 years old.",yes,"The study includes 85 MRONJ cases and 239 control cases, exceeding the 100-subject requirement for the medication group.",maybe,"The abstract only mentions ""bone-modifying agents"" without specifying oral bisphosphonates, creating uncertainty about the intervention type.",yes,The study mentions using radiographic findings according to Fleisher et al. as diagnostic criteria for MRONJ.,Include,"The study presents a case-control design examining medication-related osteonecrosis of the jaw (MRONJ) with a substantial sample size and clear diagnostic standards, but lacks explicit confirmation of key screening criteria such as patient age, specific medication type, and follow-up period. Significant uncertainties exist regarding the precise patient population and intervention details, which prevent definitive assessment against all screening requirements.",3.5
[Preserving the oral health of patients on antiresorptive drugs].,"F. Tilotta, M. Folliguet, Loredana Radoï",-,-,La Revue du praticien,0,2023,no,"The abstract discusses both osteoporotic and tumoral bone conditions, indicating a mixed population, which fails to meet the criterion requiring exclusive focus on osteoporosis patients.",no,No specific time intervals are documented.,no,"The abstract does not mention any control group, so no points were added for this criterion.",maybe,"The abstract mentions dental avulsions (extractions) and discusses MRONJ risk, but doesn't present specific incidence data, so the criterion is only partially met.",no,"This appears to be a review article rather than any of the required study designs, as the abstract discusses ""recommendations"" and ""guidelines"" rather than presenting original research.",no,"While MRONJ is discussed, there's no mention of specific follow-up periods or documented incidence rates.",maybe,"The abstract does not explicitly specify age requirements, so the reasoning for this criterion is uncertain.",maybe,"The abstract does not mention any specific number of subjects, so the reasoning for this criterion is uncertain.",maybe,"While bisphosphonates are mentioned, the abstract also discusses denosumab (a non-bisphosphonate) and doesn't specify oral administration, so the criterion is only partially met.",no,"While osteonecrosis of the jaw is mentioned, specific diagnostic standards are not provided.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific study design requirements, population exclusivity, and detailed outcome documentation. Its nature as a review article rather than original research, combined with a mixed patient population and lack of precise diagnostic and procedural standards, significantly reduces its alignment with the specified screening criteria.",1.4
Prevalence of late stage in 507 Medication-related osteonecrosis of the jaws (MRONJ) sites: comparison between cancer and osteometabolic patients,"G. Ghidini, P. De Francesco, M. Frontera, M. Manfredi, M. Meleti, P. Vescovi",10.32388/9YP1EV.2,https://doi.org/10.32388/9YP1EV.2,-,0,2021,no,"The study explicitly includes both cancer and non-cancer patients, which violates the criterion requiring only osteoporosis patients.",no,"No information is provided about the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not mention any specific dental procedures leading to MRONJ.,yes,"The abstract explicitly states this is a retrospective study, which meets the criteria.",no,"While MRONJ incidence is documented, the follow-up period is not specified.",maybe,"While not explicitly stated, the study is likely of adult patients since it involves MRONJ in cancer and non-cancer patients, but this cannot be confirmed without explicit confirmation.",yes,"The study includes 394 patients total (293 cancer + 100 non-cancer), meeting the >100 subject requirement for the medication group.",no,"The abstract does not specify the type of anti-resorptive medication used, only mentioning ""osteometabolic patients"" which is too vague to confirm oral bisphosphonate use.",no,"While the study mentions MRONJ staging, it doesn't explicitly state its diagnostic standards.",Exclude,"The study fails to meet critical screening criteria, particularly by including a mixed population of cancer and non-cancer patients, which directly violates the requirement for a focused osteoporosis patient group. Multiple key methodological details are missing, including specific dental procedures, medication types, and diagnostic standards, rendering the research insufficient for the specified screening requirements.",1.4
Medication Related Osteonecrosis of the Jaw: A Conservative Approach,"D. Rushing, A. Arango, Adam Wandell",10.1016/j.joms.2022.07.063,https://doi.org/10.1016/j.joms.2022.07.063,Journal of oral and maxillofacial surgery,0,2022,no,"The abstract mentions patients taking antiresorptive medications for osteoporosis, but also discusses cancer therapy. It appears to be a general review rather than a specific study population, so it fails this criterion.",no,"No time intervals are mentioned in the abstract, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"No specific dental procedures are mentioned in the abstract, so it fails this criterion.",no,"This appears to be a review article or position paper rather than an original research study, so it fails this criterion.",no,"While MRONJ incidence rates are mentioned, there is no mention of follow-up periods or specific documentation of outcomes after dental procedures, so it fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning for this criterion is unknown.",maybe,"The abstract does not mention any specific subject numbers, so the reasoning for this criterion is unknown.",maybe,"While antiresorptive medications are mentioned, the specific type (oral bisphosphonates) is not specified, so the reasoning for this criterion is unknown.",maybe,"The abstract mentions AAOMS guidelines for diagnosis and management but does not specify the diagnostic standards, so the reasoning for this criterion is unknown.",Exclude,"The abstract fails multiple critical screening criteria, including lacking a specific research design, not documenting dental procedures, and not providing clear outcome measurements. It appears to be a review article rather than an original research study, which fundamentally disqualifies it from meeting the required screening standards. The text provides general information about MRONJ but does not satisfy the detailed methodological requirements for inclusion.",0.1
"“MRONJ: Dentistry and Physician Events under Bisphosphonates, Denosumab and Antiangiogenic Drugs”","Silvana Noemi P, Genta R, Eduardo R",10.51737/2766-4996.2020.023,https://doi.org/10.51737/2766-4996.2020.023,SunText Review of Dental Sciences,0,2020,no,"While the abstract discusses MRONJ, it does not specifically state that the subjects are osteoporosis patients taking medication, nor does it exclude cancer patients. Therefore, this criterion is not met.",no,"No information about time intervals is provided in the abstract, so this criterion is not met.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While dental procedures are mentioned generally, the abstract does not report specific MRONJ incidence following specific dental procedures. Therefore, this criterion is not met.",no,"This appears to be a review or commentary paper rather than an original research study, as it discusses ""published guidelines"" and general recommendations. Therefore, this criterion is not met.",no,"The abstract does not document specific MRONJ incidence or follow-up periods, so this criterion is not met.",maybe,"The abstract does not specify the age of the subjects, so the information is unknown.",maybe,"The abstract does not mention any sample size, so the information is unknown.",maybe,"The abstract does not specify the type of medication (oral bisphosphonates vs others), so the information is unknown.",no,"The abstract does not mention any diagnostic standards for MRONJ, so this criterion is not met.",Exclude,"The abstract lacks critical details required by the screening criteria, including specific population characteristics, study design, intervention type, and outcome documentation. Multiple key requirements remain unaddressed, such as diagnostic standards, MRONJ latency, and specific dental procedure outcomes. The text appears to be a general commentary rather than a research study meeting the comprehensive screening requirements.",0.1
Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives,"Bence Bojtor, B. Balla, M. Vaszilkó, Szófia Szentpéteri, Zsuzsanna Putz, J. Kósa, P. Lakatos",10.3390/ijms251910488,https://doi.org/10.3390/ijms251910488,International Journal of Molecular Sciences,0,2024,no,"While the abstract discusses MRONJ in relation to antiresorptive drugs, it does not specifically focus on osteoporosis patients or exclude cancer patients, so this criterion is not met.",no,"No information about time intervals is provided, so no points are added for this criterion.",no,"The abstract does not mention any control group, so no points are added for this criterion.",no,"While MRONJ is discussed, the abstract does not mention any specific dental procedures or their relationship to MRONJ incidence, so this criterion is not met.",no,"This appears to be a review article discussing genetic factors and pathogenesis, not an original research study with any of the required designs, so this criterion is not met.",no,"The abstract does not discuss follow-up periods or specific MRONJ incidence rates, so this criterion is not met.",maybe,"The abstract does not specify the age of the subjects, so the information is unknown.",maybe,"The abstract does not mention any subject numbers, so the information is unknown.",no,"The abstract only mentions ""antiresorptive drugs"" generally, without specifying oral bisphosphonates, so this criterion is not met.",no,"The abstract does not mention any diagnostic standards for MRONJ, so this criterion is not met.",Exclude,"The abstract describes a review of genetic factors in medication-related osteonecrosis of the jaw, but lacks critical details required by the screening criteria such as specific patient population, intervention type, study design, and outcome documentation. Multiple key screening requirements are not met, including control group presence, subject size, diagnostic standards, and specific dental procedure outcomes, rendering the paper unsuitable for inclusion based on the established criteria.",0.1
Bisphosphonate-related Osteonecrosis of The Jaw : Is the Medication Duration Related to Advanced Disease Stage?,"Yu-Pin Su, Wen-Chung Liu, Cheng-Ta Lin, Hsin-I Chien, Kuo‐Chung Yang",10.1097/fs9.0000000000000121,https://doi.org/10.1097/fs9.0000000000000121,Formosan Journal of Surgery,0,2024,no,"The study includes a mixed population of cancer patients (multiple myeloma and breast cancer) and osteoporosis patients, which explicitly violates the criterion requiring only osteoporosis patients.",no,"The study documents medication duration but doesn't clearly document the time interval between medication start and dental procedure, or procedure to MRONJ incidence.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract doesn't mention any specific dental procedures leading to MRONJ.,no,"This appears to be a case series, which is explicitly excluded by the criteria.",maybe,"While the study documents BRONJ outcomes, it doesn't mention a specific follow-up period.",maybe,"While the age of the subjects is not explicitly stated, the context of osteoporosis and cancer patients suggests they are likely adults, but this is not certain.",no,"The study only includes 13 total patients (6 osteoporosis patients), which is well below the required 100 subjects.",maybe,"While bisphosphonates are mentioned, the abstract doesn't specify if they were oral or intravenous.",yes,"The study mentions using the AAOMS MRONJ staging system, which meets this criterion.",Exclude,"The study fails key screening criteria due to its mixed patient population including cancer patients, small sample size of only 13 patients, and case series design. Critical methodological limitations include lack of a control group, absence of specific dental procedure documentation, and insufficient subject numbers for meaningful statistical analysis. These fundamental shortcomings render the study unsuitable for inclusion in a systematic review.",0.1
MEDICATION-RELATED OSTEONECROSIS OF THE JAWS IN A PATIENT WITH RHEUMATOID ARTHRITIS AND SECONDARY INFECTION BY SERRATIA MARCESCENS,"Pedro Augusto Bulhões Curioso, G. Machado, A. Rocha, D. Fernandes, P. Vargas, A. S. Silva, M. Lopes",10.1016/j.oooo.2020.04.298,https://doi.org/10.1016/j.oooo.2020.04.298,"Oral surgery, oral medicine, oral pathology and oral radiology",0,2020,no,"The patient is taking alendronate for rheumatoid arthritis, not specifically for osteoporosis, so this fails to meet the criterion of osteoporosis patients only.",yes,"The abstract documents the time interval between medication start and dental procedure (7 years) and between procedure and MRONJ (5 years), meeting this criterion.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The study does report MRONJ following dental extraction, meeting this criterion.",no,"This is explicitly a case report, which is specifically excluded in the criteria.",yes,"The study documents MRONJ incidence and has a follow-up period of 2 years, meeting the 6-month minimum requirement.",yes,"The subject is 72 years old, meeting the >18 years old criterion.",no,"This is a single case report (n=1), far below the required 100 subjects.",yes,"The patient is taking oral alendronate, which is a bisphosphonate, meeting this criterion.",maybe,"While MRONJ is diagnosed, the abstract doesn't explicitly mention diagnostic standards.",Exclude,"This case report fails multiple critical screening criteria, including insufficient sample size (n=1), inappropriate study design, and patient population not specifically focused on osteoporosis. Despite meeting some criteria like age, intervention type, and outcome documentation, the fundamental methodological limitations disqualify the study from systematic review inclusion.",0.1
Infections in cancer patients with medication-related osteonecrosis of the jaws,"Leandro Dorigan de Macedo, Victor Augusto Minari, L. M. A. Ramos Innocentini, Ana Laura Polizel Ranieri, Adriano Tadeu Dias Marangoni, Hilton Marcos Alves Ricz",10.15406/jcpcr.2022.13.00505,https://doi.org/10.15406/jcpcr.2022.13.00505,Journal of Cancer Prevention &amp; Current Research,0,2022,no,"The study specifically focuses on cancer patients taking zoledronic acid, which explicitly violates the criterion requiring patients taking medication for osteoporosis, excluding cancer patients.",no,"The abstract doesn't document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract doesn't specify which dental procedures were involved in the MRONJ cases.,yes,"The study is described as ""retrospective, longitudinal and observational,"" which meets the acceptable study design criteria.",no,"While the study documents MRONJ outcomes, the follow-up period is not specified.",maybe,"While not explicitly stated, the context suggests adult patients, but this isn't definitively confirmed.",no,"The study only included 21 patients, which is well below the required 100 subjects.",no,"The study uses zoledronic acid, which is an intravenous bisphosphonate, not an oral bisphosphonate as required.",maybe,"The abstract mentions classification of necrosis (Class 1, 2, 3), suggesting some diagnostic standard, though details aren't provided.",Exclude,"The study fails critical screening criteria by focusing on cancer patients instead of osteoporosis patients, using intravenous bisphosphonates instead of oral medications, and having a sample size of only 21 patients. Multiple fundamental requirements were not met, including population selection, intervention type, and subject size, rendering the study ineligible for inclusion.",0.1
Relationship Between MRONJ (Medication Related Osteonecrosis of the Jaw) and Endodontic Theraphy,P. Noemi,10.31031/MRD.2020.05.000618,https://doi.org/10.31031/MRD.2020.05.000618,Modern Research in Dentistry,0,2020,no,"While the abstract mentions bisphosphonate (BP) treatment, it does not specify if this is for osteoporosis patients or other conditions, so Elicit could not determine if this criterion was met.",no,"No information about time intervals is provided in the abstract, so Elicit could not determine if this criterion was met.",no,"The abstract does not mention any control group, so Elicit could not determine if this criterion was met.",no,"No information about specific dental procedures or MRONJ incidence is provided in the abstract, so Elicit could not determine if this criterion was met.",no,"This appears to be a definition/review paper rather than an original research study, so Elicit determined that this criterion was not met.",no,"No information about follow-up period or MRONJ incidence documentation is provided in the abstract, so Elicit could not determine if this criterion was met.",no,"The abstract does not specify the age of the subjects, so Elicit could not determine if this criterion was met.",no,"No information about sample size is provided in the abstract, so Elicit could not determine if this criterion was met.",maybe,"The abstract mentions bisphosphonates (BPs) but does not specify if they are oral or intravenous, so Elicit could only partially determine if this criterion was met.",yes,"The abstract does provide diagnostic standards for MRONJ, including the ASBMR 2007 definition and AAOMS 2014 staging system, so Elicit determined that this criterion was met.",Exclude,"The abstract provides diagnostic standards for MRONJ but lacks critical information about study design, patient population, intervention details, and outcome documentation. Multiple screening criteria remain unmet, including specifics about control groups, subject age, medication type, and dental procedure outcomes. The text appears to be a definitional review rather than an original research study addressing the required screening parameters.",1.4
384. Denosumab-Related Osteonecrosis of the Jaw: an Emergent and Potentially Complex Bone and Joint Infection,"Romain Bricca, F. Valour, Conrad Anne, E. Braun, P. Jaby, Jean-Thomas Bachelet, Pierre Breton, Arnaud Gleizal, F. Laurent, C. Chidiac, T. Ferry",10.1093/ofid/ofz360.457,https://doi.org/10.1093/ofid/ofz360.457,Open Forum Infectious Diseases,0,2019,no,"The study focuses on patients with metastatic cancer, which is explicitly excluded in the criteria, so the study fails this criterion.",no,"The abstract does not document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,The abstract mentions dental surgical procedures (58% of patients) but does not specifically detail which procedures were performed.,yes,"The study is a retrospective observational cohort study, which meets the requirement for study design.",yes,"The study has a median follow-up of 6 months, meeting the minimum requirement, and documents MRONJ outcomes.",yes,"The median age of the subjects is 71 years, which meets the requirement of being over 18 years old.",no,"The study only includes 12 patients total, which is far below the required 100 subjects for the medication group, so the study fails this criterion.",no,"The study focuses on denosumab, a non-bisphosphonate medication, rather than oral bisphosphonates, so the study fails this criterion.",maybe,"The abstract mentions grading (grade 1, 2, and 3) but does not explicitly detail the diagnostic standards for MRONJ.",Exclude,"The study fails critical screening criteria due to its focus on denosumab in cancer patients, with a sample size of only 12 subjects, which deviates from the required oral bisphosphonate population and minimum subject count. Multiple key methodological requirements were not met, including population indication, intervention type, and subject size, rendering the study ineligible for systematic review.",0.1
Denosumab-Related Osteonecrosis of the Jaw: a five year monocentric retrospective study of Ancona General Hospital,"L. Togni, M. Mascitti, A. Tesei, V. Zavaglia, A. Nori, A. Santarelli",10.32388/J240O0,https://doi.org/10.32388/J240O0,Qeios,0,2021,no,"The study includes both ""oncological and osteometabolic patients"" which violates the requirement for a pure osteoporosis population. This is a critical failure.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,The abstract does not specify which dental procedures were involved in the MRONJ cases.,yes,"The abstract explicitly states it is a ""retrospective study,"" which meets this criterion.",maybe,"While the study documents MRONJ cases over a 5-year period, it doesn't specify the follow-up period for individual cases.",maybe,"The abstract does not explicitly state the age of subjects, though it's likely they are adults given the context.",maybe,The abstract does not specify the number of subjects included in the study.,no,"The study focuses on Denosumab, which is not an oral bisphosphonate. This is a critical failure.",maybe,"While the study discusses MRONJ, it does not explicitly mention its diagnostic standards.",Exclude,"The study fails critical screening criteria by including a mixed patient population with cancer patients and focusing on Denosumab instead of oral bisphosphonates. Multiple uncertainties exist regarding subject size, diagnostic standards, and specific dental procedures, further compromising the study's alignment with the predefined screening requirements. The retrospective design and 5-year clinical experience provide some methodological value, but do not overcome the fundamental screening limitations.",1.4
"Mechanism, prevention, risk assessment and treatment in bisphosphonates induced osteonecrosis of the jaw","Jung-Chul Park, U. Jung, C. Kim, Kyoo-Sung Cho, J. Chai, Chong-Kwan Kim, Seongho Choi",10.5051/JKAPE.2009.39.1.1,https://doi.org/10.5051/JKAPE.2009.39.1.1,-,2,2009,no,"The abstract mentions that the study included both osteoporosis and other conditions (Paget's disease, bone metastasis), which indicates a mixed population study that fails this criterion.",no,"The abstract does not document time intervals between medication start, dental procedures, and MRONJ incidence, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While the abstract mentions osteonecrosis of the jaw, it does not specifically report incidence following the required dental procedures, which fails this criterion.",no,"The abstract indicates that this is a literature review (""Medline research was carried out""), not an original research study with any of the required designs, which fails this criterion.",no,"The abstract does not mention specific follow-up periods or clearly document MRONJ incidence rates, which fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning is uncertain.",maybe,"The abstract does not mention the sample size of the study, so the reasoning is uncertain.",no,"The abstract discusses both oral and IV bisphosphonates, and appears to be a review rather than an original study of oral bisphosphonate patients, which fails this criterion.",no,"The abstract does not mention specific diagnostic standards for MRONJ, which fails this criterion.",Exclude,"This literature review fails multiple critical screening criteria, including study design, population specificity, and intervention type. The abstract discusses bisphosphonates broadly across different conditions and does not meet the required methodological standards for an original research study on osteoporosis patients. Consequently, the paper does not qualify for inclusion based on the predefined screening criteria.",0.1
"Medication-related osteonecrosis of the jaws ( MRONJ ) review : what Irish dentists need to know , from international guidelines to current controversies",-,-,-,-,0,2018,no,"While the abstract mentions antiresorptive medications, it does not specify that the subjects are exclusively osteoporosis patients, and appears to cover MRONJ more broadly.",no,"The paper does not mention any time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention any control group, as this is a review paper rather than an original research study.",no,The abstract mentions dental screening but does not specifically report MRONJ incidence following specific dental procedures.,no,"This is a literature review, not one of the required study designs (RCT, cohort, or case-control study).",no,"As a review paper, it does not document specific MRONJ incidence or follow-up periods.",no,The abstract does not specify age requirements for the subjects.,no,"As this is a review paper, it does not have its own subject group.",no,"The abstract mentions ""antiresorptive and anti-angiogenic agents"" broadly, not specifically oral bisphosphonates.",no,"While the paper discusses MRONJ, it does not specify diagnostic standards.",Exclude,"This literature review fails to meet the systematic review's screening criteria, primarily because it is not an original research study with a defined patient population, intervention, or outcome measurement. The paper lacks specific details about subject demographics, medication type, dental procedures, and MRONJ incidence, rendering it ineligible for inclusion in the systematic review.",0.1
Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaws: Review of the Literature,M. Hristamyan,10.20431/2456-0030.0301003,https://doi.org/10.20431/2456-0030.0301003,-,2,2018,no,"The abstract mentions that the study population includes patients with multiple myeloma, bone metastases, and Paget disease, in addition to osteoporosis. This suggests a mixed population study, which fails this criterion.",no,"The abstract does not provide any information about time intervals, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While the abstract mentions dental procedures as risk factors, it does not report specific MRONJ incidence following these procedures, so it fails this criterion.",no,"The abstract indicates that this is a review article discussing epidemiological and clinical studies, rather than an original research study with one of the required designs, so it fails this criterion.",no,"The abstract does not mention any specific follow-up period or documented MRONJ incidence, so it fails this criterion.",maybe,"The abstract does not specify the age requirements of the study population, so the reasoning is uncertain.",maybe,"The abstract does not mention any specific sample size, so the reasoning is uncertain.",maybe,"While the abstract discusses bisphosphonates, it does not specify whether they are oral or intravenous, so the reasoning is uncertain.",no,"The abstract does not mention any specific diagnostic standards for BAONJ/MRONJ, so it fails this criterion.",Exclude,"The abstract fails multiple critical screening criteria, including lacking a clear study design, mixed patient population, and absence of specific diagnostic standards for MRONJ. Key methodological requirements such as control group, precise intervention type, and documented outcome measurements are not addressed, rendering the text unsuitable for the specified research parameters. The document appears to be a general review of bisphosphonate-associated jaw necrosis rather than a focused research study meeting the established screening criteria.",0.1
PMS2 Alendronate Use and the Risk of Osteonecrosis of Jaw in Taiwan,"Wen-Cheng Huang, P. Lu, C. Hsieh",10.1016/j.jval.2012.08.405,https://doi.org/10.1016/j.jval.2012.08.405,-,0,2012,yes,"The study specifically focuses on osteoporosis patients, excluding cancer patients.",no,"The study mentions a 3-year follow-up period but doesn't specifically document the time intervals between medication start, dental procedures, and ONJ incidence.",no,"The study does not include a control group of patients not taking anti-resorptive medications, so no points are added for this criterion.",no,"The abstract doesn't specify which dental procedures were associated with ONJ development, which is a significant limitation.",yes,"This is a retrospective cohort study, which meets the criterion.",yes,"The study has a 3-year follow-up period, exceeding the 6-month requirement, and clearly documents ONJ incidence.",yes,"While not explicitly stated, the study focuses on women with osteoporosis, implying an adult population over 18 years old.",yes,"The study includes 18,504 alendronate patients and 4,654 raloxifene patients, well exceeding the 100-subject requirement.",maybe,"The study includes oral bisphosphonate (alendronate) but also includes raloxifene (non-bisphosphonate), partially meeting the criterion as it includes both acceptable and unacceptable interventions.",yes,"The study mentions specific ICD-9-CM diagnosis codes for ONJ (526.4, 526.5, 528.3, and 730.18), meeting this criterion.",Include,"A retrospective cohort study of osteoporosis patients examining medication-related jaw necrosis, with a large sample size and clear diagnostic criteria, but lacking a non-medication control group and specific dental procedure details. The research compares alendronate and raloxifene groups, documenting ONJ incidence over a three-year period, though not fully meeting all screening requirements for comprehensive analysis.",3.2
Osteonecrosis of the Jaw (ONJ) Might Explain the Increased Oral Surgery Risk in Cancer Patients Treated with Bisphosphonates,M. Surg,-,-,-,0,2007,no,"The study focused on cancer patients (breast, prostate, lung cancer, or multiple myeloma) rather than patients taking medication for osteoporosis, which fails this criterion.",maybe,"The study documents time intervals between medication start and surgery, but does not specifically mention time to MRONJ incidence.",yes,"The study included a control group of patients not taking anti-resorptive medications, which meets this criterion.",no,"The abstract mentions ""surgery to the maxilla or mandible"" but does not specifically detail which procedures were included or clearly state MRONJ incidence.",yes,"The study appears to be a retrospective cohort study using medical claims data, which meets this criterion.",no,The abstract does not clearly indicate the follow-up period or MRONJ incidence documentation.,yes,"The study population included adult patients over 18 years old, as indicated by the median ages of 64 and 59 years.",yes,"The study analyzed data from approximately 20 million patients, which meets the requirement of over 100 subjects in the medication group.",maybe,"The study included both oral bisphosphonates (risedronate and alendronate) and intravenous bisphosphonates (pamidronate and zoledronic acid), which partially meets this criterion.",no,"The abstract does not mention the diagnostic standards for MRONJ, which is a significant omission.",Exclude,"The study focuses on cancer patients taking bisphosphonates, which critically fails the screening criteria requiring an osteoporosis patient population. While the research includes a large sample size and appears to be a retrospective cohort study, it lacks clear diagnostic standards for MRONJ and does not exclusively examine oral bisphosphonate interventions. The mixed patient population and intervention types significantly compromise its alignment with the specified screening requirements.",1.4
Idiopathic Incidence of MRONJ in Patients on Denosumab,M. Mirkhani,-,-,-,0,2017,no,"The study focuses on denosumab (not bisphosphonates) and includes cancer patients (prostate cancer), which explicitly violates this criterion.",no,"The abstract mentions that ONJ appears to be ""independent of the duration of denosumab therapy"" but doesn't document specific time intervals.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,"While the study discusses ONJ, it doesn't specifically report incidence following the required dental procedures.",no,"This appears to be a case series/case report review, which is explicitly excluded in the criteria.",maybe,"While outcomes are discussed, the follow-up period is not specified.",maybe,"The abstract doesn't explicitly state the age of subjects, though given the context of osteoporosis and prostate cancer treatment, they are likely adults.",no,"The study only identified 18 cases, which is well below the required 100 subjects.",no,"The study focuses on denosumab, which is explicitly excluded as it's not an oral bisphosphonate.",no,The abstract doesn't mention specific diagnostic standards for MRONJ.,Exclude,"The study fails multiple critical screening criteria, including using denosumab instead of oral bisphosphonates, having only 18 cases instead of the required 100 subjects, and including cancer patients. The research design as a case series and lack of specific diagnostic standards further disqualify it from meeting the established screening requirements.",0.1
Is periodontal disease a risk factor for the development of MRONJ,Danny Watts,10.1308/RCSFDJ.2015.126,https://doi.org/10.1308/RCSFDJ.2015.126,-,0,2015,no,"The abstract discusses patients taking antiresorptive agents but does not specifically focus on osteoporosis patients, mentioning both antiresorptive and antiangiogenic agents. Therefore, the study fails this criterion.",no,"No information about time intervals is provided in the abstract, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"While MRONJ is discussed, the abstract does not mention any specific dental procedures, so the study fails this criterion.",no,"The abstract appears to be from a review article rather than any of the specified study designs, so the study fails this criterion.",no,"No specific follow-up period or incidence data is mentioned in the abstract, so the study fails this criterion.",maybe,"The abstract does not specify the age of the subjects, so the information is unknown.",maybe,"No information about sample size is provided in the abstract, so the information is unknown.",no,"While bisphosphonates are mentioned, the abstract specifically focuses on intravenous bisphosphonates and only briefly mentions oral bisphosphonates. This appears to be a review or commentary rather than a primary study of oral bisphosphonate users, so the study fails this criterion.",yes,"The abstract does provide a diagnostic definition for MRONJ (""exposed necrotic bone... persisting for more than eight weeks""), so the study meets this criterion.",Exclude,"The abstract fails to meet multiple critical screening criteria, including specific study design, intervention type, and population indication for osteoporosis patients. While providing a diagnostic definition for MRONJ, the text appears to be a review or commentary that lacks the detailed research parameters required for systematic review inclusion. Insufficient information is provided to confirm compliance with key methodological requirements.",1.4
Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw Following Tooth Extraction: A Systematic Review,"Omami Mounir, Benmousa Ali",-,-,-,0,2017,no,"The study includes a mixed population of 16% for osteoporosis and 84% for malignant disease, which fails the criterion of excluding mixed populations.",maybe,"The abstract mentions the mean duration of BP administration (29.83 months) and follow-up after extraction (41.64 months), but does not clearly document the specific time intervals required.",maybe,"The abstract does not explicitly mention a control group, which is a significant limitation.",yes,"The study focuses on tooth extraction and reports BRONJ incidence, meeting this criterion.",yes,"The abstract mentions that the study is a systematic review of cohort and case-control studies, which meets the criterion of including these study designs.",yes,"The study reports BRONJ incidence (2.15%) and has a follow-up period of 41.64 months, meeting the 6-month minimum requirement.",yes,"The mean age of the subjects is 65.57 years, which meets the criterion of being over 18 years old.",yes,"The study includes 2325 patients, which exceeds the minimum requirement of 100 subjects.",no,"The study includes both oral and intravenous bisphosphonates, which fails the criterion of excluding intravenous administration.",maybe,The abstract does not explicitly mention the diagnostic standards for BRONJ.,Exclude,"The systematic review fails key screening criteria by including a mixed population with cancer patients and intravenous bisphosphonates, which are explicitly excluded from the research parameters. Despite meeting some criteria like age, sample size, and study design, the fundamental violations of population and intervention type render the study unsuitable for inclusion. Critical methodological limitations prevent the research from meeting the predefined screening requirements.",1.4
Drug-induced jaw osteonecrosis,G. Donati,10.4081/ozone.2019.8698,https://doi.org/10.4081/ozone.2019.8698,-,2,2019,no,"The study includes mixed populations - both cancer patients and osteoporosis patients, which violates the criterion requiring only osteoporosis patients.",no,"The abstract does not document the time intervals between medication start, dental procedures, and MRONJ incidence.",no,"The abstract does not mention a control group, which is a significant limitation.",yes,"The abstract mentions that MRONJ ""generally occurs after a surgical operation in the oral cavity e.g. the extraction of a tooth or the insertion of an implant,"" meeting this criterion.",no,"This appears to be a case series with an experimental protocol component, which does not meet the acceptable study design criteria.",maybe,"While the study documents MRONJ cases, it doesn't clearly specify a follow-up period of at least 6 months.",maybe,"The abstract does not explicitly state the age of subjects, so it cannot be confirmed that the population is over 18 years old.",no,"The study mentions 51 MRONJ cases total, with 14 patients in the experimental protocol, which is well below the required 100 subjects for the medication group.",no,"While the study includes oral bisphosphonate patients, it also includes other medications (pamidronate, zoledronate, bevacizumab, sunitinib, sorafenib), which violates the criterion requiring only oral bisphosphonates.",yes,"The abstract does provide a diagnostic standard for MRONJ, defining it as ""a diffuse maxillary disease characterized by the presence of bone exposed in the orofacial area, which does not tend to heal after eight weeks of observation and conventional therapy.""",Exclude,"The study fails to meet multiple critical screening criteria, including a mixed patient population, small sample size, and inappropriate study design. Significant methodological limitations include the inclusion of cancer patients, non-bisphosphonate medications, and a case series approach that does not align with the required research standards. These fundamental issues render the study unsuitable for the specified screening requirements.",1.4
Retrospective study on the bisphosphonate-related osteonecrosis of jaw.,"Yoon-Sic Han, In Woo Lee, Ho Lee, J. W. Suh, S. Kim, H. Myoung, S. Hwang, Jin-Young Choi, Jong-Ho Lee, P. Choung, Myung-Jin Kim, B. Seo",10.5125/JKAOMS.2011.37.6.470,https://doi.org/10.5125/JKAOMS.2011.37.6.470,-,1,2011,yes,"The study specifically focuses on osteoporosis patients taking bisphosphonates, excluding cancer patients.",no,"The abstract doesn't document the time intervals between medication start, dental procedure, and MRONJ incidence.",no,"The study includes two groups (osteomyelitis with osteoporosis vs osteomyelitis only), but this isn't exactly a control group of patients not taking anti-resorptive medications.",no,"The study includes surgical procedures (curettage, sequestrectomy, saucerization, decortications, and partial mandibulectomy), but these aren't the specific dental procedures listed in the criteria.",yes,"This is a retrospective study, which meets the criterion.",maybe,"While BRONJ incidence is documented, the follow-up period isn't specified.",maybe,"While not explicitly stated, the context suggests adult patients, but this isn't definitively confirmed.",no,"The study includes 64 patients with osteoporosis, which is below the required 100 subjects.",maybe,The abstract mentions bisphosphonates but doesn't specify if they are oral or intravenous.,no,The abstract doesn't mention specific diagnostic standards for BRONJ.,Include,"The study fails to meet several key screening criteria, including insufficient sample size, lack of specificity regarding oral bisphosphonates, and absence of precise diagnostic standards for MRONJ. While the research addresses bisphosphonate-related osteonecrosis in osteoporosis patients, it does not align with the required methodological and procedural specifications for inclusion. Critical gaps exist in documentation of dental procedures, follow-up periods, and comprehensive patient tracking.",2.7
“Medication Related Osteonecrosis of the Jaw (MRONJ)-case report and review of literature”,"Umme Amarah, L. Chatra, P. Shenai, K. Veena, R. Prabhu",10.5958/2395-6194.2016.00027.8,https://doi.org/10.5958/2395-6194.2016.00027.8,-,0,2016,no,"While the abstract mentioned bisphosphonate therapy, it did not specifically state that the subjects were osteoporosis patients, nor did it exclude cancer patients or mixed populations. Therefore, Elicit could not confirm that this criterion was met.",no,"The abstract did not provide any information about time intervals, so Elicit could not determine if this criterion was met.",no,"No mention of a control group in the abstract, so Elicit could not confirm whether this criterion was met.",no,"While the abstract mentioned tooth extractions as a risk factor, it did not report specific MRONJ incidence following dental procedures. Therefore, Elicit could not confirm that this criterion was met.",no,"The abstract appeared to be more of a review or commentary rather than a primary research study, and no specific study design was mentioned. Therefore, Elicit could not confirm that this criterion was met.",no,"The abstract did not mention any specific MRONJ incidence data or follow-up period, so Elicit could not confirm that this criterion was met.",no,"The abstract did not provide any specific information about the age of the subjects, so Elicit could not determine if this criterion was met.",no,"The abstract did not provide any information about the sample size, so Elicit could not determine if this criterion was met.",maybe,"The abstract mentioned ""oral bisphosphonates"", which partially meets this criterion, but it did not specify if other types of medications were included.",no,"The abstract did not mention any specific diagnostic standards for MRONJ, so Elicit could not determine if this criterion was met.",Exclude,"The abstract lacks critical details required by the screening criteria, including specific study design, sample size, diagnostic standards, and outcome documentation. While mentioning oral bisphosphonates, the text appears to be a general commentary rather than a research study, failing to meet most of the specified inclusion requirements. Consequently, the abstract does not provide sufficient information to qualify for inclusion based on the comprehensive screening criteria.",1.4
Medication Related Osteonecrosis of Jaw: A Medical Oncologist’s Perspective,H. Darling,10.18314/JDMS.V1I1.1180,https://doi.org/10.18314/JDMS.V1I1.1180,-,1,2018,no,"The abstract primarily focuses on cancer patients taking anti-resorptive medications, with only brief mention of osteoporosis patients. This fails to meet the criterion of focusing specifically on osteoporosis patients.",no,"No information about time intervals is provided, so no points were added for this criterion.",no,"The abstract does not mention any control group, so no points were added for this criterion.",no,"The abstract does not mention any specific dental procedures or their relationship to MRONJ incidence, so this criterion is not met.",no,"This appears to be a review article rather than any of the specified study designs. The abstract discusses the condition generally and its importance in cancer treatment, which fails to meet the criterion of being a randomized controlled trial, prospective cohort study, retrospective cohort study, or case-control study.",no,"The abstract does not discuss specific follow-up periods or documented MRONJ incidence rates, so this criterion is not met.",maybe,"The abstract does not explicitly specify age requirements, so the reasoning is uncertain.",maybe,"The abstract does not mention any specific sample size, so the reasoning is uncertain.",no,"While the abstract mentions bisphosphonates, it also discusses other medications (denosumab and antiangiogenic agents) and focuses on cancer treatment rather than oral bisphosphonates for osteoporosis. This fails to meet the criterion of focusing on oral bisphosphonate medication for osteoporosis treatment.",maybe,"The abstract mentions AAOMS recommendations but does not specify diagnostic standards, so the reasoning is uncertain.",Exclude,"The abstract primarily discusses medication-related osteonecrosis of the jaw in cancer patients, which fundamentally conflicts with the screening criteria focused on osteoporosis patients. Multiple critical requirements are not met, including population indication, intervention type, and study design, rendering the paper unsuitable for the specified research parameters. The document appears to be a review article that does not align with the targeted research characteristics.",0.1
"Risikofaktoren und Therapie von Antiresorptiva-assoziierten Kiefernekrosen, eine retrospektive Analyse an der Universitätsmedizin Göttingen",J. Gollasch,10.53846/goediss-9847,https://doi.org/10.53846/goediss-9847,-,0,-,no,"The study includes a mixed population with only 26.1% having osteoporosis, while the majority had various cancers. This fails to meet the criterion requiring subjects to be specifically chosen from osteoporosis patients.",maybe,"The study documents time from medication start to ARONJ (e.g., ""36 months ± 21.53 mo"" for zolendronate), but doesn't specify the time from dental procedure to ARONJ.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",no,"The abstract doesn't specify which dental procedures led to ARONJ, only mentioning that ARONJ occurred.",yes,"The study is described as a retrospective study, which meets the criterion.",yes,"The study follows patients for 3, 6, and 12 months, meeting the 6-month follow-up requirement.",yes,"The average age of the subjects was 72.77 years ± 10.47 years, which meets the criterion of being over 18 years old.",no,"The study includes 88 ARONJ patients, which is below the required 100 subjects for the medication group.",maybe,"While the study includes oral bisphosphonates (alendronate, zolendronate, pamidronate, ibandronate, risendronate), it also includes denosumab (a non-bisphosphonate) and doesn't specify if all bisphosphonates were oral.",maybe,"While the study mentions ""stages of necrosis,"" it doesn't explicitly state the diagnostic standards used.",Include,"The study fails key screening criteria due to a mixed patient population predominantly comprising cancer patients, a sample size below 100, and lack of clear documentation of dental procedures leading to ARONJ. While meeting some criteria like age and study design, significant methodological limitations prevent the study from qualifying for systematic review inclusion. The research's diverse patient population and incomplete procedural documentation create substantial barriers to meeting the predefined screening requirements.",2.5
Prevalence of Osteonecrosis of the Jaw Secondary to Antiresorptive Therapy in Patients Who have Undergone Dental Surgical Procedures: A Retrospective Study,"H. Ma, Izarra A, Bronstein D, Suzuki Jb",10.19070/2377-8075-1600072,https://doi.org/10.19070/2377-8075-1600072,-,1,2016,no,"Elicit could not determine if the research specified that its subjects were chosen from patients taking medication for osteoporosis, excluding cancer patients and mixed populations, as the provided information was only author affiliations and journal details, without any actual study details.",no,"Elicit could not determine if the study documented the time interval between the start of medication and dental procedure, and between the dental procedure and MRONJ incidence, as the provided information was only author affiliations and journal details, without any actual study details.",no,"Elicit could not determine if the study included a control group of patients not taking anti-resorptive medications, as the provided information was only author affiliations and journal details, without any actual study details.",no,"Elicit could not determine if the study reported MRONJ incidence following specific dental procedures, as the provided information was only author affiliations and journal details, without any actual study details.",no,"Elicit could not determine the study design, as the provided information was only author affiliations and journal details, without any actual study details.",no,"Elicit could not determine if the study clearly documented MRONJ incidence after dental treatment and had a follow-up period of at least 6 months, as the provided information was only author affiliations and journal details, without any actual study details.",no,"Elicit could not determine the age of the study subjects, as the provided information was only author affiliations and journal details, without any actual study details.",no,"Elicit could not determine the size of the medication group at the final statistical analysis stage, as the provided information was only author affiliations and journal details, without any actual study details.",no,"Elicit could not determine if the study only included subjects taking oral bisphosphonate medication for osteoporosis treatment, as the provided information was only author affiliations and journal details, without any actual study details.",no,"Elicit could not determine if the study mentioned its diagnostic standards for MRONJ, as the provided information was only author affiliations and journal details, without any actual study details.",Exclude,"Insufficient information is present to assess any of the screening criteria, as the text contains only author affiliations and journal details without any substantive study information. No meaningful determination can be made regarding population characteristics, intervention type, study design, or research outcomes. The lack of actual study details prevents any comprehensive screening evaluation.",0.1
Medication related osteonecrosis of the jaws : a case serial study,"M. Aksoy, G. Koçer, M. Koçer, T. Baykul",-,-,-,0,2017,no,"The study focuses on cancer patients (breast cancer, prostate cancer, multiple myeloma) rather than osteoporosis patients, so it fails this criterion.",yes,"The study documents time intervals between medication start and MRONJ development (5-120 months), meeting this criterion.",no,"The abstract does not mention a control group of patients not taking anti-resorptive medications, so no points were added for this criterion.",maybe,"The study mentions surgical procedures and denture trauma, partially meeting this criterion.",yes,"The study is a retrospective evaluation, which meets the requirement for the study design.",maybe,"The study documents MRONJ incidence and treatment outcomes, but the follow-up period is not clearly specified.",yes,"The study includes patients aged 45-82 years, which meets the requirement of subjects being over 18 years old.",no,"The study includes only 35 patients, which fails the requirement of over 100 subjects in the medication group at the final statistical analysis stage.",no,"The study focuses on intravenous zoledronic acid (82.9% of patients), not oral bisphosphonates, so it fails this criterion.",no,The abstract does not explicitly mention the diagnostic standards for MRONJ.,Exclude,"The study focuses on cancer patients taking intravenous zoledronic acid, which disqualifies it from the systematic review due to population and intervention type criteria. With only 35 patients and no control group, the research fails to meet key methodological requirements for inclusion. Multiple screening criteria were not satisfied, rendering the study ineligible for further analysis.",0.1
"Medication-related osteonecrosis of the jaw : occurence, risk factors, pathogenesis & treatment",F. Hallmer,10.24834/2043/28144,https://doi.org/10.24834/2043/28144,-,0,2019,no,"Elicit noted that the abstract mentioned bisphosphonates and denosumab, but did not specify if the subjects were patients taking medication for osteoporosis or a mixed population.",no,"Elicit noted that the abstract did not provide any information about the time intervals between the start of medication, dental procedures, and MRONJ incidence.",no,Elicit could not determine from the abstract if the study included a control group of patients not taking anti-resorptive medications.,no,Elicit indicated that the abstract did not contain any information about dental procedures or MRONJ incidence.,no,Elicit noted that the study design was not mentioned in the abstract.,no,Elicit stated that the abstract did not contain any information about the follow-up period or documentation of MRONJ incidence.,no,Elicit stated that the abstract did not provide any information about the age of the subjects.,no,Elicit stated that the abstract did not provide any information about the sample size of the study.,no,"Elicit pointed out that the abstract explicitly mentioned ""high dose intravenous bisphosphonates"", which is an excluded intervention type according to the criteria.",no,Elicit stated that the abstract did not provide any information about the diagnostic standards for MRONJ.,Exclude,"The abstract fails to meet multiple screening criteria, particularly by including intravenous bisphosphonates and denosumab, which are explicitly excluded intervention types. Insufficient details are provided about population characteristics, study design, and outcome measurements, rendering the study non-compliant with the specified screening requirements.",0.1
Advanced Stage of Medication‐Related Osteonecrosis of the Jaw Associated With Oral Bisphosphonates: Report of Three Cases,"Junu Ojha, D. Cohen, Hyden Choi, J. Schumer, Anish K Gupta, N. Dang",10.1902/CAP.2016.160036,https://doi.org/10.1902/CAP.2016.160036,-,1,2017,yes,"The abstract clearly specifies that the subjects are patients taking oral bisphosphonates (alendronate) for osteoporosis treatment, which meets this criterion.",maybe,"While the abstract mentions ""long history of use of alendronate for over 10 years,"" it doesn't clearly document the specific time intervals required.",no,"The abstract does not mention a control group, so no points were added for this criterion.",no,The abstract does not specify which dental procedures led to MRONJ.,no,"This is explicitly described as a case series, which is specifically excluded in the criteria.",no,"While MRONJ is documented, the follow-up period is not specified.",maybe,"While the age of the subjects is not explicitly stated, Elicit notes that since these are osteoporosis patients, they are likely over 18 years old, but this is not confirmed in the abstract.",no,"The abstract only presents 3 cases, which is far below the required 100 subjects minimum for the medication group.",yes,"The study specifically focuses on oral bisphosphonates (alendronate), meeting this criterion.",yes,The abstract mentions using the 2014 American Academy of Oral and Maxillofacial Surgeons position paper classification system for MRONJ staging.,Exclude,"This case series of three patients fails to meet multiple critical screening criteria, including the required minimum sample size of 100 subjects and the specified study design. The research lacks a control group, does not clearly document dental procedures leading to MRONJ, and uses a case series methodology that is explicitly excluded from the systematic review protocol.",0.1
Bisphosphonate-related osteonecrosis of the jaw in malignant tumor patients with bone metastases: clinical analysis of six cases,"Pengfei Xin, Z. Tian, G. Xue",10.3760/CMA.J.ISSN.1006-9801.2019.10.006,https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.006,-,0,2019,no,"The study specifically focuses on cancer patients with bone metastases, which is explicitly excluded in the criteria.",yes,"The study documents the average usage time of bisphosphonates (28 months) and mentions the timing of dental procedures, which meets the requirement for MRONJ latency.",no,"The abstract does not mention a control group, so no points were added for this criterion.",yes,"The study reports MRONJ incidence following tooth extractions, which meets the requirement for procedure and outcome.",yes,"The study is a retrospective cohort study, which meets the requirement for study design.",maybe,"While the study documents MRONJ incidence, the follow-up period is not specified, so it is unclear if the requirement for a 6-month follow-up period is met.",yes,"The median age of the subjects is 65.5 years, which meets the requirement of being over 18 years old.",no,"The study only includes 6 patients, which is well below the required 100 subjects for the medication group.",no,"The study uses intravenous bisphosphonates, not oral bisphosphonates as required.",maybe,"While the study mentions clinical manifestations and imaging characteristics, it does not explicitly state the diagnostic standards for MRONJ.",Exclude,"The study fails critical screening criteria by focusing on cancer patients with bone metastases instead of osteoporosis patients, using intravenous bisphosphonates instead of oral medications, and having a sample size of only 6 patients. Multiple key requirements were not met, including population type, intervention method, and subject size, rendering the study ineligible for inclusion in the systematic review.",0.1
THE ROLE OF PRE-MEDICATION DENTAL EVALUATION IN THE PREVENTION OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW IN CANCER PATIENTS: THE MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE,"A. Owosho, Haley Freymiller, Adi Z. Sax, Kant Wu, S. Yom, J. Huryn, C. Estilo",10.1016/j.oooo.2017.05.497,https://doi.org/10.1016/j.oooo.2017.05.497,-,0,2017,no,"The abstract explicitly states that the study focused on ""cancer patients,"" which directly violates the criterion that the research must specify its subject is chosen from patients taking medication for osteoporosis, excluding cancer patients.",no,"No information was provided about the time intervals between the start of medication, dental procedure, and MRONJ incidence.",no,No information was provided about whether the study included a control group of patients not taking anti-resorptive medications.,no,"While the abstract mentions ""pre-medication dental visit,"" it does not specifically detail the dental procedures listed in the criteria (extraction, periodontal surgery, implant placement, or removable prosthetic treatment).",no,The study design was not explicitly stated in the abstract.,no,No information was provided about the follow-up period or the documentation of MRONJ incidence after dental treatment.,no,No specific information was provided about the age of the study subjects.,no,No information was provided about the sample size of the medication group at the final statistical analysis stage.,no,No specific mention was made of the subjects taking oral bisphosphonate medication for osteoporosis treatment.,no,No information was provided about the diagnostic standards used for MRONJ.,Exclude,"The abstract focuses on cancer patients, which directly conflicts with the screening criteria requiring osteoporosis patients. Insufficient details are provided about study design, medication type, sample size, and diagnostic standards, rendering the study non-compliant with multiple systematic review requirements. The explicit mention of cancer patients represents a fundamental disqualifying factor for inclusion.",0.1
Características radiográficas em pacientes oncológicos com indicação de extração dentária e em risco para osteonecrose dos maxilares induzida por medicamentos,Hugo Gaêta Araújo,10.47749/t/unicamp.2020.1235601,https://doi.org/10.47749/t/unicamp.2020.1235601,-,0,-,no,"The study specifically focuses on oncologic patients undergoing intravenous antiresorptive treatment, which violates the criterion excluding cancer patients.",no,"The abstract does not mention documenting the time intervals between medication start, dental procedure, and MRONJ incidence.",yes,"The study included a control group of patients not taking anti-resorptive medications, which adds 0.2 points to the score.",yes,The study specifically looks at dental extraction sites and MRONJ incidence.,yes,"The study is a retrospective study, which is one of the accepted study designs.",maybe,"While MRONJ incidence is documented, the follow-up period is not specified.",maybe,"The age of the subjects is not explicitly mentioned in the abstract, so it is unclear if the population is over 18 years old.",no,"The study includes a total of 41 patients in the treatment group, which is below the required 100 subjects.",no,"The study uses intravenous antiresorptive treatment, not oral bisphosphonates, which violates the intervention criterion.",maybe,The abstract does not explicitly mention the diagnostic standards for MRONJ.,Exclude,"The study involves oncologic patients receiving intravenous antiresorptive treatment, which immediately disqualifies it from the review due to population and intervention type criteria. With only 41 patients and using intravenous medication instead of oral bisphosphonates, the research fails to meet key screening requirements for inclusion. Multiple critical screening criteria were not satisfied, rendering the study ineligible for the systematic review.",0.1